3/2007
‫התשס"ז‬/'‫ט‬
‫רשומות‬
ISRAEL STATE RECORDS
‫א' בתמוז התשס"ז‬
June 17, 2007
‫יומן הפטנטים והמדגמים‬
PATENTS AND DESIGNS JOURNAL
PATENTS
Applications accepted
Patents granted
Patents renewed
Patents not in force
Patents renewed for 20 years
Notices
Corrigenda
Country codes
Indices of applications accepted
DESIGNS
Designs registered
Designs renewed
Designs void
‫עמוד‬
Page
838
1047
1048
1049
1050
1051
1054
1055
i
‫פטנטים‬
‫בקשות שקובלו‬
‫פטנטים שניתנו‬
‫פטנטים שחודשו‬
‫פטנטים שתוקפם פקעו‬
‫פטנטים שחודשו לעשרים שנה‬
‫הודעות‬
‫תיקוני טעויות‬
‫קודים למדינות‬
‫מפתחות לבקשות שקובלו‬
1057
1070
1071
‫מדגמים‬
‫מדגמים שנרשמו‬
‫מדגמים שחודשו‬
‫מדגמים שבוטלו‬
‫ידיעות כלליות‬
:‫ וכו' בענייני פטנטים ומדגמים יש לשלוח אל‬,‫ מסמכים‬,‫מכתבים‬
‫ ירושלים‬,4 ‫ רח' הסדנא‬,‫רשם הפטנטים והמדגמים‬
‫ ירושלים והיא פתוחה לציבור בימי חול‬,‫ תלפיות‬,4 ‫לשכת הפטנטים נמצאת ברח' הסדנא‬
.12:30 -‫ ו‬8:30 ‫שאינם ערבי שבת או מועד בין השעות‬
‫ שקלים בעד כל‬2.50 ‫לשכת הפטנטים מספקת תצלומים של פירוטים ושרטוטים במחיר של‬
.‫עמוד או חלק ממנו‬
'‫אגרות ללשכת הפטנטים מתקבלות אך ורק על ידי תשלום לחשבון הלשכה בבנק הדואר מס‬
‫ יש להציג קבלת בנק הדואר ללשכה יחד עם הבקשה לפעולה שעבורה האגרה‬. 0-24145-2
.‫שולמה‬
GENERAL INFORMATION
Letters, documents, etc. concerning Patents and Designs should be addressed to:
The Commissioner of Patents and Designs, 4 Hasadnah St., Jerusalem
The Patent Office is located at 4 Hasadnah St., Talpiot, Jerusalem and is open to the public on
weekdays, except on Fridays or on the eves of holydays, from 08:30 to 12:30 hrs.
The Patent Office supplies photocopies of specifications and drawings at the rate of NIS 2.50
per page or part thereof.
Fees to the Patent Office can be accepted only by payment to the Postal Bank Account of the
Office, No. 0-24145-2. The receipt of the Postal Bank must be presented to the office together
with the application for the action for which the fee has been paid.
Copyright by the State of Israel. No
Extracts may be published except with the
permission of the Patent Office.
‫זכות היוצרים בתקצירים אלה שמורה‬
‫ אין להעתיק מת‬,‫למדינת ישראל‬
‫קצירים‬
.‫אלה אלא ברשות לשכת הפטנטים‬
Price per single issue (incl. VAT) : NIS 96.
.₪ 96 ).‫מ‬.‫ע‬.‫ לכל חוברת בודדת (כולל מ‬:‫מחיר‬
Annual subscription (incl. VAT):
NIS 1,152.
Available at the Distribution Service of
Government Publications, 29 B-Street,
Hakirya, Tel-Aviv.
June 17, 2007 – ‫א' בתמוז התשס"ז‬
.₪ 1,152 ).‫מ‬.‫ע‬.‫דמי חתימה לשנה (כולל מ‬
:‫אפשר להשיג אצל‬
'‫ רחוב ב‬,‫שרות ההפצה של פרסומי הממשלה‬
.‫אביב‬-‫ תל‬,‫ הקריה‬,29 '‫מס‬
836
NOTICE UNDER SECTION 26 OF THE
PATENTS LAW, 5727-1967
The applications, particulars of which are set
out below, have been accepted pursuant to
Section 17 of the Patents Law. Any person
wishing to oppose the grant of a patent on any
of the applications published here, may,
within three months from the date of this
journal, give to the Commissioner of Patents
notice under Section 30 of the Patents Law, in
the manner prescribed in regulations 57 et seq
of the Patents Regulations, 5728-1968
Particulars of the applications, where
applicable, are given in the following order:
[11] [21] Number of application
[54] Title of invention
[22] Application date
[31] [32] [33] Number and date of foreign
application – convention country.
*[51] Int.Cl.
[61] Application for patent of addition
[62] Divisional application
[71] Applicant
[72] Inventor
[87] International Publication Number
[74] Address for service
[57] Abridgement of invention (in the
language in which the specification is drawn
up)
*Note: As from Patents and Designs Journal
No.1/06, patent applications are classified
according to the Eighth Edition of the
International Patent Classification (2006)
837
- ‫ לחוק הפטנטים תשכ"ז‬26 ‫הודעה לפי סעיף‬
1976
‫הבקשות שפרטיהן מתפרסמים להלן קובלו‬
‫ כל המעונין‬.‫ לחוק הפטנטים‬17 ‫לפי סעיף‬
‫להתנגד למתן פטנט על פי בקשה מהבקשות‬
‫ תוך שלושה חדשים‬,‫המתפרסמות רשאי‬
‫ להגיש לרשם הפטנטים‬,‫מתאריך יומן זה‬
‫ לחוק‬30 ‫הודעת התנגדות לפי סעיף‬
‫ ואילך‬57 ‫הפטנטים בדרך הקבועה בתקנה‬
.1968 – ‫ תשכ"ח‬,‫לתקנות הפטנטים‬
‫פרטי הבקשות במידה ויישימים מובאים לפי‬
:‫סדר זה‬
‫מספר הבקשה‬
‫שם האמצאה‬
‫תאריך הבקשה‬
‫מספר ותאריך של בקשות החוץ – מדינת‬
‫האגוד‬
‫*סיווג בינלאומי – מהדורה שביעית‬
‫בקשה לפטנט מוסף‬
‫בקשת חלוקה‬
‫המבקש‬
‫הממציא‬
‫מס' פרסום של בקשה הבינלאומית‬
‫מען למסירת מסמכים‬
)‫תקציר האמצאה (בשפה בה ערוך הפירוט‬
'‫ החל מיומן הפטנטים והמדגמים מס‬:‫*הערה‬
‫ ניתן ציון לבקשות פטנטים הסיווג לפי‬1/06
‫המהדורה השמינית של הסיווג הבינלאומי‬
)2006 ‫של פטנטים (משנה‬
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
]54[
ANTIBODIES TO TBP-II AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM
]22[
]51[
]62[
]71[
06.08.1989
Int. Cl.8 A61K 039/395, C07K 016/18
DIVISION FROM 91229
YEDA RESEARCH AND
DEVELOPMENT CO. LTD.
INTERLAB LTD.,
KIRYAT WEIZMANN
NES ZIONA 76110
]74[
[57] An antibody to a human tumor
necrosis factor binding protein designated
TBP-II, F(ab) fragments thereof or salts,
functional derivatives or active fractions
112699
‫ ותכשירי רוקחות‬TBP–II –‫נוגדנים ל‬
‫המכילים אותם‬
‫ רחובות‬,‫ידע חברה למחקר ופיתוח בע"מ‬
,‫אינטר לאב בע"מ‬
‫ נס ציונה‬,‫קרית ויצמן‬
(as defined in the specification) of the
antibody or the fragment thereof, which
specifically recognizes said protein.
__________
]11[]21[
115792
‫ חומצות‬,AL–1 ‫חלבון גורם ניורוטרופי‬
‫ תאי‬,‫ וקטורים‬,‫גרעין המקודדות אותו‬
‫ שיטה לייצורו והשימוש‬,‫ תכשירים‬,‫מאחסן‬
‫בו‬
]54[
AL-1 NEUROTROPHIC FACTOR
PROTEIN, NUCLEIC ACIDS
ENCODING THE SAME,
VECTORS, HOST CELLS,
COMPOSITIONS, METHOD FOR
PRODUCING AND USE THEREOF
]22[
]31[
27.10.1995
08/330128
]32[ 27.10.1994
]33[ US
08/486449
07.06.1995
US
Int. Cl.8 A61K 038/18, C07K 014/475, 016/18, C12N 015/12
GENENTECH, INC., U.S.A.
S. HOROWITZ & CO.,
,'‫ הורוביץ ושות‬.‫ש‬
ZION HOUSE,
‫ תל‬,41-45 ‫ שדרות רוטשילד‬,‫בית ציון‬
41-45 ROTHSCHILD BLVD.,
‫אביב‬
TEL AVIV 65784
]51[
]71[
]74[
[57] An isolated nucleic acid encoding a
functional AL-1 neurotrophic factor
protein comprising an amino acid sequence
that is at least 75% identical to the amino
acid sequence shown in Figure 2 of the
specification for human AL-1 neurotrophic
factor.
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
838
]11[]21[
116416
‫מולקולות ותכשירים למניעת יצירת צברים‬
‫של פרוטאינים‬
]54[
ANTI-AGGREGATION
MOLECULES FOR PREVENTION
OF PROTEIN AGGREGATION
]22[
]31[
]51[
]71[
15.12.1995
08/358786
]32[ 16.12.1994
]33[ US
Int. Cl.8 A61K 039/395, 048/00, C07K 016/40, C12N 015/13
RAMOT AT TEL-AVIV
,‫אביב בע"מ‬-‫רמות ליד אוניברסיטת תל‬
UNIVERSITY LTD.
‫אביב‬-‫תל‬
]72[
]74[
BEKA SOLOMON
G.E. EHRLICH (1995) LTD.,
11 MENACHEM BEGIN STREET
RAMAT GAN 52521
[57] A pharmaceutical composition
comprising:
(A) an anti-β-amyloid antibody or an
antigen binding fragment thereof, wherein
said antibody and said fragment are
‫בקה סלומון‬
,‫) בע"מ‬1995( ‫ ארליך‬.‫אי‬.‫ג'י‬
‫ רמת גן‬,11‫מנחם בגין‬
selected so as to be capable of effectively
preventing or reducing aggregation of βamyloid or disaggregating an aggregate of
β-amyloid; and
(B) a pharmaceutically acceptable carrier.
__________
]11[]21[
839
118570
June 17, 2007 – ‫א' בתמוז התשס"ז‬
Met–GnRH ‫שימוש בחלבון כימרי הכולל‬
‫בהכנת תכשיר רוקחי לטיפול‬
‫באדנוקרצינומה או בהפאטוקרצינומה‬
]54[
USE OF A CHIMERIC PROTEIN
COMPRISING MET-GNRH IN
THE PREPARATION OF A
PHARMACEUTICAL
COMPOSITION FOR TREATING
ADENOCARCINOMA OR
HEPATOCARCINOMA
]22[
]51[
]71[
04.06.1996
Int. Cl.8 A61K 038/22, 047/48, C07K 014/575, 019/00, C12N 015/62
YISSUM RESEARCH
‫יישום חברה לפיתוח המחקר של‬
DEVELOPMENT COMPANY OF
‫ ירושלים‬,‫האוניברסיטה העברית בירושלים‬
THE HEBREW UNIVERSITY OF
JERUSALEM
SHAI YARKONI, HAYA
‫ עמוס‬,‫גלקסי‬-‫ חיה לורברבאום‬,‫שי ירקוני‬
LORBERBOUM-GALSKI, AMOS
‫ אירנה מרינובסקי‬,‫נחושתן‬
NECHUSHTAN, IRINA
MARIANOVSKY
REINHOLD COHN AND
,‫ריינהולד כהן ושותפיו‬
PARTNERS,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]72[
]74[
[57] Use of an effective amount,
sufficient to at least reduce the growth of
adenocarcinoma or hepatocarcinoma, of at
least one fused chimeric protein
comprising a linear genetically engineered
molecule consisting essentially of peptide
bonds, produced by fusing, at the level of
cDNA:
(A) DNA encoding at least one cell
targeting moiety consisting essentially of
methionine gonadotropin releasing
hormone (MetGnRH) or a Met-GnRH
analog that specifically binds to GnRH
binding sites on Caco2 adenocarcinoma
cells; and
(B) DNA encoding at least one cell killing
moiety, in the preparation of a
pharmaceutical composition for use in a
method for the treatment of said
adenocarcinoma or hepatocarcinoma in a
mammal in need of such therapy.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
122023
840
]54[
NON-TRANSFERABLE BIOMETRIC TOKEN-BASED
IDENTIFICATION METHOD
AND DEVICES
]22[
]51[
]71[
]74[
26.10.1997
Int. Cl.8 G10L 005/06, 015/00, 017/00
ENCO-TONE LTD.
ENCO-TONE LTD.,
P.O. BOX 45094 JERUSALEM
[57] An identification method for
identifying the holder of a portable, self
contained storing and transmission device
comprising the steps of:
analyzing the characteristic of the voice of
the rightful owner of the said portable
device and expressing such characteristic
by means of a string of digits, or bits;
digitally storing the said characteristic on
the portable device; and every time the
identification should be executed: the said
portable device dynamically encrypts the
said characteristic and transmits the said
dynamically encrypted characteristic to an
identification device, and, the said holder
‫שיטה ומכשור עבור זיהוי ביאומטרי המבוסס‬
‫)בלתי‬TOKEN( ‫על שימוש במכשיר זהיר‬
‫ניתן להעברה‬
‫ ירושלים‬,‫טון בע"מ‬-‫אנקו‬
,‫טון בע"מ‬-‫אנקו‬
‫ ירושלים‬,45094 .‫ד‬.‫ ת‬, 11 ‫רח' קרית מדע‬
of the portable device utters words to the
said identification device whereas the
identification device receives the
transmission from the portable device and
decrypts the dynamically encrypted
characteristic received, verifies that the
Generation Time is within tolerances
rejecting the case if negative or,
eventually, if positive capturing the voice
of the said holder, and analyzes the voice
received and compares the result of the
said analysis with the characteristic
received and decides if the utterance
belongs to the same rightful owner of the
portable device or not.
__________
]11[]21[
841
122115
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]54[
PROCESS FOR POLYMERIZING
ALPHA-OLEFINS AND
POLYMERS, COPOLYMERS AND
ELASTOMERS PREPARED
THEREBY
]22[
]51[
]61[
]71[
27.07.1997
Int. Cl.8 C08F 004/602, 010/00
121402
TECHNION RESEARCH AND
DEVELOPMENT FOUNDATION
LTD.
MORIS S. EISEN, VICTORIA
VOLKIS, MICHAL SHMULINSON,
CLAUDIA AVERBUH, EDITH TISH
G.E. EHRLICH (1995) LTD.,
11 MENACHEM BEGIN STREET
RAMAT GAN 52521
]72[
]74[
‫שיטה לפילמור אלפה – אולפינים‬
‫ קופולימרים ואלסטומרים שהוכנו‬,‫ופולימרים‬
‫לפי שיטה זו‬
‫ חיפה‬,‫מוסד הטכניון למחקר ופיתוח בע"מ‬
‫ מיכל‬,‫ ויקטוריה וולקיס‬,‫ אייזן‬.‫מוריס ס‬
‫ אדית טיש‬,‫ קלאודיה אברבוך‬,‫שמולינסון‬
,‫) בע"מ‬1995( ‫ ארליך‬.‫אי‬.‫ג'י‬
‫ רמת גן‬,11‫מנחם בגין‬
[57] A process for the polymerization of
one or more alpha-olefins having at least 3
carbon atoms, the process comprising:
(a) contacting alpha-olefin monomer or
monomers in a solvent selected from the
group consisting of polar solvents and nonpolar solvents under polymerization
conditions with a homogeneous catalyst
system including:
(i) a cationic form of a chiral or a non
octahedral transition metal complex,
comprising 1, 2 or 3 bidentate chelating
ligands and no cyclopentadienyl ligands
and having symmetry selected from the
group consisting of C1, C2 and C3
symmetries; and
(ii) an anion of an acid selected from the
group consisting of a Lewis acid and a
Bronsted acid; and
(b) adjusting the pressure to obtain either a
highly stereoregular polymer, a copolymer
or an elastomer,
provided that when said alpha-olefin is
styrene, said process is used for the
production of stereoregular polystyrene
and said octahedral transition metal
complex comprises one ligand, said ligand
is chiral.
This specification was examined in
accordance with regulation 35 of the Patent
Regulations, 5728 - 1968
‫ לתקנות‬35 ‫פירוט זה נבחן בהתאם לתקנה‬
1968 – ‫ תשכ"ח‬,‫הפטנטים‬
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
126463
842
,‫תכשיר רוקחות המכיל הורמון גידול‬
‫היסטידין ודטרגנט לא יוני‬
]54[
PHARMACEUTICAL
FORMULATION CONTAINING
GROWTH HORMONE, HISTIDINE
AND A NON-IONIC DETERGENT
]22[
]31[
]51[
24.04.1997
0490/96
]32[ 24.04.1996
]33[ DK
Int. Cl.8 A61K 009/08, 038/27, 047/10, 047/18, 047/26, 047/34, A61P 043/00, C07K
014/61
NOVO NORDISK A/S, DENMARK
WO/1997/039768
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]71[
]87[
]74[
[57] Aqueous pharmaceutical formulation
comprising:
human growth hormone (hGH) in an
amount of from 1 mg/ml to 15 mg/ml;
histidine in an amount of from 0.05 to 0.5
mg per mg of hGH; poloxamer 188 in an
amount of from 0.1 to 2 mg per mg hGH;
mannitol in an isotonicity-conferring
amount; and phenol as a preservative; said
formulation having a pH of from 6.0 to
6.3.
__________
]11[]21[
126843
II ‫ מסוג‬MHC ‫מערכות מציגות אנטיגנים‬
‫ במבחנה‬CD4+T ‫ושיטות לשפעל תאי‬
]54[
MHC CLASS II ANTIGENPRESENTING SYSTEMS AND
METHODS FOR ACTIVATING
CD4+T CELLS IN VITRO
]22[
]31[
]51[
22.05.1997
60/018175
]32[ 23.05.1996
]33[ US
Int. Cl.8 A61K 039/385, 048/00, A61P 003/10, 021/04, 037/04, 037/08, C07K
014/435, 014/705, C12N 005/06, 005/10, 015/12
THE SCRIPPS RESEARCH
INSTITUTE, U.S.A.
WO/1997/046256
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]71[
]87[
]74[
for presenting a synthetic antigen for
activating CD4+, the matrix comprising:
(a) a support comprising an insect cell, an
insect cell fragment, a liposome, a solid
[57]
843
Synthetic antigen presenting matrix
June 17, 2007 – ‫א' בתמוז התשס"ז‬
surface, a synthetic support, a porous
material, or a non-cellular support;
(b) an extracellular portion of a MHC class
II heterodimer, linked to the support and
capable of loading a selected peptide; and
(c) an extracellular portion of at least one
accessory molecule operably linked to the
support such that the extracellular portions
of the MHC class II heterodimer and
accessory molecule are present on the
support in sufficient numbers for activating
CD4+T cells when a peptide is loaded onto
the extracellular portion of the
heterodimer.
__________
]11[]21[
]54[
IMMUNOLOGICAL PROCESS
FOR DETECTING ANTIBODIES
DIRECTED TOWARDS TISSUE
TRANSGLUTAMINASE (TTG),
USE OF TTG FOR DIAGNOSTIC
PURPOSES AND THERAPY
CONTROL, AND ORAL
PHARMACEUTICAL AGENT
CONTAINING TTG
]22[
]31[
]51[
]71[
14.07.1997
19630557.8
]32[ 18.07.1996
Int. Cl.8 G01N 033/573
DETLEF SCHUPPAN, GERMANY
WALBURGA DIETERICH,
GERMANY
WO/1998/003872
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A method for the diagnosis or
therapy control of sprue or coeliac disease,
characterized in that antibodies against
tissue transglutaminase (tTG) from body
fluids are detected by means of an immune
128042
‫שיטה אימונולוגית לגילוי נוגדנים המכוונים‬
‫ באבחנה‬TTG– ‫ שימוש ב‬,)TTG(‫נגד‬
‫ובבקרה על תרפיה ותכשיר רוקחות אורלי‬
TTG ‫המכיל‬
]33[
DE
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
reaction with tissue transglutaminase
(tTG), the immunoreactive sequences or
analogues thereof, wherein the immune
reaction is not carried out with a tissue
section of animal or human tissue.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
128128
844
IGF–I ‫תרכובת המכילה אינסולין‬
]54[
COMPOSITION COMPRISING
INSULIN AND INSULIN-LIKE
GROWTH FACTOR (I-IGF)
]22[
]31[
]51[
]71[
]87[
]74[
31.07.1997
696314
]32[ 13.08.1996
]33[ US
Int. Cl.8 A61K 038/00, 038/30, C07K 014/475, 014/62
GENENTECH, INC., U.S.A.
WO/1998/006423
REINHOLD COHN AND
,‫ריינהולד כהן ושותפיו‬
PARTNERS,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A parenteral composition comprising
IGF-I and NPH insulin, in amounts of
from about 1 to 10 mg IGF-I and from
about 0.2 to 2 mg NPH insulin, in a
parenterally acceptable carrier and a
composition comprising NPH insulin in an
acetic acid salt buffer without the presence
of IGF-I.
__________
]11[]21[
128727
8–‫ ו‬a6, 5–1 ‫פולינוקלאוטיד הכולל אקסונים‬
‫ גן‬VEGF‫של ה‬
]54[
POLYNUCLEOTIDE
COMPRISING EXONS 1-5,6A AND
8 OF THE VEGF GENE
]22[
]31[
04.09.1997
60/025537
]32[ 06.09.1996
]33[ US
08/784551
21.01.1997
US
Int. Cl.8 C07K 014/52, C12N 015/19, 015/861
TECHNION RESEARCH AND
‫ חיפה‬,‫מוסד הטכניון למחקר ופיתוח בע"מ‬
DEVELOPMENT FOUNDATION
LTD.
COLLATERAL THERAPEUTICS
INC., U.S.A.
WO/1998/010071
DR. DAVID AGRANOV,
,‫ד"ר דוד אגרנוב‬
P.O.BOX 15
‫אבא‬-‫ אלוני‬,15 .‫ד‬.‫ ת‬,
ALONEY-ABA
36005
]51[
]71[
]87[
]74[
[57] Isolated polynucleotide comprising
exons 1-5, 5a and 8 of the VEGF gene,
wherein said polynucleotide does not
comprise exon 6b or exon 7 of the VEGF
gene.
845
June 17, 2007 – ‫א' בתמוז התשס"ז‬
__________
]11[]21[
130245
‫אנזימים גליקוסידאזיות‬
]54[
GLYCOSIDASE ENZYMES
]22[
]31[
08.12.1997
60/056916
]32[ 06.12.1996
]33[ US
08/949026
10.10.1997
US
Int. Cl.8 C12N 001/20, 005/00, 009/38, 009/42, 015/52, 015/56
DIVERSA CORPORATION, U.S.A.
WO/1998/024799
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] A polynucleotide encoding a
glycosidase enzyme, which comprises a
sequence selected from the group
consisting of:
(a) a sequence encoding a polypeptide as
set forth in SEQ ID NO:64;
(b) a sequence as set forth in SEQ ID
NO:60;
(c) the sequence of (a) or (b), wherein T
can also be a U;
(d) a sequence having at least 90%, 95% or
97% sequence identity to SEQ ID NO:60;
and
(e) a sequence complementary to the
sequence of (a) to (d).
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
130309
846
‫נוסחאות פרמצבטיות המכילות תרכובת‬
‫שאינה מסיסה במים להעברת תרופות‬
‫מתמשכת‬
]54[
PHARMACEUTICAL
FORMULATIONS COMPRISING A
WATER-INSOLUBLE COMPLEX
FOR SUSTAINED DRUG
DELIVERY
]22[
]31[
]51[
04.06.1993
08/762747
]32[ 11.12.1996
]33[ US
Int. Cl.8 A61K 009/22, 038/00, 038/04, 038/09, 038/22, 047/30, 047/36, 047/38,
047/48, A61P 015/00, 015/18, 035/00, C07K 007/08, 007/23, 014/575
PRAECIS PHARMACEUTICALS
INCORPORATED, U.S.A.
WO/1998/025642
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]71[
]87[
]74[
[57] Pharmaceutical composition
comprising a solid ionic complex of an
LHRH analogue and a carrier
macromolecule, wherein the carrier and
The applications for division
from this application have
not yet been published
analogue used to form the complex are
combined at a weight ratio of carrier
analogue of 0.5:1 to 0.1:1 and wherein said
complex is not a microcapsule.
,180450,180449
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
]11[]21[
131750
‫–ארילפיראזולים קוטלי מזיקים‬1
]54[
PESTICIDAL 1-ARYLPYRAZOLES
]22[
]31[
]51[
]71[
]87[
]74[
05.03.1998
60/040136
]32[ 10.03.1997
]33[ US
Int. Cl.8 A01N 043/56, C07D 231/00, 231/38, 405/04, 409/04, 411/04, 417/04
RHONE-POULENC AGRO, FRANCE
WO/1998/040359
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
[57] A compound of the formula
847
June 17, 2007 – ‫א' בתמוז התשס"ז‬
wherein:
R31 and R32 may individually be OCH3;
OC2H5; SCH3; SC2H5; R31 and R32 may
also connect to form OCH2CH2O;
O(CH2)3O; S(CH2)2S; S(O)(CH2)2S; S(O)
(CH2)2S(O); S(O)2(CH2)S(O);
S(O)2(CH2)2S(O)2;
S(CH2)2O; S(O)(CH2)2O; S(O)2(CH2)2O;
O(CH2)[CH(CH2OH)]O;
O(CH2)[C(CH2OH)(CH2OH)]O;
OCH(COOCH3)CH(COOCH3)O;
OCH(COOC2H5)CH(COOC2H5)O;
OCH2C(COOCH3)(COOCH3)CH2O;
OCH2C(COOC2H5)(COOC2H5)CH2O;
OCH2CH(CH3)O;
SCH2CH2NH; OCH2CH(CH2CH2OH)O;
or OCH2C(CH2OH)2CH2O;
O(CH2)CH(CH2SCH3)O;
O(CH2)CH(CH2SOCH3)O;
R4 is S(O)nR26; R26 is CH3 or CH2CH3; Z is
C-R16; R13 and R15 are H;
R12 is halogen, R16 is H or halogen; R14 is
CF3, OCF3, SF5; and R33 is CH3;
n is 0, 1, or 2;
R5 is NH2, CH3NH or CH3CH2NH2;
or a pesticidally acceptable salt thereof.
__________
]11[]21[
]54[
COMPOSITION FOR INDUCING
HAIR GROWTH
]22[
]51[
]71[
]72[
]74[
28.10.1999
Int. Cl.7 A61K 000/88970
MEDIDERMIS LTD.
AVI DASCALU
DR. YITZHAK HESS & PARTNERS,
279 HAYARKON ST.,
P.O.B. 6451,
TEL AVIV 61063
[57] A composition comprising a mixture
of extracts of saw palmetto and swertia, of
132625
‫תערובת הגורמת לגדילת שיער‬
‫ א"ת נתניה‬,‫מדידרמיס בע"מ‬
‫אבי דסקלו‬
,‫ד"ר יצחק הס ושותפיו‬
‫ תל אביב‬,6451 .‫ד‬.‫ ת‬, 279 ‫רחוב הירקון‬
derivatives thereof and of active
component being part of aid extracts.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
132671
848
‫שימוש של הפרינים בעלי משקל מולקולרי‬
‫נמוך להכנת תרופות למניעה וטיפול‬
‫בטראומה של מערכת העצבים המרכזית‬
]54[
USE OF LOW – MOLECULAR –
WEIGHT HEPARINS FOR
PREPARATION OF
MEDICAMENTS FOR
PREVENTING AND TREATING
CENTRAL NERVOUS SYSTEM
TRAUMA
]22[
]31[
]51[
]71[
]87[
]74[
25.05.1998
97/06550
]32[ 28.05.1997
]33[ FR
Int. Cl.8 A61K 031/727, A61P 025/00, C08B 037/00, 037/10, C12P 019/04
AVENTIS PHARMA S.A., FRANCE
WO/1998/053833
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
[57] Use of a low-molecular-weight
heparin for the preparation of a
medicament having a neuroprotective
effect for the prevention and treatment of
trauma of the central nervous system.
__________
]11[]21[
132768
‫שיטות להתמרת צמחים‬
]54[
PLANT TRANSFORMATION
METHODS
]22[
]31[
]51[
]71[
29.05.1998
08/867869
]32[ 02.06.1997
]33[ US
Int. Cl.8 A01H 005/00, C07K 014/01, C12N 005/04, 005/10, 015/29, 015/82
SYNGENTA PARTICIPATIONS AG,
SWITZERLAND
WO/1998/054961
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] Method of transforming a plant cell
with a gene of interest comprising cocultivating said plant with Agrobacterium
under conditions which inhibit
Agrobacterium Induced Necrosis (AIN)
wherein said Agrobacterium comprises a
vector comprising said gene of interest and
wherein said conditions are selected from
the group consisting of:
849
(a) co-cultivating said plant cell with
Agrobacterium after heat-shock treatment
of said plant cell; and
(b) co-cultivating said plant cell with
Agrobacterium in the presence of a
nucleotide sequence which encodes an
mRNA or protein from a gene selected
from the group consisting of: p35; iap; and
dad-1; and
June 17, 2007 – ‫א' בתמוז התשס"ז‬
(c) selecting the thus transformed cell.
__________
]11[]21[
]54[
OPTICAL MEMORY DEVICE AND
METHOD OF MANUFACTURING
IT
]22[
]31[
]51[
]71[
]87[
]74[
07.05.1998
60/045985
]32[ 08.05.1997
Int. Cl.8 G11B 007/24
OMD DEVICES, L.L.C., U.S.A.
WO/1998/050914
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A multi-layered optical memory
device comprising a plurality of spacedapart data layers containing a material
excitable by incident light to produce
fluorescence, each layer having a patterned
surface (14a) thereof, the pattern being in
the form of a plurality of regions (22a,
132796
‫התקן של זיכרון אופטי ושיטת ייצור‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
22b) containing the fluorescent material
and spaced by regions of the layer
transparent with respect to the incident
light and to said fluorescence, thereby
enabling access of all data layers by the
incident light.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
132962
850
‫מלחים של תולדות סולפואקסיד בעלי‬
‫ תכשירי רוקחות המכילים‬,‫פעילות אופטית‬
‫אותם ושימוש בהם‬
]54[
SALTS OF AN OPTICALLYACTIVE SULFOXIDE
DERIVATIVE,
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THE SAME AND THE USE
THEREOF
]22[
]31[
]51[
27.05.1998
9-141805
]32[ 30.05.1997
]33[ JP
Int. Cl.8 A61K 031/438, A61P 001/00, 009/00, 011/00, 013/00, 017/00, 025/00,
027/02, 029/00, 037/00, C07D 495/10
SANKYO COMPANY LIMITED,
JAPAN
WO/1998/054191
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]71[
]87[
]74[
[57] The hydrochloride or fumarate of 1'{2-[(2R)-(3, 4-dichlorophenyl)-4-(3,4,5trimethoxybenzoyl) morpholin-2-yl] ethyl}
spiro [benzo(c)thiophene-1-(3H),4'piperidine]-(2S)-oxide.
__________
]11[]21[
133512
– 6,1 – ‫ – אוקסאדיאזוליל‬3 ‫תולדות‬
– ‫נאפטירידין‬
‫ ) – און ותכשירי רוקחות המכילים‬H1) 2
‫אותן‬
]54[
3 - OXADIAZOLYL - 1,6 NAPHTHYRIDIN 2 (1H) - ONE DERIVATIVES AND
PHARMACEUTICAL
COMPOSITIONS
CONTAINING THEM
]22[
]31[
]51[
]71[
14.07.1998
207179/1997
]32[ 15.07.1997
]33[ JP
Int. Cl.8 A61K 031/4375, A61P 025/00, C07D 471/04
DAINIPPON SUMITOMO PHARMA
CO., LTD., JAPAN
WO/1999/003857
DR. YITZHAK HESS & PARTNERS,
,‫ד"ר יצחק הס ושותפיו‬
279 HAYARKON ST.,
‫ תל אביב‬,6451 .‫ד‬.‫ ת‬, 279 ‫רחוב הירקון‬
P.O.B. 6451,
TEL AVIV 61063
]87[
]74[
[57] A 5-substituted-3-oxadiazolyl-1,6naphthyridin-2(1H)-one derivative of
851
June 17, 2007 – ‫א' בתמוז התשס"ז‬
the formula
wherein Het is an oxadiazolyl group,
R1 is a hydrogen atom, a lower alkyl
group, a cyclo-lower alkyl group, a
trifluoromethyl group, a lower alkenyl
group, a lower alkynyl group, a lower
alkoxy group, a lower alkoxy-lower alkyl
group, a hydroxy-lower alkyl group, a
substituted or unsubstituted aryl group, or
a substituted or unsubstituted
heteroaromatic group, and R2 is a
hydrogen atom, a lower alkyl group, a
cyclo-lower alkyl group, a cyclo-lower
alkylmethyl group, a lower alkenyl group,
a cyclo-lower alkenyl group, a lower
alkynyl group, a substituted or
unsubstituted aryl group, or a substituted
or unsubstituted heteroaromatic group or a
pharmaceutically acceptable acid addition
salt thereof.
__________
]11[]21[
134192
‫ הכנתם‬,‫תיאזולו וסלנזולו בנזוהטרוציקליים‬
‫ותכשירי רוקחות המכילות אותם‬
]54[
THIAZOLO AND SELENAZOLO
BENZOHETEROCYCLES, THEIR
PREPARATION AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM
]22[
]31[
]51[
]71[
]87[
]74[
24.07.1998
97/09556
]32[ 28.07.1997
]33[ FR
Int. Cl.8 C07D 223/16, 243/14, 267/14, 281/10, 293/10, 513/06, 517/06
AVENTIS PHARMA S.A, FRANCE
WO/1999/005147
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
[57] Anti-ischaemia compounds of the
formula:
June 17, 2007 – ‫א' בתמוז התשס"ז‬
852
in which
R1 represents a sulphur or selenium atom,
R2 represents a hydrogen atom or an alkyl
radical, -R3-R4-R5-R6- represents a chain of
formula
-CH2-CH2-CH2-CH2-, -CH2-, -CH2-CH2CH2-CO-, -CH2-CH2-CH2-CH(R8)-,
-CH2-CH2--CH2-Se-, -CH2-CH2-Se-CH2-, CH2-CH2--CH2-S-,
-CH2-CH2--CH2-SO-, -CH2-CH2--CH2SO2-, -CH2-CH2--CH2-O-,
-CH2-CH2--CH2-N(R9)-, -CH2-CH2--CH2CO-CH2-,
-CH2-CH2—CH(R8)-CH2-, -CH2-CH2-SCH2-, -CH2-CH2-SO-CH2-,
-CH2-CH2-SO2-CH2-, -CH2-C (alk) (alk')S-CH2-,
-CH2-C(alk)(alk')-SO-CH2-, -CH2C(alk)(alk')-SO2-CH2-,
-CH2-CH(R10)-S-CH2-, -CH2-CH(R10)-SOCH2-,
-CH2-CH(R10)-SO2-CH2-, -CH2-CH2-OCH2-, -CH2-CH2-N(R9)-CH2or –CH2-CO-N(R9)-CH2-,
R7 represents a polyfluoroalkyl or
polyfluoroalkoxy radical;
R8 represents a hydroxyl radical,
R9 represents a hydrogen atom or an alkyl
or benzyl radical,
R10 represents an alkyl, -CH2OH, COOalk, -COOH or –CONH2 radical,
alk represents an alkyl radical,
alk' repreents an alkyl radical,
in these definitions, the alkyl radicals and
portions contain 1 to 6 straight- or
branched-chain carbon atoms, and, when
they contain one or more asymmetric
centres, their optical isomers, racemates
and enantiomers and their salts with an
inorganic or organic acid.
__________
]11[]21[
853
134593
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫תכשירי רוקחות המכילים גן המקודד חלבון‬
‫אינטרפרון–בטא‬
]54[
PHARMACEUTICAL
COMPOSITIONS COMPRISING A
GENE THAT ENCODES
INTERFERON BETA PROTEIN
]22[
]31[
]51[
]71[
]87[
]74[
25.08.1998
60/057254
]32[ 29.08.1997
]33[ US
Int. Cl.8 A61K 048/00, C07K 014/555, C12N 005/06, 015/20
BIOGEN IDEC MA INC., U.S.A.
WO/1999/010516
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
[57] Use of a viral vector comprising a
gene that encodes interferon-beta protein
for the preparation of a medicament for the
treatment of cancer, substantially as
described in the specification wherein
(a) said interferon-beta protein is expressed
from said gene; and
(b) said viral vector is selected from the
group consisting of an adenoviral vector, a
lentiviral vector, a baculoviral vector, an
Epstein Barr viral vector, a papovaviral
vector, a vaccinia viral vector, and a herpes
simplex viral vector.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
134851
854
‫ תכשירי‬,‫אגוניסטים של פרוסטגלנדין‬
‫רוקחות המכילים אותם ושימושם בהכנת‬
‫תרופות לטיפול במחלות של העצם‬
]54[
PROSTAGLANDIN AGONISTS,
PHARMACEUTICAL
COMPOSITIONS COMPRISING
THEM AND THEIR USE IN THE
PREPARATION OF
MEDICAMENTS FOR TREATING
BONE DISORDERS
]22[
]31[
]51[
05.10.1998
60/061727
]32[ 10.10.1997
]33[ US
Int. Cl.8 A61K 031/10, 031/16, 031/33, A61P 019/10, C07C 233/46, 317/14, 323/31,
C07D 211/08, 213/24, 213/60, 215/12, 215/16, 217/12, 217/22, 231/12, 233/20,
237/08, 239/26, 239/28, 263/30, 277/20, 277/60, 311/04, 319/18, 333/06, 401/12,
403/12, 405/12, 409/12, 413/12, 417/12, 471/00, 487/00
PFIZER INC., U.S.A.
WO/1999/019300
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]71[
]87[
]74[
[57] A compound of the formula
prodrugs thereof and the pharmaceutically
acceptable salts of said compounds and
said prodrugs, wherein
A is SO2 or CO;
G is Ar, AR1-V-Ar2, Ar-(C1-C6) alkylene,
Ar-CONH-(C1-C6) alkylene, R1R2-amino,
oxy(C1-C6) alkylene, amino substituted
with Ar, or amino substituted with Ar(C1C6) alkylene, amino substituted with Ar, or
amino substituted with Ar (C1-C4) alkylene
and R11, wherein R11 is H or (C1-C8) alkyl,
R1 and R2 may be taken separately and are
independently selected from H and (C1-C8)
alkyl, or R1 and R2 are taken together with
the nitrogen atom of the amino group to
form a five- or six-membered
azacycloalkyl, said azacycloalkyl
optionally containing an oxygen atom and
optionally mono, di- or tri-substituted
independently with up to two oxo,
855
hydroxy, (C1-C4) alkyl, fluoro or chloro;
B is N or CH;
Q is
-(C2-C6) alkylene-W-(C1-C3) alkylene-,
said alkylenes each optionally substituted
with up to four substituents independnently
selected from fluoro or (C1-C4) alkyl, (C4C8) alkylene-, said alkylene optionally
substituted with up to four substituents
independently selected from fluoro or (C1C4) alkyl,
-X- (C1-C5) alkylene-, said alkylene
optionally substituted with up to four
substituents independently selected from
fluoro or (C1-C4) alkyl, -(C1-C5) alkyleneX-, said alkylene optionally substituted
with up to four substituents independently
selected from fluoro or (C1-C4) alkyl, -(C1C3) alkylene-X-(C1-C3) alkylene-, said
alkylenes each optionally substituted with
June 17, 2007 – ‫א' בתמוז התשס"ז‬
up to four substituents independently
selected from fluoro or (C1-C4) alkyl, -(C2C4) alkylene-W-X-(C0-C3) alkylene-, said
alkylenes each optionally substituted with
up to four substituents each independently
selected from fluoro or (C1-C4) alkyl,
-(C0-C4) alkylene-X-W-(C1-C3) alkylene-,
said alkylenes each optionally substituted
with up to four substituents each
independently selected from fluoro or (C1C4) alkyl, -(C2-C5) alkylene-W-X-W-(C1C3) alkylene-, wherein the two occurrences
of W are independent of each other, said
alkylenes each optionally substituted with
up to four substituents each independently
selected from fluoro or (C1-C4) alkyl, -(C1C4) alkylene-ethenylene-(C1-C4) alkylene-,
said alkylenes and said ethenylene each
optionally substituted with up to four
substituents each independently selected
from fluoro or (C1-C4) alkyl, -(C1-C4)
alkylene-ethenylene-(C0-C2) alkylene-X(C0-C5) alkylene-, said alkylenes and said
ethenylene each optionally substituted with
up to four substituents each independently
selected from fluoro or (C1-C4) alkyl, -(C1C4) alkylene-ethenylene-(C0-C2) alkyleneX-W-(C1-C3) alkylene-, said alkylenes and
said ethenylene each optionally substituted
with up to four substituents each
independently selected from fluoro or (C1C4) alkyl, -(C1-C4) alkylene-ethynylene(C1-C4) alkylene-, said alkylenes and said
ethynylene each optionally substituted
with up to four substituents each
independently selected from fluoro or (C1C4) alkyl, or -(C1-C4) alkylene-ethynyleneX-(C0-C3) alkylene-, said alkylenes and
said ethynylene each optionally substituted
with up to four substituents each
independently selected from fluoro or (C1C4) alkyl;
Z is carboxyl, (C1-C6) alkoxycarbonyl,
tetrazolyl, 1,2,4-oxadiazolyl, 5-oxo- 1,2,4oxadiazolyl, 5-oxo-1,2,4-thiadiazolyl, (C1C4) alkylsulfonylcarbamoyl or
phenylsulfonylcarbamoyl;
June 17, 2007 – ‫א' בתמוז התשס"ז‬
K is a bond, (C1-C9) alkylene, thio (C1-C4)
alkylene, (C1-C4) alkylenethio (C1-C4)
alkylene, (C1-C4) alkyleneoxy (C1-C4)
alkylene or oxy (C1-C4) alkylene, said (C1C9) alkylene optionally mono-unsaturated
and wherein, when K is not a bond, K is
optionally mono-, di- or tri-substituted
independently with chloro, fluoro, hydroxy
or methyl;
M is –Ar3, -Ar4-V1-Ar5, -Ar4-S-Ar5, -Ar4SO-Ar5, -Ar4-SO-Ar5 or –Ar4-O-Ar5;
Ar is a partially saturated or fully
unsaturated five to eight membered ring
optionally having one to four heteroatoms
selected independently from oxygen, sulfur
and nitrogen, or a bicyclic ring consisting
of two fused independently partially
saturated, fully saturated or fully
unsaturated five or six membered rings,
taken independently, optionally having one
to four heteroatoms selected independently
from nitrogen, sulfur and oxygen, or a
tricyclic ring consisting of three fused
independently partially saturated, fully
saturated or fully unsaturated five or six
membered rings, taken independently,
optionally having one to four heteroatoms
selected independently from nitrogen,
sulfur and oxygen, said partially or fully
saturated ring, bicyclic ring or tricyclic
ring optionally having one or two oxo
groups substituted on carbon or one or two
oxo groups substituted on sulfur; or Ar is a
fully saturated five to seven membered
ring having one or two heteroatoms
selected independently from oxygen, sulfur
and nitrogen;
Ar1 and Ar2 are each independently a
partially saturated, fully saturated or fully
unsaturated five to eight membered ring
optionally having one to four heteroatoms
selected independently from oxygen, sulfur
and nitrogen, or a bicyclic ring consisting
of two fused independently partially
saturated, fully saturated or fully
unsaturated five or six membered rings,
taken independently, optionally having one
to four heteroatoms selected independently
856
from nitrogen, sulfur and oxygen, or a
tricyclic ring consisting of three fused
independently partially saturated, fully
saturated or fully unsaturated five or six
membered rings, optionally having one to
four heteroatoms selected independently
from nitrogen, sulfur and oxygen, said
partially or fully saturated ring, bicyclic
ring or tricyclic ring optionally having one
or two oxo groups substituted on carbon or
one or two oxo groups substituted on
sulfur;
said Ar, Ar1 and Ar2 moieties are
optionally substituted on carbon or
nitrogen, on one ring if the moiety is
monocyclic, on one both rings if the
moiety is bicyclic, or on one, two or three
rings if the moiety is tricyclic, with up to
three substitutents per moiety
independently hydroxy, nitro, halo,
carboxy, (C1-C7) alkoxy, (C1-C4) alkoxy
(C1-C4) alkyl, (C1-C4) alkoxycarbonyl, (C1C7) alkyl, (C2-C7) alkenyl, (C2-C7) alkynyl,
(C3-C7) cycloalkyl, (C3-C7) cycloalkyl (C1C4) alkyl, (C3-C7) cycloalkyl (C1-C4)
alkanoyl, formyl, (C1-C8) alkanoyl, (C1-C6)
alkanoyl (C1-C6) alkyl, (C1-C4)
alkanoylamino, (C1-C4)
alkoxycarbonylamino, hydroxysulfonyl,
aminocarbonylamino or mono-N-, di-N,N, di-N,N'- or tri-N,N,N'-(C1-C4) alkyl
substituted aminocarbonylamino,
sulfonamide, (C1-C4) alkylsulfonamido,
amino, mono-N- or di-N,N-(C1-C4)
alkylamino, carbamoyl, mono -N- or di-N,
N-(C1-C4) alkylcarbamoyl, cyano, thiol,
(C1-C6) alkylthio, (C1-C6) alkylsulfinyl,
(C1-C4) alkylsulfonyl or mono-N- or diN,N-(C1-C4) alkylaminosulfinyl;
Ar3, Ar4 and Ar5 are each independently a
partially saturated, fully saturated or fully
unsaturated five to eight membered ring
optionally having one to four heteroatoms
selected independently from oxygen, sulfur
and nitrogen, or a bicyclic ring consisting
of two fused independently partially
saturated, fully saturated or fully
unsaturated five or six membered rings,
857
taken independently, optionally having one
to four heteroatoms selected independently
from nitrogen, sulfur and oxygen, or a
tricyclic ring consisting of three fused
independently partially saturated, fully
saturated or fully unsaturated five or six
membered rings, optionally having one to
four heteroatoms selected independently
from nitrogen, sulfur and oxygen, said
partially or fully saturated ring, bicyclic
ring or tricyclic ring optionally having one
or two oxo groups substituted on carbon or
one or two oxo groups substituted on
sulfur;
said Ar3, Ar4 and Ar5 moieties are
optionally substituted on carbon or
nitrogen, on one ring if the moiety is
monocyclic, on one or both rings if the
moiety is bicyclic, or on one, two or three
rings if the moiety is tricyclic, with up to
three substituents per moiety
independently selected from R31, R41 and
R51 wherein R31, R41 and R51 are
independently hydroxy, nitro, halo,
carboxy, (C1-C7) alkoxy, (C1-C4) alkoxy
(C1-C4) alkyl, (C1-C4) alkoxycarbonyl, (C1C7) alkyl, (C2-C7) alkenyl, (C2-C7) alkynyl,
(C3-C7) cycloalkyl, (C3-C7) cycloalkyl (C1C4) alkyl, (C3-C7) cycloalkyl (C1-C4)
alkanoyl, formyl, (C1-C8) alkanoyl, (C1-C6)
alkanoyl (C1-C6) alkyl, (C1-C4)
alkanoylamino, (C1-C4)
alkoxycarbonylamino, hydroxysulfonyl,
aminocarbonylamino or mono-N-, di-N,N, di-N,N'- or tri-N,N,N'-(C1-C4) alkyl
substituted aminocarbonylamino,
sulfonamido, (C1-C4) alkylsulfonamido,
amino, mono-N- or di-N,N-(C1-C4)
alkylamino, carbamoyl, mono -N- or diN,N-(C1-C4) alkylcarbamoyl, cyano, thiol,
(C1-C6) alkylthio, (C1-C6) alkylsulfinyl,
(C1-C4) alkylsulfonyl or mono-N-or diN,N-(C1-C4) alkylaminosulfinyl;
W is oxy, thio, sulfino, sulfonyl,
aminosulfonyl-, mono-N-(C1-C4)
alkyleneaminosulfonyl-, sulfonylamino, N(C1-C4) alkylenesulfonylamino,
carboxamido,N-(C1-C4)
June 17, 2007 – ‫א' בתמוז התשס"ז‬
alkylenecarboxamido, carboxamidooxy,
N-(C1-C4)alkylenecarboxamidooxy,
carbamoyl, -mono-N-(C1-C4)
alkylenecarbamoyl,
carbamoyloxy, or-mono-N-(C1-C4)
alkylenecarbamoyloxy, wherein said W
alkyl groups are optionally substituted on
carbon with one to three fluorines;
X is a five or six membered aromatic ring
optionally having one or two heteroatoms
selected independently from oxygen,
nitrogen, and sulfur, said ring optionally
mono-, di- or tri-substituted independently
with halo, (C1-C3) alkyl, triluoromethyl,
trifluoromethyloxy, difluromethyloxy,
hydroxyl, (C1-C4) alkoxy, or carbamoyl;
R1, R2, R3, R4, R5, R11, R31, R41 and R51,
when containing an alkyl, alkylene,
alkenylene or alkynylene moiety, are
otionally mono-, di- or tri-substituted on
carbon independently with halo or
hydroxy; and V and V1 are each
independently a bond, thio (C1-C4)
alkylene, (C1-C4)alkylenethio, (C1-C4)
alkyleneoxy, oxy (C1-C4) alkylene or (C1C3) alkykene optionally mono- or disubstituted independently with hydroxy or
fluoro;
with the provisos that:
(a) when K is (C2-C4) alkylene and M is
Ar3 and Ar3 is cyclopent-1-yl, cyclohex-1yl, cyclohept-1-yl or cyclooct-1-yl then
said (C5-C8) cycloalkyl substituents are not
substituted at the one position with
hydroxy; and
(b) when K is a bond; G is phenyl,
phenylmethyl, substituted phenyl or
substituted phenylmethyl; Q is (C3-C8)
alkylene; and M is Ar3 or Ar4-Ar5, then A
is sulfonyl.
__________
]11[]21[
135103
,‫–אזאקוינוקסלין‬5 ‫תרכובות המבוססות על‬
‫שיטה להכנתן ושימוש בהן להכנת תרופות‬
]54[
5-AZAQUINOXALINE-BASED
COMPOUNDS, A METHOD FOR
THEIR PREPARATION AND USE
THEREOF FOR PREPARING
MEDICAMENTS
]22[
]31[
]51[
]71[
]87[
]74[
05.10.1998
60/061123
]32[ 06.10.1997
]33[ US
Int. Cl.8 A61K 031/4985, A61P 035/00, C07D 471/04, C12P 017/18
ZENTARIS GMBH, GERMANY
WO/1999/017759
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
[57] A 5-azaquinoxaline-based
compound of the formula
June 17, 2007 – ‫א' בתמוז התשס"ז‬
858
wherein
(a) R1, R2, R3, R4 and R6 are
independently selected from the group
consisting of
(i) hydrogen;
(ii) saturated or unsaturated aliphatic
hydrocarbon
optionally substituted with a fivemembered or six-membered aryl or
heteroaryl ring moiety, wherein said ring
moiety is optionally substituted with one,
two, or three substituents independently
selected from the group consisting of alkyl,
halogen, trihalomethyl, nitro, and ester
moieties;
(iii) an amine of formula NX2X3, where X2
and X3 are independently selected from the
group consisting of hydrogen, saturated or
unsaturated aliphatic hydrocarbon, and
five-membered or six-membered aryl or
heteroaryl ring moieties;
(iv) halogen or trihalomethyl;
(v) a ketone of formula –CO-X4, wherein
X4 is selected from the group consisting of
alkyl, and five-membered or six-membered
aryl or heteroaryl moieties;
(vi) a carboxylic group of formula-(X5)nCOOH or ester moiety of formula-(X6)nCOO-X7, wherein X5, X6 and X7 are
independently selected from the group
consisting of alkyl and five-membered or
six-membered aryl or heteroaryl moieties
and where n is 0 or 1;
(vii) an alcohol moiety of formula –(X8)nOH or an alkoxy moiety of formula (X8)n –
O-(X9), where X8 and X9 are
independently selected from the group
consisting of saturated or unsaturated
aliphatic hydrocarbon, and five-membered
or six membered aryl or heteroaryl ring
moieties, wherein said ring is optionally
substituted with one or more substituents
independently selected from the group
consisting of alkyl, halogen, trihalomethyl,
nitro, and ester and where n is 0 or1;
(viii) an amido group of formula –
NHCOX10, where X10 is selected from the
group consisting of alkyl, hydroxyl, and
five-membered or six-membered aryl or
heteroaryl ring moieties, wherein said ring
is optionally substituted with or more
substituents independently selected from
the group consisting of alkyl, alkoxy,
halogen, trihalometyl, nitro, or ester;
(ix) –SO2NX11X12, where X11 and X12 are
independently selected from the group
consisting of hydrogen, alkyl, and fivemembered or six-membered aryl or
heteroaryl ring moieties;
(x) a five-membered or six-membered aryl
or heteroaryl ring moiety optionally
subsituted with one, two, or three
substituents independently selected from
the group consisting of alkyl, halogen,
trihalomethyl, nitro, and ester moieties;
(xi) a formyl group of formula –CO-H; and
(xii) a sulfonyl group of formula –SO2-X13,
where X13 is selected from the group
consisting of saturated or unsaturated
aliphatic hydrocarbon and five-membered
or six-membered aryl or heteroaryl
moieties; and
(b) X1 is selected from the group
consisting of –NH-,sulfur and oxygen.
__________
]11[]21[
859
135458
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫ הומני בעל אפיניות נמוכה‬A ‫ריבונוקלאז‬
‫לעיכוב ריבונוקלאז‬
]54[
HUMAN RIBONUCLEASE A WITH
REDUCED RIBONUCLEASE
INHIBITOR AFFINITY
]22[
]31[
]51[
]71[
13.10.1998
08/950866
]32[ 15.10.1997
]33[ US
Int. Cl.8 A61K 038/46, C12N 009/22, 015/55
WISCONSIN ALUMNI RESEARCH
FOUNDATION, U.S.A.
WO/1999/019494
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] An engineered ribonuclease of the
RNase A superfamily having at least one
amino acid substitution in a loop region
functionally equivalent to amino acid
residues 85-94 of bovine pancreatic Rnase
A, the engineered ribonuclease having
reduced binding affinity for ribonuclease
inhibitor, the modified robonuclease
retaining ribonucleolytic activity.
__________
]11[]21[
135786
‫ יחידות נתונים‬,‫שיטה לשידור של מעגלים‬
‫ אלחוטית‬/ ‫ לווינית‬TDMA ‫ותאים במערכת‬
]54[
METHOD FOR TRANSMISSION
OF CIRCUITS, PACKETS AND
CELLS IN A
SATELLITE/WIRELESS TDMA
SYSTEM
]22[
]31[
20.10.1998
60/062496
]32[ 20.10.1997
]33[ US
60/064673
20.10.1997
US
60/062497
20.10.1997
US
Int. Cl.8 H04B 007/005, 007/015, 007/185, 007/204, 007/212, H04J 003/00, 003/06,
H04L 005/22, 007/033, 007/10, H04Q 007/38
VIASAT, INC., U.S.A.
WO/1999/021296
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]51[
]71[
]87[
]74[
[57] An assembly of signals for a
transmission architecture in a time division
multiple access (TDMA) system for
satellite or wireless communication
June 17, 2007 – ‫א' בתמוז התשס"ז‬
comprising: at least one carrier;
a plurality of frames, said frames being
transmitted on said carriers;
one or more bursts contained within said
frames including:
860
a preamble portion;
a data portion including one or more
channels, and a postamble portion, wherein
each of said one or more channels is
divided into one or more protocol data
units and a number of check bits, said
protocol data units carrying circuit data,
ATM-type cell data and packet data.
__________
]11[]21[
136738
‫שימוש באוריאות הטרוציקליות מותמרות‬
‫להכנת תרופות לטיפול במחלה שאינה‬
p38 ‫סרטן המתווכת על ידי‬
]54[
USE OF SUBSTITUTED
HETEROCYCLIC UREAS FOR
THE PREPARATION OF
MEDICAMENTS FOR TREATING
A DISEASE MEDIATED BY P38
OTHER THAN CANCER
]22[
]31[
]51[
22.12.1998
08/995750
]32[ 22.12.1997
]33[ US
Int. Cl.8 A61K 031/34, 031/38, 031/395, 031/415, 031/42, 031/425, 031/535, 031/54,
C07D 231/38, 257/06, 261/14, 263/48, 271/07, 277/38, 277/44, 285/08, 307/66,
333/36, 401/12, 403/12, 405/12, 409/12, 417/12
BAYER PHARMACEUTICALS
CORPORATION, U.S.A.
WO/1999/032111
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]71[
]87[
]74[
[57] Use of a compound of the formula
861
June 17, 2007 – ‫א' בתמוז התשס"ז‬
wherein B is a substituted or unsubstituted,
up to tricyclic, aryl or heteroaryl moiety of
up to 30 carbon atoms with at least one 5or 6-membered aromatic structure
containing 0-4 members of the group
consisting of nitrogen, oxygen and sulfur,
wherein if B is a substituted group, it is
substituted by one or more substituents
independently selected from the group
consisting of halogen, up to perhalosubstitution, and Xn, wherein n is 0-3
and each X is independently selected from
the group consisting of –CN, -CO2R5, C(O)NR5R5', -C(O)R5, -NO2, -OR5, -SR5, NR5R5',
-NR5C(O)OR5', -NR5C(O)R5', C1-C10 alkyl,
C2-C10 alkenyl, C1-C10 alkoxy, C3-C10
cycloalkyl, C6-C14 aryl, C7-C24 alkaryl, C3C13 heteroaryl, C4-C23 alkheteroaryl,
substituted C1-C10 alkyl, substituted C2-C10
alkenyl, substituted C1-C10 alkoxy,
substituted C3-C10 cycloalkyl, substituted
C4-C23 alkheteroaryl and –Y-Ar;
wherein if X is a substituted group, it is
substituted by one or more substituents
independently selected from the group
consisting of –CN, -CO2R5, -C(O)R5, C(O)NR5R5', -OR5, -SR5, -NR5R5', -NO2, NR5C(O)R5', -NR5C(O)OR5' and halogen
up to per-halosubstitution;
wherein R5 and R5' are independently
selected from H, C1-C10 alkyl, C2-C10
alkenyl, C3-C10 cycloalkyl, C6-C14 aryl, C3C13 heteroaryl, C7-C24 alkaryl, C4-C23
alkheteroaryl, up to per-halosubstituted C1C10 alkyl, up to per-halosubstituted C3-C10
cycloalkyl, up to per-halosubstituted C2C10 alkenyl, up to per-halosubstituted C6-
June 17, 2007 – ‫א' בתמוז התשס"ז‬
C14 aryl and up to per-halosubstituted C3C13 heteroaryl,
wherein Y is –O-; -S-; -N(R5)-, -(CH2)-m, C(O)-, -CH(OH)-, (CH2)mO-,
-(CH2)mS-, -(CH2)mN(R5)-, -O(CH2)m-, CHXa-,
-C(O)NR5-, -CXa2-, -S-(CH2)m-and –
N(R5)(CH2)m-,
m = 1-3, and Xa is halogen; and
Ar is a 5-10 member aromatic structure
containing 0-4 members of the group
consisting of nitrogen, oxygen and sulfur
which is unsubstituted or substituted by
halogen up to per-halosubsitution and
optionally substituted by Zn1,
wherein n1 is 0 to 3 and each Z is
independently selected from the group
consisting of –CN, -CO2R5, -C(O)NR5R5',
NO2, =O, -OR5, -SR5,NR5R5', -C(O)R5, -SO2R5, -SO2NR5R5', NR5C(O)OR5', -NR5C(O)R5', C1-C10 alkyl,
C1-C10 alkoxy, C3-C10 cycloalkyl, C6-C14
aryl, C3-C13 heteroaryl, C7-C24 alkaryl, C4C23 alkheteroaryl, substituted C1-C10 alkyl,
substituted C3-C10 cycloalkyl, substituted
C7-C24 alkaryl and substituted C4-C23
alkheteroaryl;
wherein if Z is a substituted group, it is
substituted by the one or more substituents
independently selected from the group
consisting of –CN, -CO2R5,
-C(O)R5', -C(O)NR5R5', =O, -OR5, -SR5, NO2, -NR5R5', -NR5C(O)R5',
-NR5C(O)OR5', C1-C10 alkyl, C1-C10
alkoxy, C3-C10 cycloalkyl, C1-C10
heteroaryl, C6-C14 aryl, C4-C24
alkheteroaryl and C7-C24 alkaryl;
A is a heteroaryl moiety selected from the
group consisting of
862
wherein
R1 is selected from the group consisting of
halogen, C3-C10 alkyl, C3-C10 cycloalkyl,
C1-C13 heteroaryl, C6-14 aryl, C7-24 alkaryl,
up to per-halosubsituted C1-C10 alkyl, up
to per-halosubstituted C3-C10 cycloalkyl,
up to per-halosubstituted C1-C13
heteroaryl, up to per-halosubstituted C6-14
aryl, and up to per-halosubstituted C7-24
alkaryl;
R2 is selected from the group consisting of
H, -C(O)R4, -CO2R4, -C(O)NR3R3',
C1-C10 alkyl, C3-C10 cycloalkyl, C7-C24
alkaryl, C4-C23 alkheteroaryl, substituted
C1-C10 alkyl, substituted C3-C10 cycloalkyl,
substituted C7-C24 alkaryl and substituted
C4-C23 alkhetaroaryl,
where R2 is a substituted group, it is
substituted by one or more substituents
independently selected from the group
consisting of –CN, -CO2R4, -C(O)-NR3R3',
-NO2, -OR4, -SR4, and halogen up to perhalosubstitution, wherein R3 and R3' are
independently selected from the group
consisting of H, -OR4, -SR4, -NR4R4', C(O)R4, -CO2R4, -C(O)NR4R4', C1-C10
alkyl, C3-C10 cycloalkyl,
C6-C14 aryl, C3-C13 heteroaryl, C7-C24
alkaryl,C4-C23 alkheteroaryl, up to perhalosubstituted C1-C10 alkyl, upt to perhalosubstituted C3-C10 cycloalkyl, up to
per-halosubstituted C6-C14 aryl and up to
per-halosubstituted C3-C13 heteroaryl; and
wherein R4 and R4' are independently
selected from the group consisting of H,
C1-C10 alkyl, C3-C10 cycloalkyl, C6-C14
aryl, C3-C13 heteroaryl; C7-C24 alkaryl, C4C23 alkheteroaryl, up to per-halosubstituted
C1-C10 alkyl, up to per-halosubstituted C3C10 cycloalkyl, up to per-halosubstituted
C6-C14 aryl and up to per-halosubstituted
C3-C13 heteroaryl,
Ra is C1-C10 alkyl, C3-C10 cycloalkyl, up to
per-halosubstituted C1-C10 alkyl and up to
per-halosubsituted C3-C10 cycloalkyl; and
Rb is hydrogen or halogen, Rc is hydrogen,
halogen, C1-C10 alkyl, up to perhalosubstituted C1-C10 alkyl or combines
with R1 and the ring carbon atoms to
which R1 and Rc are bound to form a 5- or
6-membered cycloalkyl, aryl or hetaryl
ring with 0-2 members selected from O, N
and S; for the preparation of a medicament
for the treatment of a disease other than
cancer mediated by p38.
__________
]11[]21[
863
137178
June 17, 2007 – ‫א' בתמוז התשס"ז‬
IL–18 ‫קולטני‬
]54[
IL-18 RECEPTORS
]22[
]31[
22.01.1999
60/072301
]32[ 23.01.1998
]33[ US
60/078835
20.03.1998
US
60/094469
28.07.1998
US
Int. Cl.8 A61K 038/17, C07K 014/715, 016/28, 019/00, C12N 015/12, 015/62
IMMUNEX CORPORATION, U.S.A.
WO/1999/037772
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] A receptor comprising at least one
IL-1Rrp1 polypeptide linked to at least one
AcPL polypeptide, wherein said IL-1Rrp1
polypeptide is encoded by a DNA selected
from the group consisting of:
(a) DNA comprising a nucleotide sequence
selected from the group consisting of the
coding region of the nucleotide sequence
presented in SEQ ID NO:3 and the coding
region of the nucleotide sequence
presented in SEQ ID NO:7;
(b) DNA that is complementary to DNA
capable of hybridizing to the DNA of (a),
wherein hybridizing conditions include
prewashing with 5X SSC, 0.5% SDS,
1.0mM EDTA (pH8.0) and hybridizing at
55oC and 5XSSC overnight; and,
(c) DNA selected from the group
consisting of: DNA that encodes a
polypeptide comprising the amino acid
sequence presented in SEQ ID NO:4 and
DNA that encodes a polypeptide
comprising the amino acid sequence
presented in SEQ ID NO:8; and, wherein
said AcPL polypeptide is encoded by a
DNA selected from the group consisting
of:
(a) DNA comprising a nucleotide sequence
selected from the group consisting of the
coding region of the nucleotide sequence
presented in SEQ ID NO:1 and the coding
region of the nucleotide sequence
presented in SEQ ID NO:5;
(b) DNA that is complementary to DNA
capable of hybridizing to the DNA of (a),
wherein hybridizing conditions include
prewashing with 5X SSC, 0.5% SDS,
1.0mM EDTA (pH 8.0) and hybridizing at
55oC and 5X SSC overnight, and
(c) DNA selected from the group
consisting of: DNA that encodes a
polypeptide comprising the amino acid
sequence presented in SEQ ID NO:2 and
DNA that encodes the amino acid
sequence presented in SEQ ID NO:6.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
137199
864
]54[
ADAPTIVE PACKET
COMPRESSION APPARATUS AND
METHOD
]22[
]31[
]51[
]71[
]72[
]87[
]74[
21.01.1999
09/013980
]32[ 27.01.1998
Int. Cl.8 H03M 007/30, 007/40, 007/46
EXPAND NETWORKS LTD.
NIR KALKSTEIN
WO/1999/038286
DR. MARK FRIEDMAN LTD.,
BEIT SAMUELOFF, 7 HAOMANIM
STREET,
TEL AVIV
[57] A method for compressing each of a
plurality of data packets to form a
compressed packet for transmission by a
communication device, the data packets
being composed of a sequence of data
elements and the data packets being stored
on a first computer such that the method is
performed by the first computer, the
method comprising the steps of:
(a) receiving one of said plurality of data
packets designated as packet Pni;
(b) parsing said packet Pm, such that the
sequence of data elements of said packet
Pm is parsed into a sequence of parsed
elements, each of said parsed elements
having a form selected from the group
consisting of a character, a pair of offset
and length components, and a run length
encoding consisting of a repetition factor
component and a character component,
and each of parsed elements and each of
said components of said parsed elements
having a frequency of occurrence;
865
‫שיטה ומתקן עבור דחיסה אדפטיבית של‬
‫מקבצים‬
]33[
US
‫אקספנד נטוורקס בע"מ‬
‫ניר קלקשטיין‬
,‫ד"ר מרק פרידמן בע"מ‬
‫ תל אביב‬,7 ‫ רח' האומנים‬,‫בית שמואלוב‬
(c) selecting an encoding table from a
historical array, said historical array
including at least one encoding table from
compression of at least one previously
compressed data packet, said encoding
table having been constructed according to
the frequencies of occurrence of a plurality
of parsed elements of said at least one
previously compressed data packet,
independent of data from said packet Pm;
(d) encoding said sequence of parsed
elements according to said encoding table
to form encoded data;
(e) packaging said encoded data into the
compressed packet;
(f) constructing a historical frequency list
of the frequencies of occurrence of said
parsed elements;
(g) constructing an additional encoding
table according to the frequencies of
occurrence of said parsed elements; and
(h) storing said additional encoding table
in said historical array.
June 17, 2007 – ‫א' בתמוז התשס"ז‬
___________
]11[]21[
]54[
VECTOR MAPPING OF THREEDIMENSIONALLY
RECONSTRUCTED INTRABODY
ORGANS AND METHOD OF
DISPLAY
]22[
]31[
]51[
]71[
]74[
16.07.2000
09/357559
]32[ 22.07.1999
Int. Cl.8 A61B 005/042
BIOSENSE, INC., U.S.A.
DR. SHLOMO COHEN & CO.,
124 IBN GABIROL ST.,
P.O.B. 11490,
TEL AVIV 62038
[57] A method of displaying a condition
in a heart, comprising the steps of:
(a) creating a map of a surface of the
heart;
(b) measuring a physiological response at
at least three sampled points on the surface
of the heart;
June 17, 2007 – ‫א' בתמוז התשס"ז‬
137322
‫מיפוי ווקטורי של איברים תוך גופיים שנבנו‬
‫ממדית ושיטה‬-‫מחדש בצורה תלת‬
‫להצגתם‬
]33[
US
,'‫ד"ר שלמה כהן ושות‬
‫ תל אביב‬,11490 .‫ד‬.‫ ת‬, 124 ‫אבן גבירול‬
(c) calculating a vector function related to
said response; and
(d) displaying a representation of said
vector function on said map.
866
]11[]21[
137449
‫תרכיב חי נגד ברוסללוסיס‬
]54[
LIVE VACCINE AGAINST
BRUCELLOSIS
]22[
]31[
]51[
]71[
21.01.1999
09/010877
]32[ 22.01.1998
]33[ US
Int. Cl.8 C07K 014/23, C12N 001/21, 015/31, 015/74
WALTER REED ARMY INSTITUTE
OF RESEARCH, U.S.A.
WO/1999/037783
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]87[
]74[
[57] An isolated Brucella DNA fragment
having the nucleotide sequence of SEQ ID
NO:1 modified to contain a non-reverting
deletion of nucleotides form position 1063
to 1670, which fragment when stably
inserted into a Brucella cell in a Brucella
vaccine will result in a Brucella vaccine
that does not cause seroconversion in a
vaccine exposed thereto.
Also claimed is an isolated Brucella DNA
fragment comprising at least 30 contiguous
nucleotides of the nucleotide sequence of
SEQ ID NO:1.
__________
]11[]21[
137522
‫ של‬E2 ‫נוגדן חד שבטי אנושי גליקופרוטאין‬
HCV
]54[
HUMAN MONOCLONAL
ANTIBODY AGAINST
HEPATITIS C VIRUS E2
GLYCOPROTEIN
]22[
]51[
]71[
26.07.2000
Int. Cl.8 A61K 039/42, C07K 016/10, C12N 005/12
DRK-BLUTSPENDEDIENDST
BADEN-WUERTTEMBERGHESSEN GEMEINNUTZIGE GMBH,
GERMANY
SHLOMO DAGAN, RACHEL EREN,
‫סילבה‬-‫ מרסיה דה‬,‫ רחל ארן‬,‫שלמה דגן‬
MARCIA DA SILVA CARDOSO,
‫ ברנרד קובנק‬,‫ קרל סימונייט‬,‫קרדוזו‬
KARL SIEMONEIT, BERNHARD
KUBANEK
REINHOLD COHN AND
,‫ריינהולד כהן ושותפיו‬
PARTNERS,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]72[
]74[
867
June 17, 2007 – ‫א' בתמוז התשס"ז‬
[57] A human monoclonal antibody being
selected from the group consisting of:
(a) a human monoclonal antibody capable
of binding to HCV envelope glycoproteins
and capable of neutralizing HCV infection
in vivo;
(b) a human monoclonal antibody HCVAB68, which is secreted by the hybridoma
cell line deposited in the European
Collection of Cell Cultures (ECACC)
under Accession No. 00051714, or a
fragment thereof which retains the antigen
binding characteristics of HCV-AB68.
__________
]11[]21[
137564
HGF– ‫חלבונים רקומביננטים הנגזרים מ‬
‫ שימושים בהם ותהליכים‬,MSP ‫או‬
‫להכנתם‬
]54[
RECOMBINANT PROTEINS
DERIVED FROM HGF AND MSP,
USES THEREOF AND PROCESSES
FOR THEIR PRODUCTION
]22[
]31[
]51[
]71[
]87[
]74[
27.01.1999
MI98A000179 ]32[ 30.01.1998
]33[ IT
Int. Cl.8 A61K 038/18, C07K 014/475, 019/00, C12N 015/12
DOMPE PHA.R.MA S.P.A., ITALY
WO/1999/038967
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
[57] Recombinant proteins comprising
two superdomains, separated by a spacer
sequence (linker), each superdomain
consisting of a combination of HL and K1K4 domains derived from the alpha chain
of either HGF or MSP, of the formula
[A] – [B] – [C] –(D)y(I)
in which
[A] corresponds to the sequence (LS) mHL-K1-(K2)n-(K3)o-(K4)p
wherein: the numbering of the following
amino acids refers to the HGF and MSP
sequences as sequences in Fig. 1 and 2, of
the specification respectively LS is an
amino acid sequence corresponding to
residues 1-31 of HGF or 1-18 of MSP;
HL is an amino acid sequence starting
between residues 32-70 of HGF α chain
and ending between residues 96-127 of the
identical chain; or it is an amino acid
sequence starting between residues 19-56
June 17, 2007 – ‫א' בתמוז התשס"ז‬
of MSP α chain and ending between
residues 78-109 of the identical chain;
K1 is an amino acid sequence starting
between residues 97-128 of HGF α chain
and ending between residues 201-205 of
the identical chain; or it its an amino acid
sequence starting between residues 79-110
of MSP α chain and ending between
residues 186-190 of the identical chain;
K2 is an amino acid sequence starting
between residues 202-206 of HGF α chain
and ending between residues 283-299 of
the identical chain; or it is an amino acid
sequence starting between residues 187-
868
191 of MSP α chain and ending between
residues 268-282 of the identical chain; K3
is an amino acid sequence starting between
residues 284-300 of HGF α chain and
ending between residues 378-385 of the
identical chain; or it is an amino acid
sequence starting between residues 269283 of MSP α chain and ending between
residues 361-360 of the identical chain;
K4 is an amino acid sequence starting
between residues 379-386 of HGF α chain
and ending between residues 464-487 of
the identical chain; or it is an amino acid
sequence starting between residues 362370 of MSP α chain and ending between
residues 448-481 of the identical chain; m,
n, o, p are 0 or 1;
the sum n + o + p is an integer from 1 to 3
or 0, with the proviso that n ≥ o ≥ p;
B is the sequence [(X)q Y]r wherein X =
Gly and Y = Ser, or Cys, or Met, or Ala;
q is an integer from 2 to 8;
r is an integer from 1 to 9;
[C] corresponds to the sequence HL-KL(K2),-(K3)-(K4)n
wherein HL, K1-K4 are as defined above,
s, t, u are 0 or 1; the sum s + t + u is a
integer from 1 to 3 or 0, with the proviso
that s ≥ t ≥ u;
D is the sequence W-Z, wherein W is a
conventional proteolytic site, Z is any tag
sequence useful for the purification and
detection of the protein; y is 0 or 1.
__________
]11[]21[
137601
‫שיטה ומתקן לזיהוי הריון בבעלי חיים‬
‫ובבני–אדם‬
]54[
METHOD AND APPARATUS FOR
DETECTING CONCEPTION IN
ANIMALS AND HUMANS
]22[
]31[
]51[
]71[
02.02.1999
09/016995
]32[ 02.02.1998
]33[
Int. Cl.8 C07K 016/18, G01N 033/543, 033/68
CONCEPTO DIAGNOSTICS, INC.,
U.S.A.
WO/1999/039208
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
]87[
]74[
[57] An isolated antibody which
specifically binds purified early conception
factor, wherein early conception factor has
US
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
a molecular weight from about 190,000
daltons to about 205,000 daltons.
__________
869
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
137661
‫שיטה לייצר עמידות צמחים לזיהום‬
‫ בשימוש בחלבון‬SSDNA ‫באמצעות וירוס‬
‫ תכשירים‬,SSDNA ‫קושר אינוויריד וירוס‬
‫ושיטות לשימוש בם‬
]54[
METHOD OF PRODUCING
RESISTANCE IN PLANTS TO
INFECTION BY SSDNA VIRUS
USING INOVIRIDAE VIRUS
SSDNA-BINDING PROTEIN,
COMPOSITIONS AND METHODS
OF USE
]22[
]31[
]51[
]71[
03.03.1999
60/076627
]32[ 03.03.1998
]33[ US
Int. Cl.8 A01H 001/00, 003/00, 005/00, C12N 005/04, 005/14, 015/05, 015/82
THE SCRIPPS RESEARCH
INSTITUTE, U.S.A.
WO/1999/045101
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A method for producing in a plant
resistance to a single stranded DNA
(ssDNA) virus of the Geminivirus family
capable of infecting a plant comprising
introducing a ssDNA-binding protein of
the the Inoviridae virus family into said
plant.
__________
]11[]21[
]54[
METHOD FOR MONITORING
FOOD INTAKE
]22[
]51[
]71[
]74[
08.08.2000
Int. Cl.8 A61B 005/00
EDDIE KARNIELI
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
[57] A method for providing information
to a person under dietary limitations, prior
and during a meal, regarding a food item
positioned before said person, and making
available in real time guidance messages
relating thereto, said method comprising
the steps:
June 17, 2007 – ‫א' בתמוז התשס"ז‬
137759
‫שיטת פיקוח לאכילה‬
‫אדי קרניאלי‬
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
(a) providing the user with video
photographic means and directing same in
the direction of food items;
(b) correlating pictures obtained in step (a)
with electronically-stored pictures of food
items for identification thereof;
870
(c) correlating said identified food item
with information stored in a data base
rearding the content of the identified food
regarding carbohydrates, protein, fat,
amino acids and food constituents
whichever is important for the person
being monitored;
(d) correlating information obtained in step
(c) with preprogrammed dietary
restrictions of the person being monitored;
and
(e) generating a display message for the
user including warning and instructions
regarding eating limitations for the
photographed food item.
__________
]11[]21[
138281
‫ שעבר שנוי‬IIIV ‫גורם‬
]54[
MODIFIED FACTOR VIII
]22[
]31[
]51[
]71[
]87[
]74[
10.03.1999
09/037601
]32[ 10.03.1998
]33[ US
Int. Cl.8 C07K 014/755, C12N 015/11, 015/12
EMORY UNIVERSITY, U.S.A.
WO/1999/046274
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
[57] Isolated and purified DNA
comprising a DNA segment having a
nucleotide sequence of cDNA encoding
the amino acid sequence of porcine factor
VIII set forth in SEQ ID NO: 37.
__________
871
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
]54[
7 - ACYLAMINO - 3 - (CYCLIC
AMINOGUANIDINES)
METHYLENE
CEPHALOSPORINS, THEIR
PREPARATION AND
PHARMACEUTICAL
COMPOSITIONS COMPRISING
THEM
]22[
]31[
]51[
]71[
19.03.1999
A515/98
]32[ 23.03.1998
Int. Cl.8 C07D 501/00, 501/56
NABRIVA THERAPEUTICS
FORSCHUNGS GMBH, AUSTRIA
WO/1999/048896
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
138477
)‫ – (אמינוגואנידין ציקלי‬3 – ‫ – אציל אמינו‬7
‫ הכנתם ותכשרי‬,‫– מתילן צפלוספורינים‬
‫רוקחות המכילים אותם‬
]33[
AT
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
[57] A compound of the formula
wherein
W denotes CH or N,
V denotes CH or NO,
R1 denotes hydrogen, (C1-12) acyl, carboxyl
or alkyl,
June 17, 2007 – ‫א' בתמוז התשס"ז‬
R3 denotes hydrogen or an ester moiety or
a cation,
R2 denotes a group of the formula
872
‫א' בתמוז התשס"ז – ‪June 17, 2007‬‬
‫‪873‬‬
wherein X and Y independently of each
other each denote (C2-5) alkylene, or (C2-5)
alkenylene wherein one –C=C—double
bond is present, or, in case of at least C4alkenylene, wherein two –C=C—double
bonds are present, R4 denotes hydrogen or
alkyl, R5 denotes hydrogen, alkyl or
aminoiminomethyl, R6 denotes hydrogen,
alkyl, cycloalkyl, amino, hydroxy, alkoxy,
unsaturated or saturated heterocyclyl
having 5 or 6 ring members and 1 or 2
hetero atoms and being unsubstituted or
substituted by alkyl, aryl, alkoxy, halogen,
hydroxy, carboxyl, --SO3 H, C(1-12) – acyl,
amino, guanidino, oxo, thiono, mercapto,
alkylthio, arylthio, imino or alkylimino, or
R6 denotes a group of formula –N=CHR8,
wherein R8 denotes alkyl, aryl or
unsaturated or saturated heterocyclyl
having 5 or 6 ring members and 1 or 2
hetero atoms and being unsubstituted or
substituted by alkyl, aryl, alkoxy, halogen,
hydroxy, carboxyl, -- SO3 H, C(1-12) - acyl,
amino, guanidino, oxo, thiono, mercapto,
alkylthio, arylthio, imino or alkylimino, or
R5 and R6 together with the nitrogen atoms
to which they are attached denote
unsaturated or saturated heterocyclyl
having 5 or 6 ring members and 1 or 2
hetero atoms and being unsubstituted or
substituted by alkyl, aryl, alkoxy, halogen,
hydroxy, carboxyl, -- SO3 H, C(1-12) – acyl,
amino, guanidino, oxo, thiono, mercapto,
alkylthio, arylthio, imino or alkylimino, R'6
denotes alkyl, R7 denotes hydrogen, or R6
and R7 together with the nitrogen atom to
which they are attached form unsaturated
or saturated heterocyclyl having 5 to 7 ring
members and 1 or 2 hetero atoms and
being unsubstituted or substituted by alkyl,
aryl, alkoxy, halogen, hydroxy, carboxyl, - SO3 H, C(1-12) – acyl, amino, guanidino,
oxo, thiono, mercapto, alkylthio, arylthio,
imino or alkylimino.
__________
]11[]21[
138745
‫ הרכבים‬,PDE IV ‫נגזרת פירידין המעכבות‬
‫ שימושיהן ותהליכים‬,‫המכילים אותן‬
‫להכנתן‬
]54[
PDE IV INHIBITING PYRIDINE
DERIVATIVES, COMPOSITIONS
CONTAINING THEM, USES
THEREOF AND PROCESSES FOR
THEIR PRODUCTION
]22[
]31[
]51[
]71[
24.03.1999
98201020.9
]32[ 01.04.1998
]33[ EP
Int. Cl.8 A61K 031/395, A61P 043/00, C07D 401/14, 405/14, 409/14, 413/14
JANSSEN PHARMACEUTICA N.V.,
BELGIUM
WO/1999/050262
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
874
[57] A compound of the formula
wherein:
L is hydrogen;
-A-B- is a bivalent radical of formula:
-CR4=CR5- or
-CHR4-CHR5-;
D is O or NR6;
Q is a radical of the formula
R1 is hydrogen or C1-4 alkyl;
R1 is hydrogen or C1-4 alkyl;
R2 is hydrogen; halo; C1-6 alkyl;
trifluoromethyl; C3-6 cyckoalkyl; carboxyl;
C1-4 alkyl-oxycarbonyl; C3-6
cycloalkylaminocarbonyl; aryl; Het1; or C16 alkyl substituted with cyano, amino,
hydroxy, C1-4 alkylcarbonylamino, aryl, or
Het1; or R2 is a radical of the formula:
-O-R9; or
-NH-R10;
R3 is hydrogen, halo, hydroxy, C1-6 alkyl or
C1-6 alkyloxy;
R4 and R5 are each independently selected
from hydrogen or C1-4 alkyl;
R6 is hydrogen, C1-4 alkyl or cyano;
R7 and R8 each independently are
hydrogen; C1-6 alkyl; difluoromethyl;
trifluoromethyl; C3-6 cycloalkyl; a
saturated 5-, 6- or 7-membered heterocycle
containing one or two heteroatoms each
independently selected from oxygen, sulfur
or nitrogen; indanyl; 6, 7-dihydro-5Hcyclopentapyridyl; bicyclo [2.2.1]-2heptenyl;
bicyclo [2.2.1] heptanyl; C1-6
alkylsulfonyl; arylsulfonyl; or C1-10 alkyl
substituted with one or two substituents
each independently selected from aryl,
pyridyl, thienyl, furanyl, indanyl, 6, 7dihydro-5H-cyclopentapyridyl, C3-7
cycloalkyl and a saturated 5-, 6- or 7membered heterocycle containing one or
two heteroatoms each independently
selected from oxygen, sulfur or nitrogen;
R9 is hydrogen; C1-6 alkyl; C1-6 alkyl
substituted with hydroxy, carboxyl, C1-4
alkyloxycarbonyl, amino, mono- or di(C1-4
alkyl) amino, Het' or aryl; R10 is hydrogen;
C1-6 alkyl; C1-4 alkylcarbonyl; C1-6 alkyl
substituted with hydroxy, carboxyl, C1-4
alkyloxycarbonyl, amino, mono- or di (C1-4
alkyl) amino, Het1 or aryl; aryl is phenyl or
phenyl substituted with one, two or three
substituents each independently selected
from halo, hydroxy, C1-4 alkyl, C1-4
alkyloxy, C3-6 cycloalkyl, trifluoromethyl,
amino, nitro, carboxyl, C1-4
alkyloxycarbonyl and C1-4
alkylcarbonylamino;
Het1 is pyridyl; pyridyl substituted with C14 alkyl; furanyl; furanyl substituted with
C1-4 alkyl; thienyl; thienyl substituted with
C1-4 alkylcarbonylamino; hydroxy-pyridyl,
hydroxypyridyl substituted with C1-4 alkyl
or C1-4 alkoxy C1-4 alkyl; imidazolyl;
875
June 17, 2007 – ‫א' בתמוז התשס"ז‬
imidazolyl substituted with C1-4 alkyl;
thiazolyl; thiazolyl substituted with C1-4
alkyl; oxazolyl; oxazolyl substituted with
C1-4 alkyl; isoquinolinyl; isoquinolinyl
substituted with C1-4 alkyl; quinolinoyl;
quinolinoyl substituted with C1-4 alkyl;
morpholinyl; piperidiyl; piperidyl
substituted with C1-4 alkyl, C1-4
alkyloxycarbonyl or aryl C1-4 alkyl;
piperazinyl; piperazinyl substituted with
C1-4 alkyl, C1-4 alkyloxycarbonyl or aryl
C1-4 alkyl; and
an N-oxide form, a pharmaceutically
acceptable acid or base addition salt and a
stereochemically isomeric form thereof.
__________
]11[]21[
]54[
SAFETY SYSTEM FOR A
PROJECTILE FUSE
]22[
]31[
06.04.1999
9807290.3
]32[ 03.04.1998
9817471.7
11.08.1998
Int. Cl.8 F42C 015/26
SPECIAL CARTRIDGE COMPANY
LIMITED, UNITED KINGDOM
MICHAEL ALCULUMBRE,
FREDERICK SHARP
WO/1999/051934
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O. B. 45087,
JERUSALEM 91450
]51[
]71[
]72[
]87[
]74[
[57] A small arms projectile (1) for a
small arms weapon, the projectile
comprising:a generally tubular casing (3) having an
axially movable firing pin (7); a
compression spring (25) providing a
resilient force;
a warhead (2) having an explosive charge;
and an initiator (23) having safe and armed
conditions and capable, when in its armed
condition and when impacted with
sufficient force by said firing pin, of
detonating the explosive charge of said
warhead; wherein the casing also contains
safety release means for releasably
restraining the firing pin, against said
resilient force which tends to move the
firing pin away from the initiator, in a
June 17, 2007 – ‫א' בתמוז התשס"ז‬
138823
‫מערכת אבטחה לנתיך של קליע‬
]33[
GB
GB
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
,45087 .‫ד‬.‫ ת‬, ‫ הר חוצבים‬,‫רחוב המרפא‬
‫ירושלים‬
safety position whereby said initiator is
held, by engagement with the firing pin, in
its safe condition, against an arming force
tending to urge the initiator towards the
armed condition; wherein the safety
release means comprising first (80) and
second (78) mechanical means; wherein
said first mechanical means includes at
least one component constructed to be
frangible in response to the forces
experienced on firing of the projectile, the
strength of the frangible element being
sufficient to withstand acceleration forces
up to 500g; and wherein said second
mechanical means includes at least one
component disposed and configured so as
to be ejected from the casing under the
influence of said resilient force when the
876
projectile leaves the weapon permitting
said resilient force to move said firing pin
away from said initiator to an extent
allowing said initiator to be urged into its
armed condition.
__________
]11[]21[
]54[
PROCESS FOR THE
PREPARATION OF NONRACEMIC
PIPERIDINYLAMINOMETHYL
TRIFLUOROMETHYL CYCLIC
ETHER COMPOUNDS
]22[
]31[
]51[
]71[
]74[
12.10.2000
60/160226
]32[ 18.10.1999
Int. Cl.8 C07D 405/12
PFIZER PRODUCTS, INC., U.S.A.
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
139012
,‫תהליך להכנת תרכובות אתר לא רצמיות‬
‫ציקליות של פיפרידינילאמינומתיל‬
‫טריפלואורומתיל‬
]33[
US
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
[57] A process for preparing a mixture of
compounds of the formulae
877
June 17, 2007 – ‫א' בתמוז התשס"ז‬
enriched in the compound of formula Ia,
and pharmaceutically acceptable salts
thereof, wherein
R1 is C1-C6 alkyl;
R2 is C1-C6 alkyl, halo C1-C6 alkyl or
phenyl or substituted phenyl;
R3 is hydrogen or halo;
m is zero, one or two;
comprising the steps of
(a1) reacting a mixture of compounds of
the formula Ia and Ib
with an acid of formula HX, wherein HX
is selected from the group consisting of
(S)- (+)-mandelic acid, D-(-)-tartaric acid,
di-p-toluoyl-D-tartaric acid, ((1R)-endo,
anti)-(+)-3-bromocamphor-8-sulfonic acid,
quinic acid, acetic acid and hydrobromic
acid, to form a mixture of diastereomeric
compounds of the formula Va and Vb,
respectively:
(b1) permitting the HX salt of the
diastereomeric product mixture of step (a1)
to crystallize out of a solution thereof in an
appropriate solvent;
(c1) treating the resulting mixture of
compounds obtained from step (b1) with a
base to obtain a mixture of compounds Ia
and Ib, that is enriched in the compound of
formula Ia.
The applications for division
from this application have
not yet been published
,163386
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
878
]11[]21[
]54[
SEEK ACTUATOR FOR OPTICAL
RECORDING
]22[
]31[
]51[
]62[
]71[
]74[
31.03.1996
08/419870
]32[ 11.04.1995
Int. Cl.8 G11B 007/00
DIVISION FROM 117742
DISCOVISION ASSOCIATES, U.S.A.
HENRY EINAV,
43 HERZL STREET RAANANA
[57] An apparatus for controlling the
position of a lens, said apparatus
comprising: a suspended body (1-210); a
lens (1-122) disposed in said suspended
body defining an optical axis, a center of
mass of said suspended body being
disposed substantially on said optical axis,
and a center of mass of said lens being
coincident with said center of mass of said
suspended body; a carriage (106)
suspending said suspended body for
relative motion therewith having at least
one degree of freedom, wherein a center of
mass of said carriage lies within 0.1 mm of
said optical axis proximate said center of
mass of said suspended body, and said
carriage has an initial attitude with respect
to three mutually orthogonal planes of
reference defined by an X axis, a Y axis,
and a Z axis, and suspensory forces of said
carriage acting on said suspended body are
symmetric about said optical axis;
879
139083
‫מפעיל חיפוס להקלטה אופטית‬
]33[
US
,‫הנרי עינב‬
‫ רעננה‬,43 ‫רחוב הרצל‬
a first drive means acting on said carriage
for producing a first plurality of balanced
forces being symmetric about said optical
axis to accelerate said carriage and said
suspended body therewith at different
frequencies along said Y axis wherein
moments produced by said first plurality of
balanced forces about said center of mass
of said carriage are effectively absent and
forces reactive to said first plurality of
balanced forces are further symmetric with
respect to said optical axis thereby
producing insubstantial moments about
said center of mass of said carriage,
inertial forces developed by said first drive
means on said carriage being balanced and
symmetric about said optical axis so that
said carriage maintains its said attitude
with respect to said planes of reference
during acceleration thereof and said
suspended body maintains an initial
position with respect to said carriage.
June 17, 2007 – ‫א' בתמוז התשס"ז‬
__________
]11[]21[
139301
‫ תהליך להכנתן‬,‫נגזרות של קוינולין‬
‫ותכשירי רוקחות המכילים אותן‬
]54[
QUINOLINE DERIVATIVES,
PROCESS FOR THEIR
PREPARATION AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM
]22[
]31[
25.05.1995
MI94A001099 ]32[ 27.05.1994
]33[ IT
MI95A000494
14.03.1995
IT
Int. Cl.8 A61K 031/47, A61P 011/00, 017/00, 025/00, 029/00, 043/00, C07D 211/50,
215/52, 221/18, 401/04, 405/04, 409/04, 417/04
DIVISION FROM 113844
GLAXOSMITHKLINE S.P.A., ITALY
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]51[
]62[
]71[
]74[
[57] Compounds or solvates or salts
thereof of the formula
June 17, 2007 – ‫א' בתמוז התשס"ז‬
880
in which:
Ar is an optionally substituted phenyl,
naphthyl or C5-7 cycloalkdienyl group, or
an optionally substituted single or fused
ring heterocyclic group, having aromatic
character, containing from 5 to 12 ring
atoms and comprising up to four hetero
atoms in the or each ring selected from S,
O, N; R is linear or branched C1-8 alkyl, C37 cycloalkyl, C4-7 cycloalkylalkyl,
optionally substituted phenyl or phenyl C16 alkyl, an optionally substituted five membered heteroaromatic ring comprising
up to four heteroatoms selected from O
and N, hydroxy C1-6 alkyl, amino C1-6
alkyl, C1-6 alkylaminoalkyl, di C1-6
alkylaminoalkyl, C1-6 acylaminoalkyl, C1-6
alkoxyalkyl, C1-6 alkylcarbonyl, carboxy,
C1-6 alkoxycarbonyl, C1-6 alkoxycarbonyl
C1-6 alkyl, aminocarbonyl, C1-6
alkylaminocarbonyl, di C1-6
alkylaminocarbonyl, halogeno C1-6 alkyl;
or is a group –(CH2)p-when cyclized onto
Ar, where p is 2 or 3.
R1 and R2, which may be the same or
different, are independently hydrogen or
C1-6 linear or branched alkyl, or together
form a –(CH2)n – group in which n
represents 3, 4, or 5; or R1 together with R
forms a group –(CH2)q-, in which q is 2, 3,
4, or 5.
R3 and R4, which may be the same or
different are independently hydrogen, C1-6
linear or branched alkyl, C1-6 alkenyl, aryl,
C1-6 alkoxy, hydroxy, halogen, nitro,
cyano, carboxy, carboxamido,
sulphonamido, C1-6 alkoxycarbonyl,
trifluoromethyl, acyloxy, phthalimido,
amino, mono-and di-C1-6 alkylamino, O(CH2)r-NT2, in which r is 2, 3, or 4 and T
is hydrogen or C1-6 alkyl or two
substituents T form with the adjacent
nitrogen a group
in which V and V1 are independently two
atoms hydrogen, or oxygen, and u is 0, 1
or 2; -O(CH2)s-OW in which s is 2, 3, or 4
and W is hydrogen or C1-6 alkyl;
hydroxyalkyl, aminoalkyl, mono-or-dialkylaminoalkyl, acylamino,
alkylsulphonylamino, aminoacylamino,
mono- or di-alkylaminoacylamino; with up
to four R3 substituents being present in the
quinoline nucleus; or R4 is a group –
(CH2)t- when cyclized onto R5 as aryl, in
which t is 1, 2, or 3;
R5 is branched or linear C1-6 alkyl, C3-7
cycloalkyl, C4-7 cycloalkylalkyl, optionally
881
June 17, 2007 – ‫א' בתמוז התשס"ז‬
substituted aryl, or an optionally
substituted single or fused ring
heterocyclic group, having aromatic
character, containing from 5 to 12 ring
atoms and comprising up to four heteroatoms in the or each ring selected from S,
N, N; X is O, S, or N-C=N excluding the
combination of Ar as phenyl, R as ethyl,
R1 and R2 as hydrogen each, R3 as
hydrogen, R4 as hydroxy, R5 as phenyl and
X as O.
__________
]11[]21[
]54[
PHARMACEUTICAL
COMPOSITIONS CONTAINING
HUMAN PARATHYROID
HORMONE
]22[
]31[
]51[
]71[
26.04.1999
9801495-4
]32[ 28.04.1998
Int. Cl.8 A61K 009/08, 038/29
ALLELIX BIOPHARMACEUTICALS,
INC., CANADA
WO/1999/055353
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
]87[
]74[
[57] A pharmaceutical formulation
comprising human parathyroid hormone at
a concentration of or above 0.3 mg/ml to
139320
‫תכשירי רוקחות המכילים הורמון‬
‫פרתירואיד אנושי‬
]33[
CA
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
10 mg/ml; a pharmaceutically acceptable
buffer having a pH from 4 to 6, and at least
one tonicity modifier.
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
882
]11[]21[
]54[
THERMOPROTECTED
MICROPARTICLE
COMPOSITIONS AND PROCESS
FOR TERMINAL STEAM
STERILIZATION THEREOF
]22[
]31[
]51[
]71[
]72[
]87[
]74[
28.05.1999
60/087331
]32[ 29.05.1998
Int. Cl.8 A61K 009/14, 009/50, 009/51
RTP PHARMA INC., U.S.A.
AWADHESH K. MISHRA
WO/1999/061001
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O. B. 45087,
JERUSALEM 91450
[57] An injectable aqueous terminally
steam sterilized composition of a
particulate suspension of a water-insoluble
or poorly water-soluble drug substance
wherein the particles in the suspension
have a volume weighted mean diameter of
up to 3 μm with not more than 3000
particles of 10 μm or greater size and not
more than 300 particles of 25 μm or
greater size, surface stabilized with one or
more phospholipid surface modifiers and a
pharmaceutically acceptable amount, safe
for parenteral administration, of a
139779
‫תכשירי מיקרו חלקיקים המוגנים מחום‬
‫ותהליך לסטריליזצייתם סופית בקיטור‬
]33[
US
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
,45087 .‫ד‬.‫ ת‬, ‫ הר חוצבים‬,‫רחוב המרפא‬
‫ירושלים‬
pharmaceutically acceptable, water soluble
polyhydroxy thermoprotecting agent, the
ratio of the drug substance to the surface
modifier is up to 5:1, the amount of the
surface modifier is from 0.2% w/w to
5.0%n w/w, and wherein the composition
is substantially completely devoid of
surfactants that require, during terminal
steam sterilization, elevation of their cloud
point temperature by addition of a cloud
point modifier and the composition is
substantially devoid of surfactant additives
which coagulate on steam sterilization.
__________
883
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
140412
‫ לשמוש‬L–LYS –L–GLU ‫דיפפטידים‬
‫בתכשירי רוקחות‬
]54[
L-LYS -L-GLU DIPEPTIDES FOR
PHARMACEUTICAL
PREPARATIONS
]22[
]31[
]51[
]71[
27.05.1999
98111342
]32[ 23.06.1998
]33[ RU
Int. Cl.8 A61K 038/05, A61P 017/02, C07K 005/068
OBSCHESTVO S OGRANICHENNOI
OTVETSTVENNOSTIJU "KLINIKA
INSTITUTA BIOREGUL YATSII I
GERONTOLOGII", RUSSIA
WO/1999/066948
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]87[
]74[
[57] Use of L-lysyl-L-glutamic acid
dipeptide (L-Lys-L-Glu) for the
manufacture of a peptide preparation for
prophylaxis and/or treatment of diseases
requiring stimulation of tissue
regeneration, substantially as described in
the specification, wherein the disease
belongs to the following group: pyoinflammatory diseases and post-operative
complications; trophic disorders, skin and
mucous diseases and injuries; after-effect
of radiation, chemical and thermal factors.
__________
]11[]21[
]54[
DEVICE FOR THE
ENCAPSULATION OF PLASTIC
SYRINGES
]22[
]51[
]71[
20.07.1998
Int. Cl.8 A61L 002/00, 002/04
IMAGINATION MEDICAL, INC.,
U.S.A.
WO/2000/004931
DR. SHLOMO COHEN & CO.,
124 IBN GABIROL ST.,
P.O.B. 11490,
TEL AVIV 62038
]87[
]74[
[57] A device for the encapsulation of
plastic syringes (101) using centrifugal
force, the device comprising a removable,
June 17, 2007 – ‫א' בתמוז התשס"ז‬
140972
‫מתקן לשיבוץ מזרקים פלסטיים בחומר‬
‫יצוק‬
,'‫ד"ר שלמה כהן ושות‬
‫ תל אביב‬,11490 .‫ד‬.‫ ת‬, 124 ‫אבן גבירול‬
rotatable melt chamber (28) to receive
plastic syringes, a housing to receive said
melt chamber, forced hot air blower means
884
comprising means to heat air and means to
deliver air into said melt chamber to
elevate the temperature within said melt
chamber to a temperature sufficient to melt
said plastic syringes, and motor means to
rotate said melt chamber after said
syringes are melted to distribute said
melted syringes by centrifugal force.
__________
]11[]21[
141157
‫ מלח של‬,‫פנטופראזול מגנזיום דיהידראט‬
‫פנטופראזול ותכשירי רוקחות המכילים‬
‫אותו‬
]54[
PANTOPRAZOLE MAGNESIUM
DIHYDRATE, A SALT FORM OF
PANTOPRAZOLE AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THE SAME
]22[
]31[
]51[
]71[
12.08.1999
19843413.8
]32[ 18.08.1998
]33[ DE
Int. Cl.8 A61K 031/44, A61P 001/00, C07D 401/12
BYK GULDEN LOMBERG
CHEMISCHE FABRIK GMBH,
GERMANY
WO/2000/010995
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]87[
]74[
[57] Pantoprazole magnesium dihydrate.
__________
885
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
141675
‫תרכיבי ליפוזומים אימונוגניים‬
]54[
IMMUNOGENIC LIPOSOME
COMPOSITIONS
]22[
]31[
22.09.1999
60/101351
]32[ 22.09.1998
]33[ US
09/400723
21.09.1999
US
Int. Cl.8 A61K 009/127, 039/00, C07K 014/16, 014/18, C12N 015/62, 015/85
MOLECULAR EXPRESS, INC.,
U.S.A.
WO/2000/016746
DR. SHLOMO COHEN & CO.,
,'‫ד"ר שלמה כהן ושות‬
124 IBN GABIROL ST.,
‫ תל אביב‬,11490 .‫ד‬.‫ ת‬, 124 ‫אבן גבירול‬
P.O.B. 11490,
TEL AVIV 62038
]51[
]71[
]87[
]74[
[57] An immunogenic unilamellar
liposome composition comprising: vesicleforming lipids; and an antigenic construct
comprising one or more antigenic
determinants and a hydrophobic domain,
wherein the hydrophobic domain has a
surface area greater than 500 A2 and is
associated with the membrane of said
unilamellar liposome composition, and
wherein the immunogenic composition
elicits a response associated with cell
mediated immunity.
__________
]11[]21[
141680
–)‫ –אילמתיל‬4 – ‫–אימידזול‬H1(– ‫שימוש של‬
‫–אול בייצור של תרופה עבור‬5–‫אינדאן‬
‫ אינטרהקול או‬,‫ניהול תוך שידרתי‬
‫אפידורל‬
]54[
USE OF 3-(1H-IMIDAZOL-4YLMETHYL)-INDAN-5-OL IN THE
MANUFACTURE OF A
MEDICAMENT FOR
INTRASPINAL, INTRATHECAL
OR EPIDURAL
ADMINISTRATION
]22[
]31[
]51[
]71[
]87[
]74[
27.09.1999
60/101986
]32[ 28.09.1998
]33[ US
Int. Cl.8 A61K 031/4164, A61P 025/04, C07D 233/00, 233/54
ORION CORPORATION, FINLAND
WO/2000/018400
DR. YITZHAK HESS & PARTNERS,
,‫ד"ר יצחק הס ושותפיו‬
279 HAYARKON ST.,
‫ תל אביב‬,6451 .‫ד‬.‫ ת‬, 279 ‫רחוב הירקון‬
P.O.B. 6451,
TEL AVIV 61063
June 17, 2007 – ‫א' בתמוז התשס"ז‬
886
[57] Use of 3-(1H-imidazol-4-ylmethyl)indan-5-ol, its enantiomer or a
pharmaceutically acceptable ester or salt
thereof in the manufacture of a
medicament for intraspinal administration.
__________
]11[]21[
141747
‫ננוחלקיקים ראקטיביים כסופחים הרסניים‬
‫לזיהום ביולוגי וכימי‬
]54[
REACTIVE NANOPARTICLES AS
DESTRUCTIVE ADSORBENTS
FOR BIOLOGICAL AND
CHEMICAL
CONTAMINATION
]22[
]31[
]51[
]71[
15.09.1999
09/153437
]32[ 15.09.1998
]33[
Int. Cl.8 A61K 009/00, 009/14, A62D 003/00
NANOSCALE MATERIALS, INC.,
U.S.A.
WO/2000/020073
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
]87[
]74[
[57] A method for the destructive
sorption or destructive chemisorption of a
target component, comprising: providing a
quantity of finely divided absorbent
selected from the group consisting of
MgO, CaO, TiO2, ZrO2, FeO, V2O5, V2O3,
Mn2O3, Fe2O3, NiO, CuO, Al2O3, ZnO and
mixtures thereof wherein the finely divided
absorbent contains either reactive atoms
selected from the group consisting of
halogens and alkali metals stabilized on
the surfaces of the absorbent in an amount
of at least two atoms of reactive atoms per
square nanometer of adsorbent surface area
US
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
or ozone, said adsorbent having an average
particle diameter of from about 3 to 20
nanometers;
contacting said adsorbent with a target
component selected from the group
consisting of hydrocarbons, bacteria, fungi
and viruses; said contacting being carried
out at a temperature of from about -40oC to
600oC and said contacting step causing the
destructive sorption or destructive
chemisorption of said target compound,
with the proviso that the method is not
applied for treating a human body.
__________
887
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
]54[
MAGNETIC FIELD APPLICATOR
FOR HEATING MAGNETIC OR
MAGNETIZABLE SUBSTANCES
OR SOLIDS IN BIOLOGICAL
TISSUE
]22[
]31[
]51[
]71[
18.07.2000
19937492.9
]32[ 07.08.1999
Int. Cl.8 A61N 001/40, 002/00
MFH HYPERTHERMIESYSTEME
GMBH, GERMANY
WO/2001/010501
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
]87[
]74[
[57] Magnetic field applicator to heat
magnetic or magnetizable substances or
solids in biological tissue,
with a magnetic yoke (2) with two pole
shoes (7, 8) facing each other on the
magnetic yoke and separated by gap in the
exposure volume and with two magnetic
coils (9, 10) for the production of a
magnetic alternating field, each of which is
assigned to a pole shoe, characterized in
142409
‫מטוש שדה מגנטי לחימום חומרים‬
‫מגנטיים או ברי–מגנוט או מוצקים ברקמה‬
‫ביולוגית‬
]33[
DE
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
that the magnetic yoke and the pole shoes
consist of ferrite building blocks (16)
mounted together and in that the magnetic
coils are disk coils with at least one
winding extending helicoidally, each
assigned to a pole shoe, and in that the
respective pole shoe ends comprise a
surrounding magnetic coil/pole shoe gap
(a) between them.
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
888
]11[]21[
]54[
ELECTROTRANSPORT DEVICE
INCLUDING A COMPATIBLE
ANTIMICROBIAL AGENT
]22[
]31[
]51[
]71[
]87[
]74[
29.10.1999
60/106873
]32[ 02.11.1998
Int. Cl.8 A61N 001/30
ALZA CORPORATION, U.S.A.
WO/2000/025858
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
[57] A transdermal electrotransport drug
delivery device comprised of an anode
(22), a cathode (24) and a source of
electrical power electrically connected to
the anode and the cathode, the cathode
including a cathodic electrode and a
cathodic reservoir (26) comprised of a
housing (16) composed of a polymeric
material and an aqueous medium in
142808
‫מכשיר אלקטרוטרנספורט הכולל חומר‬
‫אנטימיקרוביאלי תואם‬
]33[
US
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
contact with the housing, said aqueous
medium comprised of (i) a drug or an
electrolyte salt or a mixture thereof and (ii)
a cetylpridinium salt in an amount
sufficient to inhibit microbial growth in the
aqueous medium wherein said polymeric
material is compatable with the
cetylpyridinium salt.
__________
889
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
143154
‫מנגנון להכנסת מטווים‬
]54[
YARN INSERTION MECHANISM
]22[
]31[
]51[
]71[
16.11.1999
60/108729
]32[ 17.11.1998
]33[ US
Int. Cl.8 B32B 005/10, 005/18, 007/08, D05B 023/00, D05C 011/00
ALBANY INTERNATIONAL
TECHNIWEAVE, INC., U.S.A.
WO/2000/029659
SPAER, SITTON & CO.,
,'‫ סיטון ושות‬,‫שפאר‬
P.O. BOX 7530, 4 ALHARIZI ST.,
‫ ירושלים‬,4 ‫ רחוב אלחריזי‬, 7530 .‫ד‬.‫ת‬
JERUSALEM
]87[
]74[
[57] An apparatus (10) for longitudinally
inserting yarns (4) into a reinforcement
material comprised of a housing (12)
having a first end (14) for receiving yarn
and a second end (16) for passing yarn, the
first and second ends being in
communication with means for
maintaining yarn in a longitudinal path,
means for moving yarn in a longitudinal
path between an initial position and a
second position corresponding to where
yarn has been inserted into a reinforcement
material, said means is in a movable
arrangement comprised of movable means
for maintaining the yarn in a longitudinal
path, wherein said movable means are
movable between an initial position and a
second position where yarn has been
inserted into a reinforcement material,
means for engaging yarn positioned on the
movable means for maintaining the yarn in
a longitudinal path and traveling therewith;
means for actuating the means for moving
yarn between the initial position and the
second position, means for constraining
yarn against movement, and means for
boring a longitudinal path in a
reinforcement material.
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
890
]11[]21[
]54[
METHOD FOR IMPROVING
MEASUREMENTS BY LASER
INTERFEROMETER
]22[
]31[
]51[
]71[
]87[
]74[
26.11.1999
982603
]32[ 02.12.1998
Int. Cl.8 G01B 009/02
LEONID MIHALJOV, FINLAND
WO/2000/033021
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O. B. 45087,
JERUSALEM 91450
[57] A method for improving the
accuracy of distance measurements made
with a laser interferometer (1, 2)
comprising: determining air temperature
effect along the whole path of a laser beam
(3) emitted by the laser interferometer by
143453
‫שיטה לשיפור מדידות באמצעות‬
‫אינטרפרומטר לייזר‬
]33[
FI
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
,45087 .‫ד‬.‫ ת‬, ‫ הר חוצבים‬,‫רחוב המרפא‬
‫ירושלים‬
measuring the speed of sound
simultaneously traveling the same path,
and calculating air temperature dependent
adjustments on the distance measurement
values by using the measured value of the
sound speed.
__________
891
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
144017
‫שיטה וציוד לעריכת הקלטת חוזי (וידאו) עם‬
)‫בחירות שמע (אודיו‬
]54[
METHOD AND APPARATUS FOR
EDITING A VIDEO RECORDING
WITH AUDIO SELECTIONS
]22[
]51[
]71[
]87[
]74[
28.01.1999
Int. Cl.8 G11B 027/028, 027/031, H04N 005/765
INTEL CORPORATION, U.S.A.
WO/2000/045597
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
[57] A machine implemented method
comprising:
(a) receiving a signal including video
content;
(b) analyzing the video content of the
received signal to identify visual attributes
of the video content; and
(c) identifying an appropriate audio
selection from a plurality of available
audio selections with which to augment the
received signal based, at least in part, on
the identified visual attributes of the video
content.
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
892
]11[]21[
144181
1 – ‫] אינדול‬B–5,4[ ‫שימוש בנגזרות פירדזינו‬
‫– אצטאמיד להכנת תרופות לטיפול‬
‫במחלות הקשורות לבעיית תפקוד של‬
‫קולטני בנזודיאזפין היקפיים‬
]54[
USE OF PYRIDAZINO[4,5-B]
INDOLE - 1 - ACETAMIDE
DERIVATIVES FOR PREPARING
MEDICINES FOR TREATING
DISEASES RELATED TO THE
DYSFUNCTION OF PERIPHERAL
BENZODAZEPINE RECEPTORS
]22[
]31[
]51[
]71[
]87[
]74[
21.01.2000
99/00806
]32[ 26.01.1999
]33[ FR
Int. Cl.8 A61K 045/06, A61P 009/00, 013/00, 025/00
SANOFI AVENTIS, FRANCE
WO/2000/044384
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
[57] Use of a compound of the formula
in which
X represents a halogen atom,
Y represents one or more atoms or groups
chosen from hydrogen, halogens and
hydroxyl, methyl, methoxy and nitro
groups,
R1 represents a (C1-C4) alkyl group,
R2 and R3 form, with the nitrogen atom
carrying them, a pyrrolidinyl, piperidinyl
or morpholinyl group, for the preparation
of a medicament for the prevention and
treatment of diseases and disorders linked
to the dysfunctioning of peripheral-type
benzodiazepine receptors and chosen from
the degenerative diseases of the peripheral
nervous system, cardiac diseases or
disorders, and nephropathies.
__________
]11[]21[
893
144581
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫תבניות מינון יציבות מוכנות לשימוש‬
‫המכילות חומר צביעה וכלור פעיל ושיטות‬
‫לייצרן והשימוש בהן כחומרי חיטוי‬
]54[
STABLE READY-TO-USE
DOSAGE FORMS CONTAINING
COLORING MATTER AND
ACTIVE CHLORINE AND
METHODS OF MAKING AND
USING SAME AS
DISINFECTANTS
]22[
]51[
]71[
26.07.2001
Int. Cl.8 A01K 029/00, A61K 000/800000 A61L 002/18
SHIMON FREEDMAN
LEON LIPSICAS
]74[
G.E. EHRLICH (1995) LTD.,
AYALON TOWER, 15TH FLOOR,
11 MENACHEM BEGIN STREET,
52521 RAMAT GAN
[57] A method of producing a
disinfectant or sterilizing liquid, cream,
ointment, paste, or gel by dissolving in a
solvent a stable ready-to-use dosage form
containing coloring matter and an organic
chloroxidizer acting as a chlorine donor
releasing active chlorine; said coloring
matter being in its maximal level of
oxidation; said chloroxidizer with coloring
‫ הרצליה‬,‫שמעון פרידמן‬
‫ אשקלון‬,‫לאון ליפסיקס‬
,‫) בע"מ‬1995( ‫ארליך‬.‫אי‬.‫ג'י‬
,11 ‫רחוב מנחם בגין‬, 15 ‫ קומה‬,‫מגדל אילון‬
‫רמת גן‬
matter having a pH of 4 -8 and being
present in a sufficient quantity to disinfect
or sterilize the surface, vessel, or tissue as
required while the colored appearance of
the liquid, cream, ointment, paste, or gel is
stably maintained over a period of time
which exceeds the period of time that the
disinfectant would be normally used for
that purpose.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
144619
894
–‫שיטה להכנת תולדות של חומצה ביפניל‬
‫–קברוכסילית‬2
]54[
METHOD FOR PRODUCING
DERIVATIVES OF BIPHENYL-2CARBOXYLIC ACID
]22[
]31[
]51[
12.02.2000
19908504.8
]32[ 26.02.1999
]33[ DE
Int. Cl.8 C07C 051/08, 063/00, 063/331, 063/68, 065/105, 065/24, 069/017, 069/76,
205/57, 229/52
BOEHRINGER INGELHEIM
PHARMA GMBH & CO. KG,
GERMANY
WO/2000/051961
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]71[
]87[
]74[
[57] A process for preparing a compound
of the formula
wherein:
R1 and R2, which are identical or different,
are each hydrogen; C1-C6-alkyl optionally
substituted by halogen; C1-C6-alkoxy; C1C6-acyl; C1-C6-alkoxycarbonyl; COOH;
phenyl; benzyl; halogen; hydroxy; nitro; or
amino, or
R1 and R2 together with adjacent carbon
atoms of the phenyl ring form a saturated
or unsaturated 5- or 6-membered
carbocyclic group optionally substituted by
C1-C4 – alkyl, halogen, COOH, phenyl, or
hydroxy groups, the process comprising:
saponifying with hydrochloric acid at
elevated temperature under pressure, in the
presence of an organic solvent selected
from an aliphatic or aromatic hydrocarbon
or an aromatic chlorohydrocarbon with 610 carbon atoms, a compound of the
formula
wherein:
R1 and R2 are as hereinbefore defined
895
June 17, 2007 – ‫א' בתמוז התשס"ז‬
and
Rox is an oxazolin-2-yl group optionally
mono-, di-, tri- or tetra-substituted by
groups selected from C1-C6-alkyl group
optionally subsituted by halogen, hydroxy
or C1-C4 – alkoxy; C1-C6 – alkoxy; phenyl
optionally substituted by C1-C4 – alkyl, C1C4 – alkoxy, hydroxy, nitro, or amino;
benzyl; pyridyl; or C1-C6 –
alkoxycarbonyl.
__________
]11[]21[
144636
‫נגזרות של תיואמיד‬
]54[
THIOAMIDE DERIVATIVES
]22[
]31[
]51[
10.02.2000
60/120475
]32[ 18.02.1999
]33[ US
Int. Cl.8 A61K 031/167, 031/395, 031/44, A61P 029/00, C07C 327/46, 327/48, C07D
213/82, 213/83, 233/32, 295/14, 401/06
F. HOFFMANN-LA ROCHE AG,
SWITZERLAND
WO/2000/048994
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]71[
]87[
]74[
[57] Anti-inflammatory compounds of
the formula:
wherein X is a group of the formula
wherein:
June 17, 2007 – ‫א' בתמוז התשס"ז‬
R15 is halogen, nitro, C1-C6 alkylsulfonyl,
cyano, C1-C6 alkyl, C1-C6 alkoxy, C1-C6
alkoxycarbonyl, carboxy, C1-C6
896
alkyl aminosulfonyl, perfluoro C1-C6 alkyl,
C1-C6 alkylthio, hydroxy C1-C6 alkyl,
alkoxy C1-C6 alkylthio C1-C6 alkyl, C1-C6
alkylsulfinyl C1-C6 alkyl, C1-C6
alkylsulfonyl C1-C6 alkyl, C1-C6
alkylsulfinyl, C1-C6 alkanoyl, aroyl, aryl,
aryloxy;
R16 is hydrogen, halogen, nitro, cyano, C1C6 alkyl, OH, perfluoro C1-C6 alkyl, or C1C6 alkylthio; or
X is a group of formula
wherein Het is a 5- or 6-membered
heteroaromatic ring containing 1, 2 or 3
heteroatoms selected from N, O, and S, or
Het is a 9- or 10-membered bicyclic
heteroaromatic ring containing 1, 2, 3 or 4
heteroatoms selected from O, S, and N;
R15 and R16 are as in X-1 above;
R30 is hydrogen or C1-6 alkyl; and p is an
integer from 0 to 1;
or X is group of the formula
wherein:
R18 is aryl, heteroaryl, aryl C1-C6 alkyl,
heteroaryl C1-C6 alkyl,
R19 is substituted or unsubstituted C1-C6
alkyl, aryl, heteroaryl, arylalkyl, heteroaryl
alkyl, and
R20 is substituted or unsubstituted C1-C6
alkanoyl or aroyl;
and Y is a group of the formula
wherein:
R22 and R23 are independently hydrogen,
C1-C6 alkyl, C1-C6 alkoxy, cycloalkyl, aryl,
arylalkyl, nitro, cyano, C1-C6 alkylthio, C1-
897
June 17, 2007 – ‫א' בתמוז התשס"ז‬
C6 alkylsulfinyl, C1-C6 alkylsulfonyl C1-C6
alkanoyl, halogen, or perfluoro C1-C6 alkyl
and at least one of R22 and R23 is other than
hydrogen, and
R24 is hydrogen, C1-C6 alkyl, C1-C6 alkoxy,
aryl, nitro, cyano, C1-C6 alkylsulfonyl, or
halogen;
or Y is a group of the formula
Het is a five or six membered
heteroaromatic ring bonded via a carbon
atom wherein said ring contains one, two
or three heteroatoms selected from the
group consisting of N, O and S and R30
and R31 are independently hydrogen, C1-6
alkyl, cycloalkyl, halogen, cyano,
perfluoroalkyl, or aryl and at least one of
R30 and R31 is adjacent to the point of
attachment, p is an integer of 0 or 1 or Y is
a group of formula
wherein:
R25 is C1-6 alkyl, unsubstituted or fluorine
substituted C2-10 alkenyl, or a group of
formula R26-(CH2)e-, R26 is aryl,
heteroaryl, azido, cyano, hydroxy, C1-C6
alkoxy, C1-C6 alkoxycarbonyl, C1-C6
alkanoyl, C1-C6 alkylthio, C1-C6 alkyl
sulfonyl, C1-C6 alkylsulfinyl, perfluoro C1C6 alkanoyl, nitro, or R26 is a group of
formula –NR28R29,
wherein
R28 is H or C1-6 alkyl, R29 is hydrogen, C1C6 alkyl, C1-C6 alkoycarbonyl, C1-C6
alkanoyl,
aroyl, perfluoro C1-C6 alkanoylamino, C1C6 alkylsulfonyl, C1-C6
alkylaminocarbonyl, arylaminocarbonyl,
or
R28 and R29 taken together form a 4, 5 or 6membered saturated carbocyclic ring
optionally containing one heteroatom
selected from O, S, and N; with the carbon
atoms in the ring being unsubstituted or
substituted by C1-C6 alkyl or halogen,
Q is –(CH2)fO-, -(CH2)fS-, -(CH2)fN(R27)-,
-(CH2)f- or a bond,
R27 is H, C1-C6 alkyl, C1-C6 alkanoyl, aroyl
or C1-C6 alkoxycarbonyl,
e is an integer from 0 to 4,
f is an integer from 1 to 3, and
the dotted bond is optionally
hydrogenated;
and pharmaceutically acceptable salts and
esters thereof.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
144679
898
‫תהליך מיקרוביולוגי להכנת אנטיביוטיקת‬
A ‫חומצה פסאודומונית‬
]54[
MICROBIOLOGICAL PROCESS
FOR THE PREPARATION OF
ANTIBIOTIC PSEUDOMONIC
ACID A
]22[
]31[
03.02.2000
60/118457
]32[ 03.02.1999
]33[ US
60/137334
03.06.1999
US
Int. Cl.8 C07D 407/06, C12N 001/20, C12P 017/16, C12R 001/38
TEVA PHARMACEUTICAL
‫ פתח‬,‫טבע תעשיות פרמצבטיות בע"מ‬
INDUSTRIES LTD.
‫תקווה‬
]51[
]71[
]87[
]74[
WO/2000/046389
TEVA PHARMACEUTICAL
INDUSTRIES LTD.,
5 BASEL ST., P.O.BOX 3190,
PETAH TIQVA 49131
,‫טבע תעשיות פרמצבטיות בע"מ‬
‫ פתח תקוה‬,3190 .‫ד‬.‫ ת‬, 5‫בזל‬
[57] A process for the preparation of
pseudomonic acid A comprising the steps
of cultivating on a medium comprising at
least one organic nitrogen or carbon
source, in submerged aerated conditions, a
Pseudomonas bacterium strain capable of
the biosynthesis of pseudomonic acid A,
and fermenting the Pseudomonas culture
such that pseudomonic acid A is formed,
wherein said Pseudomonas bacterium
strain is Pseudomonas sp. bacterium strain
No. 19/26 deposited under accession No.
NCAIM(P)B 001235 in the National
Collection of Agricultural and Industrial
Microorganisms, Budapest, Hungary.
__________
]11[]21[
899
145043
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫תרכובת אימונוגנית וחיסונים המכילים‬
‫אנטיגנים פוליסכרידים‬
]54[
IMMUNOGENIC COMPOSITION
AND VACCINE COMPRISING
POLYSACCHARIDE
CONJUGATED ANTIGENS
]22[
]31[
17.03.2000
9906437.0
]32[ 19.03.1999
]33[ GB
9909077.1
20.04.1999
GB
9909466.6
23.04.1999
GB
9916677.9
15.07.1999
GB
Int. Cl.8 A61K 039/005, 039/116, 039/155, 039/39
SMITHKLINE BEECHAM
BIOLOGICALS S.A., BELGIUM
WO/2000/056360
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] An immunogenic composition
comprising a plurality of polysaccharide
conjugate antigens consisting of a
polysaccharide antigen derived from a
pathogenic bacterium conjugated to
protein D from Haemophilus influenzae or
a protein D fragment thereof.
__________
]11[]21[
]54[
METHOD OF USING 13C-NMR TO
DETECT BINDING
]22[
]31[
]51[
]71[
]87[
]74[
21.03.2000
09/288924
]32[ 09.04.1999
Int. Cl.8 G01N 033/542, 033/68
ABBOTT LABORATORIES, U.S.A.
WO/2000/062074
DR. SHLOMO COHEN & CO.,
124 IBN GABIROL ST.,
P.O.B. 11490,
TEL AVIV 62038
[57] A method of detecting binding
between a putative ligand and a preselected, 13C-enriched target molecule
which comprises:
June 17, 2007 – ‫א' בתמוז התשס"ז‬
145135
‫ לגילוי‬RMN–C31–‫שיטת שימוש ב‬
‫התחברות‬
]33[
US
,'‫ד"ר שלמה כהן ושות‬
‫ תל אביב‬,11490 .‫ד‬.‫ ת‬, 124 ‫אבן גבירול‬
(a) generating a first two-dimensional
13 1
C/ H NMR correlation spectrum of said
target molecule;
(b) forming a mixture of said target
molecule with at least one putative ligand
900
compound;
(c) generating a second two-dimensional
13 1
C/ H NMR correlation spectrum of the
mixture of step (b); and
(d) comparing the first and second spectra.
__________
]11[]21[
145192
,‫ תהליכים להכנתן‬,‫נגזרות פירימידין‬
‫תכשירי רוקחות המכילים אותן והשימוש‬
‫בהן להכנת תרופות יוצרות השפעה נוגדת‬
‫סרטן‬
]54[
PYRIMIDINE DERIVATIVES,
PROCESSES FOR THEIR
PREPARATION,
PHARMACEUTICAL
COMPOSITIONS COMPRISING
THE SAME AND USE THEREOF
IN THE MANUFACTURE OF
MEDICAMENTS FOR
PRODUCTION OF ANTI-CANCER
EFFECT
]22[
]31[
]51[
]71[
]87[
]74[
02.03.2000
9905075.9
]32[ 06.03.1999
]33[ GB
Int. Cl.8 A61K 031/505, A61P 035/00, C07D 401/00, 403/14, 409/14, 413/14, 417/14
ASTRAZENECA AB, SWEDEN
WO/2000/053595
S. HOROWITZ & CO.,
,'‫ הורוביץ ושות‬.‫ש‬
ZION HOUSE,
‫ תל‬,41-45 ‫ שדרות רוטשילד‬,‫בית ציון‬
41-45 ROTHSCHILD BLVD.,
‫אביב‬
TEL AVIV 65784
[57] A pyrimidine of the formula
wherein:
Rx is selected from hydrogen, halo,
hydroxy, nitro, amino, C1-3 alkylamino, di[C1-3 alkyl] amino, cyano, trifluoromethyl,
trichloromethyl, C1-3 alkyl [optionally
substituted by 1 or 2 substituents
independently selected from halo,
901
cyano, amino, C1-3 alkylamino, di-[C1-3
alkyl]
amino, hydroxy and trifluoromethyl], C3-5
alkenyl [optionally substituted by up to
three halo substituents, or by one
trifluoromethyl substituent], C3-5 alkynyl,
June 17, 2007 – ‫א' בתמוז התשס"ז‬
C1-3 alkoxy, -SH, -S-C1-3 alkyl, carboxy,
C1-3 alkoxycarbonyl;
Q1 is phenyl, and Q1 bears on an available
carbon atom not adjacent to the –NH- link
one substitutent of the formula (Ia), and –
NQ2 (defined hereinbelow) may optionally
bear on any available carbon atom further
substituents of the formula
wherein:
X is –CH2-, -O-, -NH-, -NRy-or-S[wherein Ry is C1-4 alkyl, optionally
substituted by one substituent selected
from halo, amino, cyano, C1-4 alkoxy or
hydroxy];
Y1 is H, C1-4 alkyl or as defined for Z;
Y2 is H or C1-4 alkyl;
Z is RaO-, RbRcN-, RdS-, ReRfNNRg-, a
nitrogen linked heteroaryl or a nitrogen
linked heterocycle [wherein said
heterocycle is optionally substituted on a
ring carbon or a ring nitrogen by C1-4 alkyl
or C1-4 alkanoyl] wherein Ra, Rb, Rc, Rd,
Re, Rf and Rg are independently selected
from hydrogen, C1-4 alkyl, C2-4 alkenyl, C38 cycloalkyl, and wherein said C1-4 alkyl
and C2-4 alkenyl are optionally substituted
by one or more phenyl;
n is 1, 2 or 3;
m is 1, 2 or 3;
and –NQ2 is an unquaternised N-linked 5-,
6- or 7- membered monocyclic
heterocyclic moiety containing one
nitrogen heteroatom and optionally
containing a further one or two
heteroatoms selected from nitrogen,
oxygen and sulphur or –NQ2 is an
unquaternised N-linked 8-, 9- or 10membered bicyclic heterocyclic moiety
containing one or two nitrogen
heteroatoms and optionally containing a
further one or two heteroatoms selected
from nitrogen, oxygen and sulphur and
wherein if said heterocyclic moiety
contains an –NH- moiety that nitrogen
may be optionally substituted by a group
selected from C1-6 alkyl, C1-6 alkanoyl, C1-6
alkylsulphonyl, C1-6 alkoxycarbonyl,
benzyl, benzoyl or phenylsulphonyl; and
Q1 and –NQ2 may optionally and
independently bear on any available
carbon atom up to four substituents
independently selected from halo,
hydroxy, thio, nitro, carboxy, cyano, C2-4
alkenyl [optionally substituted by up to
three halo substituents, or by one
trifluoromethyl substituent], C2-4 alkynyl,
C1-5 alkanoyl, C1-4 alkoxycarbonyl, C1-6
alkyl, hydroxy-C1-3 alkyl, fluoro-C1-4 alkyl,
amino-C1-3 alkyl, C1-4 alkylamino-C1-3
alkyl, di-[C1-4 alkyl] amino-C1-3 alkyl,
cyano-C1-4 alkyl, C2-4 alkanoyloxy-C1-4alkyl, C1-4 – alkyl, C1-4 alkoxy-C1-3 alkyl,
carboxy-C1-4 alkyl, C1-4 alkoxycarbonylC1-4 alkyl, carbamoyl-C1-4 alkyl, N-C1-4
alkylcarbamoyl-C1-4 alkyl, N,N-di-[C1-4
alkyl]-carbamoyl-C1-4 alkyl, pyrrolidin-1yl-C1-3 alkyl, piperidin-1-yl-C1-3 alkyl,
piperazin-l-yl-C1-3 alkyl, morpholino-C1-3
alkyl, thiomorpholino-C1-3 alkyl, imidazo1-yl-C1-3 alkyl, piperazin-1-yl, morpholino,
thiomorpholino, C1-4 alkoxy, cyano-C1-4
alkoxy, carbamoyl-C1-4 alkoxy, N-C1-4
alkylcarbamoyl-C1-4 alkoxy, N,N-di-[C1-4
alkyl]-carbamoyl-C1-4 alkoxy, 2aminoethoxy, 2-C1-4 alkylaminoethoxy, 2di-[C1-4 alkyl] aminoethoxy, C1-4
alkoxycarbonyl-C1-4 alkoxy, halo-C1-4
alkoxy, 2-hydroxyethoxy, C2-4
alkanoyloxy-C2-4 alkoxy, 2-C1-4
alkoxyethoxy, carboxy-C1-4 alkoxy, 2pyrrolidin-l-yl-ethoxy, 2-piperidinoethoxy, 2-piperazin-1-yl-ethoxy, 2morpholino-ethoxy, 2-thiomorpholinoethoxy, 2-imidazo-l-yl-ethoxy, C3-5
June 17, 2007 – ‫א' בתמוז התשס"ז‬
902
alkenyloxy, C3-5 alkynyloxy, C1-4 alkylthio,
C1-4 alkylsulphinyl, C1-4 alkylsulphonyl,
hydroxy C2-4 alkylthio, hydroxy C2-4
alkylsulphinyl, hydroxy C2-4
alkylsulphonyl, ureido (H2N-CO-NH-), C14 alkylNH-CO-NH-, di-[C1-4 alkyl] N-CONH-, C1-4 alkylNH-CO-N[C1-4 alkyl], di[C1-4 alkyl] N-CO-N[C1-4 alkyl]-,
carbamoyl, N-[C1-4 alkyl] carbamoyl,
N,N,-di-[C1-4 alkyl] carbamoyl, amino, C1-4
alkylamino, di-[C1-4 alkyl] amino, C2-4
alkanoylamino, sulphamoyl, N-(C1-4 alkyl)
sulphamoyl, N,N-di-(C1-4 alkyl)
sulphamoyl,
and also independently, or where
appropriate in addition to, the above
optional substituents, Q1 and –NO2 may
optionally and independently bear on any
available carbon atom up to two further
substituents independently selected from
C3-8 cycloalkyl, phenyl-C1-4 alkyl, phenylC1-4 alkoxy, phenylthio, phenyl, naphthyl,
benzoyl, phenoxy, benzimidazol-2-yl, and
a 5- or 6-membered aromatic heterocycle
(linked via a ring carbon atom and
containing one to three heteroatoms
independently selected from oxygen,
sulphur and nitrogen); wherein said
naphthyl, phenyl, benzoyl, phenoxy, 5-or
6-membered aromatic heterocyclic
substituents and the phenyl group in said
phenyl-C1-4 alkyl, phenylthio and phenylC1-4 alkoxy substituents may optionally
bear one or two substituents independently
selected from halo, C1-4 alkyl and C1-4
alkoxy; or a pharmaceutically acceptable
salt or in vivo hydrolysable ester thereof.
__________
]11[]21[
145349
‫מנוע רקטה‬
]54[
ROCKET ENGINE
]22[
]31[
]51[
]71[
10.03.2000
60/123621
]32[ 10.03.1999
]33[ US
Int. Cl.8 F02K 009/00, 009/48, F23R 003/00
WILLIAMS INTERNATIONAL CO.,
L.L.C., U.S.A.
WO/2000/057048
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]87[
]74[
[57] A rocket engine (10), comprising:
(a) a first inlet adapted to receive a first
propellant component from a source of
said first propellant component;
(b) a second inlet adapted to receive a
second propellant component from a
source of said second propellant
component;
(c) a first combustion chamber (34)
comprising an outlet;
(d) a first rotary injector (76) within said
903
first combustion chamber comprising at
least one first rotary orifice having a first
axis of rotation, wherein said least one first
rotary orifice is in fluid communication
with at least one inlet of said first rotary
injector and with said first combustion
chamber, and said at least one inlet of said
first rotary injector is in fluid
communication with said first inlet of said
rocket engine;
(e) a second rotary injector (142) within
said first combustion chamber comprising
June 17, 2007 – ‫א' בתמוז התשס"ז‬
at least one second rotary orifice (144)
having a second axis of rotation, wherein
said at least one second rotary orifice is in
fluid communication with at least one inlet
of said second rotary injector and with said
first combustion chamber, and said at least
one inlet of said second rotary injector is in
fluid communication with said second inlet
of said rocket engine; and
(f) a third rotary injector (182) within a
second combustion chamber (36)
comprising at least one third rotary orifice
having a third axis of rotation, wherein
said at least one third rotary orifice (10) is
in fluid communication with at least one
inlet of said third rotary injector and with
said second combustion chamber, and said
at least one inlet of said third rotary
injector is in fluid communication with
said second inlet of said rocket engine.
\
The applications for division
from this application have
not yet been published
,174907
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
145684
904
‫תרופות לטיפול ביתר לחץ ריאתי‬
]54[
MEDICAMENTS FOR
TREATMENT OF PULMONARY
HYPERTENSION
]22[
]31[
]51[
]71[
26.09.2001
60/237538
]32[ 04.10.2000
]33[ US
Int. Cl.8 A61K 045/00, 045/06, C07D 487/02
WARNER-LAMBERT COMPANY
LLC, U.S.A.
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]74[
[57] The use of an effective amount of a
compound of the formula
wherein R and R5 are hydrogen or lower
alkyl;
R1, R2 , and R3 independently are
hydrogen, halo, lower alkyl, lower alkoxy,
amino, alkylamino, or dialkylamino; and
R4 is hydrogen, phenyl or substituted
phenyl; and pharmaceutically acceptable
salts thereof; in the preparation of a
medicament for treating pulmonary
hypertension without affecting systemic
hemodynamics in a mammal suffering
from pulmonary hypertension and in need
of treatment.
__________
]11[]21[
905
145923
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫תולדות של חומצה טרי–ארילית כליגנדים‬
PPAR ‫של רצפטור‬
]54[
TRI-ARYL ACID DERIVATIVES
AS PPAR RECEPTOR LIGANDS
]22[
]31[
]51[
28.04.2000
60/131454
]32[ 28.04.1999
]33[ US
Int. Cl.8 A61K 031/42, 031/4245, 031/425, A61P 043/00, C07D 261/08, 263/32,
271/06, 277/20, 277/22
SANOFI-AVENTIS DEUTSCHLAND
GMBH, GERMANY
WO/2000/064876
PEARL COHEN ZEDEK LATZER,
‫ עורכי פטנטים‬,‫פרל כהן צדק לצר עורכי דין‬
5 SHENKAR STREET,
,‫ונוטריונים‬
P.O.B. 12704
,12704 .‫ד‬.‫ ת‬, 5 ‫ רח' שנקר‬,1 ‫ים‬-‫מרכז גב‬
HERZLIYA 46733
‫הרצליה‬
]71[
]87[
]74[
[57] A compound selected from the group
or a pharmaceutically acceptable salt thereof.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
145946
906
]54[
CRYSTALLINE FORMS OF AN
AZITHROMYCIN DERIVATIVE,
THEIR PREPARATION AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM
]22[
]31[
]51[
]71[
]87[
]74[
14.04.2000
60/134644
]32[ 18.05.1999
Int. Cl.8 C07H 017/08
PFIZER PRODUCTS, INC., U.S.A.
WO/2000/069874
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
,‫צורות גבישיות של תולדות אזיתרומיצין‬
‫הכנתן ותכשירי רוקחות המכילים אותן‬
]33[
US
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
[57] A crystalline antibiotic form of a
compound of the formula
__________
]11[]21[
907
146187
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫תרכובות מותמרות של פניל בעלות‬
‫פעילות לדיכוי המערכת החיסונית ותכשירי‬
‫רוקחות המכילים אותן‬
]54[
SUBSTITUTED PHENYL
COMPOUNDS WITH
IMMUNOSUPPRESSING
ACTIVITY AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM
]22[
]31[
]51[
22.05.2000
9901875-6
]32[ 25.05.1999
]33[ SE
Int. Cl.8 A61K 031/16, 031/395, A61P 019/02, 037/06, C07C 237/20, 237/42, C07D
207/08, 207/14, 211/44, 233/56, 239/42, 295/08, 295/12
ASTRAZENECA AB, SWEDEN
MARK FURBER, TIMOTHY LUKER,
MICHAEL MORTIMORE, PHILIP
THORNE, PREMJI MEGHANI
WO/2000/071529
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]71[
]72[
]87[
]74[
[57] Compounds of the formula
wherein:
each R1 independently represents a
hydrogen or halogen atom, or a
trifluoromethyl, cyano, nitro, C1-C6 alkyl
June 17, 2007 – ‫א' בתמוז התשס"ז‬
or C1-C6 alkoxy group; T represents a
group NH;
U represents an oxygen or sulphur atom or
a group NH;
Ar represents a group
908
X represents a bond, an oxygen atom or a
group CO, CH2, CH2O, O(CH2)m,
CH2OCH2, NR5, CH2NR5, NR5CH2,
CH2NR5CH2, CONR5, S(O)n or SO2NR5;
m is 1, 2 or 3;
n is 0, 1 or 2;
one of R2 and R3 represents a halogen,
cyano, nitro, amino, hydroxyl, or a group
selected from C1-C6 alkyl optionally
substituted by at least one C3-C6
cycloalkyl, C3-C8 cycloalkyl, C1-C6
alkyloxy optionally substituted by at least
one C3-C6 cycloalkyl, C3-C8 cycloalkyloxy,
S(O)pC1-C6 alkyl or S(O)q C3-C8
cycloalkyl, each of these groups being
optionally substituted by one or more
fluorine atoms, and the other of R2 and R3
represents a hydrogen or halogen atom or a
methyl group;
p is 0, 1 or 2;
q is 0, 1 or 2;
R4 represents di(C1-2 alkyl) N(CH2)t where
t is 0, 1 or 2 or imidazolyl, or R4 represents
a 3- to 9-membered saturated heterocyclic
ring system containing one or two nitrogen
atoms, the heterocyclic ring system being
optionally substituted by one or more
substituents independently selected from
fluorine atoms, hydroxyl, C1-C6 alkyl,
acetyl, hydroxy C1-C6 alkyl, -NR6R7, (CH2)rNR6R7, -CONR6R7 and pyrimidinyl,
or R4 represents a 3- to 8-membered
saturated carbocyclic ring system
substituted by one or more substituents
independently selected from NR6R7, (CH2)rNR6R7 and –CONR6R7, the ring
system being optionally further substituted
by one or more substituents independently
selected from fluorine atoms, hydroxyl and
C1-C6 alkyl; r is1, 2, 3, 4, 5 or 6; R5
represents a hydrogen atom or a C1-C6
alkyl or C3-C8 cycloalkyl group; and R6
and R7 each independently represent a
hydrogen atom or a C1-C6 alkyl or C3-C8
cycloalkyl group, or R6 and R7 together
with the nitrogen atom to which they are
attached form a 3- to 8-membered
saturated heterocyclic ring, provided that
when R3 represents a cyano group, then X
is other than a bond; or pharmaceutically
acceptable salts or solvates thereof.
__________
]11[]21[
]54[
MUTUAL CROSSTALK
ELIMINATION IN MEDICAL
SYSTEMS
]22[
]31[
]51[
]71[
29.10.2001
09/702974
]32[ 31.10.2000
Int. Cl.8 A61N 002/00, G01B 007/004
BIOSENSE, INC., U.S.A.
909
146217
‫מניעת הפרעות הדדיות בין שדות מגנטיים‬
‫במערכות רפואיות‬
]33[
US
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]74[
,'‫ד"ר שלמה כהן ושות‬
‫ תל אביב‬,11490 .‫ד‬.‫ ת‬, 124 ‫אבן גבירול‬
DR. SHLOMO COHEN & CO.,
124 IBN GABIROL ST.,
P.O.B. 11490,
TEL AVIV 62038
[57] Apparatus for generating magnetic
fields, comprising: a plurality of radiator
coils (22, 24, 26); and driver circuitry (32),
coupled thereto, which drives the coils so
as to generate magnetic fields at a plurality
of driving frequencies, such that each of
the coils is driven by a respective current
that comprises a basic current at a
respective one of the driving frequencies
and cancellation currents at one or more of
the other driving frequencies, so that each
of the radiator coils generates a field
substantially only at the respective driving
frequency, wherein the cancellation
currents are determined so as to
substantially cancel parasitic magnetic
fields generated by each of the coils in
response to the magnetic fields generated
by the other coils at the respective driving
frequencies of the other coils.
__________
]11[]21[
146396
‫נוגדן מונוקלונלי המכוון נגד תאי סרטן‬
‫הכליות של בני אדם‬
]54[
MONOCLONAL ANTIBODY
DIRECTED AGAINST CELLS OF
HUMAN RENAL CELL
CARCINOMA
]22[
]31[
]51[
10.05.2000
99/05942
]32[ 10.05.1999
]33[ FR
Int. Cl.8 A61K 039/395, 049/00, 051/10, C07K 016/18, 016/30, 016/42, C12N
005/12, G01N 033/574
June 17, 2007 – ‫א' בתמוז התשס"ז‬
910
]71[
]87[
]74[
CENTRE NATIONAL DE LA
RECHERCHE SCIENTIFIQUE
(CNRS), FRANCE
WO/2000/067792
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A hybridoma denoted 5C5, as
deposited at the CNCM under the number
I-2184, formed by fusing cells of a Balb/C
murine myeloma line Sp20 and cells from
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
inguinal and abdominal lymph nodes of
Balb/C mice having been immunized
beforehand with the BIZ human renal
carcinoma line.
__________
]11[]21[
]54[
ENERGY-ACTIVATED
COMPOSITIONS FOR
CONTROLLED SUSTAINED
RELEASE OF GAS
146440
‫תכשירים מופעלים על ידי אנרגיה לשחרור‬
‫מושהה מבוקר של גז‬
]22[
]31[
20.04.2000
60/134683
]32[ 18.05.1999
]33[ US
09/448927
24.11.1999
US
]51[ Int. Cl.8 A01N 025/12, A61L 002/16, C01B 011/14
]71[ BERNARD TECHNOLOGIES, INC.,
U.S.A.
SOUTHWEST RESEARCH
INSTITUTE, U.S.A.
]87[ WO/2000/069775
]74[ EITAN, PEARL, LATZER AND
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
COHEN ZEDEK,
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
P.O.B. 12688,
HERZLIYA 46733
dioxide, carbon dioxide, sulfur dioxide,
[57] A composition for electromagnetic
hydrogen sulfide, dichlorine monoxide,
energy-controlled generation and release
hydrocyanic acid, nitrogen dioxide, nitric
of a gas comprising: an energy-activated
oxide, nitrous oxide, and ozone, the
catalyst capable of being activated by
composition, when exposed to
electromagnetic energy, and a solid or a
electromagnetic energy, being capable of
solids-containing suspension containing
generating and releasing the gas after
anions capable of being oxidized or
activation of the catalyst and oxidation or
reacted to generate at least one gas selected
reaction of the anions.
from the group consisting of chlorine
__________
911
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
]54[
ADJUSTABLE VAGINAL
PESSARY
]22[
]51[
]71[
]74[
15.11.2001
Int. Cl.8 A61F 006/08
GYNOTECH LTD.
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
146534
‫התקן נרתיקי מתכונן‬
‫ חולון‬,‫ג'ינוטק בע"מ‬
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
[57] An adjustable vaginal pessary (2)
adapted to provide support to vaginal walls
of a patient, comprising: a body with an
outer periphery (8) defining the perimeter
of the body, an inner periphery (6),
defining an aperture (10), at least a pair of
ends (12a, b), and an adjustable portion
spacing and interfacing with said ends,
said portion being adapted for adjusting its
length in the direction along the perimeter
of the body to increase the distance
between said ends when said length is
increased and to reduce said distance when
said length is reduced, thereby adjusting
the length of said inner and outer
peripheries to provide varying degrees of
said support.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
146606
912
‫שיטה ומערכת לביצוע מקוון של תשלומים‬
]54[
METHOD AND SYSTEM FOR
ONLINE PAYMENTS
]22[
]31[
24.05.2000
PQ0559
]32[ 25.05.1999
PQ1313
30.06.1999
PQ1312
30.06.1999
PQ2912
17.09.1999
PQ3632
25.10.1999
Int. Cl.8 G06K 001/18
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2000/072241
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] A method to enable a person to make
a requested payment utilizing a bill printed
onto a surface, the bill including
information relating to the requested
payment, the surface having coded data
indicative of an identity of the bill and of a
plurality of reference points of the bill, the
method including the steps of causing the
bill and the coded data to be printed onto
the surface substantially simultaneously;
receiving, in a computer system, indicating
data from a sensing device, the indicating
data indicative of both an identity of the
]33[
AU
AU
AU
AU
AU
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
bill and a position of the sensing device
relative to the bill, the sensing device,
when placed operatively relative to the bill,
generating the indicating data based at
least partially on sensing at least some of
the coded data in the vicinity of the
position; and identifying, in the computer
system and from the indicating data, at
least one parameter relating to the
requested payment, the at least one
parameter selected from the group
comprising an action parameter and a
variable parameter.
,169597
The applications for division
from this application have
not yet been published
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
]11[]21[
]54[
SYSTEM FOR DATA TRANSFER
]22[
]31[
24.05.2000
PQ0559
]32[ 25.05.1999
PQ1313
30.06.1999
Int. Cl.8 G06K 009/22
]51[
913
146652
‫מערכת להעברת מידע‬
]33[
AU
AU
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]71[
]87[
]74[
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2000/072238
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A system for transferring data from a
portable data capturing device to a data
processing means, the system comprising:
a wireless communication means for
transmitting data from said data capturing
device to the data processing means, the
wireless communications means
comprising a transmitter (133) in
communication with said data capturing
device and a receiver (132) in
communication with the data processing
means, the transmitter having a finite
transmission range; and a buffer in
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
communication with said data capturing
device for temporarily storing at least
some of the data captured by the said data
capturing device, wherein data which is
temporarily stored in the buffer is only
transmitted to the receiver when the
receiver is located within the transmission
range of the transmitter, and when a force
sensing means provided in the data
capturing device senses that contact
between the data capturing device and a
surface has been broken.
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
914
]11[]21[
]54[
COMPUTER SYSTEM CONTROL
WITH USER DATA VIA
INTERFACE SURFACE
146680
‫מערכת בקרת מחשב המכילה מידע‬
‫למשתמש באמצעות שטח ממשק‬
]22[
]31[
24.05.2000
PQ0559
]32[ 25.05.1999
]33[ AU
PQ1313
30.06.1999
AU
]51[ Int. Cl.8 B41J 002/21, G06F 003/03, 003/033, 003/06, 003/12, G06K 009/22, 017/00,
G06Q 001/000000 H04L 009/32, H04N 001/327
]71[ SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
]87[ WO/2000/072135
]74[ REINHOLD COHN AND
,‫ריינהולד כהן ושותפיו‬
PARTNERS,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
sensing device relative to the interface
[57] A method of enabling user
surface, using at least some of the sensed
interaction with computer software via: an
coded data; and a computer system
interface surface containing information
running the computer software; the method
relating to at least one interactive element
including the steps of, in the computer
and to the computer software and having
system: (a) receiving the identifying data
disposed therein or thereon coded data
from the sensing device; (b) receiving the
indicative of an identity of the interface
indicating data from the sensing device; (c)
surface and of a plurality of reference
identifying the at least one interactive
points of the surface; a sensing device
element from the indicating data; (d)
which: contains identifying data indicative
identifying user data from the identifying
of an identity of the user; and when placed
data; and (e) operating the computer
in an operative position relative to the
software at least partly in reliance on the
interface surface, senses at least some of
user data and in accordance with
the coded data and generates indicating
instructions associated with the at least
data, indicative of the identity of the
one interactive element.
interface surface and of a position of the
915
June 17, 2007 – ‫א' בתמוז התשס"ז‬
__________
]11[]21[
]54[
SCREENING METHODS FOR
ALTERING CIRCADIAN
RHYTHM PROTEINS
]22[
]31[
]51[
]71[
07.06.2000
09/327745
]32[ 08.06.1999
Int. Cl.8 C12Q 001/48, G01N 033/68
AVENTIS PHARMACEUTICALS
INC., U.S.A.
WO/2000/075669
PEARL COHEN ZEDEK LATZER,
5 SHENKAR STREET,
P.O.B. 12704
HERZLIYA 46733
]87[
]74[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
146729
‫שיטות מיון כדי לשנות חלבוני מחזור יומי‬
]33[
US
‫ עורכי פטנטים‬,‫פרל כהן צדק לצר עורכי דין‬
,‫ונוטריונים‬
,12704 .‫ד‬.‫ ת‬, 5 ‫ רח' שנקר‬,1 ‫ים‬-‫מרכז גב‬
‫הרצליה‬
916
[57] A method for determining the ability
of a test compound to alter
phosphorylation of one or more human
Period proteins, comprising:
(1) adding a test compound to a screening
system comprising hCKIδ and/or ε protein
and one or more human Period proteins
selected from the group consisting of
hPER1, hPER2 and hPER3, and
(2) determining the level of
phosphorylation of human Period protein.
__________
]11[]21[
]54[
INFORMATION PROCESSING
METHOD, INFORMATION
TERMINAL SUPPORT SERVER,
COLLABORATION SYSTEM AND
STORAGE MEDIUM STORING
AN INFORMATION PROCESSING
PROGRAM
147015
‫ טרמינל שרת עזר‬,‫שיטה לעיבוד מידע‬
,‫ מערכת שיתוף פעולה‬,‫לטרמינל מידע‬
‫ותווך אחסון המאחסנים תוכנית לעיבוד‬
‫מידע‬
]22[
]31[
]51[
]71[
14.06.2000
11/170197
]32[ 16.06.1999
]33[ JP
Int. Cl.8 G06F 003/00, 009/00, 013/00, 015/00, 017/30, G06Q 001/000000 003/00000
INTERNATIONAL BUSINESS
MACHINES CORPORATION, U.S.A.
IBM UNITED KINGDOM LIMITED,
UNITED KINGDOM
]87[ WO/2000/077661
]74[ SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
(b) determining whether or not said HTTP
[57] An information processing method
message agrees with a predetermined
in an information processing system
condition;
having an information terminal support
(c) editing contents of said HTTP message
server which supports collaboration of a
when said HTTP message agrees with said
browser loaded on a customer-side
predetermined condition;
information terminal and a browser loaded
(d) sending said HTTP message in an
on an agent-side information terminal, the
unedited form to the customer-side
method comprising the steps of:
browser; and
(a) receiving, at the information terminal
(e) sending said HTTP message in an
support server, an HTTP message sent
edited from to the agent-side browser.
from a Web server in response to a
customer-side browser request;
917
June 17, 2007 – ‫א' בתמוז התשס"ז‬
__________
]11[]21[
]54[
METHOD FOR PLACING AN
ORTHODONTIC ELEMENT ON A
TOOTH SURFACE
]22[
]51[
]62[
]71[
]72[
30.09.1997
Int. Cl.8 A61C 007/14, 013/00
DIVISION FROM 121872
CADENT LTD.
AVI KOPELMAN, ELDAD TAUB,
BARUCH NISSENBAUM
June 17, 2007 – ‫א' בתמוז התשס"ז‬
147260
‫שיטה למיקום של אלמנט אורטודנטי על גבי‬
‫משטח שן‬
80406 ‫ אור יהודה‬,‫קדנט בע"מ‬
‫ ברוך ניסבאום‬,‫ אלדד טאוב‬,‫אבי קופלמן‬
918
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
[57] A method for comparing between an
orthodontic element's actual position on
the surface of a tooth and a proper
position, the method comprising:
(a) monitoring the element, the tooth or
both once the element and the tooth are
proximal to one another by an image
acquisition unit mounted on a positioning
device that can hold the element and
position it on a tooth surface, the image
acquisition unit transmitting an image to a
screen that displays said image;
(b) displaying information on said screen
regarding proper position of said element
in a manner allowing to compare between
the actual and the proper position.
]74[
__________
]11[]21[
147320
‫תרכובות המופקות מטיטן והכנתן ושימושן‬
]54[
TITANIUM DERIVED
COMPOUNDS AND
PREPARATION AND USE
THEREOF
]22[
]31[
]51[
]71[
11.07.2000
99/09194
]32[ 16.07.1999
]33[ FR
Int. Cl.7 A61K 006/00, 031/555, C07F 007/00, 007/18, 007/28
DENTSPLY INTERNATIONAL INC.,
U.S.A.
WO/2001/005797
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]87[
]74[
[57] Titanium-derived compound
satisfying the formula
[TiFxLy]zin which L represents a compound of the
formula
919
June 17, 2007 – ‫א' בתמוז התשס"ז‬
in which m is 1 and n is 0, 1 or 2, and x
represents 2, 4 or 5, y represents 1 or 2 and
z represents 0, 1 or 2; in the form of
enantiomers, of diastereoisomers, as well
as the mixtures thereof, including the
racemic mixtures, of free bases or of
pharmaceutically acceptable salts.
__________
]11[]21[
147399
‫ והתקנים בעלי זיהוי‬,‫שיטה לטרנסאקציה‬
‫ביומטרי‬
]54[
TRANSACTION METHOD AND
DEVICES WITH BIOMETRIC
IDENTIFICATION
]22[
]51[
]71[
22.07.1999
Int. Cl.8 G06K 009/00, G06Q 003/000000 G07F 007/10, H04L 009/32
SWISSCOM MOBILE AG,
SWITZERLAND
WO/2001/008056
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]87[
]74[
[57] A transaction method in which
object picture data (120) relating to a
transaction object (110), for example a
product or service are made visible to a
user, in which eye features (180) of the
user are determined and in which the
determined eye features are linked in a
transaction record (190) to object data
June 17, 2007 – ‫א' בתמוז התשס"ז‬
(130) relating to the transaction object and
containing at least an object identification
(131) of the transaction object, and the
transaction record is transmitted to a
processing unit (23, 43), characterized in
that the eye features of the user are
determined while the object picture data
made visible, is being viewed by the user.
920
__________
]11[]21[
]54[
DISPOSABLE OPTICAL
STORAGE MEDIA AND
MANUFACTURING METHOD
]22[
]31[
12.07.2000
60/143474
]32[ 12.07.1999
09/608328
29.06.2000
Int. Cl.8 G11B 007/24
FLEXPLAY TECHNOLOGIES, INC.,
U.S.A.
WO/2001/004887
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
]51[
]71[
]87[
]74[
[57] An optically-readable media for
storing data and instructions to be read by
a reading device, said optionally-readable
media comprising:
at least one substrate layer (110) having
defined thereon a region for storing control
data, said control data including
instructions used by said reading device to
read said optically-readable media; at least
one substrate layer; at least one reflective
layer (120) coupled to said at least one
substrate layer; at least one reactive
substance that changes at least one optical
921
147543
‫התקן אחסון אופטי חד–פעמי ושיטה‬
‫לייצורו‬
]33[
US
US
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
property or physical property in response
to a predefined stimulus, wherein said at
least one reactive substance is in at least
one of said substrate layer or said
reflective layer and is localized to said
region for storing control data; and an
agent for controlling the rate said at least
one reactive substance changes at least one
optical property or physical property,
wherein said agent controls the rate of
change by at least one of slowing or
stopping the rate of change until said agent
is exhausted.
June 17, 2007 – ‫א' בתמוז התשס"ז‬
__________
]11[]21[
]54[
ESCAPE APPARATUS
]22[
]51[
]71[
]72[
]74[
17.01.2002
Int. Cl.8 A62B 001/12
MOSEROTH LTD.
AMNON SHILONI, ARIK FRANK
DEBORAH GADOR, BLUM,
GADOR & CO.,
53 DERECH HASHALOM
23 RD FLOOR
GIVATAYIM 53454
[57] A device (70) for escaping from a
multistory building, the device comprising:
a drum adapted to be attached to the
building; a non-rotating cable (80) wound
about the drum and of sufficient length so
that a free end of the cable can reach the
ground; the drum being rotatable in a first
direction for paying out the cable and
lowering the free end thereof to the
ground; an hydraulic circuit including: a
uni-directional gear pump operatively
coupled to the drum, such that rotation of
the drum in one direction causes the gear
pump to operate and generate a flow of
hydraulic fluid through the circuit, while
rotation of the drum in the other direction
generates no fluid flow; the gear pump
June 17, 2007 – ‫א' בתמוז התשס"ז‬
147685
‫התקן חילוץ‬
‫מוסרות בע"מ‬
‫ אריק פרנק‬,‫עמנון שילוני‬
,'‫ גדור ושות‬,‫דבורה גדור עו"ד בלום‬
‫ גבעתיים‬,23 ‫ קומה‬, 53 ‫דרך השלום‬
including a narrowed outlet tube serving to
limit the rate of flow through the hydraulic
circuit, to control and limit a rate of
rotation of the drum so that the cable is
lowered at a predetermined speed when a
load is applied to it free end, irrespective
of a fluid pressure generated by the gear
pump; and an hydraulic fluid tank (50) for
holding a quantity of hydraulic fluid,
coupled for fluid flow to the gear pump,
the hydraulic fluid tank including an outlet
(52) to and an inlet (54) from the pump
disposed diagonally opposite one another
on a single face of the tank, to permit
mounting the tank in a substantially
horizontal or substantially vertical
position.
922
‫__________‬
‫א' בתמוז התשס"ז – ‪June 17, 2007‬‬
‫‪923‬‬
]11[]21[
]54[
METHOD FOR DETERMINING
LOCATION OF NOXIOUS
EMISSIONS
]22[
]51[
]71[
]74[
17.01.2002
Int. Cl.8 G01M 003/04
METEO-TECH LTD.
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
147725
‫שיטה למציאת המיקום של פליטות‬
‫מזהמות‬
‫ בני ברק‬,‫טק בע"מ‬-‫מטאו‬
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
[57] A method for tracking air pollution,
comprising: monitoring weather
conditions, at a plurality of points
distributed over a geographical area;
receiving an indication of presence of a
pollutant in the air at a detection location
in the area in a given time interval; and
responsive to the indication, tracing a
possible flow path of the pollutant through
the air based on the monitored weather
conditions prior to the given time and
independently of measurements of
concentration of the pollutant, in order to
determine a possible source of the
pollutant.
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
924
]11[]21[
]54[
METHOD FOR ESTIMATING
INTERFERENCE IN A
COMMUNICATION SYSTEM
]22[
]31[
]51[
]71[
18.08.2000
09/377796
]32[ 20.08.1999
Int. Cl.8 H04B 001/10, 007/216, 017/00
QUALCOMM INCORPORATED,
U.S.A.
WO/2001/015328
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
]87[
]74[
[57] In a code division multiple access
system, a method for improving the
transmission of an information signal
having message information in a
communication system with an
information channel, comprising the steps
of:
(a) receiving the information signal after
transmission through the information
channel wherein the received information
signal has signal noise;
147792
‫שיטה להערכת הפרעה במערכת‬
‫תקשורת‬
]33[
US
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
(b) removing the message information
from the received information signal to
provide a symbol sequence;
(c) applying the symbol sequence to a first
filter to provide a first filtered signal;
(d) determining the power of the first
filtered signal to provide a determined
power signal; and
(e) applying the determined power signal
to a second filter to provide a second
filtered signal representative of the signal
noise of the received information signal.
__________
]11[]21[
925
147876
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫שימוש באגוניסטים של רצפטורים של‬
‫גאבאב או נגזרות קבילות פרמצבטיות‬
‫שלהם בהכנת תכשיר תרופתי לריפוי של‬
‫התמדת ההתנזרות מניקוטין בפציינטים‬
‫התלויים בו‬
]54[
USE OF AGONISTS OF GABAB
RECEPTORS OR
PHARMACEUTICALLY
ACCEPTABLE DERIVATIVES
THEREOF FOR THE
PREPARATION OF
PHARMACEUTICAL
COMPOSITIONS FOR REDUCING
THE WISH OF SMOKING IN
NICOTINE-DEPENDENT
PATIENTS
]22[
]31[
]51[
]71[
30.06.2000
MI99A001715 ]32[ 30.07.1999
]33[ IT
Int. Cl.8 A61K 045/00, 045/06, C07C 211/26, 229/34, C07F 009/32
L. MOLTENI & C. DEI FRATELLI
ALITTI SOCIETA' DI ESERCIZIO
S.P.A., ITALY
WO/2001/008675
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] Use of agonists of GABAB receptors,
or pharmaceutically acceptable derivatives
thereof, for the preparation of
pharmaceutical compositions for reducing
the wish of smoking in nicotine-dependent
patients in the treatment for maintaining
nicotine abstinence wherein such agonist
of GABAB is not the γ-hydroxy-butyric
acid (GHB).
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
147879
926
‫ מערכת ומדיום אחסון הניתן‬,‫שיטה‬
‫לקריאה על ידי מחשב עבור תצורת מנהל‬
‫התקן אוטומטית‬
]54[
METHOD, SYSTEM AND
COMPUTER READABLE
STORAGE MEDIUM FOR
AUTOMATIC DEVICE
DRIVER CONFIGURATION
]22[
]31[
]51[
]71[
01.08.2000
09/366108
]32[ 02.08.1999
]33[ US
Int. Cl.8 G06F 003/00, 009/00, 009/24, 015/163, 015/177
COMPUTER ASSOCIATES THINK,
INC., U.S.A.
WO/2001/010073
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A method of automatically
configuring a computer having at least one
network interface card, comprising the
steps of: applying at least one standardized
access method to said computer to identify
at least one network interface card;
obtaining information in response to said
application of said standardized access
method; randomizing a Media Access
927
Controller (MAC) address of said network
interface card if said computer does not
support automatic detection of said
network interface card; and loading
software appropriate for said network
interface card onto said computer in
response to said information if said
computer does support automatic detection
of said network interface card.
June 17, 2007 – ‫א' בתמוז התשס"ז‬
__________
]11[]21[
147958
‫תולדות קרבמט וקוטל פטריות‬
‫גננות‬/‫לחקלאות‬
]54[
CARBAMATE DERIVATIVES AND
AGRICULTURAL/HORTICULTURAL
FUNGICIDE
]22[
]31[
]51[
03.08.2000
11/221896
]32[
05.08.1999
]33[ JP
Int. Cl.8 A01N 047/12, 047/28, C07C 271/20, 275/24, 317/28, 323/12, C07D 213/63,
213/89, 215/14, 237/14, 239/22, 241/12, 251/30, 277/24, 277/64, 295/08, 307/12,
307/40, 317/18, 333/16
IHARA CHEMICAL INDUSTRY CO., LTD.,
JAPAN
KUMIAI CHEMICAL INDUSTRY CO., LTD.,
JAPAN
WO/2001/010825
EITAN, PEARL, LATZER AND COHEN
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
ZEDEK,
,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
P.O.B. 12688,
‫הרצליה‬
HERZLIYA 46733
]71[
]87[
]74[
[57] Carbamate compounds of the formula
wherein X is a halogen atom, a C1-C6 alkyl
group, a C1-C6 alkoxy group, a C1-C6
haloalkyl group or a C1-C6 haloalkoxy
group, n is 0 or an integer of from 1 to 4,
R1 is a C1-C6 alkyl group, R2 is a hydrogen
atom, a C1-C6 alkyl group, a C2-C6 alkenyl
group, a C2-C6 alkynyl group, a C1-C6
alkoxy group, a C1-C6 alkoxy C1-C6 alkyl
group, a C1-C6 alkylcarbonyl group, a C1June 17, 2007 – ‫א' בתמוז התשס"ז‬
C6 alkoxycarbonyl group, a C1-C6
alkylcarbonyl C1-C6 alkyl group or a
benzyl group which may the substituted,
R3 is a hydrogen atom or a C1-C6 alkyl
group, G is an oxygen atom, a sulfur atom
or a – NR4 – group, wherein R4 is a
hydrogen atom or a C1-C6 alkyl group, Y is
a hydrogen atom, a C1-C10 alkyl group
which may be substituted a halogen atom,
928
cyano group, nitro group, hydroxyl group,
C3-C6 cycloalkyl group, C1-C6 alkoxy
group, amino group, mono C1-C6
alkylamino group, di- C1-C6 alkylamino
group, C1-C6 alkylthio group, C1-C6
alkylsulfinyl group, carboxyl group, C1-C6
alkylcarbonyl group, C1-C6 alkoxycarbonyl
group, C1-C6 alkoxyimino group, or
C(O)NR5R6, wherein each of R5 and R6
which are the same or different, is a
hydrogen atom or a C1-C6 alkyl group, a
C2-C10 alkenyl group which may be
substituted by a halogen atom, cyano
group, nitro group, hydroxy group, C1-C6
alkoxy group, amino group, mono C1-C6
alkylamino group, di- C1-C6 alkylamino
group, C1-C6 alkylthio group, C1-C6
haloalkyl group, C1-C6 alkylcarbonyl
group, C1-C6 alkoycarbonyl group, or
C(O)NR5R6, wherein each of R5 and R6
which are the same or different, is a
hydrogen atom or a C1-C6 alkyl group, a
C2-C10 alkynyl group which may be
substituted by a halogen atom, cyano
group, nitro group, cycloalkyl group,
hydroxyl group, C1-C6 alkoxy group,
amino group, mono C1-C6 alkylamino
group, di- C1-C6 alkylamino group, C1-C6
alkylthio group, C1-C6 haloalkyl group, C1C6 alkylcarbonyl group, C1-C6
alkoxycarbonyl group, or C(O)NR5R6,
wherein each of R5 and R6 which are the
same or different, is a hydrogen atom or a
C1-C6 alkyl group, a C3-C6 cycloalkyl
group which may be substituted by a
halogen atom, cyano group, nitro group,
C1-C6 alkyl group, C2-C6 alkenyl group,
C2-C6 alkynyl group, hydroxyl group, C1C6 alkoxy group, amino group, mono C1C6 alkylamino group, di- C1-C6 alkylamino
group, C1-C6 alkoxy group, C1-C6 alkylthio
group, C1-C6 haloalkyl group, C1-C6
alkylcarbonyl group, C1-C6 alkoxycarbonyl
group, or C(O)NR5R6, wherein each of R5
and R6 which are the same or different, is a
hydrogen atom or a C1-C6 alkyl group, a
phenacyl group which may be substituted
by a halogen atom, C1-C6 alkyl group, C1-
929
C6 alkoxy group, C1-C6 haloalkyl group,
C1-C6 alkylcarbonyl group or C1-C6
alkoxycarbonyl group, an aryl group which
may be subsituted by a halogen atom,
cyano group, nitro group, C1-C6 alkyl
group, C2-C6 alkenyl group, C2-C6 alkylnyl
group, hydroxyl group, C1-C6 alkoxy
group, amino group, mono C1-C6
alkylamino group, di- C1-C6 alkylamino
group, C1-C6 alkylthio group, C1-C6
haloalkyl group, C1-C6 alkylcarbonyl
group, C1-C6 alkoxycarbonyl group, or
C(O)NR5R6, wherein each of R5 and R6
which are the same or different, is a
hydrogen atom or a C1-C6 alkyl group, a
heteroaryl group which may be substituted
by a halogen atom, cyano group, nitro
group, C1-C6 alkyl group, C2-C6 alkenyl
group, C2-C6 alkynyl group, hydroxyl
group, C1-C6 alkoxy group, amino group,
mono C1-C6 alkylamino group, di- C1-C6
alkylamino group, C1-C6 alkylthio group
C1-C6 haloalkyl group, C1-C6 alkylcarbonyl
group, C1-C6 alkoycarbonyl group, or
C(O)NR5R6, wherein each of R5 and R6
which are the same or different, is a
hydrogen atom or a C1-C6 alkyl group, an
aryl- C1-C6 alkyl group, wherein the aryl in
said group may be substituted by a halogen
atom, cyano group, nitro group, C1-C6
alkyl group, C2-C6 alkenyl group, C2-C6
alkynyl group, phenoxy group which may
be substituted, hydroxyl group, C1-C6
alkoxy group, amino group, mono C1-C6
alkylamino group, di- C1-C6 alkylamino
group, C1-C6 alkylthio group, C1-C6
haloalkyl group, C1-C6 haloalkoxy group,
C1-C6 alkylcarbonyl group, C1-C6
alkoxycarbonyl group, C1-C6 alkoxyimino
C1-C6 alkyl group, or C(O)NR5R6, wherein
each of R5 and R6 which are the same or
different, and is a hydrogen atom or a C1C6 alkyl group, an aryl- C1-C6 alkenyl
group wherein the aryl in said group may
be substituted by a halogen atom, cyano
group, nitro group, C1-C6 alkyl group, C2C6 alkenyl group, C2-C6 alkynyl group,
hydroxyl group, C1-C6 alkoxy group,
June 17, 2007 – ‫א' בתמוז התשס"ז‬
amino group, mono C1-C6 alkylamino
group, di- C1-C6 alkylamino group, C1-C6
alkylthio group, C1-C6 haloalkyl group, C1C6 alkylcarbonyl group, C1-C6
alkoxycarbonyl group, or C(O)NR5 R6,
wherein each of R5 and R6 which are the
same or different, is a hydrogen atom or a
C1-C6 alkyl group or a heterocyclic - C1-C6
alkyl group wherein the heterocycle in said
group may be substituted by a halogen
atom, cyano group, nitro group, C1-C6
alkyl group, C2-C6 alkenyl group, C2-C6
alkynyl group, hydroxyl group, C1-C6
alkoxy group, amino group, mono C1-C6
alkylamino group, di C1-C6 alkylamino
group, C1-C6 alkylthio group, C1-C6
haloalkyl group, C1-C6 alkylcarbonyl
group, C1-C6 alkoxycarbonyl group, or
C(O)NR5R6, wherein each of R5 and R6
which are the same or different, is a
hydrogen atom or a C1-C6 alkyl group, and
Q is a hydrogen atom, a haloalkyl group, a
cyano group, a C1-C6 alkyl group, a C3-C6
cycloalkyl group, a C1-C4 alkylthio group,
a C1-C4 alkylsulfinyl group, a C1-C4
alkylsulfonyl group or a phenyl group,
wherein said group may be substituted by a
halogen atom, cyano group, nitro group,
C1-C4 alkyl group, C2-C4 alkenyl group,
C2-C4 alkynyl group, hydroxyl group, C1C4 alkoxy group, C1-C4 haloalkyl group,
C1-C4 haloalkoxy group, C1-C4
alkylcarbonyl group or C1-C4
alkoxycarbonyl group.
__________
]11[]21[
148069
‫שיטה והתקן לגילוי קצב אפס של מסגרות‬
‫במערכת תקשורת‬
]54[
METHOD AND APPARATUS FOR
DETECTING ZERO RATE
FRAMES IN A
COMMUNICATIONS SYSTEM
]22[
]31[
]51[
]71[
31.08.2000
09/388029
]32[ 01.09.1999
]33[ US
Int. Cl.8 H03M 013/00, 013/45, H04L 001/00, 001/20, 027/06, H04Q 007/38
QUALCOMM INCORPORATED,
U.S.A.
WO/2001/017158
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]87[
]74[
[57] A method for identifying zero rate
frames in a received data transmission, the
method comprising: receiving a modulated
June 17, 2007 – ‫א' בתמוז התשס"ז‬
signal; demodulating the modulated signal
in accordance with a particular
demodulation format to generate
930
demodulated symbols; partitioning the
demodulated symbols into a plurality of
received frames; computing a quality
metric for each of the plurality of received
frames; comparing the quality metric for a
particular received frame against a
threshold value, wherein the threshold
value is selected based, in part, on the
quality metrics of received frames; and
identifying the particular received frame as
being a zero rate frame or not a zero rate
frame based on the comparing.
,179415
The applications for division
from this application have
not yet been published
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
]11[]21[
]54[
CLEAN ROOM AND METHOD
]22[
]31[
]51[
]71[
07.08.2000
391113
]32[ 07.09.1999
Int. Cl.8 E04C 002/42, E04F 015/024
SPEEDFAM-IPEC CORPORATION,
U.S.A.
WO/2001/018323
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A clean room facility comprising: a
facilities room (30); a bearing floor (2)
positioned over said facilities room and
capable of supporting equipment at any
location thereon; a regular array of
931
148274
‫חדר נקי ושיטה‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
openings (22) in said bearing floor through
which a flow of air can pass to said
facilities room; a movable wall structure
(70) positioned on said bearing floor to
surround a selected area on said bearing
June 17, 2007 – ‫א' בתמוז התשס"ז‬
floor; a ceiling (80) above said wall
structure having a plurality of filtered air
inlets (82) therein; a plurality of grates (50)
positioned in a portion of said regular array
of openings located within said selected
area; and a plurality of solid, air
impervious members (53) positioned in a
second portion of said regular array of
openings located outside said selected
area.
__________
]11[]21[
148367
‫שיטה והתקן לסיבוב מופע של אות מאופנן‬
]54[
METHOD AND APPARATUS FOR
ROTATING A PHASE OF A
MODULATED SIGNAL
]22[
]31[
]51[
]71[
14.09.2000
09/397429
]32[ 17.09.1999
]33[ US
Int. Cl.8 H03F 001/32, H04B 001/707, H04L 027/36
QUALCOMM INCORPORATED,
U.S.A.
WO/2001/020866
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]87[
]74[
[57] An apparatus comprising: a signal
processor to receive a data stream and
generate a modulated signal processor to
condition the modulated signal based on a
gain control signal and a bias control
signal which are used to adjust one or
June 17, 2007 – ‫א' בתמוז התשס"ז‬
more characteristics of the at least one
circuit element, wherein the signal
processor comprises: a spreader to spread
the data stream with pseudo-random noise
(PN) sequences to generate spread data,
and a modulator to modulate the spread
932
data with one or more carrier signals,
wherein a phase rotation of the modulated
signal cause by adjustment of one or more
characteristics of the at least one circuit
element is determined and compensated
based on the gain control signal and the
bias control signal, and is further based on
rotating a phase of at least one of (a) the
pseudo-random noise (PN) sequences, (b)
the spread data generated by the spreader,
and (c) one or more carrier signals that are
used to modulate the spread data, wherein
the phase rotation is by an amount of the
determined phase rotation and in an
opposite direction relative to the direction
of the determined phase rotation.
__________
]11[]21[
148370
‫אלגוריתם מותאם להקצאות אצבע עבור‬
‫שיחות בעלות צפיפות נתונים‬/‫קריאות‬
‫גבוהה‬
]54[
MODIFIED FINGER
ASSIGNMENT ALGORITHM FOR
HIGH DATA RATE CALLS
]22[
]31[
]51[
]71[
15.09.2000
09/398905
]32[ 15.09.1999
]33[ US
Int. Cl.8 H04B 001/38, 001/707, 007/216, H04J 003/14
QUALCOMM INCORPORATED,
U.S.A.
WO/2001/020802
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]87[
]74[
[57] In a wireless communication system,
a method of creating a path list for finger
assignment comprising: choosing a base
station sector for consideration; receiving a
signal from said sector; estimating a
(Ec/Io) of the received signal; if said sector
933
is transmitting a supplemental channel,
biasing the (Ec/Io) of the received signal
by a predetermined value; and adding said
biased Ec/Io of the received signal to said
path list.
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫__________‬
‫‪148378‬‬
‫כוס אשר מתקפלת לצורה שטוחה‬
‫אלי לויס‪ ,‬רמת גן‬
‫אלי לויס‪,‬‬
‫הרואה ‪ ,101‬רמת גן‬
‫[‪ ]57‬כוס מתקפלת בעלת שלוש דפנות‬
‫אשר ניתנת להעמדה על תחתיתה‪,‬‬
‫במצבה הפתוח‪ ,‬ואשר כל דפנותיה וגם‬
‫תחתיתה עשויות יציקה אחת‪ ,‬באופן‬
‫שחוסם מעבר של חומר אשר נתון‬
‫‪934‬‬
‫[‪]11[]21‬‬
‫‪CUP THAT FOLDS INTO A FLAT‬‬
‫‪FORM‬‬
‫[‪]54‬‬
‫‪26.02.2002‬‬
‫‪Int. Cl.8 A45F 003/16‬‬
‫‪ELI LEVIS‬‬
‫‪ELI LEVIS,‬‬
‫‪HA'ROE ST. 101 RAMAT-GAN‬‬
‫[‪]22‬‬
‫[‪]51‬‬
‫[‪]71‬‬
‫[‪]74‬‬
‫בתוכה‪ ,‬ואשר במצבה המקופל‪ ,‬תחתיתה‬
‫מקופלת קיפול יחיד ומשוכה כלפי פנים‬
‫הכוס וכן מקופלת כלפי פנים הכוס דופן‬
‫אחת שלה‪.‬‬
‫א' בתמוז התשס"ז – ‪June 17, 2007‬‬
__________
]11[]21[
148400
‫מבנה מודולרי ושיטה ליצורו‬
]54[
MODULAR CONSTRUCTION
AND METHOD FOR ITS
CONSTRUCTION
]22[
]51[
]71[
]74[
26.02.2002
Int. Cl.8 E04B 001/12, 002/86, E04C 002/20, 002/40
DYNAMIC SHELLS LTD.
‫ תל אביב‬,‫דיינמיק שלס בע"מ‬
REINHOLD COHN AND
,‫ריינהולד כהן ושותפיו‬
PARTNERS,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A building construction assembly
comprising:
(a) a group of modules (11A, 11C) which
are interconnectable to create a shell of an
935
edifice, each module in the group is
defined by a pair of parallel lateral
longitudinal panels (21) having opposite
ends, wherein said lateral panels are
June 17, 2007 – ‫א' בתמוז התשס"ז‬
bridged by at least one transversal web
(22) extending between the panels;
(b) a joiner (SJ) for interconnecting
modules in the group, said joiner having at
least two faces (23, 24) detachably
connectable to the opposite ends of the
module, characterized in that each lateral
panel terminates at either of the opposite
ends thereof with a flexible catch region
having a long portion and a short, bent-in
portion and either face of the joiner is
provided with a pair of teeth adapted when
a face of the joiner is pressed against either
of the catch regions of the module to urge
the long portion to flex and the bent-in
portion to snap into and behind the teeth
and thus to connect either of the opposite
ends of the module to the joiner.
__________
]11[]21[
148412
‫העברה באמצעות אנטנה במערכת‬
CDMA ‫תקשורת‬
]54[
TRANSMISSION USING AN
ANTENNA IN A CDMA
COMMUNICATION SYSTEM
]22[
]31[
]51[
]71[
17.08.2000
394452
]32[ 10.09.1999
]33[ US
Int. Cl.8 H04B 001/707, 007/04, 007/216
INTERDIGITAL TECHNOLOGY
CORPORATION, U.S.A.
WO/2001/018993
REINHOLD COHN AND
,‫ריינהולד כהן ושותפיו‬
PARTNERS,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A method for use in a spread
spectrum communication system having a
June 17, 2007 – ‫א' בתמוז התשס"ז‬
plurality of transmitting antennas, the
method characterized by: transmitting
936
from each transmitting antenna a pilot
signal having a pseudo random chip code
sequence uniquely associated with that
antenna receiving at the receiver all of said
transmitted pilot signals; filtering each said
transmitted pilot signal using that pilot
signal's pseudo random chip code
sequence; weighting each said filtered pilot
signal by a particular weight; cornbining
said weighted pilot signals as a combined
signal; adaptively adjusting each said pilot
signal's weight based in part on a signal
quality of the combined signal;
transmitting a data signal such that
different spread spectrum versions of the
data signal are transmitted from each
antenna, each version having a different
chip code identifier for the respective
transmitting antenna; and receiving the
data signal via filtering each version with
its associated chip code and combining the
filtered versions, wherein the different data
signal versions are weighted in accordance
with the adjusted weights associated with
the pilot signal of the respective antenna.
,181375
The applications for division
from this application have
not yet been published
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
]11[]21[
]54[
METHOD FOR THE
TRANSMISSION OF IMAGE
DATA
]22[
]51[
]71[
30.12.1999
Int. Cl.8 H04N 007/173, 007/24
SWISSCOM MOBILE AG,
SWITZERLAND
ERIC LAUPER,, RUDOLF RITTER
WO/2001/050754
]72[
]87[
937
148431
‫שיטה למשלוח נתוני דמות‬
June 17, 2007 – ‫א' בתמוז התשס"ז‬
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688, HERZLIYA 46733
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
[57] Sending device, characterized in that
is includes the following components: a
receiver for receiving data comprising the
viewing direction of at least one user (9)
transmitted over a reverse channel, a first
encoding module (3) for compressing first
image data with a low resolution and
sending them over a first transmission
channel (4) in broadcast mode, a second
encoding module (5) for compressing
second image data corresponding to image
areas viewed currently or in future by said
at least one user, with a high resolution and
sending them over a second transmission
channel(7).
]74[
__________
]11[]21[
148464
‫פניל סולפאמואיל קרבוקסאמידים‬
‫מותמרים באורציל‬
]54[
URACIL SUBSTITUTED PHENYL
SULFAMOYL CARBOXAMIDES
]22[
]31[
]51[
30.04.2001
60/201824
]32[ 04.05.2000
]33[ US
Int. Cl.8 A01N 043/00, C07D 213/61, 231/20, 237/14, 239/54, 249/12, 401/12,
471/04
BASF AKTIENGESELLSCHAFT,
GERMANY
WO/2001/083459
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]71[
]87[
]74[
[57] Substituted phenyl sulfamoyl
carboxamides of the formula
June 17, 2007 – ‫א' בתמוז התשס"ז‬
938
wherein the variables have the following
meanings:
A oxygen or sulfur;
X1 hydrogen, halogen, or C1-C4-alkyl;
X2 hydrogen, cyano, CS-NH2, halogen, C1C4-alkyl or C1-C4-haloalkyl;
X3 hydrogen, cyano, C1-C6 – alkyl, C1-C6 –
alkoxy-alkyl, C3-C7-cycloalkyl, C3-C6alkenyl, C3-C6-alkynyl or optionally
substituted benzyl;
R1 and R2 independently of one another
hydrogen, halogen, OR48, C1-C10 – alkyl,
C2-C10 – alkenyl, C3-C10-alkynyl, C3-C7cycloalkyl, phenyl, benzyl or C5-C7cycloalkenyl, whereas each of the last –
mentioned 7 groups can be substituted
with any combination of one to six halogen
atoms, one to three C1-C6 – alkoxy groups,
one or two C1-C8 – haloalkoxy groups, one
or two cyano groups, one or two C3-C7 –
cycloalkyl groups, one or two C(O)R49
groups, one or two CO-OR50 groups, one
or two CO-SR51 groups, groups, one to
three SR54 groups, one optionally
substituted four to 10-membered
monocyclic or fused bicyclic heterocyclic
ring, one or two optionally substituted
phenyl groups or one or two optionally
substituted benzyl groups; pyridyl; or
naphthyl; or R1 and R2 together with the
atom to which they are attached form a 3to 7-membered heterocyclic ring; Q is
selected from 5 or 6 membered nitrogen
containing heterocyclic rings defined in the
specification and R48, R49, R50, R51, R52,
R53, R54, independently of one another are
hydrogen, C1-C6 –alkyl, C1-C6 – haloalkyl,
C3-C7-cycloalkyl, C2-C6 – alkenyl, C3-C6 –
alkynyl, optionally substituted phenyl or
optionally substituted benzyl; and their
agriculturally useful salts.
__________
]11[]21[
148560
‫תוף עשוי חומר פלסטי המורכב על כלי‬
‫רכב לצורך עירבול בטון ושיטות ליצורו‬
]54[
VEHICLE MOUNTED PLASTICS
DRUM FOR CONCRETE MIXING
AND METHODS OF
MANUFACTURE THEREOF
]22[
]31[
09.10.2000
PQ3338
]32[ 08.10.1999
]33[ AU
PQ4054
15.11.1999
AU
Int. Cl.8 B28C 005/18, 005/42, B29C 041/22
ANTHONY KHOURI, AUSTRALIA
WO/2001/026871
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]51[
]71[
]87[
]74[
939
June 17, 2007 – ‫א' בתמוז התשס"ז‬
[57] A heavy duty rotary concrete mixing
drum comprising: a first end which
engages a vehicle powered drive assembly
which rotates said drum for mixing of said
concrete and a second end from which
mixed concrete is discharged; wherein said
drum is manufactured from at least one
layer of plastics material, wherein the
drum includes a wall having integral
internal formations which promote mixing
and discharge of said concrete and an inner
surface which promotes mixing of the
concrete, wherein the internal formations
radially project toward an axial centerline
of the drum and wherein the internal
formations have a radial midportion having
a cross-section formed entirely from one or
more layers of substantially non-metallic
materials.
__________
]11[]21[
]54[
METHOD AND SYSTEM FOR
OVERLAY MEASUREMENT
]22[
]51[
]71[
07.03.2002
Int. Cl.8 G03F 007/20
NOVA MEASURING
INSTRUMENTS LTD.
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]74[
148566
‫שיטה ומערכת למדידת דיוק חפיפה‬
‫ רחובות‬,‫נובה מכשירי מדידה בע"מ‬
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
[57] A method for imaging two target
structures in two parallel layers,
respectively, of a sample, the method
enabling determination of a registration
between the two target structures along
two mutually perpendicular axes of the
layer, the method comprising:
(a) illuminating the sample with incident
radiation to produce a radiation response
of the sample to said incident radiation;
(b) collecting the radiation response by an
objective lens arrangement;
(c) splitting the collected radiation
response into two spatially separated
radiation components and directing the
split radiation components towards at least
one imaging plane along different optical
channels characterized by optical paths of
different lengths, respectively;
(d) detecting said two split radiation
components in said at least one imaging
plane, thereby concurrently acquiring two
image parts, each containing images of the
two target structures, and enabling
determination of the relative distance
between the two target structures.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
148700
940
SYSTEM AND APPARATUS FOR
‫מערכת ומכשור לטלקומוניקציה‬
TELECOMMUNICATION
]22[ 03.07.2000
]31[ 397959
]32[ 17.09.1999
]33[ US
]51[ Int. Cl.8 H04L 012/56, 012/66, 029/06, H04M 011/00
]71[ INTERTEX DATA AB, SWEDEN
]72[ KARL ERIK STAHL
]87[ WO/2001/020890
]74[ JEREMY M. BEN-DAVID & CO.
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
LTD.,
,45087 .‫ד‬.‫ ת‬, ‫ הר חוצבים‬,‫רחוב המרפא‬
HAR HOTZVIM HI-TECH PARK,
‫ירושלים‬
P.O. B. 45087,
JERUSALEM 91450
telecommunication network; and gateway
[57] System for telecommunication
means for establishing a path between said
utilizing both a circuit switched
first port and said second port inside said
telecommunication network and a packet
telecommunication apparatus in response
based telecommunication network,
to a request imbedded in an incoming call
comprising: multiple telecommunication
from the packet telecommunication
apparatus for initiating and receiving voice
network, whereby said telecommunication
and data calls, each said
apparatus can serve as part of a distributed
telecommunication apparatus having a first
gateway system between said circuit
port connected to said circuit switched
switched telecommunication network and
telecommunication network; a second port
said packet based telecommunication
connected to said packet based
network.
]54[
__________
941
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
]54[
PRINTED WELDABLE FLEXIBLE
POLYMER MATERIAL FOR
PRODUCING STRETCHED
STRUCTURES SUCH AS FALSE
CEILINGS
]22[
]31[
]51[
]71[
]87[
]74[
29.09.2000
99/12426
]32[ 30.09.1999
Int. Cl.8 B32B 033/00, E04B 009/30
NEWMAT, S.A., FRANCE
WO/2001/023683
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
[57] A prefabricated material for making
hot-tensioned structures to form a false
ceiling or a false wall, the material
comprising: one or more thin flexible
sheets (2a-2b); each sheet being sized and
configured to be retained in a respective
frame in a tensioned state at an ambient
temperature; each sheet including direct
printing of predeformed designs of shapes
June 17, 2007 – ‫א' בתמוז התשס"ז‬
148911
‫חומר פולימרי מודפס גמיש הניתן לריתוך‬
‫לייצור מבנים גמישים כמו תיקרות מדומות‬
]33[
FR
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
and dimensions, the predeformed designs
taking account of differential lengthening
of the printed material during hottensioning, said predeformed designs
substantially compensating for distortion
in the design caused by the being hottensioned, and thus ensuring that a
properly proportioned design is obtained
on the tensioned material.
942
__________
]11[]21[
149010
,‫–איל–אמין ביציקליות‬5–‫נגזרות אימידאזו‬
‫הכנתן ותכשירי רוקחות המכילים אותן‬
]54[
BICYCLIC IMIDAZO-5-YL-AMINE
DERIVATIVES, THEIR
PREPARATION AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM
]22[
]31[
18.09.2000
19948436.8
]32[ 08.10.1999
]33[ DE
19948434.1
08.10.1999
DE
Int. Cl.8 A61K 031/4196, 031/429, 031/433, 031/675, 031/695, A61P 029/00, C07D
487/04, 513/00, 513/04, C07F 007/10, 009/645, 009/6518
GRUNENTHAL GMBH, GERMANY
WO/2001/027118
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] A bicyclic imidazo-5-yl-amine of the
formula
943
June 17, 2007 – ‫א' בתמוז התשס"ז‬
wherein
R1 denotes C(CH3)3; (CH2)6 CN;
optionally substituted phenyl; C4-C8 –
cycloalkyl; CH2 CH2 R (R=4-morpholino);
1, 1, 3, 3-tetramethylbutyl; or CH2 Ra,
wherein Ra represents hydrogen, branched
or unbranched C1-C8 – alkyl, optionally
substituted phenyl, CO(OR') (where
R'=branched or unbranched C1-C8 – alkyl),
PO(OR")2 (where R"=branched or
unbranched C1-C4 – alkyl) or Si (Rx Ry Rz)
(where Rx, Ry and Rz in each case
independently of one another are branched
or unbranched C1-C8
– alkyl, C4-C8 – cycloalkyl or phenyl), R2
denotes hydrogen; CORb, wherein Rb
represents hydrogen, branched or
unbranched C1-C8 – alkyl, C3-C8 –
cycloalkyl, CH2, CH2 CO (OR') (where
R'=branched or unbranched C1-C8 – alkyl),
adamantyl, optionally substituted phenyl,
optionally substituted 1-naphthyl, 2naphthyl, 2-pyridyl, 3-pyridyl, 4-pyridiyl,
thiazolyl or furoyl; CH2 Rc represents
hydrogen, branched or unbranched C1-C8 –
alkyl or optionally substituted phenyl; CH2
CH2 Rd, wherein Rd represents optionally
substituted phenyl; or CONHRe, wherein
Re represents phenyl,
R3 denotes branched or unbranched C1-C8
– alkyl, C3-C8 – cycloalkyl, optionally
substituted phenyl, optionally substituted
1-naphthyl, 2-naphthyl, quinoline,
anthracene, phenanthrene, benothiophene,
benzofurfuryl, optionally substituted
pyrrole, 2-pyridyl, 3-pyridyl, 4-pyridyl,
optionally substituted furfuryl or
optionally substituted thiophene,
X denotes S, and
June 17, 2007 – ‫א' בתמוז התשס"ז‬
Y is N or CR6,
R4, R5 and R6 independently of one another
denote hydrogen; branched or unbranched
C1-C8 – alkyl; fluorine; chlorine; bromine;
CF3; CN; NO2 NHRf, wherein Rf
represents hydrogen, branched or
unbranched C1-C8 – alkyl or optionally
substituted phenyl; SRg, wherein Rg
represents hydrogen, branched or
unbranched C1-C8 – alkyl, phenyl,
pyridine, benzyl or fluorenyl; ORh,
wherein Rh represents branched or
unbranched C1-C8 – alkyl, optionally
subsituted phenyl or CO(OR')
(R'=branched or unbranched C1-C8 –
alkyl); CO(OR') or CH2 CO (OR'),
wherein R' in each case has the
abovementioned meaning or in the case of
the group CH2 CO (OR') also denotes
hydrogen, or an optionally substituted
phenyl group, wherein optionally
substituted phenyl, optionally substituted
1-naphthyl, optionally substituted pyrrole,
optionally substituted thiophene, and
optionally substituted alkyl is optionally
substituted by one or more substituents
selected from the group consisting of a
halogen atom, cyano group, nitro group,
carboxyl group, hydroxyl group, C1-C4
alkylamido group, C1-C4 alkylamino
group, pyrrolidino group,branched or
unbranched C1-C6 alkyl group, C1-C4 alkyl
group substituted with one or more
halogen atoms, C1-C4 alkoxy group, C1-C4
alkoxy group substituted with one or more
halogen atoms, and halogen substituted
phenoxy group,
or a pharmaceutically acceptable salt
thereof, excluding compounds in which
simultaneously R1 denotes C(CH3)3, R2
944
denotes hydrogen, R3 denotes
unsubstituted phenyl, X denotes S, and Y
denotes N or CR6, where R6 =hydrogen or
CH2 – CO2 –ethyl, or simultaneously R1
denotes C(CH3)3, R2 denotes hydrogen, R3
denotes unsubstituted phenyl, Y denotes
NH, and X denotes N or CR5, where R5
=CO2 ethyl.
__________
]11[]21[
149030
,‫תכשירי רוקחות המכילים ריפאמפיצין‬
‫אזוניאזיד או תערובות שלהן‬
]54[
PHARMACEUTICAL
COMPOSITIONS CONTAINING
RIFAMPICIN, ISONIAZID OR
COMBINATIONS THEREOF
]22[
]31[
]51[
]71[
]87[
]74[
10.04.2001
720/DEL/2000 ]32[ 09.08.2000
]33[ IN
Int. Cl.8 A61K 009/00, 009/48, C07D 498/00
PANACEA BIOTEC LIMITED, INDIA
WO/2002/011728
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
[57] An oral pharmaceutical composition
of anti-tubercular drugs comprising
Rifampicin and Isoniazied, characterized
in that the degradation of Rifampicin due
to interaction with Isoniazid is avoided by
preventing their contact with each other in
the acidic environment of the gastric
region by delaying or extending the release
of Rifampicin or Isoniazid or both such
that minimal drug is dissolved at a pH
between 1 and 4.
__________
]11[]21[
945
149080
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]54[
SYSTEM AND METHOD FOR
DATA VISUALIZATION
]22[
]31[
]51[
]71[
17.10.2000
09/426811
]32[ 22.10.1999
Int. Cl.8 G06T 011/20
BATTELLE MEMORIAL
INSTITUTE, U.S.A.
WO/2001/031586
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
]87[
]74[
[57] A data visualization apparatus
comprising: an image device configured to
provide a visual image, and digital
processing circuitry coupled with the
image device and configured to access data
including a plurality of themes, to generate
a thematic illustration corresponding to the
themes and having a plurality of outer
‫מערכת ושיטה להחזיית נתונים‬
]33[
US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
contour lines which are spaced at varying
distances relative to a reference line, and to
control the image device to depict the
thematic illustration, wherein at least one
of the outer contour lines is spaced at the
varying distances relative to the reference
line corresponding to strengths of plural
ones of the themes.
__________
]11[]21[
]54[
PHARMACEUTICAL
COMPOSITIONS CONTAINING
TOFISOPAM
June 17, 2007 – ‫א' בתמוז התשס"ז‬
149134
‫תכשירי רוקחות המכילים טופיזופם‬
946
]22[
]31[
]51[
]71[
]74[
15.04.2002
60/292026
]32[ 18.05.2001
]33[ US
10/008516
08.11.2001
US
Int. Cl.8 A61K 031/551, A61P 025/08, C07D 243/10
VELA PHARMACEUTICALS, INC.,
U.S.A.
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
[57] A composition comprising a
therapeutically effective amount of Stofisopam, a prodrug or a pharmaceutically
acceptable salt thereof, substantially free
of its (R) enantiomer, with a
pharmaceutically acceptable carrier.
__________
]11[]21[
149303
‫מערכת מרכזית לכתיבת סתרים ושיטה‬
‫בעלת קצב גבוה לכתיבת סתרים‬
]54[
CENTRALIZED
CRYPTOGRAPHIC SYSTEM AND
METHOD WITH HIGH
CRYPTOGRAPHIC RATE
]22[
]31[
]51[
]71[
02.11.2000
2045/99
]32[ 08.11.1999
]33[ CH
Int. Cl.8 G06K 019/00, G07F 007/10, H04L 009/00, H04N 007/167
NAGRAVISION S.A.,
SWITZERLAND
WO/2001/035659
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]87[
]74[
[57] A centralized high cryptographic rate
system localized in an operating centre and
intended to treat data to be transmitted to a
plurality of user modules, comprising: a
control module (CM) to administer the
entry/exit of data to be processed by the
system, and at least one cryptographic
module to ensure the authenticity of the
data, characterised in that each
947
cryptographic module comprises at least
one interface module to provide an
interface between the control module and a
plurality of monolithic security units
(PIM), the monolithic security units PIM
physically protecting the control module
and the interface module, and are
connected in parallel to the at least one
interface module.
June 17, 2007 – ‫א' בתמוז התשס"ז‬
__________
]11[]21[
149370
‫–טריאזול‬H1–1,2,4–‫–אריל‬5 ‫תרכובות של‬
‫ ותכשירי‬2– ‫כמעכבים של ציקלוקסיג'נז‬
‫רוקחות המכילים אותם‬
]54[
5-ARYL-1H-1,2,4-TRIAZOLE
COMPOUNDS AS INHIBITORS OF
CYCLOOXYGENASE-2 AND
PHARMACEUTICAL
COMPOSITIONS CONTAINING
THEM
]22[
]31[
]51[
]71[
06.11.2000
99402784.5
]32[ 09.11.1999
]33[ EP
Int. Cl.8 A61K 031/4196, A61P 029/00, C07D 249/08, 401/04, 405/04
LABORATOIRE THERAMEX,
MONACO
WO/2001/034577
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A compound of the formula
June 17, 2007 – ‫א' בתמוז התשס"ז‬
948
in which:
Ri is hydrogen; a (C1-C6) alkyl; a halo (C1C6) alkyl; or a phenyl optionally
substituted by one or several substituents
selected from the group consisting of a
(C1-C4) alkyl, a halogen, a halo (C1-C4)
alkyl, a hydroxy, a (C1-C4) alkoxy, an
amino, a mono- or di-(C1-C4) alkylamino,
a (C1-C4) alkylcarbonylamino, a (C1-C4)
allkylthiocarbonylamino, a (C1-C4)
alkoxycarbonylamino, a (C1-C4)
alkoxythiocarbonylamino, a (C1-C4)
alkylsulfonyl, a (C1-C4)
alkylsulfonylamino, a methylenedioxy, a
nitro and a cyano; R2 is a (C1-C6) alkyl; a
(C3-C8) cycloalkyl; or a phenyl or a phenyl
(C1-C4) alkyl in which the phenyl is
optionally substituted by one or several
substituents selected from the group
consisting of a (C1-C4) alkyl, a halogen, a
halo (C1-C4) alkyl, a hydroxy, a (C1-C4)
alkoxy, an amino, a mono-or di-(C1-C4)
alkylamino, a (C1-C4)
alkylcarbonaylamino, a (C1-C4)
alkylcarbonylamino, a (C1-C4)
alkylthiocarbonylamino, a (C1-C4)
alkoxythiocarbonylamino, a (C1-C4)
alkylsulfonyl, a (C1-C4)
alkylsulfonylamino, a methylenedioxy, a
nitro and a cyano; or a heteroaromatic
group selected among pyridinyl,
pyridazinyl, pyrazinyl, pyrimidinyl,
pyrazolyl, quinolinyl, isoquinolinyl,
benzimidazolyl, benzoxazolyl,
benzothiazolyl, indolyl or indazolyl
radical; R3 is hydrogen; a halogen; a
hydroxy; a (C1-C6) alkoxy; an amino; a
mono- or di-(C1-C6) alkylamino; a (C1-C6)
alkylcarbonylamino; a (C1-C6)
alkylthiocarbonylamino; a (C1-C6)
carbonylamino; a (C1-C6)
alkoxythiocarbonylamino; a nitro; or a
cyano;
R4 is a (C1-C6) alkyl; an amino; a mono-or
di-(C1-C6) alkylamino; a (C1-C6)
alkylcarbonylamino; a (C1-C6)
alkylthiocarbonylamino; a (C1-C6)
alkoxycarbonylamino; or a (C1-C6)
alkoxythiocarbonylamino; or a
pharmaceutical acceptable salt thereof.
__________
]11[]21[
]54[
COMPOSITION CONTAINING AN
ANGIOTENSIN II ANTAGONIST
FOR THE TREATMENT OF
GLAUCOMA
]22[
]31[
01.12.2000
11/341524
2000-78769
949
]32[
01.12.1999
21.03.2000
149444
II ‫תכשיר המכיל אנטגוניסט לאנגיוטנזין‬
‫לטפול בברקית‬
]33[
JP
JP
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]51[
]71[
]87[
]74[
Int. Cl.8 A61K 031/41, 031/44, 045/00, A61P 027/06, C07D 257/00, 257/04, 401/12,
403/12
SANKYO COMPANY LIMITED,
JAPAN
WO/2001/039805
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
[57] An agent for the prophylaxis or
treatment of glaucoma, which comprises
an angiotensin II antagonist and a
prostaglandin as active ingredients for
simultaneous, separate or successive use of
said active ingredients, wherein the
angiotensin II antagonist is a compound of
the below-described formula (I) or a
pharmacologically acceptable salt or ester
thereof:
wherein R1 represents a group having the
below-described structural formula
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
149601
950
‫מלחי אמינו פרודרגים חד–ודו אורגניים של‬
‫ מלחות‬,‫ פוספטי‬A–4 ‫קומברטסטטין‬
‫ ומלחות אסטר‬,‫חומצות חד–ודו–אמיניות‬
‫חומצות חד–ודו–אמיניות‬
]54[
COMBRETASTATIN A-4
PHOSPHATE PRODRUG MONOAND DI-ORGANIC AMINE
SALTS, MONO-AND DI-AMINO
ACID SALTS AND MONO-AND
DI-AMINO ACID ESTER SALTS
]22[
]31[
12.09.2001
60/232568
]32[ 14.09.2000
]33[ US
60/251921
07.12.2000
US
Int. Cl.8 A61K 031/66, A61P 035/00, C07C 211/14, 215/10, 215/12, 229/08, 279/14,
C07D 209/20, 233/61, C07F 009/00, 009/12, 009/6506
BRISTOL-MYERS SQUIBB
COMPANY, U.S.A.
WO/2002/022626
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]51[
]71[
]87[
]74[
[57] A compound of the formula
wherein:
one of –OR1 or –OR2 is –O-QH+, and the
other is hydroxyl or –O-QH+; and Q is
(A) an optionally substituted aliphatic
organic amine containing at least one
nitrogen atom which, together with a
proton, forms a quaternary ammonium
cation QH+;
(B) an amino acid containing at least two
nitrogen atoms where one of the nitrogen
The applications for division
from this application have
not yet been published
atoms, together with a proton, forms a
quaternary ammonium cation QH+; or
(C) an amino acid containing one or more
nitrogen atoms where one of the nitrogen
atoms, together with a proton, forms a
quaternary ammonium cation QH+ and
where, further, all carboxylic acid groups
of the amino acid are in the form of esters.
,176088
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
]11[]21[
951
149637
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫שיטה למיקרואנקפסולציה‬
]54[
METHOD OF
MICROENCAPSULATION
]22[
]31[
]51[
]71[
]72[
16.11.2000
9927202.3
]32[ 17.11.1999
Int. Cl.8 A61K 009/00, 009/16, 009/50
TAGRA BIOTECHNOLOGIES LTD.
VLADIMIR BABTSOV, YURI
SHAPIRO, EMMA KVITNITSKY
WO/2001/035933
PAULINA BEN-AMI, BEN-AMI &
ASSOCIATES,
P.O.BOX 94
REHOVOT 76100
]87[
]74[
[57] A method for the production of
microcapsules for dermal application,
wherein the microcapsules consist of a
polymer shell and a core made of an
encapsulated substance, said method
comprising the steps of:
(a) dissolving or dispersing the substance
in an organic solvent of a kind that is
partially miscible in water and is capable
of dissolving or dispersing said substance,
together with a wall-forming polymeric
material selected from the group consisting
of a polyacrylate, a polymethacrylate, a
cellulose ether, a cellulose ester, and poly
(styrene-co-maleic anhydride), to form an
organic solution or dispersion;
]33[
GB
‫טאגרה ביוטכנולוגיות בע"מ‬
‫ אמה קויטניצקי‬,‫ יורי שפירו‬,‫ולדימיר בבצוב‬
,'‫ בן עמי ושות‬, ‫עמי‬-‫פאולינה בן‬
‫ רחובות‬,94 .‫ד‬.‫ת‬
(b) preparing an aqueous continuous phase
saturated with said organic solvent and
comprising an emulsifier;
(c) while agitating, pouring the organic
solution or dispersion obtained in (a) into
the aqueous continuous phase obtained in
(b), to form an emulsion;
(d) adding an excess amount of water to
the emulsion obtained in (c) for extraction
of the organic solvent from the emulsion,
thus forming solid microcapsules; and
(e) either (i) isolating the microcapsules,
washing with water, and drying at a
temperature not higher than 20o C., or (ii)
immersing the microcapsules in an
aqueous solution of alcohol, separating the
microcapsules, and drying at a temperature
not higher than 20o C.
__________
]11[]21[
]54[
POLYMORPHIC FORM OF
ATORVASTATIN CALCIUM
]22[
]31[
]51[
]71[
16.11.2000
60/166153
]32[ 17.11.1999
Int. Cl.8 A61K 031/40, C07D 207/335
TEVA PHARMACEUTICAL
INDUSTRIES LTD.
]87[
WO/2001/036384
June 17, 2007 – ‫א' בתמוז התשס"ז‬
149681
‫צורה פולימורפית של אטורבסטטין‬
‫קלציום‬
]33[
US
‫ פתח‬,‫טבע תעשיות פרמצבטיות בע"מ‬
‫תקווה‬
952
]74[
,‫טבע תעשיות פרמצבטיות בע"מ‬
‫ פתח תקוה‬,3190 .‫ד‬.‫ ת‬, 5‫בזל‬
TEVA PHARMACEUTICAL
INDUSTRIES LTD.,
5 BASEL ST., P.O.BOX 3190,
PETAH TIQVA 49131
[57] A crystalline form of atorvastatin
calcium or hydrate thereof, characterized
by data selected from the group consisting
of:
an X-ray diffraction pattern having peaks
at 5.3±0.2 and 8.3±0.2 degrees two theta
and a broad peak at 18-23±0.2 degrees two
theta; and a solid state 13C NMR spectrum
having signals at 21.9, 25.9, 118.9, 122.5,
128.7, 161.0 and 167.1 ppm.
__________
]11[]21[
]54[
MIXTURE AND METHOD FOR
PRESERVING SENSITIVE
BIOLOGICAL MATERIAL SUCH
AS VIRUS, BACTERIA OR OTHER
CELLS
]22[
]31[
]51[
]71[
22.11.2000
60/166928
]32[ 22.11.1999
Int. Cl.8 A01N 001/02
UNIVERSAL PRESERVATION
TECHNOLOGIES, INC., U.S.A.
WO/2001/037656
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
953
149778
‫תערובת ושיטה לשימור חומר ביולוגי רגיש‬
‫ בקטריה או תאים אחרים‬,‫כגון וירוס‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
June 17, 2007 – ‫א' בתמוז התשס"ז‬
[57] A preservation mixture comprising:
a virus, bacteria or other cell which is
sensitive to loss of viability during drying
and storage at ambient or higher
temperatures; a methylated
monosaccharide selected from the group
consisting of methyl α-glucopyranoside
and methyl β-glucopyranoside; and a
disaccharide selected from the group
consisting of sucrose and trehalose, or
alternatively, an oligosaccharide, wherein
the preservation mixture has a total solute
mass, and wherein the methylated
monosaccharide comprises between 5%
and 80% wt% of the total solute mass, and
the disaccharide, or alternatively an
oligosaccharide, comprises between 5%
and 80% wt% of the total solute mass.
__________
]11[]21[
]54[
METHOD FOR SURVEILLANCE
OF THE QUALITY OF SERVICE
IN A DIGITAL TELEVISION LINK
149877
‫שיטת מעקב אחר איכות השירות בחיבור‬
‫טלוויזיוני דיגיטלי‬
]22[
]31[
]51[
]71[
08.11.2000
99/15926
]32[ 13.12.1999
]33[ FR
Int. Cl.8 H04H 001/00, H04N 007/26, 017/00
TELEDIFFUSION DE FRANCE,
FRANCE
]87[ WO/2001/045427
]74[ SELIGSOHN GABRIELI & CO.,
,'‫זליגסון גבריאלי ושות‬
31 YAVNE ST.,
‫ תל אביב‬,1426 .‫ד‬.‫ ת‬, 31 ‫רח' יבנה‬
P.O.B. 1426,
TEL AVIV 61013
determining (E1 to E6) the maximum of
the variations (∆TSSL, ∆PATE, ∆PMTE)
[57] A quality-of-service surveillance
in the preselected first analysis parameters
method for use in a transmission link of
and the maximum of the variations (∆CCE,
digital television signal including cyclic
∆TE; ∆CRCE, ∆PCRE, ∆NITE, ∆SDTE)
analysis of transport stream (TS) packets
in the preselected second analysis
constituting the signal to deduce therefrom
parameters to deduce therefrom,
a predetermined number of analysis
respectively, a first parameter (SS)
parameters, characterized by the following
tepresentative of the synchronization
steps: preselecting first analysis parameters
relative to equipment units (EM, REC, LI)
(TSSL, PATE, PMTE) and second analysis
in the link and a second parameter (DS;
parameters (CCE, TPE; CRCE, PCRE,
FD) representative of a degradation of
NITE, CDTE), and periodically
services.
June 17, 2007 – ‫א' בתמוז התשס"ז‬
954
__________
]11[]21[
]54[
TANGENTIAL CUTTING INSERT
AND MILLING CUTTER
]22[
]51[
]71[
]72[
]74[
04.06.2002
Int. Cl.8 B23B 027/16, B23C 005/22
ISCAR LTD.
AMIR SATRAN, DANIEL DAGAN
ISCAR LTD.,
P.O. BOX 11, TEFEN 24959
[57] A tangential cutting insert (10)
comprising: two identical
955
150012
‫שימה טנגנצ'יאלית וכרסום‬
‫ תפן‬,‫ישקר בע"מ‬
‫ דניאל דגן‬,‫אמיר סטרן‬
,‫ישקר בע"מ‬
‫ תפן‬,11 .‫ד‬.‫ת‬
opposing end surfaces having 180o
rotational symmetry about a first axis
June 17, 2007 – ‫א' בתמוז התשס"ז‬
passing therethrough, a peripheral side
surface (14) extending between the two
opposing end surfaces (12), and a
peripheral edge formed at the intersection
of each end surface and the peripheral side
surface, at least two sections of each
peripheral edge constituting cutting edges;
the peripheral side surface comprising: two
identical opposing major side surfaces (18)
having 180o rotational symmetry about a
second axis passing therethrough, the
second axis being perpendicular to the first
axis;
two identical opposing minor side surfaces
having 180o rotational symmetry about a
third axis passing therethrough, the third
axis being perpendicular to the first axis
and the second axis; a minor plane defined
by the first axis and the second axis; a
major plane defined by the first axis and
the third axis; a median plane being
defined by the second axis and the third
axis; each end surface having four corners,
two lowered corners and two raised
corners, the lowered corners being closer
to the median plane than the raised
corners; each end surface being provided
with at least one projecting abutment
member having a projecting abutment
surface, wherein in a side view of either
major surface, the projecting abutment
surface lies on a concave surface.
__________
]11[]21[
]54[
ROTARY CUTTING TOOL
]22[
]51[
]71[
]72[
]74[
04.06.2002
Int. Cl.8 B23B 051/00, B23C 005/10
ISCAR LTD.
GIL HECHT
ISCAR LTD.,
P.O. BOX 11
TEFEN 24959
[57] A rotary cutting tool (10) having a
forward end and a rearward end and a
June 17, 2007 – ‫א' בתמוז התשס"ז‬
150013
‫כלי חיתוך מסתובב‬
‫ תפן‬,‫ישקר בע"מ‬
‫גיל הכט‬
,‫ישקר בע"מ‬
‫ תפן‬,11 .‫ד‬.‫ ת‬,
longitudinal axis A passing through the
forward and rear ends, the cutting tool
956
comprising a cutting head (10), a screw
member (18) and a tool shank (20); the
cutting head comprising a generally
cylindrical main body portion and a
rearwardly extending concial portion, and
an axially directed through bore having a
bore surface; a plurality of axially
extending and inwardly radially protruding
locking wings each having a sloping
locking surface protruding from the bore
surface; an axially extending stopper
having a tangentially facing stop surface,
protruding from each locking wing; the
screw member comprises a plurality of
axially extending and outwardly radially
protruding wings on a forward end thereof
and an external screw thread rearward of
the clamping wings, each clamping wing
having a sloping clamping surface, and
each clamping wing having an associated
side abutment surface; the tool shank
having a receiving bore opening to a
forward end thereof and comprising a
conical forward portion and an internally
threaded portion rearward of the conical
portion; wherein, the external screw thread
of the screw member is in threaded
engagement with the internally threaded
portion of the tool shank, the conical
portion of the cutting head is located
within the conical portion of the tool
shank, the clamping wings and locking
wings are aligned in pairs with the locking
and clamping surfaces of each pair in
abutment, and with each stop surface in
abutment with a given side abutment
surface.
__________
]11[]21[
]54[
CUTTING INSERT AND
MILLING CUTTER
]22[
]51[
]71[
]72[
]74[
04.06.2002
Int. Cl.8 B23B 027/16, B23C 005/10
ISCAR LTD.
AMIR SATRAN
ISCAR LTD.,
P.O. BOX 11
TEFEN 24959
[57] A cutting insert (54) comprising: a
top surface (56), a bottom surface
957
150015
‫שימת חיתוך וכרסום‬
‫ תפן‬,‫ישקר בע"מ‬
‫אמיר סטרן‬
,‫ישקר בע"מ‬
‫ תפן‬,11 .‫ד‬.‫ ת‬,
(58), and a peripheral side surface (60)
extending therebetween, the peripheral
June 17, 2007 – ‫א' בתמוז התשס"ז‬
side surface comprising a pair of opposing
major side surfaces (62) and a pair of
opposing minor side surfaces (64); two
opposing major cutting edges, formed at
the intersection of the opposing major side
surfaces with the top surface;
wherein each one of the pair of opposing
major side surfaces comprises two spaced
apart generally flat and non-coplanar
abutment surfaces; wherein a first of the
two spaced apart abutment surfaces makes
a first angle α with a normal N to a plane P
passing through the bottom surface of the
cutting insert and a second of the two
spaced apart abutment surfaces makes a
second angle β with the normal N; and
wherein each major side surface further
comprises at least one upper relief surface
disposed between the abutment surfaces
and the major cutting edge, and forming a
relief angle γ with the normal N.
__________
]11[]21[
]54[
METHOD AND APPARATUS FOR
IMPROVING SAFETY DURING
EXPOSURE TO A
MONOCHROMATIC LIGHT
SOURCE
]22[
]51[
]71[
]74[
06.06.2002
Int. Cl.8 A61B 018/20
INOLASE 2002 LTD.
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352, BEER-SHEVA 84152
[57] An eye safe handpiece, comprising:
June 17, 2007 – ‫א' בתמוז התשס"ז‬
150094
‫שיטה ומתקן לשיפור הבטיחות בעת‬
‫חשיפה למקור אור מונוכרומטי‬
‫ נתניה דרום‬,‫ בע"מ‬2002 ‫אינולייז‬
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
(a) a handpiece body for transmitting
monochromatic light (4) through a distal
958
end (6) of said body to a target (not shown)
said distal end being positionable at a
predetermined location substantially in
contact with said target;
(b) light delivery means (5) for delivering
said light from a monochromatic light
source (10) to said distal end;
(c) means for directing the light which is
transmitted through said distal end to said
target; and
(d) a diffusing unit (200) attachable to said
body, said diffusing unit including at least
one diffusively transmitting element (202)
that is transparent to said light wherein a
diffusing surface of said diffusively
transmitting element is disposed internally
to said handpiece body; wherein the
energy density of the light exiting said
distal end at said position ranges from 1 to
90 J/cm2,
wherein the radiance of the light exiting
said distal end at said position is less than
14 J/cm2/sr or less than 10*k1*k2*(t^1/3)
J/cm2/sr, where t is a laser pulse duration
in seconds, k1=k2=1 for a
wavelength ranging from 400 to 700 nm,
k1=1.25 and k2=1 for a
wavelength of approximately 750 nm,
k1=1.6 and k2=1 for a
wavelength of approximately 810 nm,
k1=3 and k2=1 for a
wavelength of approximately 940 nm, and
k1=5 and k2=1for a
wavelength ranging from 1060 to 1400
nm.
__________
]11[]21[
]54[
METHOD AND SYSTEM FOR
CONTENT-BASED DOCUMENT
SECURITY, ROUTING AND
ACTION EXECUTION
]22[
]31[
]51[
]71[
22.12.2000
09/469753
]32[ 22.12.1999
Int. Cl.8 G06F 002/100000 012/00
SEQUOIA SOFTWARE
CORPORATION, U.S.A.
WO/2001/046839
]87[
959
150106
‫שיטה ומערכת לאבטחת מסמכים‬
‫ ניתוב וביצוע פעולות‬,‫מבוססת תוכן‬
]33[
US
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]74[
BOROCHOV, KORAKH, ELIEZRI &
CO.,
15TH FLOOR, ATIDIM TOWER,
KIRYAT ATIDIM,
P.O.BOX 58100,
TEL AVIV 61580
[57] A method for determining, in a
computerized system, document content
based actions, comprising the steps of:
(A) providing, to a rule engine, a document
to be acted on, the document having
document content and the document is
defined to be in extensible markup
language (XML) format;
,'‫בורוכוב קורח אליעזרי ושות‬
‫אביב‬-‫ תל‬,58100 .‫ד‬.‫ ת‬, ‫מגדל כלל עתידים‬
(B) providing, to the rule engine, a set of
rules and associated actions to be taken
upon special conditions;
(C) evaluating the document according to
the rules and the document contents; and
(D) initiating at least a portion of the
actions associated with the rules.
__________
]11[]21[
]54[
METHODS AND COMPOSITIONS
FOR THE MANUFACTURE OF
OPHTHALMIC LENSES
]22[
]31[
]51[
]71[
15.12.2000
468973
]32[ 21.12.1999
Int. Cl.8 B29D 011/00
ESSILOR INTERNATIONAL
(COMPAGNIE GENERALE
D'OPTIQUE), FRANCE
WO/2001/046717
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060, TEL AVIV 61040
]87[
]74[
[57] A method for producing spectacle
lenses comprising the steps of: (a)
exposing to low intensity ultraviolet light a
mold assembly comprising a mold half and
an optical preform and a surface-forming
effective amount of a resin comprising
reactive groups, the low intensity UV light
exposure carried out under conditions
suitable to convert at least about 50 percent
or more of the resin reactive groups; and
150234
‫שיטות ותכשירים חדשים ליצור עדשות‬
‫תוך עיניות‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
(b) exposing, subsequently, the resin to
high intensity UV light under conditions
suitable to substantially complete through
curing of the resin and lens formation,
wherein the low intensity ultraviolet light
is about 1 to about 5 mW/cm2 at about 300
to about 450 nm and the high intensity
ultraviolet light is about 500 to about 1500
mW/cm2 at about 300 to about 450 nm.
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
960
]11[]21[
150377
‫ תרופות המכילות‬,‫פיפרידינים מותמרים‬
‫תרכובות אלו ושיטות ליצורן‬
]54[
SUBSTITUTED PIPERIDINES,
MEDICAMENTS CONTAINING
THESE COMPOUNDS AND
METHODS FOR THE
PRODUCTION THEREOF
]22[
]31[
]51[
22.12.2000
19963868.3
]32[ 30.12.1999
]33[ DE
Int. Cl.8 A61K 038/04, A61P 029/00, C07D 401/14, 405/14, 409/14, 413/14, 417/04,
471/02, 487/02, 491/02, 493/02, 495/02, 498/02, 513/02, C07K 005/06
BOEHRINGER INGELHEIM
PHARMA GMBH & CO. KG,
GERMANY
WO/2001/049676
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]71[
]87[
]74[
[57] Substituted piperidines of the formula
wherein
R denotes a saturated, mono- or diunsaturated 5- to 7-membered aza, diaza,
triaza, oxaza, thiaza, thiadiaza or S, Sdioxido-thiadiaza heterocyclic group,
whilst the abovementioned heterocyclic
groups are linked via a carbon or nitrogen
atom and contain one or two carbonyl
groups adjacent to a nitrogen atom, may be
substituted by an alkyl group at one of the
nitrogen atoms, may be substituted at one
or two carbon atoms by an alkyl group, by
a phenyl, phenylmethyl, naphthyl,
biphenylyl, pyridinyl, diazinyl, furyl,
thienyl, pyrrolyl, 1,3-oxazolyl, 1, 3thiazolyl, isoxazolyl, pyrazolyl, 1methylpyrazolyl, imidazolyl or 1methylimidazolyl groups, whilst the
961
substituents may be identical or different,
and wherein a double bond of one of the
abovementioned unsaturated heteroycic
groups may be fused with a benzene,
pyridine, diazine, 1,3-oxazole, thiophene,
furan, thiazole, pyrrole, N-methyl-pyrrole
or quinoline ring, with a 2(1H)oxoquinoline ring optionally substituted at
the nitrogen atom by an alkyl group or
with an imidazole or N-methyl-imidazole
ring or two olefinic double bonds of one of
the abovementioned unsaturated
heterocyclic groups may each be fused to a
benzene ring, whilst the phenyl, pyridinyl,
diazinyl, furyl, thienyl, pyrrolyl, 1,3oxazolyl, 1,3-thiazolyl, isoxazolyl,
pyrazolyl, 1-methylpyrazolyl, imidazolyl,
or 1-methylimidazolyl groups contained in
June 17, 2007 – ‫א' בתמוז התשס"ז‬
R as well as benzo-, thieno-, pyrido-and
diazino-fused heterocyclic groups may
additionally be mono-, di- or trisubstituted
in the carbon skeleton by fluorine, chlorine
or bromine atoms, by alkyl, alkoxy, nitro,
alkylthio, alkylsulphinyl, alkylsulphonyl,
alkylsulphonylamino, phenyl,
trifluoromethyl, alkoxycarbonyl, carboxy,
dialkylamino, hydroxy, amino,
acetylamino, propionylamino,
aminocarbonyl, alkylaminocarbonyl,
dialkylaminocarbonyl, (4-morpholinyl)
carbonyl, (1-pyrrolidinyl) carbonyl, (1piperidinyl) carbonyl, (hexahydro-1azepinyl) carbonyl, (4-methyl-1piperazinyl) carbonyl, methylenedioxy,
aminocarbonylamino, alkanoyl, cyano,
trifluoromethoxy, trifluoromethylthio,
trifluoromethylsulphinyl or
trifluromethylsulphonyl groups, whilst the
substituents may be identical or different,
R1 denotes a phenyl, 1-naphthyl, 2naphthyl, 1H-indol-3-yl,
1-methyl-1H-indol-3-yl, 1-formyl-1Hindol-3-yl, 4-imidazolyl,
1-methyl-4-imidazolyl, 2-thienyl, 3thienyl, thiazolyl, 1Hindazol-3-yl, 1-methyl-1H-indazoly-3-yl,
benzo [b] fur-3-yl,
benzo[b] thien-3-yl, pyridinyl, quinolinyl
or isoquinolinyl group,
whilst the abovementioned aromatic and
heteroaromatic groups in the carbon
skeleton may additionally be mono-, di- or
trisubstituted by fluorine, chlorine or
bromine atoms, by alkyl groups, cycloalkyl
groups with 3 to 8 carbon atoms,
phenylalkyl groups, alkenyl, alkoxy,
phenyl, phenylalkoxy, trifluoromethyl,
alkoxycarbonyl, carboxy, dialkylamino,
nitro, hydroxy, amino, alkylamino,
acetylamino, propionylamino,
methylsulphonyloxy, aminocarbonyl,
alkylaminocarbonyl,
dialkylaminocarbonyl, alkanoyl, cyano,
tetrazolyl, phenyl, pyridinyl, thiazolyl,
furyl, trifluoromethoxy,
trifluoromethylthio,
trifluoromethylsulphinyl or
trifluoromethylsulphonyl groups and the
substituents may be identical or different,
R2 denotes the hydrogen atom or a C1-3alkyl group,
one of the groups A1 and A2 denotes the
hydrogen atom and the other denotes the
amino, the [1,4'] bipiperidinyl-1'-yl or an
alkylamino group or the group
wherein R3 denotes the hydrogen atom or
an alkyl group,
Z denotes the carbonyl or the sulphonyl
group and
R4 denotes an alkoxy, amino, alkylamino
or dialkylamino group, a piperidinyl group
optionally substituted by a 1-methyl-4piperidinyl, 4-methyl-1-piperazinyl or
piperidinyl group, a 1-methyl-4piperidinyloxy group, a pyridinylamino,
benzo[b] furanyl, 1, 2,4-triazol-1-yl or 1Hindolyl group, a piperazinyl or 4-arylalkyl-
1-yl-piperazinyl group or a branched or
unbranched alkyl group comprising 1 to 7
carbon atoms, which may be substituted in
the ω position by an amino, phenyl,
pyridinyl, phenoxy, phenylamino,
phenylmethyoxycarbonylamino or Nalkylphenylamino group, by a
dialkylamino group, by a piperidinyl or
piperazinyl group optionally substituted by
a phenyl, pyridinyl, dimethylamino, 4morpholinyl, 4-alkyl-hexahydro-1H-1, 4diazepin-1-yl, 4-alkyl-1-piperazinyl, 4-
June 17, 2007 – ‫א' בתמוז התשס"ז‬
962
(alkylsulphonyl)-1-1-piperzinyl, 4(dialkylaminoalkyl)-1-piperazinyl, 1-alkyl4-piperidinyl or piperidinyl group, by a 4methyl-1-piperazinyl group, by an N-(C1-3
– alkyl)-N-(1'-C1-3-alkyl-[1, 4']
bipiperidinyl-1-yl) amino or 4-(1piperidinylmethyl)-1-piperidinyl group and
independently thereof in the α position by
an amino, tert-allkoxycarbonylamino or
{{{[1, 4'] bipiperidinyl-1-'-yl}acetyl}amino} group,
whilst the abovementioned alkyl and
alkenyl groups or the alkyl groups
contained in the abovementioned groups,
unless otherwise specified, contain 1 to 5
carbon atoms and may be branched or
unbranched and the abovementioned
aromatic and heteroaromatic groups may
additionally be mono-, di- or trisubstituted
by fluorine, chlorine or bromine atoms, by
cyano or hydroxy groups and the
substituents may be identical or different,
or tautomers or salts thereof.
__________
]11[]21[
]54[
IBUPROFEN CONTAINING
ACTIVE AGENT PREPARATION
]22[
]31[
]51[
]71[
19.01.2001
10003757.7
]32[ 28.01.2000
Int. Cl.8 A61K 009/00, C07C 057/32
BASF AKTIENGESELLSCHAFT,
GERMANY
WO/2001/054683
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A process for producing an active
ingredient preparation comprising
ibuprofen, wherein ibuprofen or its salt is
coated with
hydroxypropylmethylcellulose, or gelatin
as binder, where the proportion of the
150528
‫תכשיר של מרכיב פעיל המכיל איבופרופן‬
]33[
DE
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
binder is from 0.1 to 10% by weight and
the proportion of ibuprofen or its salts is
from 90 to 99.9% by weight, based on the
dry weight of the active ingredient
preparation.
__________
]11[]21[
963
150552
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]54[
ELECTRODE DEVICE FOR USE
IN LAPAROSCOPIC SURGERY
]22[
]31[
10.01.2001
480727
]32[ 10.01.2000
713553
15.11.2000
Int. Cl.8 A61F 002/02, A61N 001/05
TRANSNEURONIX, INC., U.S.A.
WO/2001/052932
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] An implant device for
electrostimulation or electrical monitoring
of tissue to be treated, said implant device
comprising (1) an elongated body having a
distal end and a proximal end, (2) a
penetration mechanism attached to the
distal end to penetrate the tissue to be
treated and to form a penetration tunnel
through the tissue, wherein the penetration
tunnel has a distal terminus and a proximal
terminus, (3) a quick release connecting
mechanism adjacent to the penetration
mechanism, (4) a first immobilizing
mechanism and a second immobilizing
mechanism along the elongated body to
engage tissue at either end of the
penetration tunnel, in order to secure the
implant device to the tissue to be treated,
wherein the first immobilizing mechanism
engages tissue outside the distal terminus
and the second immobilizing mechanism
engages tissue at the proximal terminus of
the penetration tunnel, (5) at least first and
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫התקן אלקטרודה לשימוש בניתוח‬
‫לפרוסקופי‬
]33[
US
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
second electric poles located between the
first and second immobilizing mechanism,
wherein the first and second electric poles
are in good electrical contact with tissue
forming the penetration tunnel, and (6) an
electrical connection terminal at the
proximal end for connection to a power
source; wherein the first and second
electric poles are electrically connected to
the electrical connection terminal; wherein
the quick release connecting mechanism is
effective to separate the penetration device
from the elongated body once the implant
device is properly positioned in the endoabdominal cavity; and wherein the first
immobilizing mechanism comprises at
least one suture hole through the elongated
body whereby, once the implant device is
properly positioned in the endo-abdominal
cavity, the distal end of the implant device
can be sutured to tissue outside the distal
terminus using at least one suture hole.
964
__________
]11[]21[
]54[
METHOD AND APPARATUS FOR
USING AN ASSIST PROCESSOR
TO PRE-FETCH DATA VALUES
FOR A PRIMARY PROCESSOR
]22[
]31[
08.01.2001
60/176235
]32[ 14.01.2000
565637
04.05.2000
Int. Cl.8 G06F 009/38, 009/45
SUN MICROSYSTEMS INC., U.S.A.
WO/2001/052061
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] An apparatus that facilitates prefetching from memory, comprising: a
primary processor that is configured to
execute executable code; an assist
processor that is configured to
simultaneously execute a reduced version
of the executable code, wherein the
reduced version of the executable code
executes more quickly than the executable
code, and generates the same pattern of
memory references as the executable code,
so that the assist processor generates the
same pattern of memory references that the
primary processor generates in advance of
when the primary processor generates the
memory references;
a compilation mechanism that is
configured to:
965
150583
‫עזר להבאה‬-‫שיטה והתקן לשימוש במעבד‬
‫מוקדמת של ערכים למעבד ראשוני‬
]33[
US
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
compile source code into the executable
code for the primary processor; and to
produce the reduced version of the
executable code for the assist processor
from the executable code for the primary
processor by eliminating instructions from
the executable code that have no effect on
a pattern of memory references generated
by the executable code; and a store that is
configured to store results of memory
references generated by the assist
processor; wherein the store is configured
to be shared between the assist processor
and the primary processor, so that the
primary processor is able to access the
results of the memory references generated
by the assist processor.
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫__________‬
‫‪150621‬‬
‫‪966‬‬
‫[‪]11[]21‬‬
‫א' בתמוז התשס"ז – ‪June 17, 2007‬‬
]54[
METHOD FOR PRODUCING
ARYL-IMINOMETHYLCARBAMIC ACID ESTERS
]22[
]31[
]51[
]71[
11.01.2001
100000907.7
]32[ 12.01.2000
Int. Cl.8 C07C 255/54, 269/00, 271/62
BOEHRINGER INGELHEIM
PHARMA GMBH & CO. KG,
GERMANY
WO/2001/051457
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
–‫שיטה לייצור אסטרים של חומצה אריל‬
‫אימינומתיל קרבמית‬
]33[
DE
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
[57] Process for preparing compounds of
the formula
wherein
R1 denotes a group selected from among
methyl, ethyl, propyl, cyclopentyl,
cyclohexyl, phenyl, benzyl and –C(Me2)
phenyl, each of which may be mono-, di-or
trisubstituted by hydroxy;
R2 denotes a group selected from among
methyl, ethyl, propyl and benzyl,
characterised in that a compound of the
formula
wherein
R1' denotes a group selected from among
methyl, ethyl, propyl, cyclopentyl,
cyclohexyl, phenyl, benzyl and –C(Me2)
phenyl, each of which may be mono-, di-or
trisubstituted by a group –O-PG, the group
methoxymethyloxy, 2methoxyethoxymethyloxy, 1ethoxyethyloxy, 2-tetrahydropyranyloxy,
1-butoxyethyloxy, tert-butyloxy,
benzyloxy and 4-methoxybenzyloxy, is
first reacted in an ethereal or aromatic
–O-PG denoting a protected hydroxyl
function selected from among
967
June 17, 2007 – ‫א' בתמוז התשס"ז‬
solvent with an alkali metal
hexaalkyldislazane and is then treated with
a compound of the formula
R2-O-COX'
wherein
R2 is as hereinbefore defined and
X' denotes chlorine, bromine or -O-R2,
after working up using an acid of formula
HY a compound of the formula
and/or the tautomeric form thereof,
wherein the groups R1 and R2 are as
hereinbefore defined and Y denotes any
desired acid group,
is isolated and from this the compound of
formula (I) is liberated.
Claimed as novel are the intermediate
products of the formula
and/or the tautomeric forms thereof
wherein the groups R1 and R2 are as above;
of the formula
wherein X denotes hydroxy, chlorine,
bromine, mesylate, triflate or tosylate and
of the formula
June 17, 2007 – ‫א' בתמוז התשס"ז‬
968
wherein R' denotes C1-4-alkyl.
__________
]11[]21[
150850
‫תכשירים לציפוי אנטרי המכילים שרף‬
‫אקרילי‬
]54[
ENTERIC COATING
COMPOSITIONS CONTAINING
ACRYLIC RESIN
]22[
]31[
09.02.2001
501866
]32[ 10.02.2000
]33[ US
766859
19.01.2001
US
Int. Cl.8 A61K 009/00, 009/20, 009/30, B05D 003/00, C08K 005/10, 005/34
ROHM GMBH & CO. KG,
GERMANY
BPSI HOLDINGS, INC., U.S.A.
WO/2001/058429
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]51[
]71[
]87[
]74[
[57] A non-toxic, edibile, enteric film
coating, dry powder composition for use in
making an aqueous enteric suspension
which may be used in coating
pharmaceutical tablets comprising
(a) an acrylic resin, said resin comprising:
(i) from 20 to 85 percent by weight of at
least one alkyl acrylate or alkyl
methacrylate moiety,
(ii) from 80 to 15 percent by weight of a
least one vinyl or vinylidene moiety
having a carboxylic acid group capable of
salt formation, and
(iii) from 0 to 30 percent by weight of at
least one other vinyl or vinylidene moiety
copolymerizable with (i) and (ii);
(b) an alkalizing agent capable of reacting
with the acrylic resin such that, after
reaction, 0.1 to 10 mole percent of the
acidic groups in (la-ii) are present in the
salt form; and
(c) a film coating detackifier.
__________
]11[]21[
969
150871
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫פס מסייע גילוח עבור מחסנית של סכין‬
‫גילוח‬
]54[
SHAVING AID STRIP FOR
RAZOR CARTRIDGE
]22[
]31[
06.02.2002
506629
]32[ 18.02.2000
737267
14.12.2000
Int. Cl.8 B26B 021/44
THE GILLETTE COMPANY, U.S.A.
WO/2001/060572
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] A razor cartridge comprising a blade
and a skin-engaging portion in proximity
to said blade, said skin-engaging portion
including a solid polymeric shaving aid
strip comprising, prior to first use of said
cartridge, a first exposed lengthwiseextending portion (24) containing a
lubricous water-soluble polymer and an
adjacent, second exposed lengthwise-
]33[
US
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
extending portion (26) containing a
lubricous water-soluble polymer, wherein
said first portion comprises a greater
amount of said lubricous water-soluble
polymer, in percent by weight, than said
second portion, and wherein said first
portion is adapted to wear at a faster rate
than said second portion during shaving.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
151083
970
‫חיזור מימני של כלורידים סולפונילים‬
‫לתיולים‬
]54[
HYDROGEN REDUCTION OF
SULFONYL CHLORIDES TO
THIOLS
]22[
]31[
]51[
]71[
26.02.2001
60/186902
]32[ 03.03.2000
]33[ US
Int. Cl.8 C07B 061/00, C07C 319/02, 321/26
THE TEXAS A&M UNIVERSITY
SYSTEM, U.S.A.
WO/2001/066517
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]87[
]74[
[57] A process for the production of an
aryl thiol comprising: hydrogenating an
aryl sulfonyl chloride with hydrogen in a
solvent in the presence of (i) a catalyst
comprising palladium and (ii) an effective
amount of a base whose conjugate acid has
a pKa of about 2 or greater, wherein the
base is selected from the group consisting
of ionic bases soluble in water and tertiary
amines soluble in the solvent, the tertiary
amines not having a methyl group attached
to the amine nitrogen.
__________
]11[]21[
151248
–1,6–‫מעכבים של אריל פרוקטוז‬
‫ביספוספטאז‬
]54[
ARYL FRUCTOSE-1,6BISPHOSPHATASE INHIBITORS
]22[
]31[
]51[
07.03.2001
60/187750
]32[ 08.03.2000
]33[ US
Int. Cl.8 A61K 031/662, 031/67, A61P 003/06, 003/10, C07F 009/00, 009/38,
009/547, 009/6587
METABASIS THERAPEUTICS, INC.,
U.S.A.
WO/2001/066553
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]71[
]87[
]74[
[57] A compound of the formula
wherein R5 is:
971
June 17, 2007 – ‫א' בתמוז התשס"ז‬
wherein:
X3, X4, and X5 are C;
J2, J3, J4, J5, and J6 are independently
selected from the group consisting of –H,
-NR42, -CONR42, -CO2R3, halo, S(O)2NR42, -S(O)R3, -SO2R3, alkyl,
alkenyl, alkynyl, alkylenearyl,
perhaloalkyl, haloalkyl, aryl, heteroaryl,
alkylene –OH, -C(O)R11, -OR11, -alkyleneNR42,-alkylene-CN, -CN, -C(S)NR42, OR2, -SR2, -N3, -NO2, -NHC(S)NR42, and
–NR18COR2;
L is selected from the group consisting of:
(i) a linking group having 2-4 atoms
measured by the fewest number of atoms
connecting the carbon of the aromatic ring
and the phosphorus atom and is selected
from the group consisting of –furanyl-, thienyl-, pyridyl-, -oxazolyl-, -imidazolyl-,
-pyrimidinyl-, -pyrazinyl-, and –alkynyl-,
all of which may be optionally substituted;
and
(ii) a linking group having 3-4 atoms
measured by the fewest number of atoms
connecting the carbon of the aromatic ring
and the phosphorus atom and is optionally
substituted-alkyleneoxy;
Y is independently selected from the group
consisting of –O-, and –NR6- when Y is –
O-, then R1 attached to –O- is
independently selected from the group
consisting of –H, alkyl, optionally
substituted aryl, optionally substituted
heterocyclic alkyl where the cyclic moiety
contains a carbonate or thiocarbonate,
optionally substituted arylalkylene-,
C(R2)2OC(O)NR22, -NR2-C(O)-R3, C(R2)2-OC(O)R3, -C(R2)2-O-C(O)OR3, C(R2)2OC(O)SR3, -alkylene-S-C(O)R3, alkylene-S-S-alkylenehydroxy, and –
alkylene-S-S-S-alkylenehydroxy,
when one Y is –NR6-, and R1 attached to it
is –(CR12R13)n-C(O)-R14, then the other
YR1 is selected from the group consisting
of –NR15R16, -OR7, and NR6-(CR12R13)nC(O)-R14;
or when either Y is independently selected
from –O– and –NR6–, then together R1 and
R1 are alkylene-S-S-alkylene- to form a
cyclic group, or together R1 and R1 are
wherein
(a) V is selected from the group of aryl,
substituted aryl, heteroaryl, substituted
heteroaryl, 1-alkynyl and 1-alkenyl;
June 17, 2007 – ‫א' בתמוז התשס"ז‬
972
Z is selected from the group of –CHR2OH,
-CHR2OC(O)R3, -CHR2OC(S)R3,
-CHR2OC(S)OR3, -CHR2OC(O)SR3, CHR2OCO2R3, -CHR2OCO2R3, -OR2, SR2, -CHR2N3, -CH2aryl, -CH(aryl)OH, CH(CH=CR22)OH, -CH(C=CR2)OH, -R2, NR22, -OCOR3,
-OCO2R3, -SCOR3, -SCO2R3, -NHCOR2, NHCO2R3, -CH2NHaryl, -(CH2)p-OR19,
and -(CH2)p-SR19; or
together V and Z are connected via an
additional 3-5 atoms to form a cyclic
group, optionally containing 1 heteroatom,
said cyclic group is fused to an aryl group
at the beta and gamma position to the Y
adjacent to V; or together Z and W are
connected via an additional 3-5 atoms to
form a cyclic group, optionally containing
one heteroatom, and V must be aryl,
substituted aryl, heteroaryl, or substituted
heteroaryl; or
W and W' are independently selected from
the group of –H, alkyl, aralkyl, alicyclic,
aryl, substituted aryl, heteroaryl,
substituted heteroaryl, 1-alkenyl and 1alkynyl and –R9; or
together W and W' are connected via an
additional 2-5 atoms to form a cyclic
group, optionally containing 0-2
heteroatoms, and V must be aryl,
substituted aryl, heteroaryl, or substituted
heteroaryl;
(b) V2, W2 and W"; are independently
selected from the group of –H, alkyl,
aralkyl, alicyclic, aryl, substituted aryl,
heteroaryl, substituted heteroaryl, 1alkenyl, and 1-alkynyl;
Z2 is selected from the group of –
CHR2OH, -CHR2OC(O)R3, CHR2OC(S)R3,
-CHR2OCO2R3, -CHR2OC(O)SR3, CHR2OC(S)OR3, -CH(aryl)OH,
-CH(CH=CH22) OH, -CH(C=CR2)OH, SR2, -CH2NH aryl, -CH2aryl; or
together V2 and Z2 are connected via an
additional 3-5 atoms to form a cyclic group
containing 5-7 ring atoms, optionally
containing 1 heteroatom, and substituted
973
with hydroxy, acyloxy,
alkyleneoxycarbonyloxy, or
aryloxycarbonyloxy attached to a carbon
atom that is three atoms from a Y attached
to phosphorus;
(c) Z' is selected from the group of –OH, OC(O)R3, -OCO2R3, -OCO2R3, and –
OC(O)SR3;
D' is –H;
D" is selected from the group of –H, alkyl,
-OR2, -OH, and –OC(O)R3;
each W3 is independently selected from the
group consisting of –H, alkyl, aralkyl,
alicyclic, aryl, substituted aryl, heteroaryl,
substituted heteroaryl, 1-alkenyl, and
1-alkynyl;
p is an integer 2 or 3;
with the provisos that:
(a) V, Z, W, W' are not all –H and V2, Z2,
W" are not all –H; and
R2 is selected from the group consisting of
R3 and –H;
R3 is selected from the group consisting of
alkyl, alicyclic, and aralkyl;
each R4 is independently selected from the
group consisting of –H, alkylene,
-alkylenearyl and aryl, or together R4 and
R4 are connected via 2-6 atoms, optionally
including one heteroatom selected from the
group consisting of O, N, and S;
R6 is selected from the group consisting of
–H, lower alkyl, acyloxyalkyl aryl, aralkyl,
alkyloxycarbonyloxalkyl, and lower acyl,
or together with R12 is connected via 1-4
carbon atoms to form a cyclic group;
R7 is lower R3;
each R9 is independently selected from the
group consisting of –H, alkyl, aralkyl, and
alicyclic, or together R9 and R9 form a
cyclic alkyl group;
R11 is selected from the group consisting of
alkyl, aryl, -NR22, and –OR2; and
each R12 and R13 is independently selected
from the group consisting of H, lower
alkyl, lower aryl, lower aralkyl, all
optionally substituted, or R12 and R13
together are connected via a chain of 2-6
atoms, optionally including 1 heteroatom
June 17, 2007 – ‫א' בתמוז התשס"ז‬
selected from the group consisting of O, N,
and S, to form a cyclic group;
each R14 is independently selected from
the group consisting of –OR17, -N(R17)2, NHR17, -SR17, and –NR2OR20;
R15 is selected from the group consisting of
–H, lower aralkyl, lower aryl, lower
aralkyl, or together with R16 is connected
via 2-6 atoms, optionally including 1
heteratom selected selected from the group
consisting of O, N, and S;
R16 is selected from the group consisting of
–(CR12R13)n-C(O)-R14, -H, lower alkyl,
lower aryl, lower aralkyl, or together with
R15 is connected via 2-6 atoms, optionally
including 1 heteroatom selected from the
group consisting of O, N, and S;
each R17 is independently selected from
the group consisting of lower alkyl, lower
aryl, and lower aralkyl, or together R17 and
R17 on N is connected via 2-6 atoms,
optionally including 1 heteroatom selected
from the group consisting of O, N and S;
R18 is selected from the group consisting of
–H and lower R3;
R19 is selected from the group consisting of
–H, and lower acyl;
R20 is selected from the group consisting of
–H, lower R3, and –C(O)-(lower R3);
n is an integer from 1 to 3;
with the provisos that:
(1) when L is substituted furanyl, then at
least one of J2, J3, J4, and J5 is not –H or
null;
(2) when L is not substituted furanyl, then
at least two of J2, J3, J4, J5, and J6 on
formula I(b) are not –H or null;
(3) if both Y groups are –NR6-, and R1
and R1 are not connected to form a cyclic
phosphoramidate, then at least one R1 is –
(CR12R13)n-C(O)-R14;
(4) when R5 is substituted phenyl, then J3,
J4, and J5 is not purinyl, purinylalkylene,
deazapurinyl, or deazapurinylalkylene;
(5) R1 can be selected from the lower alkyl
only when the other YR1 is –NR6C(R12R13)n –C(O)-R14;
(6) when R5 is substituted phenyl and L is
1, 2-ethynyl, then J3 or J5 is not a
heterocyclic group;
and pharmaceutically acceptable salts
thereof.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
151392
974
‫ – אנילינו‬2 – ‫ – ציאנו‬5 – ‫ – אמינו‬4 ‫נגזרות‬
‫– פירימידין והשימוש בהן כמעכבי קינאזות‬
‫של מחזור–התא‬
]54[
4 - AMINO - 5 - CYANO - 2 ANILINO - PYRIMIDINE
DERIVATIVES AND THEIR USE
AS INHIBITORS OF CELL-CYCLE
KINASES
]22[
]31[
]51[
]71[
]87[
]74[
23.03.2001
0007371.8
]32[ 28.03.2000
]33[ GB
Int. Cl.8 A61P 035/00, C07D 239/28, 239/48, 401/12, 403/12, 405/12, 413/12
ASTRAZENECA AB, SWEDEN
WO/2001/072717
S. HOROWITZ & CO.,
,'‫ הורוביץ ושות‬.‫ש‬
ZION HOUSE,
‫ תל אביב‬,41-45 ‫ שדרות רוטשילד‬,‫בית ציון‬
41-45 ROTHSCHILD BLVD.,
TEL AVIV 65784
[57] A compound of the formula
wherein:
R1 is halo, nitro, cyano, hydroxy, amino,
carboxy, carbamoyl, mercapto, C1-6 alkyl,
C2-6 alkenyl or C2-6 alkynyl;
p is 0-4; wherein the values of R1 may be
the same or different;
R2 is sulphamoyl or a group B-E-; wherein
B is selected from C1-6 alkyl, C2-6 alkenyl,
C2-6 alkynyl, C3-8 cycloalkyl,
C3-8 cycloalkyl C1-6 alkyl, phenyl, a
heterocyclic group, phenyl C1-6 alkyl or
(heterocyclic group) C1-6 alkyl; wherein
said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl,
C3-8 cycloalkyl, C3-8 cycloalkyl C1-6 alkyl,
phenyl, heterocyclic group, phenyl C1-6
alkyl or (heterocyclic group) C1-6 alkyl are
optionally substituted on carbon by one or
more D; and
wherein if said heterocyclic group contains
an –NH- moiety that nitrogen may be
optionally substituted by a group selected
from G;
975
E is –C(O)-, -N(Ra)C(O)-, -C(O)N(Ra)-, S(O)r-, -SO2N(Ra)- or –N(Ra)SO2-;
wherein Ra is hydrogen or C1-6 alkyl
optionally substituted by one or more D
and r is 1-2;
D is independently selected from halo,
nitro, cyano, hydroxy, trifluoromethyl;
trifluoromethoxy, amino, carboxy,
carbamoyl, mercapto, sulphamoyl, C1-6
alkyl, C2-6 alkenyl, C1-6 alkoxy, C1-6
alkanoyl, C1-6 alkanoyloxy, N-(C1-6 alkyl)
amino,
N, N-(C1-6 alkyl)2 amino, C1-6
alkanoylamino, N-(C1-6 alkyl) carbamoyl,
N, N-(C1-6 alkyl)2 carbamoyl, C1-6
alkylS(O)a wherein a is 0 to 2, C1-6
alkoxycarbonyl, N-(C1-6 alkyl) sulphamoyl
and N, N-(C1-6 alkyl)2 sulphamoyl;
G is selected from C1-4 alkyl, C1-4 alkanoyl,
C1-4 alkylsulphonyl, C1-4 alkoxycarbonyl,
carbamoyl, N-(C1-4 alkyl) carbamoyl, N,N(C1-4 alkyl) carbamoyl, benzyl,
June 17, 2007 – ‫א' בתמוז התשס"ז‬
benzyloxycarbonyl, benzoyl and
phenylsulphonyl; and
q is 0-2; wherein the values of R2 may be
the same or different; and wherein p+q=15;
with the proviso that that compound is not
2-(2,4-dimethylanilino)-4-amino-5-
cyanopyrimidine; 4-amino-5-cyano-2-[2(2-hydroxyethoxycarbonyl) aniline]
pyrimidine; or 4-amino-5-cyano-2-[2(methoxycarbonyl) aniline] pyrimidine;
or a pharmaceutically acceptable salt or an
in vivo hydrolysable ester thereof.
__________
]11[]21[
]54[
FITTING FOR A WINDOW OR
DOOR
]22[
]31[
20.03.2001
10014285.0
]32[ 22.03.2000
10051965.2
20.10.2000
10052598.9
24.10.2000
10054849.0
04.11.2000
10063832.5
21.12.2000
Int. Cl.8 E05D 015/58
SCHUCO INTERNATIONAL KG,
GERMANY
WO/2001/071140
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] Fitting unit for a window or a door
having a leaf which can be moved relative
to a blind frame, by means of which the
leaf can be opened in parallel and can be
pivoted about an axis of rotation from a
parallel open position into a rotated open
position, at least one cam guide through
which a guide pin can be moved for the
parallel opening of the leaf being provided
June 17, 2007 – ‫א' בתמוז התשס"ז‬
151447
‫יחידה עבור חלון דלת‬
]33[
DE
DE
DE
DE
DE
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
in the rabbet between blind frame and leaf,
characterized in that, on the side of the axis
of rotation of the leaf, a fitting is provided
between the blind frame and the leaf and is
fixed by a first part to the leaf and by a
second part to the blind frame, and the first
part and the second part interact in order to
permit a rotational movement of the leaf.
976
__________
]11[]21[
]54[
MINIATURIZED NEEDLELESS
INJECTOR
]22[
]31[
]51[
]71[
02.03.2001
10010123.2
]32[ 03.03.2000
Int. Cl.8 A61M 005/30
BOEHRINGER INGELHEIM
INTERNATIONAL GMBH,
GERMANY
WO/2001/064268
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A needleless injector for a liquid,
which is in the form of a hand unit,
comprising a housing and a supply
container (14) for the liquid, wherein the
housing includes two portions (1, 2) which
are connected together and are arranged
rotatably relative to each other, and the
needleless injector includes a locking
stressing mechanism with a sprung portion
(3) which is displaceable between two
977
151465
‫מזרק מוקטן ללא מחט‬
]33[
DE
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
abutments (17) and which is provided with
a triggering device, and a hollow plunger
(7) which is fixed in the sprung portion
and which is driven by the locking
stressing mechanism, wherein the hollow
plunger is arranged slidably within a
cylinder (8) and includes a single valve
body (12) and mounted at the end of the
cylinder is a nozzle with at least one
opening and the space between the nozzle
June 17, 2007 – ‫א' בתמוז התשס"ז‬
and the valve body forms a pump chamber
(13), and the supply container for the
liquid is arranged within the housing and is
in the form of a container separate from
the needleless injector and is connected to
the end of the hollow plunger which
projects out of the cylinder, and the
amount of liquid which has been conveyed
through the hollow plunger into the pump
chamber when the hollow plunger is pulled
out of the cylinder is determined by the
stroke travel and the cross-section of the
hollow plunger, and the position of the
hollow plunger stroke travel within the
needleless injector is determined by the
position of the two abutments.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
151579
978
‫התקן למסירת תרופה‬
]54[
DRUG DELIVERY DEVICE
]22[
]51[
]71[
02.09.2002
Int. Cl.8 A61M 005/24
MERIDIAN MEDICAL
TECHNOLOGIES, INC., U.S.A.
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
]74[
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
[57] An automatic injection device
containing a pre-loaded charge of
medicament for automatically selfadministering the medicament upon
actuation thereof, the device comprising:
a housing assembly (110) having an
interior chamber, the interior chamber
including a dry compartment (152)
containing a dry medicament component,
and a wet compartment (151) containing a
liquid component to be mixed with the dry
component; a seal structure (160) between
the dry compartment and the wet
compartment, the seal structure being
initially in a sealing condition that
maintains the dry component sealed from
the wet component, the seal structure
including at least one flow path formed
therein, the seal structure being converted
to a mixing condition as a result of
activation of the device;
a fluid distributing member disposed
between the liquid component and the dry
medicament component; a needle
assembly (141) that dispenses the charge
of medicament from the housing; an
activation assembly carried by the housing
and including a stored energy from the
stored energy source, and wherein the
release of the stored energy causes (a) the
seal structure to be converted from the
sealing condition to the mixing condition
and thereby permit the liquid component to
pass through the at least one flow path
from the wet compartment to the dry
compartment, (b) the liquid component to
be forced through the fluid distributing
member and distributed to the dry
component and facilitate mixing and
dissolution of the dry medicament
component in the liquid component, and
(c) force the mixed liquid and dry
components through the needle assembly.
__________
]11[]21[
979
151612
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]54[
SIMULTANEOUS DETERMINATION
OF MULTIPHASE FLOWRATES AND
CONCENTRATIONS
]22[
]31[
]51[
]71[
05.03.2001
PCT/NL00/00159 ]32[ 09.03.2000
Int. Cl.8 G01F 001/74
NEST INTERNATIONAL N.V.,
NETHERLANDS ANTILLES
VLADIMIR DROBKOV, RUSSIA
VLADIMIR MELNIKOV, RUSSIA
ANDREY SHUSTOV, RUSSIA
WO/2001/067051
PEARL COHEN ZEDEK LATZER,
5 SHENKAR STREET,
P.O.B. 12704
HERZLIYA 46733
]87[
]74[
[57] Method for determining flow rates of
gas and liquid phases of a flow of a
multiphase mixture along a pipeline,
comprising the steps of:
(a) measuring a real velocity w of at least
one phase of the mixture in a section (1) of
the pipeline;
(b) measuring an acoustic conductivity of
the mixture in the pipeline section;
(c) determining a volume concentration (φ)
of a gas phase of the mixture in the
pipeline section on the basis of the
measured acoustic conductivity of the
mixture in the pipeline section;
(d) determining volume flow rates of the
gas phase Qg, and of first and second
components Q1, Q2 of the liquid phase Q,
of the mixture by using values of said real
velocity w and said volume concentration;
characterized by,
with said pipeline section being a first
pipeline section:
(e) providing a second pipeline section (2)
in series with the first pipeline section, the
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫קביעה בו–זמנית של רמות–זרימה‬
‫וריכוזים רב–שלביים‬
]33[
WO
‫ עורכי‬,‫פרל כהן צדק לצר עורכי דין‬
,‫פטנטים ונוטריונים‬
.‫ד‬.‫ ת‬, 5 ‫ רח' שנקר‬,1 ‫ים‬-‫מרכז גב‬
‫ הרצליה‬,12704
first and second pipeline sections having
different cross sections, such that a change
in flow velocity of the mixture occurs at
the junction of the two sections;
(f) measuring the real velocity in the
second pipeline section;
(g) measuring the acoustic conductivity in
the second pipeline section;
(h) determining the volume concentration
φ of the gas phase in the second pipeline
section on the basis of the measured
acoustic conductivity of the mixture in the
second pipeline section;
(i) determining a volume concentration of
different liquid phase components of the
mixture on the basis of the measured
acoustic conductivity of the mixture in at
least one pipeline section;
(j) determining the volume flow rates, by
using values of the real velocity and the
volume concentrations obtained for the
first and second pipeline sections in
combination.
980
__________
]11[]21[
151766
‫לוח מבני שניתן לכיווץ‬
]54[
COMPRESSIBLE STRUCTURAL
PANEL
]22[
]31[
]51[
]71[
23.04.2001
60/199208
]32[ 24.04.2000
]33[ US
Int. Cl.8 B32B 003/12, E04B 009/00, E04C 002/32
HUNTER DOUGLAS INDUSTRIES
B.V., THE NETHERLANDS
PAUL G. SWISCZ, KO KUPERUS,
WENDELL B. COLSON, JASON T.
THRONE
WO/2001/081684
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]72[
]87[
]74[
981
June 17, 2007 – ‫א' בתמוז התשס"ז‬
[57] A compressible structural ceiling or
wall panel (50), comprising: at least one
outer sheet (54) of material having an inner
face and an outer face; a plurality of
compressible dividers (52), secured to and
protruding from said inner face; and
connector means (56), for securing said
dividers together at locations distal from
said outer sheet; wherein each divider is
longitudinally-elongated and comprises
longitudinally-extending side partitions
and longitudinally-extending fold lines
such that, by applying pressure to the outer
sheet or the connector means said dividers
are caused to fold along said fold lines and
be compressed to reduce the thickness of
the panel wherein each divider is expanded
when in a resting condition and is resilient
so as to return to that configuration after
having been compressed such that the
panel will assume an expanded form in its
normal at rest condition; and wherein said
dividers comprise separate sheets of a
semi-rigid but foldable material;
characterized in that: the foldable material
is made of glass fibers bonded together in
a resin such that each said fold line is
resilient and comprises a crease formed
without damaging significantly said fibers.
__________
]11[]21[
]54[
PLANT ACARICIDAL
COMPOSITIONS AND METHODS
]22[
]31[
]51[
]71[
]87[
]74[
16.03.2001
09/527258
]32[ 17.03.2000
Int. Cl.8 A01N 029/00, 031/08, 065/00
CODENA INC., CANADA
WO/2001/067868
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
[57] A composition comprising an
acaricidal essential oil-extract derived
from Chenopodium ambrosioides
151786
‫תכשירים ושיטות נגד אקריות בצמחים‬
]33[
US
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
comprising alpha-terpinene, p-cymene,
limonene, thymol, and carvacrol, wherein
the extract is produced by distillation.
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
982
]11[]21[
]54[
CLAY-CONTAINING MIXTURE
OR BLEND CAPABLE OF
FORMING A MOISTURE
RESISTANT GEL AND USE OF
THAT MIXTURE AND BLEND
]22[
]31[
]51[
]71[
16.03.2001
1014690
]32[ 20.03.2000
Int. Cl.8 C09K 017/42
TRISOPLAST INTERNATIONAL
B.V., THE NETHERLANDS
WO/2001/070903
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
]87[
]74[
[57] A clay-containing mixture which
comprises a powdered or ground smectite
and/or a smectite-containing natural rock
and 0.8-10% by weight of an at least
partially water-soluble and/or waterswellable polymer and optionally at least
0.5% by weight of a solid activating agent,
or a blend which additionally comprises as
diluting agent more than 0.5% by weight
of one or more solid inert filler(s), all the
151803
‫תערובת או ממזג המכיל(ה )טיט שניתן‬
,‫ממנו ליצור ג'ל עמיד ללחות‬/‫ממנה‬
‫ושימוש בתערובת ההיא וממזג ההוא‬
]33[
NL
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
weight percentages being calculated on the
weight of the smectite, characterised in
that said polymner is a linear chain
acrylamide type (co)polymer with a
molecular weight of at least 500,000, a
hydrolysis degree of at most 30%, and a
particle size of 2 μm to 1 mm, and the
mixture or blend also comprises 3-20% by
weight of water, calculated for the total
weight of the mixtue of the blend.
__________
]11[]21[
]54[
SANITARY PAD
]22[
]31[
]51[
]71[
]87[
]74[
13.03.2001
09/523814
]32[ 13.03.2000
Int. Cl.8 A61F 013/15
NORA MARKOWIECKI
WO/2001/067982
BOROCHOV, KORAKH, ELIEZRI &
CO.,
15TH FLOOR, ATIDIM TOWER,
KIRYAT ATIDIM,
P.O.BOX 58100,
TEL AVIV 61580
983
151826
‫תחבושת סינטארית‬
]33[
US
‫ ראשון לציון‬,‫נורה מרקובייקי‬
,'‫בורוכוב קורח אליעזרי ושות‬
‫אביב‬-‫ תל‬,58100 .‫ד‬.‫ ת‬, ‫מגדל כלל עתידים‬
June 17, 2007 – ‫א' בתמוז התשס"ז‬
[57] A sanitary pad having an upper
surface for facing the body of a user and a
lower surface for facing an undergarment,
the sanitary pad comprising a forward
wide portion (52); and a rear narrow
portion (54) connected to said wide portion
(52) characterized in that said sanitary pad,
further comprises two lateral notches (61,
63) dividing between said wide portion
and said narrow portion and at least two
fold lines (56, 58) preformed on said
narrow portion, said at least two fold lines
inwardly emanating from said two lateral
notches and curving rearwards away from
said wide portion and towards a
longitudinal median of said narrow
portion, said narrow portion being adapted
for upwardly folding about said at least
two fold lines to form a longitudinal
upward protrusion (68) inwardly disposed
between outwardly inclined sides of said
narrow portion.
__________
]11[]21[
]54[
METHODS AND APPARATUS
FOR GUIDING A GUIDE WIRE
]22[
]31[
]51[
]71[
28.03.2001
539015
]32[ 30.03.2000
Int. Cl.8 A61B 006/02, A61M 025/09
INTRALUMINAL THERAPEUTICS,
INC., U.S.A.
JOHN M. NEET, THOMAS R.
WINSTON, NICHOLAS WOLFE
WO/2001/074249
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O. B. 45087,
JERUSALEM 91450
]72[
]87[
]74[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
151864
‫שיטות והתקנים להנחיית חוט מנחה‬
]33[
US
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
,45087 .‫ד‬.‫ ת‬, ‫ הר חוצבים‬,‫רחוב המרפא‬
‫ירושלים‬
984
[57] Apparatus (20) configured to guide a
guide wire through body tissue, said
apparatus comprising: a guide wire (28)
having a first proximal end (30) and
second distal end (32); and at least one
interferometric guidance system
comprising: a first optic fiber (42)
comprising a first end and a second end,
said second end coupled to and extending
beyond said guide wire distal end; and a
circuit for generating Doppler shift
information relating to neovascular flow
through the tissue by revealing relative
changes in blood flow velocity at the said
second end of said first optic fiber, said
interference guidance system configured
for generating interference information
from body tissue.
__________
]11[]21[
]54[
PRE-FILLED SYRINGE
]22[
]31[
]51[
]71[
28.03.2001
2000-105386 ]32[ 03.04.2000
Int. Cl.8 A61M 005/28
ASTRAZENECA UK LIMITED,
UNITED KINGDOM
MALCOLM JOHN HENDERSON,
TOSHIKAZU HIRAYAMA,
MASAFUMI ARAMATA
WO/2001/074424
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]72[
]87[
]74[
[57] A pre-filled syringe comprising a
barrel made of glass and having at a distal
end thereof a medical liquid discharge port
formed into the shape of a vial mouth; a
985
151930
‫מזרק ממולא מראש‬
]33[
JP
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
sealing member fitted in the medical liquid
discharge port of said barrel and having a
through-hole in the axial direction; a tip
member including a skirt provided with an
June 17, 2007 – ‫א' בתמוז התשס"ז‬
engagement pawl on a lower end inner
wall thereof, a top wall, a needle mounting
portion and a medical liquid deriving
portion and forming a medical liquid
passage through said medical liquid
deriving portion, said top wall and said
needle mounting portion, and so mounted
around said sealing member on the
medical liquid discharge port of said barrel
as to slide along the outer wall of said
medical liquid discharge port; a cap
member mounted around said tip member;
a closing member made integral with said
cap member and inserted into the medial
liquid passage of said tip member and the
through-hole of said sealing member for
closing said through-hole; and a holding
member for mounting and fixing said tip
member on the medical liquid discharge
port of said barrel, wherein said tip
member is mounted liquid-tightly on the
medical liquid discharge port by mounting
said holding member around said tip
member and sliding downward along the
skirt of said tip member to bring said
engagement pawl of said tip member into
engagement with said medical liquid
discharge port of said syringe.
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
986
]11[]21[
152017
‫תכשיר היפוקסית לכבוי שריפה ומערכת‬
‫המשתמשת בו‬
]54[
HYPOXIC FIRE EXTINGUISHING
COMPOSITION AND A SYSTEM
UTILIZING THE SAME
]22[
]31[
05.04.2001
09/551026
]32[ 17.04.2000
]33[ US
09/566506
08.05.2000
US
09/750801
28.12.2000
US
Int. Cl.8 A62C 003/00, 039/00, A62D 001/06, E21F 005/00
IGOR K. KOTLIAR, U.S.A.
WO/2001/078843
WOLFF, BREGMAN AND GOLLER,
,‫ ברגמן וגולר‬,‫וולף‬
19B KEREN HAYESOD ST.,
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
P.O.B. 1352,
JERUSALEM 91013
]51[
]71[
]87[
]74[
[57] A prefabricated breathable hypoxic
fire-preventive or fire-suppressive
composition for providing a breathable
fire-preventive or fire-suppressive
atmosphere in enclosed spaces, said
composition being ready-to-use for
injecting into said spaces and comprising a
gas mixture containing oxygen and
nitrogen, characterized in that said gas
mixture contains more than 12% and less
than 18% of oxygen for permanent use as a
fire-preventive atmosphere; or said
mixture contains more than 10% and less
than 16.8% of oxygen for episodic use as a
fire suppression agent.
__________
]11[]21[
]54[
PROCESS OF MICROGEL
SYNTHESIS AND PRODUCTS
PRODUCED THEREFROM
152087
‫תהליך לסינתיזת מיקרוג'ל ומוצרים‬
‫המיוצרים ממנו‬
]22[
]31[
]51[
]71[
06.04.2001
PQ6794
]32[ 07.04.2000
]33[ AU
Int. Cl.8 C08F 293/00, C08L 053/00, C09D 153/00
E.I. DU PONT DE NEMOURS AND
COMPANY, U.S.A.
COMMONWEALTH SCIENTIFIC
AND INDUSTRIAL RESEARCH
ORGANISATION, AUSTRALIA
]87[ WO/2001/077198
]74[ SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
comprising:
[57] A process for preparing a microgel
987
June 17, 2007 – ‫א' בתמוז התשס"ז‬
(i) RAFT polymerizing in the presence of a
RAFT chain transfer agent, one or more
solvophobic monomers and one or more
solvophilic monomers to form one or more
block copolymers comprising one or more
solvophobic blocks and one or more
solvophilic blocks wherein said
solvophobic block is insoluble in a
dispersing medium and said solvophilic
block is soluble in said dispersing medium;
(ii) dispersing said block copolymer in said
dispersing medium to form micelles; and
(iii) stabilizing said micelles to form said
microgel.
__________
]11[]21[
]54[
TRANSMIT/RECEIVE MODULE
FOR ACTIVE PHASED ARRAY
ANTENNA
]22[
]31[
]51[
]71[
09.04.2001
415/DEL/2000 ]32[ 07.04.2000
Int. Cl.8 G01S 007/03, H01Q 021/06
THE CHIEF CONTROLLER,
RESEARCH AND DEVELOPMENT,
INDIA
WO/2001/077706
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A transmit/receive module for a high
power active phased array antenna system
operating in L-band based upon a
combination of hybrid microwave
integrated circuit (MIC) and monolithic
microwave integrated circuit (MMIC)
technology and having power monitoring
means (22-25) for on line diagnostic
purposes, a transmitter protector means
and a receiver protector means, the said
transmit/receive module comprising: signal
transmit chain (10) incorporating power
conditioner (38), and signal receive chain
(11) incorporating control electronics (37)
and bias sequencer-modulator (39);
wherein the said signal transmit chain
comprises: T/R switching means (35) for
switching the module to the transmit mode,
connected to the transmit amplifier chain
(12-20) through shared 6-bit digital phase
shifter (36); duplexer means (21) receiving
June 17, 2007 – ‫א' בתמוז התשס"ז‬
152139
‫קלט עבור אנטנת פאזה‬/‫מודל פלט‬
‫אקטיבית‬
]33[
IN
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
the amplified signal from the transmit
amplifier chain and forming the said
transmitter protector means of the said
transmit chain; a high power switch (28)
having a drop in circulator (27) connected
to its input end which together with a high
power limiter (29) of the said receive chain
form the said receiver protector means of
the said receive chain; on-line power
monitoring means (22-25); a Single Pole
Single Throw (SPST) switch (26) for on
line sampling of transmit power; Tx/Rx
interface PCBs (40, 41) for
interconnections between the said transmit
chain and the said receive chain; wherein,
the said receive chain receives signal from
said drop-in circulator and said high power
switch in receive mode and comprises:
high power limiter (29); RF pre-selection
filter (30) connected to the said high power
limiter; low noise amplifier means (31-33);
988
6-bit digital attenuator means (34)
connected to said shared digital phase
shifter through said T/R switching means;
all connected through said control
electronics, said bias sequencer-modulator
and said power conditioner means.
__________
]11[]21[
]54[
APPARATUS AND METHOD FOR
EXTENDING FOOD DOUGH
]22[
]31[
14.02.2002
2001-39041
]32[ 15.02.2001
2002-860
07.01.2002
2002-28681
05.02.2002
Int. Cl.8 A21C 003/02
RHEON AUTOMATIC MACHINERY
CO., LTD., JAPAN
MICHIO MORIKAWA
WO/2002/063964
DR. MARK FRIEDMAN LTD.,
BEIT SAMUELOFF, 7 HAOMANIM
STREET,
TEL AVIV
]51[
]71[
]72[
]87[
]74[
[57] An apparatus for extending food
dough comprising a lower frame (3)
having a food-conveying member to
convey food dough in one direction, an
upper frame (5) located above the lower
frame, and a cluster of a plurality of
extending rollers (7A, 7B) that are located
within the upper frame, said extending
989
152240
‫מתקן ושיטה לרידוד בצק מזון‬
]33[
JP
JP
JP
,‫ד"ר מרק פרידמן בע"מ‬
‫ תל אביב‬,7 ‫ רח' האומנים‬,‫בית שמואלוב‬
rollers being arranged to be endless and
rotatable to extend the food dough,
wherein the upper frame is moved up and
down in relation to be lower frame, to
move the cluster of the plurality of
extending rollers far from the foodconveying member so that the foodconveying member can be cleaned.
June 17, 2007 – ‫א' בתמוז התשס"ז‬
__________
]11[]21[
]54[
DEVICE FOR SEPARATING THE
CONNECTING END OF A
HYPODERMIC
NEEDLE FROM THE TIP OF AN
INJECTION
INSTRUMENT
]22[
]31[
]51[
]71[
14.05.2001
00810416.8
]32[ 15.05.2000
Int. Cl.8 A61M 005/32
ARES TRADING S.A.,
SWITZERLAND
WO/2001/087387
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] Device for separating the connecting
end (2a) of a hypodermic needle (2) from
the tip of an injection instrument (4), in
which the hypodermic needle is retracted
inside a cylindrical barrel, the connecting
end of the hypodermic needle having
connectors complementary to connectors
on the said tip, one of the said connectors
June 17, 2007 – ‫א' בתמוז התשס"ז‬
152321
‫התקן להפרדת הקצה המחבר של מחט‬
‫תת–עורית מהחוד של מכשיר הזרקה‬
]33[
EP
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
having radial elasticity and devices for
converting an axial force exerted between
the said needle and the said injection
instrument into at least one radial
component capable of deforming the said
elastic connectors, comprising an opening
delimited by locking elements forming one
piece with elastic pieces to allow its
990
diameter to vary between a minimum
diameter and maximum diameter at least
equal to the diameter of the said
connecting end and at least one piece
associated with the said locking elements
for the purpose of converting an axial force
exerted on the said piece into at least one
radial component capable of being applied
to the said elastic pieces to deform them
radially so as to increase the diameter of
the said opening when the said connecting
end is displaced along its axis with its
needle pointing forward through the said
opening and to restore its initial diameter
after the said connecting end has passed
through it and allow the said locking
elements to engage with the rear face of
the said connecting end, wherein the
device has a guiding surface (10a)
concentric with the said opening and
extending outside said opening for a
sliding engagement with said cylindrical
barrel of the injection instrument when
said connecting end is displaced along its
axis.
__________
]11[]21[
991
152537
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫סוספנסיות מיימות מיוצבות לשימוש תוך‬
‫ורידי‬
]54[
STABILIZED AQUEOUS
SUSPENSIONS FOR
PARENTERAL USE
]22[
]31[
]51[
]71[
25.04.2001
571395
]32[ 15.05.2000
]33[ US
Int. Cl.8 A61K 009/00, 009/10, C07C 323/23
PHARMACIA & UPJOHN
COMPANY, U.S.A.
PFIZER ITALIA S.R.L, ITALY
WO/2001/087266
REINHOLD COHN AND
,‫ריינהולד כהן ושותפיו‬
PARTNERS,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A pharmaceutical aqueous
suspension formulation for parenteral
administration having substantially
stabilized pH comprising a biologically
active steroidal compound and a pH
controlling effective concentration of LMethionine.
__________
]11[]21[
153205
‫שימושי תליפורפין או נגזרותיו בהכנת‬
‫תרופות לטיפול במחלות לב‬
]54[
USES OF THALIPORPHINE OR
ITS DERIVATIVES IN THE
PREPARATION OF
MEDICAMENTS FOR
TREATMENT OF CARDIAC
DISEASES
]22[
]31[
]51[
]71[
28.02.2001
09/644932
]32[ 23.08.2000
]33[ US
Int. Cl.8 A61K 031/435, A61P 009/00, C07D 221/18
LOTUS PHARMACEUTICAL CO.
LTD., TAIWAN R.O.C.
WO/2002/016325
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
]87[
]74[
[57] A compound of the formula
June 17, 2007 – ‫א' בתמוז התשס"ז‬
992
or ester derivatives or pharmaceuticaly
acceptable salts thereof, wherein R is
hydrogen, acetyl, propionyl, butyryl or
tert-butoxycarbonyl.
__________
]11[]21[
]54[
HOLLOW THREAD FILM
CARTRIDGE, HOLLOW THREAD
FILM MODULE USING THE
CARTRIDGE AND TANK TYPE
FILTER
]22[
]31[
]51[
]71[
10.07.2001
2000-208339 ]32[ 10.07.2000
Int. Cl.8 B01D 063/04
ASAHI KASEI KABUSHIKI
KAISHA, JAPAN
WO/2002/004101
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A hollow fiber membrane cartridge
(4) comprising a bundle of a plurality of
hollow fiber membranes (3a) both ends of
which are fixed by adhesion in adhesion
and fixation layers (11, 14), a cartridge
head (12) fixed at periphery of the bundle
at one end so as not to permit passage of
liquid either in or out, and a bottom ring
(13) fixed at periphery of the bundle at the
other end so as not to permit passage of
liquid either in or out, the hollow portion at
the end of each hollow fiber membrane on
the cartridge head side is open, the hollow
993
153377
‫ מודול‬,‫מחסנית עבור פתיל חליל‬
‫המשתמש במחסנית זו ומסנן מסוג מיכל‬
]33[
JP
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
portion at the end of each hollow fiber
membrane on the bottom ring side is
sealed, and a plurality of through-holes
(14a) are provided in the adhesion and
fixation layer on the bottom ring side and
are located in the bundle of the hollow
fiber membranes which is characterized in
that said cartridge head and said bottom
ring are connected and fixed to a plurality
of rods or pipes (3b), wherein said rods
and pipes are located in an inner portion of
the bundle of fibers which extends over a
distance of one-fourth the diameter of the
June 17, 2007 – ‫א' בתמוז התשס"ז‬
bundle of fibers from the periphery surface
of the bundle of fibers or are located so as
to be dispersed in the bundle of fibers.
__________
]11[]21[
]54[
LIPOSOMAL PHARMACEUTICAL
COMPOSITIONS
]22[
]31[
29.06.2001
60/215556
]32[ 30.06.2000
60/264616
26.01.2001
Int. Cl.8 A61K 009/00, 009/127
INEX PHARMACEUTICALS
CORPORATION, CANADA
WO/2002/002077
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
]51[
]71[
]87[
]74[
[57] A liposomal formulation, said
liposomal formulation comprising:
(a) an antineoplastic drug; and
(b) a liposome having free antineoplastic
drug and precipitated antineoplastic drug,
153676
‫תכשירי רוקחות ליפוסומיים‬
]33[
US
US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
wherein the precipitated antineoplastic
drug in said liposome is at least 50% of the
total antineoplastic drug, and wherein said
liposome comprises sphingomelin and
cholesterol.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
153925
994
]54[
SYSTEM AND METHOD FOR
AUTOMATICALLY DETECTING
NEUTRAL EXPRESSIONLESS
FACES IN DIGITAL IMAGES
]22[
]31[
]51[
]71[
]74[
14.01.2003
10/051595
]32[ 17.01.2002
Int. Cl.8 G06K 009/00
IBM CORPORATION, U.S.A.
IBM LABORATORIES,
HAIFA UNIVERSITY,
HAIFA 31905
[57] A system for automatically detecting
neutral, expressionless face images in
digital images, the system comprising: an
image acquisition unit; face detector
receiving input from the image acquisition
unit, detecting one or more face subimages
of one or more faces in the image; a
characteristic point detector that receives
input from the face detector and that
estimates one or more characteristic facial
features as characteristic points in each
detected face subimage, one of the
‫מערכת ושיטה לזיהוי אוטומטי של פנים‬
‫נטולות הבעה בתמונות ספרתיות‬
]33[
US
,‫מחלקת קניין רוחני מעבדות יבמ‬
‫ חיפה‬,‫אוניברסיטת חיפה הר הכרמל‬
characteristic points being a first and a
second mouth corner on a mouth of the
face; a facial feature detector that detects
one or more contours of one or more facial
components; a facial feature analyzer that
determines a mouth shape of the mouth
from the contour of the mouth and creates
a representation of the mouth shape, the
mouth being one or the facial components;
and a face classification unit that classifies
the representation into one of a neutral
class and a non-neutral class.
__________
995
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
]54[
METHOD FOR PRODUCING SLABS
OF MARBLE CONGLOMERATE
]22[
]31[
]51[
]71[
]87[
]74[
14.06.2002
RM2001A000390 ]32[ 04.07.2001
Int. Cl.8 C04B 040/04
FRANCO BRUTTI, ITALY
WO/2003/004440
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] Process for the production of marble
conglomerate slabs, starting from marble
sand and/or granulates, additivated with
binders, said process being of the kind
comprising a step of mixing the raw
materials, a step of placing the mixture on
a conveyor belt or on moulds, a vibrocompaction step under vacuum and a
subsequent step of polymerization of the
binder, plus optional further lapping and
finishing steps of the final product,
characterised in that it further comprises a
step of placing a protective sheet on said
conveyor belt or on the base of said
154335
‫שיטה משופרת לייצור דברי לוחות שיש‬
]33[
IT
,‫ריינהולד כהן ושותפיו‬
‫ תל‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
‫אביב‬
moulds, before pouring the mixture, and
on said mixture, after having poured the
same and before covering the mixture with
an optional lid of the mould, or in any case
before carrying out the vibro-compaction,
said protective sheet being comprised of
watersoluble plastic material in such a way
as to coat the mixture at the top and at the
bottom surfaces before the vibrocompaction step, said watersoluble
material sheet being automatically
removed, after the binder polymerization
step, by the water of the slab finishing
workings.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
154630
996
]54[
"MELT BLOWN"
ARRANGEMENT FOR AN
APPARATUS FOR PRODUCING
NON-WOVEN WEBS
]22[
]31[
26.02.2003
02004616.5]32[ 28.02.2002
2124
Int. Cl.8 D04H 001/56
REIFENHAUSER GMBH & CO.
MASCHINENFABRIK, GERMANY
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
]51[
]71[
]74[
[57] An apparatus for producing meltblown products comprising: a nozzle (1)
for discharging thermoplastic synthetic
resin filaments (3) collectable to form a
melt-blown product; a continuously
movable deposit screen (5) below said
nozzle for collecting said filaments
therefrom as said screen is displaced in a
longitudinal direction; a plurality of
mutually separated suction areas formed in
succession in said direction below said
screen for drawing air therethrough to
effect deposition of said filaments on said
screen, said suction areas being delimited
by respective partitions (10) directly
‫אמצעי "התך ונפח" עבור מתקן ליצירת‬
‫מרקמים לא ארוגים‬
]33[
EP
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
separating one suction area from another
and reaching upwardly to the screen, said
suction areas including a primary suction
area directly below said nozzle and
drawing a greater quantity of said
filaments onto said screen than any other
of said suction areas, an initial suction area
and a second suction area provided
upstream of said primary suction area in
said direction, and a third suction area
provided downstream of said primary
suction area in said direction; and means
for adjusting suction speeds in said suction
areas independently from one another.
__________
]11[]21[
997
154669
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]54[
ENCAPSULATED BARRIER FOR
FLEXIBLE FILMS AND A
METHOD OF MAKING THE
SAME
]22[
]31[
]51[
]71[
28.08.2001
650385
]32[ 29.08.2000
Int. Cl.8 B32B 027/28
PECHINEY EMBALLAGE
FLEXIBLE EUROPE, FRANCE
WO/2002/018139
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A film structure comprising; a
barrier layer (110) comprising ethylene
vinyl alcohol copolymer; first adhesive
material (112) encapsulating said barrier
layer and forming first (112) and second
(114) adhesive layers disposed on opposite
surfaces of said barrier layer wherein said
first adhesive material is selected from the
group consisting of acid terpolymer,
polyolefin having maleic anhydride grafted
thereto, and polyamide; a third adhesive
layer disposed adjacent to said first
adhesive layer wherein said third adhesive
‫מחסום מתורמל עבור קרומים גמישים‬
‫ושיטה ליצורו‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
layer comprises a polyethylene or
polyethylene copolymer; a fourth adhesive
layer (116) disposed adjacent to said
second adhesive layer wherein said fourth
adhesive layer comprises a polyethylene or
polyethylene copolymer; a heat sealant
layer (120) comprising ethylene vinyl
acetate copolymer disposed adjacent to
said third adhesive layer; and an outer
layer (118) comprising polyester wherein
said barrier and first, second, third and
fourth adhesive layers are extrusion
laminated to said outer layer.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
154672
998
]54[
METHOD OF REINFORCING AN
EXISTING METAL STRUCTURE
]22[
]31[
21.08.2001
0022072.3
]32[ 08.09.2000
0107803.9
28.03.2001
Int. Cl.8 B63B 001/00, 009/04
INTELLIGENT ENGINEERING
(BAHAMAS) LIMITED, BAHAMAS
WO/2002/020341
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]51[
]71[
]87[
]74[
[57] A method of reinforcing a panel of
an existing metal structure comprising the
steps of:
providing a reinforcing metal layer on said
panel in spaced apart relation to thereby
form at least one cavity between inner
surfaces of said panel and said reinforcing
metal layer; injecting an intermediate layer
‫שיטה לחיזוק מבנה מתכתי‬
]33[
GB
GB
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
comprised of an uncured plastics material
into said at least one cavity; and curing
said plastics material so that it adheres to
said inner surfaces of said panel and said
reinforcing metal layer with sufficient
strength to transfer shear forces between
said panel and said reinforcing metal layer.
__________
]11[]21[
]54[
METHOD AND APPARATUS FOR
NON-INVASIVELY EVALUATING
ENDOTHELIAL ACTIVITY IN A
PATIENT
]22[
]31[
]51[
]71[
]72[
22.10.2001
60/242054
]32[ 23.10.2000
Int. Cl.8 A61B 005/00
ITAMAR MEDICAL LTD.
PERETZ LAVIE, ROBERT
SCHNALL, JACOB SHEFFY
WO/2002/034105
G.E. EHRLICH (1995) LTD.,
AYALON TOWER, 15TH FLOOR,
11 MENACHEM BEGIN STREET,
52521 RAMAT GAN
]87[
]74[
154833
‫שיטה ומכשיר לבדיקה לא חודרנית של‬
‫פעילות אנדותל בחולה‬
]33[
US
‫ קיסריה‬,‫איתמר מדיקל בע"מ‬
‫ יעקב שפי‬,‫ רוברט שנל‬,‫פרץ לביא‬
,‫) בע"מ‬1995( ‫ארליך‬.‫אי‬.‫ג'י‬
,11 ‫רחוב מנחם בגין‬, 15 ‫ קומה‬,‫מגדל אילון‬
‫רמת גן‬
[57] Apparatus for non-invasively
evaluating endothelial activity in a patient,
comprising: an occluding cuff for applying
an occluding pressure to a predetermined
999
June 17, 2007 – ‫א' בתמוז התשס"ז‬
part of an arm or leg of the patient to
occlude blood flow therein for a
predetermined time period; a monitoring
digit-probe for monitoring a digit of said
arm or leg for changes in the peripheral
arterial tone therein before and after the
application of said occluding pressure to
the arm or leg of the patient; and a
processor (23) for utilizing any detected
changes in said peripheral arterial tone for
evaluating endothelial activity in the
patient; wherein said processor is
controlled by said monitoring digit-probe
to indicate when an occluding pressure has
been applied to said predetermined part of
the patient's arm or leg., which is indicated
when said monitoring digit-probe
measures no pulsatile volume flow in said
digit.
__________
]11[]21[
154938
‫מגש להשרשת צמחים צעירים‬
]54[
CULTURE TRAY FOR THE
ROOTING OF YOUNG PLANTS
]22[
]31[
]51[
]71[
]74[
17.03.2003
10211723.3
]32[ 18.03.2002
]33[ DE
Int. Cl.8 A01G 009/02, 009/10, A01H 004/00
MARGA DUMMEN, GERMANY
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
[57] A culture tray (1) for young plants to
take root comprising: (a) a plurality of
parallel channels having respective
June 17, 2007 – ‫א' בתמוז התשס"ז‬
1000
sidewalls and at least one open end, said
channels extending in a longitudinal
direction and arranged at selected distances
from each other for accommodating the
plants; and (b) a plurality of independent
bilaterally open-sided planting row
skeletons (20), each skeleton comprising a
bottom ledge having a plurality of partition
webs (21) connected by the ledge and
being arranged in a respective channel so
that said partition webs are arranged in the
channel transversely to said longitudinal
direction to define a plurality of planting
areas, each planting area being limited by
two sidewalls (3, 4) of the channel
arranged right-angled to the planting area
to define space boundaries for radicular
planting bales during breeding of the
plants, and wherein the planting row
skeleton is formed in such a way that the
planting row skeleton, after rooting of the
plants, can laterally be pushed out of the
respective channel so that the radicular
planting bales rest on the ledge and are
merely separated by partition webs and
two radicular bales rest on the ledge and
are merely separated by partition webs and
two radicular bale surfaces arranged
transversely to the longitudinal direction
are open.
__________
]11[]21[
1001
155352
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]54[
NON-INVASIVE ELECTRONIC
THERMOMETER
]22[
]31[
]51[
]71[
]87[
]74[
11.10.2001
00/13173
]32[ 13.10.2000
Int. Cl.8 G01K 013/00
SEB S.A., FRANCE
WO/2002/031457
SELIGSOHN GABRIELI & CO.,
31 YAVNE ST.,
P.O.B. 1426,
TEL AVIV 61013
[57] A non-invasive electronic
thermometer for measuring body
temperature, the thermometer comprising a
case having arranged at its end a
temperature sensor (10) mounted on a
insulating support (30) the case containing
electronic processing means
communicating with said sensor to
‫מדחום אלקטרוני לא חודרני‬
]33[
FR
,'‫זליגסון גבריאלי ושות‬
‫ תל אביב‬,1426 .‫ד‬.‫ ת‬, 31 ‫רח' יבנה‬
transform the signals received from the
sensor into values for the temperature of
the human body and for displaying them,
the thermometer being characterized in
that the support includes at least one cavity
(36) surrounding the sensor in leaktight
manner when the sensor is brought into
contact with the skin.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
155475
1002
]54[
METHODS AND DEVICES FOR
POLARISED NMR SAMPLES
]22[
]31[
02.11.2001
0004034-5
]32[ 03.11.2000
60/256974
05.01.2001
Int. Cl.8 A61B 005/055
GE HEALTHCARE AS, NORWAY
WO/2002/036005
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] A device configured for melting a
solid hyperpolarized sample, comprising: a
cryostat (1); coils (31', 31") within said
cryostat; a means (5) for hyperpolarizing
said solid sample at a low temperature
within the cryostat, wherein the means for
hyperpolarizing is also located within a
magnetic field generated within the device,
‫שיטות והתקנים לדגימות תמ"ג מקוטבות‬
]33[
SE
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
a means (8) for melting said
hyperpolarized solid sample wherein said
means for melting is positioned inside said
cryostat and within said generated
magnetic field; and wherein said coils
within said cryostat are configured for
performing an NMR analysis of a melted
hyperpolarized sample.
__________
]11[]21[
1003
155562
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]54[
SYSTEM AND METHOD FOR
IMPROVING VOICE
RECOGNITION IN NOISY
ENVIRONMENTS AND
FREQUENCY MISMATCH
CONDITIONS
]22[
]31[
]51[
]71[
25.10.2001
09/703191
]32[ 31.10.2000
Int. Cl.7 G01L 015/00
QUALCOMM INCORPORATED,
U.S.A.
WO/2002/082033
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
]87[
]74[
[57] A voice recognizer of a distributed
voice recognition system, comprising: a
bark amplitude generation module (12)
configured to convert a digitized speech
signal to bark amplitudes; a mu-log
compression module (14) coupled to the
bark amplitude generation module, the mulog compression module configured to
perform mu-log compression of the bark
amplitudes;
‫מערכת ושיטה לשיפור הכרת קול‬
‫בסביבות רועשות ובתנאי–אי–התאמת תדר‬
]33[
US
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
a RASTA filtering module (18) coupled to
the mu-log compression module, the
RASTA filtering module configured to
RASTA filter the mu-log bark amplitudes;
and a cepstral transformation module (16)
coupled to the RASTA filtering module,
the cepstral transformation module
configured to generate j static cepstral
coefficients and j dynamic cepstral
coefficients.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
155875
1004
]54[
PIPERAZINYLPYRAZINE
COMPOUNDS AS ANTAGONISTS
OF SEROTONIN 5-HT2
RECEPTOR
]22[
]31[
20.11.2001
0004244-0
]32[ 20.11.2000
60/253702
28.11.2000
Int. Cl.8 A61K 031/4995, C07D 403/00
BIOVITRUM AB, SWEDEN
WO/2002/040457
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]51[
]71[
]87[
]74[
‫תרכובות פיפראזינילפיראזינים כאגוניסטים‬
‫ של סרוטונין‬TH5–2 ‫של קולטן‬
]33[
SE
US
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
[57] A compound of the formula
wherein
R1 is hydrogen, C1-4 alkyl, C3-4 – alkenyl,
C1-4 – acyl, C1-4-alkoxycarbonyl, 2hydroxyethyl, 2-cyanoethyl,
tetrahydropyran-2-yl, or a nitrogen
protecting group;
R2 is hydrogen, C1-4-alkyl, hydroxymethyl,
C1-4-alkoxymethyl, or fluoromethyl;
R3 and R4 independently of each other are
hydrogen, methyl, C1-4-alkyl, aryl,
heteroaryl wherein aryl and heteroaryl
residues in turn may be substituted in one
or more positions independently of each
other by halogen, C1-4-alkyl, C1-4-alkoxy,
C1-4-alkylthio, C1-4-alkylsulphonyl,
methanesulphonamido, acetyl, nitro,
cyano, hydroxy, trifluroethyl,
trifluromethoxy,
1005
trifluoromethylthio, amino, methylamino,
dimethylamino, or acetamido;
or
R3 and R4 together with the carbon atoms
to which they are bound form a 5-or 6membered aromatic or heeroaromatic ring,
which may be substituted in one or more
positions by halogen, methyl, methoxy,
methylthio, methylsulphonyl, nitro, cyano,
hydroxy, trifluoromethyl,
trifluoromethylthio, amino, methylamino,
dimethylamino or acetamido;
R5 and R6 independently of each other are
hydrogen, C1-C4-alkoxy-C2-C4-alkyl,
hydroxy- C2-C4-alkyl, C1-C6-alkyl, C2-C6 –
acyl, aryl, heteroaryl, aryl- C1-C2 – alkyl,
heteroaryl-C1-C2-alkyl, aryl- C1-C2-acyl,
heteroaryl- C1-C2-acyl, and wherein any
June 17, 2007 – ‫א' בתמוז התשס"ז‬
aryl or heteroaryl, alone or as part of
another group, may be independently
substituted in one or more positions by C1-4
– alkyl, C1-4 – alkoxy, C1-4 – alkylthio, C24- acyl, C1-4 – alkylsulphonyl, cyano, nitro,
hydroxy, C2-3-alkenyl, C2-3-alkynyl,
fluoromethyl, trifluromethyl,
trifluoromethoxy, halogen, dimethylamino,
or methylamino; or
R5 and R6 together with the nitrogen atom
to which they are bound form a saturated
heterocyclic ring having 4-7 ring members
which ring may contain an additional
heteroatom and which may be substituted
by methyl, oxo, or hydroxy, R7 is
hydrogen or a substituent selected from
halogen, methyl, methoxy, and ethoxy; and
n = 1 -3;
and pharmaceutically acceptable salts,
hydrates, geometrical isomers, tautomers,
optical isomers, N-oxides or prodrug forms
thereof.
__________
]11[]21[
]54[
CONTACT-FREE OR HYBRID
CONTACT/CONTACT-FREE
SMART CARD WITH ENHANCED
STRENGTH OF THE
ELECTRONIC MODULE
]22[
]31[
13.09.2002
01/11918
]32[ 14.09.2001
02/02161
20.02.2002
Int. Cl.8 G06K 019/077
ASK S.A., FRANCE
WO/2003/025850
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] A smart card including an antenna
(18) on a support made of paper type
fibrous material (12), two card bodies on
each side of said support each made up of
at least one layer of plastic material having
a low fluidizing temperature, and an
electronic module comprising a chip (26)
connected to the antenna, said module
being housed in a cavity made through one
of said card bodies and said antenna
support, the assembly formed by the
antenna support and the two card bodies
being welded together by hot-lamination
under pressure;
June 17, 2007 – ‫א' בתמוז התשס"ז‬
155882
‫ ללא מגע או בשילוב של מגע‬,‫כרטיס חכם‬
‫ בעל חוזק משופר של המודול‬,‫וללא מגע‬
‫האלקטרוני‬
]33[
FR
FR
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
said card being characterised in that said
support made of fibrous material includes
one or several recesses (14, 16) located
such that they are superposed on the glue
spots (34, 36) securing said module to said
card body such that the plastic material
layers (23, 25) of said card bodies come
into close contact via said recesses during
the lamination process, said recesses thus
filled forming a weld between the card
bodies thereby reinforcing the connection
of the module.
1006
__________
]11[]21[
]54[
MODIFIED OILSEED MATERIAL
AND METHOD FOR ITS
PRODUCTION
]22[
]31[
20.11.2001
09/717923
]32[ 21.11.2000
09/883496
18.06.2001
09/883552
18.06.2001
09/883558
18.06.2001
09/883495
18.06.2001
09/883849
18.06.2001
Int. Cl.8 A23J 003/16
CARGILL, INCORPORATED, U.S.A.
WO/2002/100186
DR. SHLOMO COHEN & CO.,
124 IBN GABIROL ST.,
P.O.B. 11490,
TEL AVIV 62038
]51[
]71[
]87[
]74[
[57] A method for producing a modified
oilseed material comprising: extracting
oilseed material with an aqueous solution
to form a suspension of particulate matter
in an oilseed extract; and passing the
extract through a filtration system
comprising a microporous membrane to
156017
‫תוצר של זרע המכיל שמן שעבר שינוי‬
‫ושיטה לייצורו‬
]33[
US
US
US
US
US
US
,'‫ד"ר שלמה כהן ושות‬
‫ תל אביב‬,11490 .‫ד‬.‫ ת‬, 124 ‫אבן גבירול‬
produce a first permeate and a proteinenriched retentate, wherein the
microporous membrane has an MWCO of
at least 25,000 and a filtering surface with
a contact angle of no more than 40
degrees.
__________
]11[]21[
1007
156109
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫מיכל מבודד עבור מזון או משקה‬
]54[
INSULATED BEVERAGE OR
FOOD CONTAINER
]22[
]31[
11.06.2002
60/298386
]32[ 18.06.2001
]33[ US
923332
08.08.2001
US
Int. Cl.8 B32B 005/18, 027/10, B65D 081/36
APPLETON PAPERS INC., U.S.A.
WO/1992/102671
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] An insulated container stock material
comprising: an interior surface and an
exterior surface; a paper stock layer (2),
wherein said paper stock layer forms said
exterior surface; a foam layer (3), wherein
said foam layer is heat laminated foam
formed from at least one of high density
polyethylene, low density polyethylene,
linear low density polyethylene, and
oriented polypropylene; and a polymer
barrier shrink film layer (4) having a
percent shrink of 5-30%, wherein said heat
laminated foam layer and said polymer
shrink film layer form said interior surface.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
156353
1008
]54[
WATER-FREE SKIN CARE
FORMULATIONS COMPRISING
MICRONIZED UREA AND
METHOD OF MANUFACTURING
THE SAME
]22[
]31[
14.12.2001
00127556.9
]32[ 15.12.2000
60/255401
15.12.2000
Int. Cl.8 A61K 000/800000 031/00
SCHERING
AKTIENGESELLSCHAFT,
GERMANY
WO/2002/047643
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]51[
]71[
]87[
]74[
[57] A water-free medical skin care
formulation in the form of a semi-solid
ointment comprising 0.5 to 10% by weight
(%w/w) of micronized urea dispersed in a
fatty phase which is essentially free from
fragrances, preservatives, colorings, plant
extracts PEGs, cetylstearyl alcohol, lanolin
‫הרכב ללא מים לטיפול בעור המכיל‬
‫חלקיקים זעירים של אוריאה ושיטה ליצורו‬
]33[
EP
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
alcohol, lower alcohols and proteins,
wherein the fatty phase consists essentially
of hydrocarbons, and wherein the
dispersed urea particles have a
homogenous particle size distribution with
a particle size of less than about 100 μm.
__________
]11[]21[
]54[
OMNI-DIRECTIONAL RADIATION
SOURCE AND OBJECT LOCATOR
]22[
]31[
20.03.2002
60/276933
]32[ 20.03.2001
60/322737
18.09.2001
PCT/IL02/00074
24.01.2002
Int. Cl.8 G01C 003/00
WAVE GROUP LTD.
WO/2002/075348
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
]51[
]71[
]87[
]74[
[57] A method for determining elevation
angle of an object imaged by a focal plane
1009
156362
‫איתור מקורות קרינה ואובייקטים‬
‫במפתח כלל כיווני‬
]33[
US
US
WO
‫ תל אביב‬,‫קבוצת גל בע"מ‬
,'‫ קולב ושות‬.‫סנפורד ט‬
,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
‫רחובות‬
array sensor, comprising the following
stages:
June 17, 2007 – ‫א' בתמוז התשס"ז‬
(a) imaging a cylindrical field of view
using an omni-directional imaging system
which comprises of an omni-direction lens
assembly and a focal plane array;
(b) detection of an object imaged by a first
sensor element on the said focal plane
array;
(c) registration of the coordinates of said
first sensor element relative to its position
on the said focal plane array;
(d) registration of the coordinates of a
second sensor element which occupies the
center of the entire image, relative to its
position on the said focal plane array;
(e) determination of the distance between
said first sensor element and said second
sensor element;
(f) determination of a transformation
function, which assigns each said distance
the appropriate elevation angle value, said
transformation function being compatible
to the design of the omni-directional
imaging system;
(g) extraction of elevation angle value
which corresponds to the said distance
value from the said transformation
function,
wherein said focal plane array images an
omni-directional field of view.
__________
]11[]21[
]54[
CHOKE COIL
]22[
]31[
]51[
]71[
]87[
]74[
25.10.2001
2000-386964 ]32[ 20.12.2000
Int. Cl.8 H01F 017/04
KUNIFUMI KOMIYA, JAPAN
WO/2002/050849
DR. MARK FRIEDMAN LTD.,
BEIT SAMUELOFF, 7 HAOMANIM
STREET,
TEL AVIV
[57] A choke coil (1) comprising: a coil
having an insulated conducting wire
wound in a coil shape; and a conducting
June 17, 2007 – ‫א' בתמוז התשס"ז‬
156426
‫כבל משנק‬
]33[
JP
,‫ד"ר מרק פרידמן בע"מ‬
‫ תל אביב‬,7 ‫ רח' האומנים‬,‫בית שמואלוב‬
ring (3) having a centerline extending in
the axial direction of the coil.
1010
__________
]11[]21[
]54[
PROCESS FOR DEPOSITING A
METAL COATING CONTAINING
NICKEL AND BORON
]22[
]31[
]51[
]71[
16.01.2002
01100161.7
]32[ 16.01.2001
Int. Cl.8 C23C 018/34
MCCOMAS TECHNOLOGIES AG,
GERMANY
WO/2002/066701
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A process for depositing a metal
coating containing nickel and boron on a
substrate, said process comprising:
preparing a plating bath having a pH in the
range of about 10.5 to 14 and a
temperature above ambient temperature,
comprising:
(a) nickel ions according to a nickel
concentration in the range of about 4.76 to
1011
156656
‫תהליך להשמת ציפוי מתכתי המכיל ניקל‬
‫ובורון‬
]33[
EP
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
about 5 g/l of plating bath;
(b) an effective amount of a stabilizer;
(c) a metal ion complexing agent in an
amount effective to inhibit precipitation of
said metal ions from the plating bath;
(d) an effective amount of a borohydride
reducing agent; and
(e) optionally up to 0.25 moles of cobalt
per liter of plating bath;
June 17, 2007 – ‫א' בתמוז התשס"ז‬
immersing said substrate to be coated into
said plating bath, electrolessly depositing
the coating on the substrate and optionally
heat treating said metal coating for about
one to about 24 hours subsequently,
characterized in that the plating bath is
prepared on the basis of deionized water
having a conductivity in the range of about
0.05 to about 0.1 μS.
__________
]11[]21[
156757
‫מתכתי‬-‫מתג דו‬
]54[
BI-METALLIC SWITCH
]22[
]31[
]51[
]71[
]74[
03.07.2003
10/206465
]32[ 26.07.2002
Int. Cl.8 H01H 001/58
DAVID M. ALLEN, U.S.A.
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
[57] A low cost convoluted test strip for
testing a battery powered device, the strip
being positionable between terminals of a
power supply circuit incorporating the
battery, comprising:
an elongated, flexible insulating layer (26)
defining upper and lower sides and first
and second ends; an upper conductive
layer on the upper side; a lower conductive
layer on the lower side, the conductive
layers (30) being substantially electrically
insulated from one another by the
]33[
US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
insulating layer; and, a convoluted portion
adjacent to the first end of the strip, such
that a portion (46) of the lower conductive
layer is cantilevered above and resiliently
suspended with respect to an adjacent noncantilevered portion (48) of the upper
conductive layer whereby the cantilevered
portion of the strip can be depressed with
respect to the non-cantilevered portion of
the strip to establish electrical continuity
between the conductive layers.
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
1012
]11[]21[
156797
‫ ושסתום הידראולי הכולל אותה‬,‫סרעפת‬
]54[
DIAPHRAGM AND
HYDRAULICALLY-OPERATED
VALVE USING SAME
]22[
]51[
]71[
06.07.2003
Int. Cl.8 F16K 031/145, 031/165, 031/365, 031/385
RAPHAEL VALVES INDUSTRIES
‫ אור‬,‫) בע"מ‬1975( ‫תעשיות מגופים‬-‫רפאל‬
(1975) LTD.
‫עקיבא‬
]72[
]74[
BORIS FRENKEL
EITAN, PEARL, LATZER AND
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
[57] An elastomer diaphragm (10) for use
in a hydraulically-operated valve (50), said
diaphragm being provided with an upper
face arranged to be exposed to a control
hydraulic pressure and a lower face (26)
arranged to seal and open a passage
between a valve inlet (52) and a valve
outlet (54), ribs (22) on said upper face
urging said diaphragm towards a sealing
position, said diaphragm being
characterized by the addition of an
elastomer ring element (24) disposed
adjacent to said upper face and adjacent to
the largest diameter of the diaphragm
‫בוריס פרנקל‬
,‫ לצר וכהן צדק‬,‫ פרל‬,‫איתן‬
‫ הרצליה‬,12688 .‫ד‬.‫ ת‬, 7 ‫רחוב שנקר‬
exposed inside a valve to which it may be
assembled, an upper face of said flexible
ring element being in pressure contact with
a portion of the rigid body of said valve,
said elastomer ring element further urging
said diaphragm towards its lower position
and allowing closure of said valve without
use of a metallic compression spring,
wherein said urging of said diaphragm
towards its lower position by said
elastomer ring is enabled also when the
hydraulic pressure above and below said
diaphragm are equal.
__________
1013
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
]54[
APPARATUS AND METHOD FOR
ASSEMBLING A FLEXIBLE
BATTERY THAT IS
ELECTROLYTE-TIGHT
]22[
]31[
]51[
]71[
07.02.2002
779247
]32[ 08.02.2001
Int. Cl.8 H01M 002/36
EVEREADY BATTERY COMPANY,
INC., U.S.A.
WO/2002/063702
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] An assembly system for assembling
a flexible battery comprising: a flexible
battery precursor comprising a battery
enclosure, the battery enclosure
comprising an electrode pouch including a
fill opeining that is open when electrolyte
is introduced into the electrode pouch and
unsealed surfaces which are thereafter
sealed; and an assembly apparatus, the
assembly apparatus comprising: a support
body adapted to support the battery
enclosure with the fill opening located in
June 17, 2007 – ‫א' בתמוז התשס"ז‬
157252
‫התקן ושיטה להרכבת סוללה גמישה‬
‫אטומה לאלקטרוליט‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
an upper portion of the electrode pouch;
and a dispensing element for introducing
electrolyte into the battery enclosure, the
dispensing element having a discharge
orifice that directs the flow of electrolyte
into the electrode pouch and away from the
surfaces surrounding the fill opening;
wherein the dispensing element is
retractable from the flexible battery
precursor following electrolyte
introduction.
1014
__________
]11[]21[
]54[
REMOVABLE
ELECTROMAGNETIC
INTERFERENCE SHIELD
]22[
]31[
]51[
]71[
15.02.2002
09/793754
]32[ 26.02.2001
Int. Cl.8 H05K 009/00
GORE ENTERPRISE HOLDINGS,
INC., U.S.A.
WO/2002/069687
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
]87[
]74[
[57] An apparatus comprising:
(a) a substrate (10) having at least one
electrical component (11) disposed
thereon;
(b) a plurality of discrete electrically
conductive fastening units (14) disposed in
1015
157410
‫מגן להפרעה אלקטרומגנטי הניתן להסרה‬
]33[
US
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
a pattern on said substrate surrounding said
at least one electrical component;
(c) an EMI shield comprising a dielectric
material layer having an inner surface and
June 17, 2007 – ‫א' בתמוז התשס"ז‬
an outer surface and an electrically
conductive layer over at least one of said
inner and outer surface;
(d) a plurality of apertures formed in said
EMI shield such that said apertures
correspond to said pattern of said
electrically conductive fastening unit;
(e) wherein at least one of said apertures
has a contact region and wherein both said
dielectric material layer and said
electrically conductive layer of said EMI
shield at said contact region of said
aperture are deflectable to the extent
necessary to allow said contact region to
engage and retain at least one of said
electrically conductive fastening units;
(f) and wherein said electrically conductive
layer of said EMI shield at said contact
region is in electrical contact with at least
one said electrically conductive fastening
unit.
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
1016
]11[]21[
]54[
METHOD AND APPARATUS FOR
DETERMINING THE
POSITIONING OF VOLUMETRIC
SENSOR ARRAY LINES
]22[
]31[
]51[
]71[
21.08.2003
242823
]32[ 13.09.2002
Int. Cl.8 G01S 003/86
GENERAL DYNAMICS ADVANCED
INFORMATION SYSTEMS, INC.,
U.S.A.
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]74[
[57] A method of determining the relative
position of an array line within a volumetric array connected to a receiver, the
method comprising the steps of: generating
a specific pseudo-random number (PRN)
sequence; sending the specific PRN
sequence to a specific transmitter
subsystem and at least one receive line of
the volumetric array; transmitting the
specific PRN sequence by modulating a
carrier wave being sent from the specific
transmitter subsystem with the specific
157521
‫שיטה והתקן לקביעת המיקום של מערך‬
‫קווים של גלאי נפח‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
PRN sequence, the carrier wave having a
frequency which is outside an analysis
band for the volumetric array and the
receiver; identifying the specific PRN
sequence at at least two sensors on the
receive line of the volumetric array and
determining a transit time for the PRN
sequence from the specific transmitter
subsystem to the sensors; and
communicating thr transit time to the
receiver for position determination.
__________
1017
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
157525
‫פילטרי אויר דיסקה‬
]54[
DISC TYPE AIR FILTERS
]22[
]31[
]51[
]71[
26.02.2002
60/271652
]32[ 28.02.2001
Int. Cl.8 B03C 003/47
MILOW LTD., U.S.A.
GIDEON ROSENBERG
]87[
]74[
WO/2002/068125
G.E. EHRLICH (1995) LTD.,
AYALON TOWER, 15TH FLOOR,
11 MENACHEM BEGIN STREET,
52521 RAMAT GAN
[57] An air filter, comprising: a housing
(2) having an air inlet (3), an air outlet (5),
and a stack of filter discs (10, 20) within
the housing for removing solid particles
from the air passing from said inlet to said
outlet; said filter discs in the stack being
formed with contacting faces having
surface formations defining filtering
passageways between adjacent discs for
removing solid particles from the air
passing through said stack of filter discs;
said filter discs in the stack including
electrodes spaced from each other axially
]33[
US
‫ קרית טבעון‬,‫גדעון רוזנברג‬
,‫) בע"מ‬1995( ‫ארליך‬.‫אי‬.‫ג'י‬
,11 ‫רחוב מנחם בגין‬, 15 ‫ קומה‬,‫מגדל אילון‬
‫רמת גן‬
of the stack and connectable to a voltage
source (30) for producing an electrical
field attracting solid particles towards the
discs to thereby enhance removal of the
solid particles from the air passing through
said stack of filter discs; characterized in
that said filter discs in the stack include a
first plurality of insulating discs of
insulating material alone, and a second
plurality of electrode discs of electricallyconductive material alone, with the
electrode discs separated from each other
by at least one insulating disc.
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
1018
]11[]21[
‫מכלל צילינדר הדראולי בעל פתחים‬
‫פנימיים‬
]54[
INTERNALLY PORTED
HYDRAULIC CYLINDER
ASSEMBLY
]22[
]31[
]51[
]71[
08.09.2003
10/238035
]32[ 09.09.2002
Int. Cl.8 B63H 005/125
T.J. BROOKS COMPANY-DIVISION
OF HANNA CYLINDERS, U.S.A.
WOLFF, BREGMAN AND GOLLER,
19B KEREN HAYESOD ST.,
P.O.B. 1352,
JERUSALEM 91013
]74[
157804
[57] A fluid cylinder (10) comprising: a
rod (18), said rod having a proximal end,
an internal fluid inlet channel (27) and an
internal fluid outlet channel (29); a
cylinder body (14); said body having a
generally cylindrical exterior, a proximal
end with a base and an distal end with an
aperture, and said body further having an
interior, a piston (16) slidably fitted into
said interior so to divide said interior into a
first fluid chamber (22), said chamber
communicating with an internal fluid inlet
passage and a second fluid chamber (24),
said chamber communicating with an
internal outlet fluid passage, said piston
further carries the rod, said rod extending
generally parallel to the cylinder body and
extending beyond the body at the distal
]33[
US
,‫ ברגמן וגולר‬,‫וולף‬
‫ ירושלים‬,1352 .‫ד‬.‫ ת‬, '‫ב‬19 ‫רחוב קרן היסוד‬
end, said end having means to hermetically
seal the aperture while adapted to slidably
receive said rod; a fluid inlet port located
on the proximal end of the rod, said port
communicating with the internal fluid inlet
channel of the rod and wherein said
channel communicates with the internal
inlet fluid passage of the body, said inlet
port communicating with the internal inlet
fluid passage; a fluid outlet port located on
the proximal end of the rod, said port
communicating with the internal fluid
outlet channel of the rod and wherein said
channel communicates with the internal
outlet fluid passage of the body, and a
means for mounting the cylinder to a
selected object of interest.
__________
1019
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
]54[
NAVIGATION SYSTEM USING
PAGING CHANNEL AND
METHOD FOR PROVIDING
TRAFFIC INFORMATION
]22[
]31[
10.09.2003
10-2003]32[ 11.01.2003
0001873
Int. Cl.8 G08G 001/0968
SAMSUNG ELECTRONICS CO.,
LTD., REPUBLIC OF KOREA
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
]51[
]71[
]74[
[57] A navigation system utilizing a
paging channel of a mobile communication
service for a navigation apparatus
including a mobile communication
function, the navigation system
comprising: a base station controller
(BSC)-based traffic server (200) for
periodically extracting/synthesizing traffic
157864
‫מערכת ניווט שמשתמש בערוץ קריאה‬
‫ובשיטה לאספקת מידע על תנועה‬
]33[
KR
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
information in an area of a BSC (300) and
then transmitting the traffic information in
the area which is controlled by the BSC;
and a BSC for inserting the traffic
information received from the BSC-based
traffic server into the paging channel for a
mobile communication terminal and then
transmitting the paging channel.
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
1020
]11[]21[
]54[
7 - SUBSTITUTED 3 - ALKYL - 3H ISOBENZOFURAN - 1 - ONE
DERIVATIVES, A PROCESS FOR
THE PREPARATION THEREOF
AND A USE THEREOF IN THE
PREPARATION OF
MEDICAMENTS
]22[
]31[
]51[
]71[
21.05.2002
954/01
]32[ 22.05.2001
Int. Cl.8 C07D 307/00, 307/88
SYNGENTA PARTICIPATIONS AG,
SWITZERLAND
WO/2002/094760
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
158360
‫ – און‬1 – ‫ – איזובנזופורן‬H3 – ‫ – אלקיל‬3
,‫ תהליך להכנתו‬,7 ‫המותמרות בעמדה‬
‫ושימוש בו להכנת תרופה‬
]33[
CH
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
[57] A process for the preparation of a
compound of the formula
wherein
R is halogen, R1S(O)2 or (R1)2NC(X)O;
R1 is C1-C8 alkyl, aryl-C1-C8 alkyl, C1-C8
haloalkyl or aryl;
X is O or S; and
R2 is hydrogen, C1-C4 alkyl or C1-C4
haloalkyl, in which process the benzoic
acid derivative of the formula
wherein
R is as defined above, and R3 is C1-C5
alkyl or C1-C5 haloalkyl, is subjected to
benzylic lactonisation in the ortho-position
alkyl chain R3 in the presence of a freeradical initator and a halogenating agent.
__________
1021
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
]54[
COMPOSITION AND PROCESS
FOR ENHANCING BIO-MASS
PRODUCTION IN GREENHOUSES
]22[
]31[
]51[
]71[
20.10.2003
02405904.0
]32[ 22.10.2002
Int. Cl.8 C08K 005/34, C08L 101/10
CIBA SPECIALTY CHEMICALS
HOLDING INC., SWITZERLAND
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]74[
158505
‫תכשיר ותהליך להגברת ייצור המוני‬
‫בחממות של חומר ביולוגי‬
]33[
EP
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
[57] A polymer composition for
agricultural applications in the form of
films for greenhouses and small tunnel
covers, films or filaments for shading nets
and screens, mulch films, non-wovens or
molded articles for the protection of young
plants comprising
(a) a thermoplastic polymer;
(b) the condensation product of
wherein R101 and R102 are independently
hydrogen or C1-C18 alkyl;
(c1) a UV-absorber; or
(c2) a sterically hindered amine,
containing at least one radical of the
formula
in which R is hydrogen or methyl; or
(c3) a UV-absorber and a sterically
hindered amine, containing at least one
radical of the formula
June 17, 2007 – ‫א' בתמוז התשס"ז‬
1022
in which R is hydrogen or methyl.
__________
]11[]21[
]54[
PACKAGING SYSTEM FOR
TRANSDERMAL DRUG
DELIVERY SYSTEMS
]22[
]31[
]51[
]71[
23.04.2002
60/285976
]32[ 23.04.2001
Int. Cl.8 A61K 009/70, B65D 081/26
NOVEN PHARMACEUTICALS,
INC., U.S.A.
WO/2002/090210
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A product packaging system for
preventing degradation of a drug in a
carrier composition of a transdermal
delivery system having (a) a substantially
moisture impermeable and thermoplastic
product package (14) configured in the
shape of a container having one opening
and a substantially moisture impermeable
cover sheet (16) coextensive to said
opening and affixed by means of heat or an
adhesive, and (b) a desiccant (15)
characterized in that the product package
contains one or more child-resistant and
moisture permeable pouches (9) including:
(i) a primary layer (11) of a non-drug
absorbing or reactive thermoplastic
material;
1023
158551
‫מערכת אריזה למערכות למתן תרופה דרך‬
‫העור‬
]33[
US
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
(ii) a secondary layer sheet or laminate
(12) selected from the group consisting of
metal foils, polyethylenes, polyesters,
vinyl acetate resins, ethylene/vinyl acetate
copolymers, polyurethanes, polyvinyl
chloride, woven fabric, non-woven fabric,
cloth and papers, affixed to the primary
layer by means of heat or an adhesive; and
(iii) a transdermal delivery system (10)
comprising a therapeutically effective
amount of a drug in a non-aqueous carrier
composition, each said transdernal delivery
system being sealed within each one or
more pouches, wherein the one or more
pouches and the desiccant are sealed
within the product package.
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫__________‬
‫‪158726‬‬
‫קולט שמש‬
‫דורון חכימי‪ ,‬ירושלים‬
‫דורון חכימי‪,‬‬
‫חננאל ‪ ,25‬ירושלים‬
‫[‪ ]57‬הגדרת תכונותיה הטכניות של‬
‫האמצאה מתבטאות‪:‬‬
‫(א) מבנה קולט השמש (‪ )1‬המוצא הוא‬
‫תמידי ואין צורך בפינויו ממקומו בכל פעם‬
‫שצנרת של קולט השמש ניזוקה‪ ,‬משמוחלף‬
‫הנו רק הצנרת הפנימית‪,‬‬
‫(ב) מסגרת (‪ )8‬קולט השמש המוצא הינו‬
‫עשוי מפלסטיק קשיח או מפרופיל‬
‫אלומיניום המקנה לו משקל קל ומקל על‬
‫ההובלה ועל ההתקנה של הקולט‪,‬‬
‫(ג) קולט השמש בעל מכסה עליון (‪ )3‬פריק‬
‫הנפתח על שני ציריו בזוית של ‪ 180‬מעלות‬
‫ומאפשר החלפת צנרת הנחושת הפנימית‬
‫בשעת צורך ללא הזזת מבנה של קולט‬
‫השמש ממקומו‪,‬‬
‫(ד) הרפלקטור (‪8‬א) שבתחתית הארגז של‬
‫קולט השמש בעל תכונות גליות מושלמות‬
‫בצורה גלי סינוס טהורים המקנים לו יתרון‬
‫מירבי בניצול קרני השמש וגורמים לאספקת‬
‫יתר של מיים חמים‬
‫‪1024‬‬
‫[‪]11[]21‬‬
‫‪SOLAR COLLECTOR‬‬
‫[‪]54‬‬
‫‪03.10.2003‬‬
‫‪Int. Cl.8 F24J 002/04, 002/20‬‬
‫‪DORON HAKIMI‬‬
‫‪DORON HAKIMI,‬‬
‫‪25 HANANEL ST., JERUSALEM‬‬
‫[‪]22‬‬
‫[‪]51‬‬
‫[‪]71‬‬
‫[‪]74‬‬
‫(ה) מכסה העליון של קולט השמש הנפתח‬
‫מצופה בפרספקס שקוף [או לבחירה זכוכית‬
‫שקופה]‪ ,‬הפרספקס בניגוד לזכוכי עמיד בפני‬
‫מכת ברד או גופים זרים הנופלים לעתים על‬
‫פני הקולט‬
‫(ו) רשת צנרת הנחושת בקולט השמש צבועה‬
‫בצבע שחור מט עמיד לחום‪ ,‬רשת הנחושת‬
‫ניתנת לפירוק ע"י הזזת הרשת לאחד‬
‫הצדדים והרמתה מחוץ לקולט השמש‬
‫לצורך תיקון או החלפה‬
‫(ז) הטפסים או "המהדקים" המורכבים על‬
‫פני הרפלקטור מיועדים להרמת רשת‬
‫הנחושת לאספקת מירב קרני השמש לחלקה‬
‫האחורי של צנרת הנחושת באמצעות‬
‫הרפלקטור‪,‬‬
‫(ח) הגומיות (‪ )5‬המורכבות סביב המכסה‬
‫הנפתח של קולט השמש מיועדות לאיטום‬
‫ולבידוד קולט השמש מפני השפעות‬
‫חיצוניות‪.‬‬
‫א' בתמוז התשס"ז – ‪June 17, 2007‬‬
__________
]11[]21[
158798
‫סינטזה של קאנבינואידים‬
]54[
SYNTHESIS OF CANNABINOIDS
]22[
]31[
]51[
09.05.2002
0112752.1
]32[ 25.05.2001
]33[ GB
Int. Cl.8 C07C 069/013, 069/612, 069/736, 069/78, 069/80, 205/57, C07D 311/00,
311/80, C07F 007/18, 009/145, 009/146
JOHNSON MATTHEY PUBLIC
LIMITED COMPANY, UNITED
KINGDOM
WO/2002/096899
REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
]71[
]87[
]74[
[57] A process for the production of a
compound of the formula
1025
June 17, 2007 – ‫א' בתמוז התשס"ז‬
wherein Rc, Rd and Re are independently
H, alkyl, or substituted alkyl; and R1 to R4
are independently H, OH, OR' (R' is alkyl,
aryl, substituted alkyl or aryl, silyl, acyl, or
phosphonate), alkyl, substituted alkyl, aryl,
acyl, halide, amine, nitrate, sulphonate or
phosphonate; comprising reacting
compound B with compound C:
wherein Ra is H, alkyl, aryl, acyl or silyl;
Rb is alkyl, aryl or acyl; Rc, Rd, Re and R1
to R4 are as hereinbefore defined;
and comprising, when necessary, a ring
closure reaction. Claimed as novel is the
intermediate compound, of the formula
wherein ORa and ORb are independently
(provided that only one of ORa and ORb is
chosen from acetate, propionate, butyrate,
acetate), and Rc, Rd and Rc are
trimethylacetate, phenylacetate,
independently H, alkyl, or substituted
phenoxyacetate, diphenylacetate, benzoate,
alkyl.
p-nitrobenzoate, phthalate and succinate
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
1026
]11[]21[
159329
‫מבנה למיקום של מחיצות משרדיות‬
]54[
OFFICE PANEL POSITIONING
STRUCTURE
]22[
]51[
]71[
]87[
]74[
14.06.2001
Int. Cl.8 E04B 002/74, E04C 002/52, E04F 015/18
NOZOMU SAHASHI, JAPAN
WO/2002/103132
SHIBOLETH, YISRAELI,
,'‫ זיסמן ושות‬,‫ רוברטס‬,‫ ישראלי‬,‫שיבולת‬
ROBERTS, ZISMAN & CO,
‫ תל אביב‬,4'‫ רחוב ברקוביץ‬,‫מגדל המוזיאון‬
MUSEUM TOWER
4 BERKOWITZ ST.
TEL AVIV
64238
[57] An office panel positioning
structure,
wherein an office space is divided by
partitioning panels (12a) into a passageway
(11) and a plurality of booths (B)
positioned along the passageway,
characterized in that:
cabling floor panels (13) are laid down
only on the passageway;
wherein the floor panels comprise a space
capable of storing cables (15) for cabling
in a laid state;
wherein a lower side surface of the
partitioning panels abuts a side surface of
the cabling floor panels positioned on the
passageway so that the partitioning panels
positioned along the passageway are
directly positioned on an office floor; and a
cable draw-in opening (13b) is formed at a
side surface portion of the cabling floor
panel that adjoins each booth for drawing
into the booths the cables that are laid in
the space inside the cabling floor panles.
__________
1027
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
]54[
CONTROL OF DEVELOPMENT
OF BIOFILMS IN INDUSTRIAL
PROCESS WATER
]22[
]31[
05.08.2002
60/310623
]32[ 06.08.2001
10/211965
02.08.2002
Int. Cl.8 C02F 001/50
A.Y. LABORATORIES LTD.
WO/2003/014029
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT
]51[
]71[
]87[
]74[
‫בקרת התפתחות של סליל ביולוגי במים‬
‫מעובדים תעשייתית‬
]33[
US
US
‫ תל אביב‬,‫ מעבדות בע"מ‬.‫י‬.‫א‬
,'‫ קולב ושות‬.‫סנפורד ט‬
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
[57] A method for reducing effects in
industrial process water of an enzyme
produced by a collection of
microorganisms attached to a surface in an
industrial water environment, the method
comprising:
causing a substance formed by the reaction
of a hypochlorite oxidant and an amine
source selected from the group consisting
of ammonium bromide and ammonium
chloride and capable of interfering with the
production of an enzyme by a collection of
microorganisms attached to a surface in an
industrial water environment to contact
said collection of microorganisms when
attached to said surface in said industrial
water environment by introducing said
substance into water in said industrial
The applications for division
from this application have
not yet been published
159911
water environment at a first concentration
and for a first duration, and thereafter, after
a second duration during which said
substance is not introduced into said water,
again causing said substance to contact
said collection of microorganisms by again
introducing said substance into said water
in said industrial water environment,
wherein said first duration and said first
concentration are selected to be sufficient
to substantially eliminate the production of
said enzyme by said collection of
microorganisms in said industrial water
environment during said second duration,
but insufficient to completely eradicate
said collection of microorganisms and
insufficient to inactivate said enzyme.
,174725
‫בקשות חלוקה מבקשה זו‬
.‫שטרם פורסמו‬
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
160096
1028
]54[
SINGLE-VANE ROTARY PUMP
OR MOTOR
]22[
]31[
]51[
]71[
]74[
28.01.2004
0314231.2
]32[ 18.06.2003
Int. Cl.8 F04C 002/332
CARMELI ADAHAN
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A rotary vane pump (10) or motor
comprising a housing (16) with a
cylindrical inner peripheral wall defining a
cavity (2), a rotor (20) with a cylindrical
peripheral surface and a socket (41)
internal to said peripheral surface, said
rotor being disposed eccentrically in said
cavity and being adapted to scroll said
inner peripheral wall in close proximity
thereto, said inner peripheral wall and the
rotor peripheral surface defining between
them a working chamber, said housing
having a vane (22) with an end received in
said socket so as to enable said vane to
slide within said socket maintaining
predetermined fluid tightness
‫שבשבתי‬-‫משאבה או מנוע סיבובי חד‬
]33[
GB
‫ ירושלים‬,‫ רמות‬,‫כרמלי אדהאן‬
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
therebetween, and to enable said rotor to
orbit within said cavity, said housing
having an inlet port (24) adjacent to one
side of said vane and an outlet port (26)
adjacent to the other side of said vane, both
ports being in fluid communication with
said cavity via said inner peripheral wall,
wherein said socket has an opening with
swivel jaws, said vane has uniform
thickness, is rigidly attached to said
housing, and is received between said jaws
so as to form a swivel joint (42) allowing
sliding of said vane through said joint and
rocking of the vane together with said
joint, while maintaining said fluid
tightness.
__________
]11[]21[
1029
160418
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫מיכל רב–תאי למגיבים המכיל אמצעיים‬
‫המונעים שימוש מחדש בהם‬
]54[
MULTI-COMPARTMENT
REAGENT CONTAINER HAVING
MEANS TO INHIBIT RE-USE
THEREOF
]22[
]31[
]51[
]71[
]87[
]74[
13.08.2002
949132
]32[ 07.09.2001
]33[ US
Int. Cl.8 B01J 019/00, B01L 003/00, G01N 033/48
DADE BEHRING INC., U.S.A.
WO/2003/022441
REINHOLD COHN AND
,‫ריינהולד כהן ושותפיו‬
PARTNERS,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A method for determining that a
reagent container (10) having at least one
edge-wall and a weakened bridge (24) is
unused when said reagent container is
placed onto an analyzer, the method
comprising: attaching said weakened
bridge to the at least one edge-wall;
displacing the weakened bridge with a
sensor probe (20) when said container is
placed onto the analyzer, is weakened by a
notch formed in its central region is
supported between two pylons extending
from the edge-wall and wherein the probe
is adapted to signal the force required to
displace said weakened bridge when said
reagent container is placed onto the
analyzer; and, analyzing said signals to
determine if the signal values generated
when the reagent container is placed upon
the analyzer fall within a range of signal
values previously determined for known
unused containers when said known
unused containers are placed upon the
analyzer.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
161555
1030
]54[
‫חומר מרוכב המכיל יהלום–סיליקון‬
‫וקרביד–סיליקון ושיטה ליצורו‬
METHOD OF MANUFACTURING
A DIAMOND-SILICON CARBIDESILICON COMPOSITE AND A
COMPOSITE PRODUCED BY
THIS METHOD
]22[
]31[
16.07.1998
97115171
]32[ 05.09.1997
]33[ RU
97115169
05.09.1997
RU
97115186
05.09.1997
RU
97115172
05.09.1997
RU
]51[ Int. Cl.8 B23B 027/14, C04B 035/573, 041/87
]62[ DIVISION FROM 134575
]71[ SKELETON TECHNOLOGIES AG,
SWITZERLAND
]87[ WO/1999/012866
]74[ REINHOLD COHN AND PARTNERS,
,‫ריינהולד כהן ושותפיו‬
21 AHAD HA'AM ST.,
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
P.O.B. 4060,
TEL AVIV 61040
[57] A body in which diamond particles
silicon carbide, preferably more than 15
are bonded to a matrix of silicon carbide,
vol-% of silicon carbide, and silicon, the
said body comprising 20-75% vol-% of
Young's modulus exceeding 450 GPa.
diamond particles, at least 5 vol-% of
__________
]11[]21[
]54[
FREE-FLOW FLUID
MEASUREMENT METER
]22[
]31[
]51[
]71[
31.12.2002
10/041135
]32[ 07.01.2002
Int. Cl.8 G01F 001/24
S.A.E. AFIKIM- COMPUTERIZED
DAIRY MANAGEMENT SYSTEMS
]72[
ALEXANDER KAPITULSKIY, NIV
PINSKY, RONY ANDREI, ZVI
HERMAN
WO/2003/058174
JEREMY M. BEN-DAVID & CO.
LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O. B. 45087, JERUSALEM 91450
]87[
]74[
[57] Apparatus for measuring the flow of
a liquid tending to froth, which includes:
(a) a flow-through housing having an
1031
162821
‫מד למדידת זורמים בזרימה חופשית‬
]33[
US
‫ מערכות חליבה‬-‫ אפיקים‬.‫מ‬.‫ח‬.‫צ‬
‫ קיבוץ אפיקים‬,‫ממוחשבות‬
‫ רוני‬,‫ ניב פינסקי‬,‫אלכסנדר קפיטולסקי‬
‫ צבי הרמן‬,‫אנדרי‬
,‫דוד ושות' בע"מ‬-‫ בן‬.‫ירמיהו מ‬
,45087 .‫ד‬.‫ ת‬, ‫ הר חוצבים‬,‫רחוב המרפא‬
‫ירושלים‬
interior and a floor, and which further
includes;
June 17, 2007 – ‫א' בתמוז התשס"ז‬
(i) a separation wall which divides said
housing into a measurement chamber and a
discharge chamber, said wall having a slot
therein which allows the liquid to freely
flow from said measurement chamber into
said discharge chamber; and
(ii) an inlet communicating with said
measurement chamber, whereby liquid
enters said housing, and an outlet
communicating with said discharge
chamber, whereby liquid exits said
housing; and
(b) electrical sensor apparatus for sensing
the level of the liquid in the measurement
chamber, wherein said electrical sensor
apparatus include:
(i) a reference sensor and a common
sensor both positioned proximate to said
floor, and
(ii) a plurality of measurement sensors
positioned within said measurement
chamber, wherein said measurement
sensors are spaced apart in a generally
vertical stepped continuum stretching from
said floor of said housing to a height
substantially equal to the top of said
separation wall at predetermined
measurement intervals; and
(c) processing apparatus for evaluating a
flow rate, according to a preprogrammed
process, based on readings received from
said sensors.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
163225
1032
]54[
PROCESS FOR THE EXTRACTION,
PURIFICATION AND ENZYMATIC
MODIFICATION OF SOY 7S
GLOBULIN ALPHA SUBUNIT FOR
USE AS HYPOCHOLESTEROLEMIC
AGENT
]22[
]31[
]51[
]71[
]87[
]74[
27.01.2003
MI2002A000147 ]32[ 29.01.2002
Int. Cl.8 A23J 003/16
INDENA S.P.A., ITALY
WO/2003/063608
REINHOLD COHN AND PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
[57] A process for the selective
extraction, purification and enzymatic
modification of soy β-conglycinin α'
subunit, which process comprises the
following steps:
(a) extraction of a defatted ground soy with
a sodium bisulfite aqueous solution at
slightly acidic pH to obtain a βconglycinin – enriched soluble protein
fraction;
(b) precipitation of the β-conglycinin
fraction from step (a) by treatment with
ethanol;
‫ טיהור ושינוי אנזימתי של‬,‫תהליך למיצוי‬
‫ גלובולין אלפא מסויה לשימוש‬S7 ‫יחידת‬
‫כחומר נוגד כולסטרול‬
]33[
IT
,‫ריינהולד כהן ושותפיו‬
‫ תל‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
‫אביב‬
(c) purification of the precipitatred fraction
from step (b) by Metal Affiity
Chromatography (MAC) under denaturant
conditions, to isolate the α' subunit;
(d) precipitation of the α' subunit with
organic solvents;
(e) enzymatic treatment of the α' subunit
from step (d) with a proteolytic enzyme
and further purification by MAC
chromatography.
__________
]11[]21[
1033
163494
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫חותמת דיגיטלית‬
]54[
DIGITAL STAMP
]22[
]31[
]51[
]71[
12.02.2003
PS0490
]32[ 13.02.2002
]33[ AU
Int. Cl.8 B41J 002/01, B41K 001/36, 001/40
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2003/068520
LUZZATTO & LUZZATTO,
,‫לוצאטו את לוצאטו‬
INDUSTRIAL PARK, OMER,
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A programmable marking device for
printing print data on print media (26) by
movement of a printing mechanism with
respect to print media while said print
media is substantially statonary, said
printing mechanism including a printing
means (30) for printing an indicia (24),
memory (14) for storing print data in an
electronic form, means for receiving said
print data from an external source, and
processor means for processing said
information and for controlling said
printing means to print said indicia as said
printing means is moved with respect to
said print media.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
163496
1034
]54[
MANUALLY MOVEABLE
PRINTER WITH SPEED SENSOR
]22[
]31[
]51[
]71[
12.02.2003
PS0484
]32[ 13.02.2002
Int. Cl.7 B41J 003/39
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2003/068515
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A printer adapted to be moveable by
a user relative to print media (22)
comprising: a printhead arrangement (30)
adapted to effect printing onto the print
media as the printer is moved relative to
the print media, the printhead arrangement
including a plurality of ink ejection
nozzles;
an ink supply (32) adapted to store ink and
to supply the ink to the printhead
arrangement; a speed sensor adapted to
measure the speed at which the printhead
arrangement is moved relative to the print
media and to generate speed data;
a print controller adapted to:
(a) receive image data from an image
source;
(b) convert the image data into a plurality
of drop ejection control signals;
(c) receive the speed data from the speed
sensor; and
(d) operate the ink ejection nozzles in the
printhead arrangement in accordance with
the drop ejection control signal at a rate
1035
‫מדפסת הנעה ידנית עם חיישן מהירות‬
]33[
AU
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
determined using the speed data, to thereby
effect printing of the image data onto the
print media;
a capping arrangement (50) moveable
between a capped position in which the
capping arrangement obstructs the ejection
of ink from the ink ejection nozzles and an
un-capped position in which the capping
arrangement does not substantially
obstruct the ejection of ink from the ink
ejection nozzles, the capping arrangement
comprising a mounting portion pivotally
mounted on the printer and a capping arm
extending substantially perpendicularly
from the mounting portion to a distal end,
the distal end lying adjacent the ink
ejection nozzles to obstruct ink ejection
from the ink ejection nozzles when the
capping arrangement is mounted on the
printer and is in the capped position; and
a capping actuator (55) disposed on the
printer so as to be operable by a user as the
user moves the printhead arrangement
relative to the print media.
June 17, 2007 – ‫א' בתמוז התשס"ז‬
__________
]11[]21[
]54[
PROCESSING OF IMAGES FOR
HIGH VOLUME PAGEWIDTH
PRINTING
]22[
]31[
]51[
]71[
14.06.2002
10/120350
]32[ 12.04.2002
Int. Cl.8 B41J 002/01
SILVERBROOK RESEARCH
PTY.LTD., AUSTRALIA
WO/2003/086762
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A method of processing an image for
printing, the method comprising the steps
of: receiving image data in an image
storage format; transforming the image
June 17, 2007 – ‫א' בתמוז התשס"ז‬
164447
‫עיבוד דמויות להדפסה בנפח גבוה לרוחב‬
‫עמוד‬
]33[
US
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
data into print data at a rate of at least one
billion pixels per second; and
communicating the print data to a
printhead.
1036
__________
]11[]21[
164561
‫ציוד לדכא עבור דיכוי וויברציות‬
]54[
DAMPING APPARATUS FOR THE
DAMPING OF VIBRATIONS
]22[
]31[
]51[
]71[
]87[
]74[
14.04.2003
20022077
]32[ 30.04.2002
]33[ NO
Int. Cl.8 F16F 007/00, F16L 041/00, 041/02
TEENESS ASA, NORWAY
WO/2003/093696
SANFORD T.COLB & CO.,
,'‫ קולב ושות‬.‫סנפורד ט‬
P.O.B. 2273,
‫ רחובות‬,2273 .‫ד‬.‫ ת‬, ‫ מרמורק‬,4 ‫שער הגיא‬
REHOVOT
[57] Damping apparatus for the damping
of vibrations in tool holders, machine
elements and work pieces in machine tools
and other objects exposed to unwanted
vibrations, adapted to be provided in or on
the object, including a substantially
cylindrical damping body (1) with a boring
(6) going therethrough and a through the
boring extending longitudinal central body
(3), two elastic elements (2) with two
substantially opposing end faces and an
opening where the longitudinal central
body passes, provided on each side of the
damping body, a washer (5) provided on
the longitudinal central body on each side
of the damping body and the elastic
1037
elements such that the elastic elements are
placed between the two washers and the
damping body, characterized in that the
central body is adapted for rigid
connection to the object that is to be
dampened, and the damping body is
connected to the longitudinal central body
via the two elastic elements; the boring
going through the damping body includes
a gap to the longitudinal central body to
allow mutual motion between this and the
damping body; the washer on each side of
the damping body and the elastic elements
are rigidly connected to the longitudinal
central body; and one of the end faces of
each elastic element is rigidly connected to
each of the two washers and the other of
June 17, 2007 – ‫א' בתמוז התשס"ז‬
the end faces of each elastic element is
rigidly connected to the damping body.
__________
]11[]21[
]54[
MODULAR PRINTHEAD
ASSEMBLY
]22[
]31[
]51[
]62[
]71[
07.12.2000
PQ4559
]32[ 09.12.1999
Int. Cl.8 B41J 002/155, 002/235
DIVISION FROM 149962
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2001/042027
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]87[
]74[
[57] A printhead assembly (10) for use in
an inkjet printer housing defining a media
movement path, the assembly comprising:
an elongate support member (14) for
mounting within the printer housing
transverse to the media movement path; a
plurality of printhead modules (12)
detachably mounted along the support
member, each of the printhead modules
having a printhead chip (18) with an array
of nozzles and respective drop ejection
June 17, 2007 – ‫א' בתמוז התשס"ז‬
164691
‫מכלול ראש מדפסת מודולרי‬
]33[
AU
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
actuators, such that, the printhead chip of
each module partially overlaps at least one
adjacent module in a direction transverse
to the media movement path; wherein,
adjacent printhead modules abut each other
along respective side surfaces, the side
surfaces of each printhead module having
a step formation that mates with a
complementary step formation in the side
surface of the abutting printhead module.
1038
__________
]11[]21[
]54[
PRINT ENGINE AND A PRINTING
STATION FOR PRINTER
]22[
]31[
]51[
]62[
]71[
17.02.2000
PP9960
]32[ 23.04.1999
Int. Cl.8 B41J 2
DIVISION FROM 146071
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2000/064679
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A printhead assembly for a
pagewidth printer, the assembly including
a pair of printheads (112), each printhead
including a plurality of inkjet nozzles
constructed using microelectromechnical
164953
‫ייצור ראש הדפסה למדפסת ברוחב דף‬
]33[
AU
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
techniques, the printheads being selected
and matched so that no two corresponding,
paired nozzles of the printheads are both
defective.
__________
1039
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
]54[
PRINTER CARTRIDGE
INCLUDING INK READABLE BY
AN OPTICAL READER DEVICE
]22[
]31[
24.05.2000
PQ 0559
]32[ 25.05.1999
PQ 1313
30.06.1999
Int. Cl.8 B41J 002/175
DIVISION FROM 146646
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2000/071350
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]51[
]62[
]71[
]87[
]74[
[57] A digital printer adapted to print
information onto a media substrate in a
form that can be read by the human eye
and a form that is invisible to the human
eye but readable to an optical reader
device, the printer including: a pagewidth
printhead (602, 603) and a removable
cartridge, the cartridge including a housing
165540
‫מדפסת דיגיטלית עם מחסנית המאחסנת‬
‫דיו הנקרא על–ידי מכונה‬
]33[
AU
AU
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
defining a plurality of storage areas
wherein at least one of the storage areas
contains colorant for printing information
that is visible to the human eye and at least
one of the other storage areas contains
colorant for printing information in a form
that is invisible to the human eye but
readable by the optical reader device.
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
1040
]11[]21[
165639
‫צינור בעל קשיחות משתנה‬
]54[
PIPE WITH MODIFIABLE
RIGIDITY
]22[
]51[
]71[
]72[
]74[
08.12.2004
Int. Cl.8 A47K 003/22, F16L 003/16, 011/18
AVISHAI MELAMED
OSRI MESHULAM
MILLER-SIERADZKI ADV & PAT
ATT,
P.O.BOX 6145
HAIFA 31061
[57] A pipe (10) with modifiable rigidity
comprising: an internal flexible pipe
having an inlet (18) and an outlet (16), the
outlet fluidically communicating with a
flow restrictor; a plurality of interlaced
rigid joints (14) forming a skeletal
structure over the internal pipe, the skeletal
struture coupled at two or more places to
the internal pipe, each joint having a
bulging portion (22) and a reciprocal
cavity (20), so that the bulging portion of a
joint is hosted within the reciprocal cavity
of an adjacent joint, wherein opposing
areas on the bulging portion and the
reciprocal cavity are each provided with a
rough surface,
‫ אתא‬.‫ ק‬,‫אבישי מלמד‬
‫אושרי משולם‬
,‫שרצקי עו"ד ועו"פ‬-‫מילר‬
‫ חיפה‬,6145 .‫ד‬.‫ ת‬, 18‫מחניים‬
whereby the skeletal structure is
characterized by possessing some freedom
of relative motion between the interlaced
joints when in a slack state, and when fluid
flows through the internal pipe internal
pressure builds up within the internal pipe,
the internal pipe extends longitudinally
causing the skeletal structure to stretch so
that the bulging portion of joints press
against the reciprocal cavity of adjacent
joints, the rough surfaces of the bulging
portion and the reciprocal cavity being
pressed against each other, thus increasing
friction between the joints and holding
them in position to form a rigid pipe.
__________
]11[]21[
1041
166422
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]54[
PRINT ENGINE/CONTROLLER
TO WORK IN MULTIPLES AND
A PRINTHEAD DRIVEN BY
MULTIPLE PRINT
ENGINE/CONTROLLERS
]22[
]51[
]62[
]71[
30.06.2000
Int. Cl.8 B41J 002/21
DIVISION FROM 153723
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2002/002338
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A print engine/controller (10)
configured to be coupled with other similar
print engine/controllers to drive an ink
drop printhead (33) comprising: an
interface (27) at which to receive
compressed page data; image decoders
(28, 39) to decode compressed image
planes in the received compressed page
data; a half-toner/compositer (29) to
composite respective strips of the decoded
‫סדר‬/‫בקר הדפסה עם חצי–טונר‬/‫מנוע‬
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
image planes by halftoning a contone layer
to a bi-level version and compositing a
spot l bi-level layer over an appropriate
halftoned contone layer; and a printhead
interface (32) to output the composite strip
to a printhead the printhead interface
including: a multi-segment printhead
interface outputting printhead formatted
data; and a synchronization signal
generator.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
166723
1042
]54[
PRINTHEAD WITH AIR SUPPLY
ARRANGEMENT
]22[
]51[
]62[
]71[
24.05.2000
Int. Cl.8 B41J 002/165
DIVISION FROM 153035
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2001/089847
LUZZATTO & LUZZATTO,
INDUSTRIAL PARK, OMER,
P.O.B. 5352,
BEER-SHEVA 84152
]87[
]74[
[57] A printhead (11) for an inkjet
printer, the printhead comprising: a
plurality of print nozzles (30) for
selectively ejecting drops of ink towards a
print medium passing the nozzles; a
plurality of apertures (44) spaced from the
nozzles in the direction of the ink ejection,
each of the apertures being aligned with a
‫ראש מדפסת עם סדור אספקת אוויר‬
,‫לוצאטו את לוצאטו‬
‫ באר שבע‬,5352 .‫ד‬.‫ ת‬, ‫ עומר‬,‫גן תעשייה‬
corresponding nozzle so that ink drops
ejected from the nozzles pass through the
apertures; and air supply means supplying
positive air pressure to the space at least
partially enclosed between the nozzles and
the apertures to reduce unwanted build-up
at the apertures.
__________
]11[]21[
1043
166910
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫תבנית הדפסה בעלת מגוון אזורים‬
‫שטוחים מבחינה פונקציונלית‬
]54[
PRINTING FORM HAVING A
PLURALITY OF PLANAR
FUNCTIONAL ZONES
]22[
]31[
]51[
]71[
15.02.2005
102004007600.6 ]32[ 17.02.2004
]33[
Int. Cl.8 B41C 001/10, B41N 001/08, 001/14
HEIDELBERGER
DRUCKMASCHINEN AG, GERMANY
BERND VOSSELER, MARTIN
GUTFLEISCH, GERALD ERIK
HAUPTMANN
EITAN, MEHULAL, PAPPO, KUGLER,
11 HAMENOFIM ST.
HERZLIYA 46120
]72[
]74[
[57] A printing form having a plurality of
substantially planar functional zones,
which have at least one informational zone
(110) that is modifiable in accordance with
image information and an absorption zone
(112) for absorbing energy from a
DE
,‫ קוגלר‬,‫ פאפו‬,‫ מהולל‬,‫איתן‬
‫ הרצליה‬,11‫המנופים‬
radiation, wherein a buffer zone (114) is
provided which differs at least partially
from the absorption zone, receives energy
from the absorption zone and releases
energy to the informational zone.
__________
]11[]21[
June 17, 2007 – ‫א' בתמוז התשס"ז‬
167402
1044
]54[
ARTICULATED ELEVATABLE
BED
]22[
]51[
]71[
13.03.2005
Int. Cl.8 A47C 020/04
AMINACH BEDDING &
FURNITURE MANUFACTURING
LTD.
REINHOLD COHN AND
PARTNERS,
21 AHAD HA'AM ST.,
P.O.B. 4060,
TEL AVIV 61040
]74[
[57] A bed (10) comprising at least a first
mattress (12) having at least a first section
and a second section pivotally articulated
to one another by a first axis transverse to
the length of the bed and located within an
interior of the first mattress, said first
mattress comprising at least one fixed
section fixedly articulated to a rigid
‫מיטת מפרקות מתרוממת‬
,‫עמינח תעשית רהיטים ומזרונים בע"מ‬
‫רמלה‬
,‫ריינהולד כהן ושותפיו‬
‫ תל אביב‬,4060 .‫ד‬.‫ ת‬, 21 ‫רחוב אחד העם‬
support frame (14) which in turn is
pivotally articulated to a bed base (16) and
is pivotable about a frame pivot axis
parallel to said first axis and where the bed
base is formed with a base and side walls
so as to form a confined space serving as a
linen compartment accessible by pivotal
displacement of the support frame.
This specification was examined in
accordance with regulation 35 of the Patent
Regulations, 5728 - 1968
‫ לתקנות‬35 ‫פירוט זה נבחן בהתאם לתקנה‬
1968 – ‫ תשכ"ח‬,‫הפטנטים‬
__________
1045
June 17, 2007 – ‫א' בתמוז התשס"ז‬
]11[]21[
172637
‫מסחטת מיץ‬
]54[
JUICE EXTRACTOR
]22[
]31[
]51[
]71[
]72[
]87[
]74[
23.12.2004
60/532653
]32[ 24.12.2003
Int. Cl.8 A23N 001/00, A47J 019/00
YEHONATAN LAVEE
YEHONATAN LAVEE
WO/2005/060770
SOROKER-AGMON,
14 SHENKAR STREET,
HERZLIYA PITUAH 46725
[57] A juice extractor device comprising
a bottom filtering member (20) and a top
pressing member (30) pivotally connected
to each other, the filtering member
comprises a concave receiving chamber
(12) having a perforated bottom (15) for
allowing liquids to flow therethrough and
]33[
US
‫יונתן לביא‬
‫יונתן לביא‬
,‫אגמון‬-‫סורוקר‬
‫ הרצליה פיתוח‬,14 ‫בית נולטון רחוב שנקר‬
pulp to be collected therein, the pressing
member comprises a pressing surface (32)
substantially conforming to and adapted o
fit into the receiving chamber for gradually
pressing a fruit or a vegetable placed in the
receiving chamber.
This specification was examined in
accordance with regulation 35 of the Patent
Regulations, 5728 - 1968
‫ לתקנות‬35 ‫פירוט זה נבחן בהתאם לתקנה‬
1968 – ‫ תשכ"ח‬,‫הפטנטים‬
__________
June 17, 2007 – ‫א' בתמוז התשס"ז‬
1046
‫פטנטים‬
‫‪PATENTS‬‬
‫פטנטים שניתנו‬
‫‪PATENTS GRANTED‬‬
‫‪132651‬‬
‫‪146702‬‬
‫‪146992‬‬
‫‪148116‬‬
‫‪148629‬‬
‫‪149556‬‬
‫‪151204‬‬
‫‪151581‬‬
‫‪127325‬‬
‫‪142738‬‬
‫‪143441‬‬
‫‪143733‬‬
‫‪144762‬‬
‫‪145158‬‬
‫‪145400‬‬
‫‪145948‬‬
‫‪134087‬‬
‫‪135585‬‬
‫‪152394‬‬
‫‪154066‬‬
‫‪156331‬‬
‫‪158405‬‬
‫‪138951‬‬
‫‪140476‬‬
‫‪141045‬‬
‫‪159158‬‬
‫‪162279‬‬
‫‪164775‬‬
‫‪132101‬‬
‫‪146664‬‬
‫‪146977‬‬
‫‪147944‬‬
‫‪148551‬‬
‫‪149499‬‬
‫‪151192‬‬
‫‪151536‬‬
‫‪127193‬‬
‫‪142570‬‬
‫‪143370‬‬
‫‪143694‬‬
‫‪144747‬‬
‫‪145157‬‬
‫‪145350‬‬
‫‪145799‬‬
‫‪133078‬‬
‫‪135499‬‬
‫‪152222‬‬
‫‪153673‬‬
‫‪156236‬‬
‫‪158305‬‬
‫‪138647‬‬
‫‪140368‬‬
‫‪141039‬‬
‫‪141848‬‬
‫‪161466‬‬
‫‪164505‬‬
‫‪131418‬‬
‫‪146460‬‬
‫‪146956‬‬
‫‪147895‬‬
‫‪148414‬‬
‫‪149489‬‬
‫‪150726‬‬
‫‪151511‬‬
‫‪125628‬‬
‫‪142484‬‬
‫‪143354‬‬
‫‪143576‬‬
‫‪144486‬‬
‫‪145156‬‬
‫‪145336‬‬
‫‪145783‬‬
‫‪123514‬‬
‫‪135371‬‬
‫‪152192‬‬
‫‪153657‬‬
‫‪155910‬‬
‫‪158210‬‬
‫‪138435‬‬
‫‪140080‬‬
‫‪140804‬‬
‫‪141780‬‬
‫‪160122‬‬
‫‪164504‬‬
‫א' בתמוז התשס"ז – ‪June 17, 2007‬‬
‫‪131275‬‬
‫‪146384‬‬
‫‪146917‬‬
‫‪147703‬‬
‫‪148355‬‬
‫‪149338‬‬
‫‪150715‬‬
‫‪151504‬‬
‫‪124977‬‬
‫‪142457‬‬
‫‪143112‬‬
‫‪143495‬‬
‫‪144358‬‬
‫‪145121‬‬
‫‪145318‬‬
‫‪145767‬‬
‫‪122832‬‬
‫‪135295‬‬
‫‪137096‬‬
‫‪153630‬‬
‫‪155255‬‬
‫‪157711‬‬
‫‪138425‬‬
‫‪139849‬‬
‫‪140702‬‬
‫‪141727‬‬
‫‪159760‬‬
‫‪164448‬‬
‫‪165038‬‬
‫‪131147‬‬
‫‪146287‬‬
‫‪146897‬‬
‫‪147634‬‬
‫‪148316‬‬
‫‪148910‬‬
‫‪150616‬‬
‫‪151471‬‬
‫‪124471‬‬
‫‪142132‬‬
‫‪142978‬‬
‫‪143490‬‬
‫‪144352‬‬
‫‪145011‬‬
‫‪145316‬‬
‫‪145561‬‬
‫‪121614‬‬
‫‪135166‬‬
‫‪136773‬‬
‫‪153448‬‬
‫‪155211‬‬
‫‪157622‬‬
‫‪116609‬‬
‫‪139666‬‬
‫‪140661‬‬
‫‪141707‬‬
‫‪159522‬‬
‫‪164445‬‬
‫‪164931‬‬
‫‪129561‬‬
‫‪146254‬‬
‫‪146872‬‬
‫‪147614‬‬
‫‪148290‬‬
‫‪148816‬‬
‫‪150512‬‬
‫‪151293‬‬
‫‪108316‬‬
‫‪142112‬‬
‫‪142954‬‬
‫‪143487‬‬
‫‪144106‬‬
‫‪144905‬‬
‫‪145305‬‬
‫‪145554‬‬
‫‪121402‬‬
‫‪134980‬‬
‫‪136768‬‬
‫‪153396‬‬
‫‪155187‬‬
‫‪156918‬‬
‫‪116398‬‬
‫‪139252‬‬
‫‪140636‬‬
‫‪141501‬‬
‫‪159400‬‬
‫‪163503‬‬
‫‪164930‬‬
‫‪129319‬‬
‫‪132813‬‬
‫‪146721‬‬
‫‪147557‬‬
‫‪148194‬‬
‫‪148743‬‬
‫‪150230‬‬
‫‪151244‬‬
‫‪106357‬‬
‫‪127770‬‬
‫‪142879‬‬
‫‪143479‬‬
‫‪144084‬‬
‫‪144847‬‬
‫‪145177‬‬
‫‪145517‬‬
‫‪146103‬‬
‫‪134602‬‬
‫‪136469‬‬
‫‪153026‬‬
‫‪154926‬‬
‫‪156537‬‬
‫‪158663‬‬
‫‪139199‬‬
‫‪140552‬‬
‫‪141411‬‬
‫‪159245‬‬
‫‪163497‬‬
‫‪164834‬‬
‫‪114982‬‬
‫‪132793‬‬
‫‪146705‬‬
‫‪147413‬‬
‫‪148128‬‬
‫‪148637‬‬
‫‪150023‬‬
‫‪151241‬‬
‫‪99435‬‬
‫‪127769‬‬
‫‪142868‬‬
‫‪143457‬‬
‫‪143797‬‬
‫‪144775‬‬
‫‪145159‬‬
‫‪145437‬‬
‫‪145986‬‬
‫‪134224‬‬
‫‪135945‬‬
‫‪152986‬‬
‫‪154765‬‬
‫‪156403‬‬
‫‪158409‬‬
‫‪139035‬‬
‫‪140491‬‬
‫‪141183‬‬
‫‪159213‬‬
‫‪163265‬‬
‫‪164782‬‬
‫‪1047‬‬
‫פטנטים שחודשו‬
‫‪PATENTS RENEWED‬‬
‫‪89428‬‬
‫‪89602‬‬
‫‪104829‬‬
‫‪104891‬‬
‫‪105017‬‬
‫‪120249‬‬
‫‪120325‬‬
‫‪120380‬‬
‫‪121790‬‬
‫‪125214‬‬
‫‪125598‬‬
‫‪125748‬‬
‫‪125856‬‬
‫‪125975‬‬
‫‪126153‬‬
‫‪129319‬‬
‫‪131716‬‬
‫‪135499‬‬
‫‪137548‬‬
‫‪138690‬‬
‫‪140476‬‬
‫‪141591‬‬
‫‪141848‬‬
‫‪142570‬‬
‫‪143354‬‬
‫‪143645‬‬
‫‪144199‬‬
‫‪145158‬‬
‫‪145767‬‬
‫‪146664‬‬
‫‪147089‬‬
‫‪147668‬‬
‫‪148743‬‬
‫‪150512‬‬
‫‪151416‬‬
‫‪153026‬‬
‫‪155934‬‬
‫‪159222‬‬
‫‪163497‬‬
‫‪169917‬‬
‫‪1048‬‬
‫‪89410‬‬
‫‪89577‬‬
‫‪104821‬‬
‫‪104881‬‬
‫‪105009‬‬
‫‪120213‬‬
‫‪120295‬‬
‫‪120361‬‬
‫‪121614‬‬
‫‪124977‬‬
‫‪125590‬‬
‫‪125735‬‬
‫‪125848‬‬
‫‪125968‬‬
‫‪126096‬‬
‫‪128592‬‬
‫‪130941‬‬
‫‪134536‬‬
‫‪136811‬‬
‫‪138647‬‬
‫‪140458‬‬
‫‪141557‬‬
‫‪141814‬‬
‫‪142132‬‬
‫‪143086‬‬
‫‪143637‬‬
‫‪144100‬‬
‫‪145157‬‬
‫‪145745‬‬
‫‪146562‬‬
‫‪146958‬‬
‫‪147663‬‬
‫‪148637‬‬
‫‪150230‬‬
‫‪151281‬‬
‫‪152488‬‬
‫‪155499‬‬
‫‪159158‬‬
‫‪163485‬‬
‫‪168934‬‬
‫‪89399‬‬
‫‪89545‬‬
‫‪104800‬‬
‫‪104880‬‬
‫‪105003‬‬
‫‪120157‬‬
‫‪120280‬‬
‫‪120354‬‬
‫‪121218‬‬
‫‪124850‬‬
‫‪125504‬‬
‫‪125711‬‬
‫‪125841‬‬
‫‪125954‬‬
‫‪126086‬‬
‫‪127325‬‬
‫‪130447‬‬
‫‪133610‬‬
‫‪136773‬‬
‫‪138577‬‬
‫‪140423‬‬
‫‪141522‬‬
‫‪141763‬‬
‫‪141989‬‬
‫‪142978‬‬
‫‪143602‬‬
‫‪143998‬‬
‫‪145156‬‬
‫‪145606‬‬
‫‪146219‬‬
‫‪146956‬‬
‫‪147634‬‬
‫‪148414‬‬
‫‪150023‬‬
‫‪151107‬‬
‫‪152286‬‬
‫‪155498‬‬
‫‪158305‬‬
‫‪163484‬‬
‫‪165038‬‬
‫‪89357‬‬
‫‪89541‬‬
‫‪104789‬‬
‫‪104868‬‬
‫‪104995‬‬
‫‪120121‬‬
‫‪120279‬‬
‫‪120352‬‬
‫‪120455‬‬
‫‪124760‬‬
‫‪125492‬‬
‫‪125688‬‬
‫‪125838‬‬
‫‪125945‬‬
‫‪126054‬‬
‫‪126358‬‬
‫‪130368‬‬
‫‪133609‬‬
‫‪136768‬‬
‫‪138435‬‬
‫‪140379‬‬
‫‪141411‬‬
‫‪141758‬‬
‫‪141970‬‬
‫‪142879‬‬
‫‪143601‬‬
‫‪143997‬‬
‫‪145121‬‬
‫‪145437‬‬
‫‪146204‬‬
‫‪146910‬‬
‫‪147422‬‬
‫‪148316‬‬
‫‪149651‬‬
‫‪151103‬‬
‫‪151581‬‬
‫‪154944‬‬
‫‪158210‬‬
‫‪162279‬‬
‫‪164931‬‬
‫‪89311‬‬
‫‪89477‬‬
‫‪104776‬‬
‫‪104853‬‬
‫‪104970‬‬
‫‪119944‬‬
‫‪120260‬‬
‫‪120351‬‬
‫‪120442‬‬
‫‪124572‬‬
‫‪125483‬‬
‫‪125649‬‬
‫‪125822‬‬
‫‪125926‬‬
‫‪126050‬‬
‫‪126331‬‬
‫‪130229‬‬
‫‪133469‬‬
‫‪136469‬‬
‫‪138277‬‬
‫‪140080‬‬
‫‪141320‬‬
‫‪141752‬‬
‫‪141964‬‬
‫‪142784‬‬
‫‪143590‬‬
‫‪143739‬‬
‫‪144847‬‬
‫‪145393‬‬
‫‪145993‬‬
‫‪146897‬‬
‫‪147413‬‬
‫‪148128‬‬
‫‪149556‬‬
‫‪150989‬‬
‫‪151549‬‬
‫‪154926‬‬
‫‪157622‬‬
‫‪161466‬‬
‫‪164930‬‬
‫‪89303‬‬
‫‪89465‬‬
‫‪104774‬‬
‫‪104844‬‬
‫‪104965‬‬
‫‪119417‬‬
‫‪120257‬‬
‫‪120348‬‬
‫‪120430‬‬
‫‪122647‬‬
‫‪125392‬‬
‫‪125645‬‬
‫‪125819‬‬
‫‪125911‬‬
‫‪126028‬‬
‫‪126303‬‬
‫‪130169‬‬
‫‪132793‬‬
‫‪136125‬‬
‫‪138094‬‬
‫‪139910‬‬
‫‪141045‬‬
‫‪141740‬‬
‫‪141942‬‬
‫‪142738‬‬
‫‪143556‬‬
‫‪143733‬‬
‫‪144775‬‬
‫‪145305‬‬
‫‪145948‬‬
‫‪146872‬‬
‫‪147374‬‬
‫‪148116‬‬
‫‪149489‬‬
‫‪150715‬‬
‫‪151511‬‬
‫‪154153‬‬
‫‪156851‬‬
‫‪159999‬‬
‫‪164834‬‬
‫‪89277‬‬
‫‪89461‬‬
‫‪104506‬‬
‫‪104835‬‬
‫‪104930‬‬
‫‪105048‬‬
‫‪120255‬‬
‫‪120345‬‬
‫‪120425‬‬
‫‪122315‬‬
‫‪125361‬‬
‫‪125622‬‬
‫‪125805‬‬
‫‪125909‬‬
‫‪126022‬‬
‫‪126180‬‬
‫‪130168‬‬
‫‪132651‬‬
‫‪135893‬‬
‫‪137970‬‬
‫‪139387‬‬
‫‪140933‬‬
‫‪141672‬‬
‫‪141939‬‬
‫‪142687‬‬
‫‪143495‬‬
‫‪143698‬‬
‫‪144465‬‬
‫‪145219‬‬
‫‪145799‬‬
‫‪146759‬‬
‫‪147339‬‬
‫‪147895‬‬
‫‪149485‬‬
‫‪150647‬‬
‫‪151504‬‬
‫‪154013‬‬
‫‪156476‬‬
‫‪159522‬‬
‫‪164775‬‬
‫‪89094‬‬
‫‪89442‬‬
‫‪99435‬‬
‫‪104830‬‬
‫‪104896‬‬
‫‪105036‬‬
‫‪120251‬‬
‫‪120332‬‬
‫‪120407‬‬
‫‪121981‬‬
‫‪125356‬‬
‫‪125615‬‬
‫‪125796‬‬
‫‪125861‬‬
‫‪125986‬‬
‫‪126179‬‬
‫‪129760‬‬
‫‪132425‬‬
‫‪135523‬‬
‫‪137757‬‬
‫‪139035‬‬
‫‪140702‬‬
‫‪141632‬‬
‫‪141889‬‬
‫‪142645‬‬
‫‪143479‬‬
‫‪143694‬‬
‫‪144229‬‬
‫‪145159‬‬
‫‪145783‬‬
‫‪146705‬‬
‫‪147226‬‬
‫‪147703‬‬
‫‪148816‬‬
‫‪150519‬‬
‫‪151464‬‬
‫‪153657‬‬
‫‪156331‬‬
‫‪159396‬‬
‫‪163501‬‬
‫א' בתמוז התשס"ז – ‪June 17, 2007‬‬
‫פטנטים שתוקפם פקעו בגלל אי תשלום אגרת חידוש‬
PATENTS NOT IN FORCE DUE TO NON-PAYMENT OF RENEWAL
FEES
123446
1049
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫פטנטים שחודשו לעשרים שנה‬
‫‪PATENTS RENEWED FOR 20 YEARS‬‬
‫‪146287‬‬
‫‪1050‬‬
‫‪142068‬‬
‫א' בתמוז התשס"ז – ‪June 17, 2007‬‬
‫הודעה‬
NOTICE
Under section 66 of the Patents
Law, 5727-1967
This is to notify that permission
has been granted to the owner of
Patent Application No.
Acceptance published in journal
To amend the specification of the
said Patent Application.
Any person may oppose such
grant of permission within three
months from the date of this
Patents Journal, as prescribed by
section 67 of the Law and by
regulation 99 of the Patent
Regulations, 5728-1968.
1051
133835
7/2003
,‫ לחוק הפטנטים‬66 ‫לפי סעיף‬
1967-‫תשכ"ז‬
‫מודע בזאת כי ניתנה רשות‬
'‫לבעלת בקשת הפטנט מס‬
‫דבר הקיבול פורסם ביומן‬
‫לתקן את הפירוט של בקשת‬
‫הפטנט האמורה‬
‫כל אדם רשאי להתנגד למתן‬
‫הרשות תוך שלושה חודשים‬
‫ כפי‬,‫מתאריך יומן פטנטים זה‬
‫ לחוק ובתקנה‬67 ‫שנקבע בסעיף‬
-‫ התשכ"ח‬,‫ לתקנות הפטנטים‬99
.1968
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫הודעה‬
NOTICE
Under section 66 of the Patents
Law, 5727-1967
This is to notify that permission
has been granted to the owner of
Patent Application No.
Acceptance published in journal
To amend the specification of the
said Patent Application.
Any person may oppose such
grant of permission within three
months from the date of this
Patents Journal, as prescribed by
section 67 of the Law and by
regulation 99 of the Patent
Regulations, 5728-1968.
June 17, 2007 – ‫א' בתמוז התשס"ז‬
139592
5/2005
,‫ לחוק הפטנטים‬66 ‫לפי סעיף‬
1967-‫תשכ"ז‬
‫מודע בזאת כי ניתנה רשות‬
'‫לבעלת בקשת הפטנט מס‬
‫דבר הקיבול פורסם ביומן‬
‫לתקן את הפירוט של בקשת‬
‫הפטנט האמורה‬
‫כל אדם רשאי להתנגד למתן‬
‫הרשות תוך שלושה חודשים‬
‫ כפי‬,‫מתאריך יומן פטנטים זה‬
‫ לחוק ובתקנה‬67 ‫שנקבע בסעיף‬
-‫ התשכ"ח‬,‫ לתקנות הפטנטים‬99
.1968
1052
‫הודעה‬
NOTICE
Under section 66 of the Patents
Law, 5727-1967
This is to notify that permission
has been granted to the owner of
Patent Application No.
Acceptance published in journal
To amend the specification of the
said Patent Application.
Any person may oppose such
grant of permission within three
months from the date of this
Patents Journal, as prescribed by
section 67 of the Law and by
regulation 99 of the Patent
Regulations, 5728-1968.
1053
153657
8/2006
,‫ לחוק הפטנטים‬66 ‫לפי סעיף‬
1967-‫תשכ"ז‬
‫מודע בזאת כי ניתנה רשות‬
'‫לבעלת בקשת הפטנט מס‬
‫דבר הקיבול פורסם ביומן‬
‫לתקן את הפירוט של בקשת‬
‫הפטנט האמורה‬
‫כל אדם רשאי להתנגד למתן‬
‫הרשות תוך שלושה חודשים‬
‫ כפי‬,‫מתאריך יומן פטנטים זה‬
‫ לחוק ובתקנה‬67 ‫שנקבע בסעיף‬
-‫ התשכ"ח‬,‫ לתקנות הפטנטים‬99
.1968
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫תיקון טעות‬
Corrigendum
Journal No. 9/2006 ‫יומן‬
129332 '‫ בקשת פטנט מס‬3464 '‫ע‬
12933
-‫תקן המען למסירת הודעות ל‬
'‫ד"ר וב ושות‬
2 ‫רח' פקריס‬
2189 .‫ד‬.‫ת‬
76121 ‫רחובות‬
P. 3464 Patent application No
Correct address for service toWEBB & ASSOCIATES
2 PEKERIS STREET
P.O.B. 2189
REHOVOT 76121
Journal No. 11/2006 ‫יומן‬
P. 4364 Patent application No
Delete international publication no.-
WO/1998/032411
127828 '‫ בקשת פטנט מס‬4364 '‫ע‬
127828
- ‫מחק את מספר הפרסום הבינלאומי‬
Journal No. 11/2006 ‫יומן‬
P. 4548 Patent Application
No. 153792 153792 '‫ בקשת פטנט מס‬4548 '‫ע‬
Delete the application
The application was published by mistake
The application has not yet
been accepted and is not
June 17, 2007 – ‫א' בתמוז התשס"ז‬
:‫מחק את הבקשה‬
‫הבקשה פורסמה בטעות‬
‫הבקשה עוד לא קובלה‬
‫ואיננה פתוחה לעיון‬
1054
COUNTRY CODES APPEARING IN THIS JOURNAL
Code
AR
AT
AU
BA
BE
BR
CA
CH
CN
CU
CZ
DE
DK
EC
EP
ES
FI
FR
GB
GE
GR
GT
HR
HU
IE
IL
IN
IT
JP
KR
LK
LU
LV
MX
Country or Organization
Argentina
Austria
Australia
Herzegovina
Belgium
Brazil
Canada
Switzerland
China
Cuba
Czech Republic
Germany
Denmark
Ecuador
European Patent Office
Spain
Finland
France
United Kingdom
Georgia
Greece
Guatemala
Croatia
Hungary
Ireland
Israel
India
Italy
Japan
Republic of Korea
Sri Lanka
Luxembourg
Latvia
Mexico
MY
Malaysia
1055
June 17, 2007 – ‫א' בתמוז התשס"ז‬
NL
NO
NZ
PL
PT
RU
SE
SG
SI
SK
TH
TR
TW
UA
US
UY
UZ
WO
ZA
The Netherlands
Norway
New Zealand
Poland
Portugal
Russian Federation
Sweden
Singapore
Slovenia
Slovakia
Thailand
Turkey
Taiwan
Ukraine
United States of America
Uruguay
Uzbekistan
World Intellectual Property Organization (W.I.P.O.)
South Africa
June 17, 2007 – ‫א' בתמוז התשס"ז‬
1056
‫מדגמים‬
DESIGNS
‫מדגמים שנרשמו‬
DESIGNS REGISTERED
38808
11(01)
19. 1.2004
Class
‫סוג‬
H. STERN COMERCIO E INDUSTRIA S.A.
Gemstone
6.8.2003
Convention date (Brazil)
Class
39649, 41245, 41246
25(03)
5. 9.2004
‫אבן חן‬
)‫(ברזיל)הברית‬
‫האמנה(ארצות‬
‫תאריך אמנה‬
‫סוג‬
‫כתר פלסטיק בע"מ‬
KETER PLASTIC LTD.
‫מחסן‬
Shed
Class
39665
22(01)
12.9.2004
‫סוג‬
‫יוחנן מגני רענן וולק‬
YOHANAN MAGENY AND
RAANAN VOLK
‫מחזיק למחסנית‬
Magazine holder
Class
39771
2(02)
13. 10.2004
‫סוג‬
‫מנסור ירושלמי‬
MANSUR YERUSHALMI
‫חולצה‬
Shirt
Class
39839
11(01)
4.11.2004
‫סוג‬
H. STERN COMERCIO E INDUSTRIA S.A.
Jewel
1057
‫תכשיט‬
June 17, 2007 – ‫א' בתמוז התשס"ז‬
Class
40011
13(03)
1.12.2004
‫סוג‬
RIT TECHNOLOGIES LTD.
Electrical connector for telecommunication
2.6.2004
Convention date (U.S.A.)
Class
40179
23(01)
17. 1.2005
‫מחבר אלקטרוני לתקשורת‬
)‫הברית‬
)‫(ארצותהברית‬
‫האמנה(ארצות‬
‫תאריך אמנה‬
‫סוג‬
‫יאיר משולם‬
YAIR MESULAM
‫ברזיה‬
Drinking fountain
Class
40434
10(04)
10. 3.2005
‫סוג‬
‫אורית אברבנאל‬
ORIT ABARBANEL
‫תרמומטר‬
Thermometer
Class
40443
23(01)
13. 3.2005
‫סוג‬
‫יאיר משולם‬
YAIR MESULAM
‫ברזיה‬
Drinking fountain
Class
RAFAEL ARMAMENT
DEVELOPMENT AUTHORITY
LTD.
Protective element
June 17, 2007 – ‫א' בתמוז התשס"ז‬
40489
22(04)
24. 3.2005
‫סוג‬
‫רפא"ל רשות לפיתוח אמצעי‬
‫לחימה בע"מ‬
‫אלמט מיגון‬
1058
Class
40529, 40530, 40532,
42957, 42959, 42961,
42963, 42964, 42965,
42966
13(03)
30. 3.2005
‫סוג‬
LUTRON ELECTRONICS CO., INC.
Dimmer switch
1.10.2004
Convention date (U.S.A.)
Class
‫מתג מעמעם‬
)‫הברית‬
)‫(ארצותהברית‬
‫האמנה(ארצות‬
‫תאריך אמנה‬
40953
9(03)
4. 7.2005
‫סוג‬
UNILEVER PLC
Dust bin
17.1.2005
Convention date (OHIM)
Class
‫פח אשפה‬
)‫הברית‬
)‫(אוהיים‬
‫אמנהנה(ארצות‬
‫תאריך האמ‬
40962
4(02)
5. 7.2005
‫סוג‬
THE GILLETTE COMPANY
Toothbrush head
10.1.2005
Convention date (U.S.A.)
Class
‫ראש למברשת שיניים‬
)‫הברית‬
)‫(ארצותהברית‬
‫האמנה(ארצות‬
‫תאריך אמנה‬
41259
28(03)
22. 8.2005
‫סוג‬
THE GILLETTE COMPANY
Dispenser for razor cartridge
Convention date (U.S.A.)
Class
IGAL BLECHER
Profile
1059
24.2.2005
41267
25(01)
23. 8.2005
‫מושיט למחסנית של סכין גילוח‬
)‫הברית‬
)‫(ארצותהברית‬
‫האמנה(ארצות‬
‫תאריך אמנה‬
‫סוג‬
‫יגאל בלכר‬
‫פרופיל‬
June 17, 2007 – ‫א' בתמוז התשס"ז‬
41331
11(01)
1.9.2005
Class
‫סוג‬
H. STERN COMERCIO E INDUSTRIA S.A.
‫תכשיט‬
Jewel
41380
25(03)
18.9.2005
Class
‫סוג‬
TAKEI NISHIKUBO
‫בית טרומי‬
Pre-fabricated house
Class
41602
19(06)
16.11.2005
‫סוג‬
MOROCOLOR ITALIA S.P.A.
‫עיפרון צבע‬
Crayon
Class
41683
23(02)
4. 12.2005
‫סוג‬
‫ יציקות בע"מ‬.‫מ‬.‫א‬.‫ר‬
R.A.M. CASTING LTD.
‫אגנית למקלחת‬
Shower tray
Class
41685
8(08)
4. 12.2005
‫סוג‬
‫לינאה מקלחונים בע"מ‬
LINEA MIKLAHONIM LTD.
‫ציר‬
Hinge
Class
IGAL BLECHER
Profile
June 17, 2007 – ‫א' בתמוז התשס"ז‬
41706
25(01)
11. 12.2005
‫סוג‬
‫יגאל בלכר‬
‫פרופיל‬
1060
Class
41804
8(08)
27. 12.2005
‫סוג‬
‫ בע"מ‬1982 ‫בליסניה‬
BLISANIA 1982 LTD.
‫פקק לפרופיל במיוחד למערכת רשת‬
‫זבובים חשמלית‬
Profile closure particularly for electric fly
screens
Class
41806
25(01)
27. 12.2005
‫סוג‬
‫ בע"מ‬1982 ‫בליסניה‬
BLISANIA 1982 LTD.
‫פקק לפרופיל במיוחד למערכת רשת‬
‫זבובים חשמלית‬
Profile closure particularly for electric fly
screens
Class
41826
26(01)
5. 1.2006
‫סוג‬
‫הצורפים בע"מ‬
HAZORFIM LTD.
‫פמוט‬
Candlestick
Class
42097
20(02)
2. 3.2006
‫סוג‬
‫טמבור בע"מ‬
TAMBOUR LIMITED
‫ארון תצוגה‬
Display cabinet
Class
42219, 42220, 42221,
42222
18(02)
23. 3.2006
‫סוג‬
BROTHER INDUSTRIES LTD.
Ink cartridge
18.11.2005
Convention date (Japan)
Class
42363
9(03)
25. 4.2006
‫מחסנית דיו‬
)‫(ארצות הברית‬
)‫האמנה (יפן‬
‫תאריך אמנה‬
‫סוג‬
ODESA GELISTIRILMIS POLIMER YATIRIMLARI VE DIS TICARET
ANONIM SIRKETI
Foldable crate
Convention date (Turkey)
1061
24.3.2006
‫ארגז מתקפל‬
)‫הברית‬
)‫(טורקיה‬
‫האמנה(ארצות‬
‫תאריך אמנה‬
June 17, 2007 – ‫א' בתמוז התשס"ז‬
42372
15(09)
27. 4.2006
Class
‫סוג‬
‫ מפעלי מתכת בע"מ‬.‫א‬.‫ב‬.‫ש‬
S.B.A. METAL WORKS LTD.
‫כלי עבודה‬
Tool
42393, 42394
11(01)
27. 4.2006
Class
‫סוג‬
H. STERN COMERCIO E INDUSTRIA S.A.
‫תכשיט‬
Jewel
42461
24(01)
16. 5.2006
Class
‫סוג‬
LIFESCAN, INC.
Analyte test meter
Convention date (U.S.A.)
16.12.2005
42486
11(01)
22. 5.2006
Class
PELED DIAMONDS LTD. AND
EFRAIM ALUF
‫מודד כמות חומר מומס‬
)‫הברית‬
)‫ארצותהברית‬
‫(ארצות‬
( ‫האמנה‬
‫תאריך אמנה‬
‫סוג‬
‫פלד יהלומים בע"מ ואפרים אלוף‬
‫אבן חן‬
Precious stone
42490
12(16)
22. 5.2006
Class
‫סוג‬
SKODA AUTO A.S.
Front wing
Convention date (Czech Republic)
25.1.2006
42492
12(16)
22. 5.2006
Class
‫כנף קידמית‬
)‫תאריך האמנה (צ'כיה‬
)‫צות הברית‬
‫מראת מבט אחורי‬
)‫תאריך האמנה (צ'כיה‬
)‫צות הברית‬
‫סוג‬
SKODA AUTO A.S.
Rearview mirror
Convention date (Czech Republic)
June 17, 2007 – ‫א' בתמוז התשס"ז‬
25.1.2006
1062
Class
42531
25(02)
29. 5.2006
MATY HOD ARCHITECTURE &
ENGINEERING LTD.
‫סוג‬
‫מתי הוד אדריכלות והנדסה בע"מ‬
‫מעקה‬
Rail
Class
42557
8(07)
7. 6.2006
‫סוג‬
‫אלבא פרזול לבניה בע"מ‬
ALBA BUILDING IRONWORK
LIMITED
‫סגר לחלון‬
Window closer
Class
42591
14(03)
8. 6.2006
‫סוג‬
SONY COMPUTER ENTERTAINMENT, INC.
GPS receiver
14.3.2006
Convention date (Japan)
Class
42592
16(01)
8. 6.2006
‫מקלט של מערכת איכון עולמית‬
)‫(ארצות הברית‬
)‫האמנה (יפן‬
‫תאריך אמנה‬
‫סוג‬
SONY COMPUTER ENTERTAINMENT, INC.
Camera
31.1.2006
Convention date (Japan)
Class
42607
11(01)
14. 6.2006
‫מצלמה‬
)‫(ארצות הברית‬
)‫האמנה (יפן‬
‫תאריך אמנה‬
‫סוג‬
MY DIAMOND PLACE LTD.
‫יהלום‬
Diamond
Class
IDAN HESKIA
Package
1063
42608
9(03)
15. 6.2006
‫סוג‬
‫עידן חזקיה‬
‫אריזה‬
June 17, 2007 – ‫א' בתמוז התשס"ז‬
Class
42609
9(03)
15. 6.2006
‫סוג‬
‫עידן חזקיה‬
IDAN HESKIA
‫מארז‬
Package
Class
42610
7(01)
14. 6.2006
‫סוג‬
VILLEROY & BOCH AG
Bowl
Convention date (OHIM)
Class
19.12.2005
42650
4(02)
25. 6.2006
‫קערה‬
)‫הברית‬
)‫(אוהיים‬
‫האמנה(ארצות‬
‫תאריך אמנה‬
‫סוג‬
‫דן טירולר‬
DAN TYROLER
‫מברשת‬
Brush
Class
42690
28(03)
5. 7.2006
‫סוג‬
KONINKLIJKE PHILIPS ELECTRONICS N.V.
Cover for shaver
Convention date (OHIM)
Class
6.1.2006
42722
26(05)
9. 7.2006
‫מכסה למכונת גילוח‬
)‫הברית‬
)‫(אוהיים‬
‫האמנה(ארצות‬
‫תאריך אמנה‬
‫סוג‬
‫רשתות תאורה בע"מ‬
LIGHTING NETWORK LTD.
‫גוף תאורה‬
Lighting fixture
Class
SANWA (1984) LTD.
Bottle cap
June 17, 2007 – ‫א' בתמוז התשס"ז‬
42760
9(07)
17. 7.2006
‫סוג‬
‫) בע"מ‬1984( ‫זנוה‬
‫מכסה לבקבוק‬
1064
42817, 42818
23(01)
27. 7.2006
Class
‫סוג‬
E. HAWLE ARMATURENWERKE GMBH
Pipe connector
30.1.2006
Convention date (OHIM)
42826
28(03)
30. 7.2006
Class
‫מחבר לצינור‬
)‫הברית‬
)‫(אוהיים‬
‫האמנה(ארצות‬
‫תאריך אמנה‬
‫סוג‬
‫קט'י רף‬
CATHY RAFF
‫כיסוי עיניים‬
Eye cover
42897
8(06)
13. 8.2006
Class
‫סוג‬
SMILDO S.L.
‫ידית‬
Handle
42899
11(01)
13. 8.2006
Class
EZRA SHAKED AND GIL SIMCHI
‫סוג‬
‫עזרא שקד וגיל שמחי‬
‫יהלום‬
Diamond
42952
9(01)
28. 8.2006
Class
‫סוג‬
BULGARI S.P.A.
Dispenser for cosmetic preparation
Convention date (OHIM)
Class
3.3.2006
42955
10(07)
29. 8.2006
‫מושיט למוצרי קוסמטיקה‬
)‫הברית‬
)‫(אוהיים‬
‫האמנה(ארצות‬
‫תאריך אמנה‬
‫סוג‬
BULGARI TIME (SWITZERLAND) S.A.
Watch bracelet
Convention date (OHIM)
1065
2.3.2006
‫צמיד לשעון‬
)‫הברית‬
)‫(אוהיים‬
‫האמנה(ארצות‬
‫תאריך אמנה‬
June 17, 2007 – ‫א' בתמוז התשס"ז‬
42968, 42971, 42974,
42980, 42981, 42977,
42978, 42979
13(03)
30. 3.2005
Class
‫סוג‬
LUTRON ELECTRONICS CO., INC.
Lighting control
Convention date (U.S.A.)
‫בקרת תאורה‬
)‫הברית‬
)‫(ארצותהברית‬
‫האמנה(ארצות‬
‫תאריך אמנה‬
8.10.2004
43036
11(01)
10. 9.2006
Class
‫סוג‬
H. STERN COMERCIO E INDUSTRIA S.A.
‫תכשיט‬
Jewel
43083
21(01)
17. 9.2006
Class
‫סוג‬
SMART BABY TOYS
‫אופן‬-‫תלת‬
Tricycle
Class
43084
2(04)
18. 9.2006
ANTELOPE SHIVUK(1994) LTD.ׂ
‫סוג‬
)1994( ‫חברת אנטילופ שיווק‬
‫בע"מ‬
‫נעל‬
Shoe
Class
GOLAN SHANS
Pants
June 17, 2007 – ‫א' בתמוז התשס"ז‬
43103, 43104, 43105,
43106, 43107, 43108,
43109
2 (02)
25. 9.2006
‫סוג‬
‫גולן שאנס‬
‫מכנסיים‬
1066
Class
43112
3(02)
25. 9.2006
‫סוג‬
SONY COMPUTER ENTERTAINMENT, INC.
Case for storage medium
8.5.2006
Convention date (Japan)
Class
43113
14(02)
25. 9.2006
‫קופסא עבור תווך אחסנה‬
)‫(ארצות הברית‬
)‫האמנה (יפן‬
‫תאריך אמנה‬
‫סוג‬
SONY COMPUTER ENTERTAINMENT, INC.
Controller for arithmetic and control unit
8.5.2006
Convention date (Japan)
Class
43114
3(02)
25. 9.2006
‫שלט עבור יחידת חשבון ובקרה‬
)‫(ארצות הברית‬
)‫האמנה (יפן‬
‫תאריך אמנה‬
‫סוג‬
SONY COMPUTER ENTERTAINMENT, INC.
Case for electronic device
8.5.2006
Convention date (Japan)
Class
43146
7 (07)
27. 9.2006
‫קופסא עבור התקן אלקטרוני‬
)‫(ארצות הברית‬
)‫האמנה (יפן‬
‫תאריך אמנה‬
‫סוג‬
‫ברמלי תעשיות פלסטיק בע"מ‬
BRAMLI PLASTIC INDUSTRIES
LTD.
‫קופסה‬
Box
Class
43151
3(02)
25. 9.2006
‫סוג‬
SONY COMPUTER ENTERTAINMENT, INC.
Case for electronic device
8.5.2006
Convention date (Japan)
Class
43167
11 (02)
5. 10.2006
SHAHAM Y. ARICHA AND SONS
LTD.
Flower pot
1067
‫קופסא עבור התקן אלקטרוני‬
)‫(ארצות הברית‬
)‫האמנה (יפן‬
‫תאריך אמנה‬
‫סוג‬
‫ אריכא ובניו בע"מ‬.‫שחם י‬
‫עציץ‬
June 17, 2007 – ‫א' בתמוז התשס"ז‬
43184
8 (03)
15. 10.2006
Class
‫סוג‬
TEFEN TOOLS LTD.
‫תפן טולס בע"מ‬
Swivel mitre box
‫מתקן לחיתוך זויות‬
43219, 43220, 43221
11(01)
22. 10.2006
Class
‫סוג‬
H. STERN COMERCIO E INDUSTRIA S.A.
‫תכשיט‬
Jewel
43238, 43239, 43240,
43241, 43242, 43243
11(01)
23. 10.2006
Class
‫סוג‬
H. STERN COMERCIO E INDUSTRIA S.A.
‫תכשיט‬
Jewel
43289
26 (05)
7. 11.2006
Class
NEW LIGHT LASRY
MANUFACTURING &
MARKETING LAMPS PARTS LTD.
‫סוג‬
‫ייצור ושיווק גופי‬-‫ניו לייט לסרי‬
‫תאורה בע"מ‬
‫גוף תאורה‬
Light fixture
43322, 43323
11(01)
14. 11.2006
Class
‫סוג‬
H. STERN COMERCIO E INDUSTRIA S.A.
‫תכשיט‬
Jewel
43384
12(16)
30. 5.2006
Class
‫סוג‬
DAF TRUCKS N.V.
Roof fairing for a truck
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫מסיט רוח לגג משאית‬
1068
43385
12(16)
30. 5.2006
Class
‫סוג‬
DAF TRUCKS N.V.
‫גג למשאית‬
Roof for a truck
Class
43399, 43400, 43401,
43402, 43403
25(01)
28.11.2006
‫סוג‬
‫קליל תעשיות בע"מ‬
KLIL INDUSTRIES LTD.
‫פרופיל‬
Profile
Class
43405
24(04)
29. 11.2006
‫סוג‬
NORTON HEALTHCARE LTD.
Inhaler device
Convention date (OHIM)
Class
16.6.2006
43407
21(03)
29. 11.2006
‫משאף‬
)‫הברית‬
)‫(אוהיים‬
‫האמנה(ארצות‬
‫תאריך אמנה‬
‫סוג‬
SMOBY
Slide
Convention date (OHIM)
Class
GAZIT SHOES T. VINER LTD.
Shoe
1069
29.6.2006
43427
2 (04)
5. 12.2006
‫מגלשת ילדים‬
)‫הברית‬
)‫(אוהיים‬
‫האמנה(ארצות‬
‫תאריך אמנה‬
‫סוג‬
‫ וינר ובניו בע"מ‬.‫נעלי גזית ט‬
‫נעל‬
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫מדגמים שחודשו‬
‫‪DESIGNS RENEWED‬‬
‫‪36158‬‬
‫‪36310‬‬
‫‪36392‬‬
‫‪36461‬‬
‫‪38990‬‬
‫‪36120‬‬
‫‪36304‬‬
‫‪36381‬‬
‫‪36458‬‬
‫‪38690‬‬
‫‪28082‬‬
‫‪36261‬‬
‫‪36370‬‬
‫‪36457‬‬
‫‪37649‬‬
‫‪27913‬‬
‫‪36207‬‬
‫‪36369‬‬
‫‪36434‬‬
‫‪36641‬‬
‫‪27891‬‬
‫‪36203‬‬
‫‪36354‬‬
‫‪36432‬‬
‫‪36638‬‬
‫‪27890‬‬
‫‪36161‬‬
‫‪36353‬‬
‫‪36428‬‬
‫‪36508‬‬
‫‪27814‬‬
‫‪36160‬‬
‫‪36324‬‬
‫‪36425‬‬
‫‪36490‬‬
‫‪40379‬‬
‫‪27707‬‬
‫‪36159‬‬
‫‪36315‬‬
‫‪36417‬‬
‫‪36481‬‬
‫‪40378‬‬
‫מדגמים שבוטלו‬
‫‪1070‬‬
‫א' בתמוז התשס"ז – ‪June 17, 2007‬‬
DESIGNS VOID
19187
19207
26677
26732
26758
35514
35528
35537
35559
35570
35594
35646
35662
35681
19194
19209
26708
26733
26762
35520
35529
35538
35560
35571
35600
35649
35663
35687
19195
19210
26709
26734
26763
35521
35530
35539
35561
35572
35602
35652
35666
38681
Dr. Meir Noam
Commissioner of Patents,
Designs and Trade Marks
1071
19198
19213
26727
26748
26764
35522
35531
35540
35562
35573
35603
35653
35667
38682
19199
19225
26728
26749
26768
35523
35532
35541
35563
35574
35605
35654
35668
19200
19234
26729
26750
35511
35525
35533
35556
35564
35579
35607
35655
35670
19201
19237
26730
26751
35512
35526
35534
35557
35567
35581
35615
35658
35671
19205
26675
26731
26754
35513
35527
35536
35558
35569
35593
35624
35660
35680
‫ד"ר מאיר נועם‬
‫ המדגמים‬,‫רשם הפטנטים‬
‫וסימני מסחר‬
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫שינויים בפרטים רשומים בפנקס‬
‫‪CHANGES IN PARTICULARS ENTERED IN REGISTER‬‬
‫מפתחות לבקשות שקובלו‬
‫‪INDICES OF APPLICATIONS ACCEPTED‬‬
‫מפתח שמי‬
‫‪ 3‬די‪.‬וי‪ .‬מערכות בע"מ ‪116223‬‬
‫אוניברסיטת בן‪-‬גוריון בנגב‪ ,‬הרשות‬
‫למחקר ופיתוח ‪147199‬‬
‫אוריקל יישומים בע"מ ‪140429‬‬
‫אי‪.‬סי‪.‬איי‪ .‬טלקום בע"מ ‪149324‬‬
‫איי‪.‬סי‪ .‬קוד בע"מ ‪147169‬‬
‫אליעזר כץ ‪167283‬‬
‫אם‪-‬סיסטמס פלאש דיסק פיונירס בע"מ‬
‫‪148619‬‬
‫אנה ברמן ‪145572‬‬
‫‪NAME INDEX‬‬
‫ידע חברה למחקר ופיתוח בע"מ ‪,143202‬‬
‫‪150301‬‬
‫יצחק גוילי ‪151000‬‬
‫ישראל אליעזרוב ‪144966‬‬
‫ישראל מרמורשטיין ‪167283‬‬
‫ניטי טכנולוגיות רפואיות בע"מ ‪150855‬‬
‫סולל מערכות סולריות בע"מ ‪161917‬‬
‫סלריס בע"מ ‪125855‬‬
‫ספידביט בע"מ ‪149823 ,149822‬‬
‫ספייסלוג'יק בע"מ ‪150251‬‬
‫בינימין רון ‪140367‬‬
‫פוליקום ישראל בע"מ ‪149439‬‬
‫גיוון אימג'ינג בע"מ ‪150880‬‬
‫גן יישומים בביולוגיה בע"מ ‪155138‬‬
‫די‪-‬פארם בע"מ ‪133693‬‬
‫קלוקוייז טכנולוגיות בע"מ ‪135332‬‬
‫קראוס תעשיות מתכת בע"מ ‪153136‬‬
‫קראל (טכנולוגיות קרמיקה) בע"מ‬
‫‪143780‬‬
‫זולי החזקות בע"מ ‪137455‬‬
‫טויטופלסט בע"מ ‪148375‬‬
‫טי‪.‬די‪.‬אי‪ .‬מערכות נשק בע"מ ‪151953‬‬
‫טראנספארמה מדיקל בע"מ ‪143014‬‬
‫‪i‬‬
‫ראובן ברמן ‪145572‬‬
‫רפאל‪-‬רשות לפיתוח אמצעי לחימה בע"מ‬
‫‪141710‬‬
‫א' בתמוז התשס"ז – ‪June 17, 2007‬‬
DV SYSTEMS LIMITED 1162233
ABBOTT GMBH & CO. KG 146232
ACCENT OPTICAL TECHNOLOGIES,
INC. 157691
ADSIL, LC 151390
AKZO NOBEL N.V. 145483
ALEXANDER BECKMANN 145362
ALLA PAVLOVNA TUZOVA 154360
ALOIS PICHLER 157258
ALZA CORPORATION 144756
ANDEROL, INC. 159091
ANGIOTECH INTERNATIONAL AG.
145069
ANGIOTECH PHARMACEUTICALS,
INC. 145069
ANNA BERMAN 145572
APPLIED VISION SYSTEMS, INC.
147672
ARJO WIGGINS LIMITED 165463
ASAT AG APPLIED SCIENCE &
TECHNOLOGY 142876
ASK 141761
ASTRAZENECA AB 139297
ASTRAZENECA AB 141410, 150403
ATHEROS COMMUNICATIONS, INC.
147916
AVENTIS PHARMA S.A. 136647
BANDSPEED, INC. 145090
BASF AKTIENGESELLSCHAFT
147767
BASF AKTIENGESELLSCHAFT
150173, 154303
BAYER AKTIENGESELLSCHAFT
149748
BAYER CROPSCIENCE S.A. 148162
BELDEN WIRE & CABLE COMPANY
146993
BEN GURION UNIVERSITY OF THE
NEGEV RESEARCH AND
DEVELOPMENT AUTHORITY 147199
BENYAMIN RON 140367
BIOFRONTERA BIOSCIENCE GMBH
142876
Biogen Idec MA Inc. 126918
BIOPHYSICA, INC. 143709
ii
BOARD OF REGENTS, THE
UNIVERSITY OF TEXAS SYSTEM
151011
BOEHRINGER INGELHEIM PHARMA
GMBH & CO. KG 149984
BOREALIS TECHNOLOGY OY 158429
CABOT CORPORATION 151825
CELGENE CORPORATION 135288
CELLARIS LTD. 125855
CENTAUR PHARMACEUTICALS,
INC. 150403
CEREL (CERAMIC TECHNOLOGIES)
LTD. 143780
CHUGAI SEIYAKU KABUSHIKI
KAISHA 136310
CLEAN EARTH TECHNOLOGIES,
LLC 165884, 165885, 165886
CLOCKWISE TECHNOLOGIES LTD.
135332
COLEY PHARMACEUTICALS, INC.
139813
COMPUTER ASSOCIATES THINK,
INC. 142572, 143693, 143940
COMPUTER ASSOCIATES THINK,
INC. 144067, 145325
COULTER PHARMACEUTICAL INC.
140028
CV THERAPEUTICS, INC. 146471
DEERE & COMPANY 164542, 164842
DERMATRENDS, INC. 150177
DONALDSON COMPANY, INC.
154569, 154570
D-PHARM LIMITED 133693
DSM IP ASSETS B.V. 151586
ECI TELECOM LTD. 149324
EGIS GYOGYSZERGYAR RT. 146420
EISAI CO.,LTD. 151314
ELI LILLY AND COMPANY 146810,
155700
ELIEZER KATZ 167283
ENZO THERAPEUTICS, INC. 137292
ETHYPHARM 142787
F. HOFFMANN-LA ROCHE AG 150549
F. LLI CITTERIO S.P.A. 152305
June 17, 2007 – ‫א' בתמוז התשס"ז‬
FABBRICA D'ARMI PIETRO
BERETTA S.P.A. 155711
FIDELINE 137257
FUMAKILLA LIMITED 150888
JANE, S.A. 156952
JANSSEN PHARMACEUTICA N.V.
147327, 147328
JONATHAN DALLAS TOYE 129912
GALENIX DEVELOPPEMENT 148003
GALMED INTERNATIONAL LIMITED
142650
GE MEDICAL SYSTEMS GLOBAL
TECHNOLOGY COMPANY, LLC
150811
GENE BIO-APPLICATION LTD.
155138
GENENTECH, INC. 135345
GENZYME CORPORATION 146211
GIVAUDAN SA 137893
GIVEN IMAGING LTD. 150880
GLAXOSMITHKLINE S.P.A. 147012
GPI NIL HOLDINGS, INC. 128792
GRUNENTHAL GMBH 148406
KIRIN-AMGEN INC. 140669
KRAUSZ METAL INDUSTRIES LTD.
153136
KREIDO LABORATORIES 157789
HARRIS CORPORATION 145125
HARRY CONNICK, JR. 149816
HONEYWELL INC. 149730
I.C. CODE LTD. 147169
IBM CORPORATION 141458, 143013
IBM CORPORATION 157506
IHARA CHEMICAL INDUSTRY CO.,
LTD. 146758
IMMUGEN PHARMACEUTICALS,
INC. 145470
INNOVAPARK, LLC 149880
INSTITUT FIZIKI TVERDOGO TELA
ROSSIISKOI AKADEMII NAUK
151182
INTEL CORPORATION 149538
INTER IKEA SYSTEMS B.V. 155357
INTERNATIONAL BUSINESS
MACHINES CORPORATION 142265,
147118
INTROGENE B.V. 133032
ISRAEL ELIEZEROV 144966
ISRAEL MARMORSTEIN 167283
ITALDATA INGEGNERIA DELL'IDEA
S.P.A. 155372
ITZHAK GVILI 151000
June 17, 2007 – ‫א' בתמוז התשס"ז‬
LABORATOIRE L. LAFON 148042
LABORATOIRE THERAMEX 148953
LIFESCAN, INC. 150669
LILLY ICOS LLC 146098
LOEB HEALTH RESEARCH
INSTITUTE AT THE OTTAWA
HOSPITAL 139813
LONZA AG 143229
LOOK DYNAMICS, INC. 146688
LTS LOHMANN THERAPIESYSTEME AG 148568
LTS LOHMANN THERAPIESYSTEME AG 149812
M. KAINDL 161371
MASSACHUSETTS INSTITUTE OF
TECHNOLOGY 137299
MASSACHUSETTS INSTITUTE OF
TECHNOLOGY 148137
MEDA PHARMA GMBH & CO. KG
148068
MERCK & CO., INC. 159109
MERCK PATENT GMBH 146707
MIKKEL G. MANDT 158662
MILKHAUS LABORATORY, INC.
131478, 138336
MOELLER GEBAUDEAUTOMATION
KG 146058
M-SYSTEMS FLASH DISK PIONEERS
LTD. 148619
N.V. ORGANON 145483
NAGRACARD S.A. 148521
NDS LIMITED 126552
NEOTHERMIA CORPORATION
150159
NEPHROS, INC. 155408, 156103
NEWMAT, S.A. 148683
iii
NEXMED HOLDINGS, INC. 150306
NIKEM RESEARCH S.R.L. 147012
NITI MEDICAL TECHNOLOGIES
LTD. 150855
NORTH CAROLINA STATE
UNIVERSITY 150560
NOVAMONT S.P.A. 151212
NOVEXEL 136647
NOVO NORDISK A/S 124939
OBSCHESTVO S OGRANICHENNOI
OTVETSTVENNOSTIJU "KLINIKA
INSTITUTA BIOREGUL YATSII I
GERONTOLOGII" 146432
OCCIDENTAL CHEMICAL
CORPORATION 154653
OLIVER BRUESTLE 136833
ORTHOFIX INTERNATIONAL B.V.
145553
ORTHO-MCNEIL
PHARMACEUTICAL, INC. 137954,
147510
ORYCLE APPLICATIONS LTD.
140429
PHARMACIA & UPJOHN COMPANY
LLC 151789
POLYCOM ISRAEL LTD. 149439
POWDERJECT RESEARCH LIMITED
145668
PRODEMEX, S.A. DE C.V. 151586
QLT USA, INC. 155006
QUALCOMM INCORPORATED
138090, 147418, 147761, 147791, 147795
QUALCOMM INCORPORATED
147628
RAFAEL-ARMAMENT
DEVELOPMENT AUTHORITY LTD.
141710
RECORDATI IRELAND LIMITED
147441
RECORDATI S.A. CHEMICAL AND
PHARMACEUTICAL COMPANY
147441
REM TECHNOLOGIES, INC. 157290
iv
RESEARCH CORPORATION
TECHNOLOGIES, INC. 140553
REUBEN BERMAN 145572
RHEINMETALL W & M GMBH 152972
ROGER DE LATHOUWER 143886
ROGUE VALLEY NATURAL
SPRINGS, INC. 153892
RTP PHARMA INC. 138767
SAMSUNG ELECTRONICS CO., LTD.
141743
SAMSUNG ELECTRONICS CO., LTD.
157663
SANOFI AVENTIS 145150
SANOFI AVENTIS 163286
SANOFI-AVENTIS DEUTSCHLAND
GMBH 146276, 149209
SCANNEX TECHNOLOGIES, LLC
147319
SCHERING AKTIENGESELLSCHAFT
136455
SECURELOGIC LTD. 150251
SILVERBROOK RESEARCH PTY.
LTD. 146619, 164924, 166724
SIMULA, INC. 154957
SMITHKLINE BEECHAM
CORPORATION 140028
SMITHKLINE BEECHAM
CORPORATION 148325
SNECMA MOTEURS 149738
SOCIETE DES PRODUITS NESTLE
S.A. 143270
SOLEL SOLAR SYSTEMS LTD.
161917
SPEEDBIT LTD. 149822, 149823
SPS VERPACKUNGS-SYSTEM GMBH
149898
SUGEN, INC. 124728
T.D.I. ARMS SYSTEMS LTD. 151953
TECHNISCHE UNIVERSITAT
DRESDEN 143952
THALES 149659
THALES NEDERLAND B.V. 154133
THE MOWER FAMILY CHF
TREATMENT IRREVOCABLE TRUST
144290
THE OTTAWA HEALTH RESEARCH
June 17, 2007 – ‫א' בתמוז התשס"ז‬
INSTITUTE 139813
THE PROCTER & GAMBLE
COMPANY 147265
THE REGENTS OF THE UNIVERSITY
OF CALIFORNIA 128058
THE REGENTS OF THE UNIVERSITY
OF CALIFORNIA 143202
THE REGENTS OF THE UNIVERSITY
OF MICHIGAN 140028
TOSHIO KITAMURA 136310
TRANSPHARMA MEDICAL LTD.
143014
TRIUMPH BRANDS, INC. 163624
T-SYSTEMS INTERNATIONAL, INC.
143253
TWITOPLAST LTD. 148375
UNITED TECHNOLOGIES
CORPORATION 147091, 160163,
163398
UNITED TECHNOLOGIES
CORPORATION 163443
UNIVERSITY OF BRITISH
COLUMBIA 145069
UNIVERSITY OF NORTH CAROLINA
AT CHAPEL HILL 144411
WARCOP INVESTMENT LTD. 140367
WAYPORT, INC. 149356
WISCONSIN ALUMNI RESEARCH
FOUNDATION 146923
WORLDWIDE COATINGS IP PTY
LTD 152333
WORLDWIDE FIRE RETARDANT IP
PTY LTD. 152333
WORLDWIDE THERMAL
MANAGEMENT IP PTY LTD. 152333
WYETH HOLDINGS CORPORATION
137617
YEDA RESEARCH AND
DEVELOPMENT CO. LTD. 143202,
150301
ZULI HOLDINGS LTD. 137455
VACUUMSCHELZE GMBH 138199
June 17, 2007 – ‫א' בתמוז התשס"ז‬
v
‫מפתח ענייני‬
SUBJECT MATTER INDEX
A01G – 154938
A01H – 137661
A62D – 141747, 152017
A01 N – 148464, 149778, 151786
B01D – 153377
A21C – 152240
B03C – 157525
A23J – 156017, 163225
B23B – 150012
A23N – 172637
B23C – 150013, 150015
A45F – 148378
B26B – 150871
A47C – 167402
B28C – 148560
A47K – 165639
B29D – 150234
A61B – 137322, 137759, 150094
154833, 155475
B32B – 143154, 148911, 151766,
154669, 156109
A61C – 147260
B41J – 163494, 163496, 164447,
164691, 164953, 165540,
166422, 166723
A61F – 146534, 151826
A61K – 114616, 126463, 128128,
132625, 134593, 139320,
139779, 140412, 141675,
144181, 144581, 145043,
145684, 145923, 147320,
147876, 149370, 149637,
150850, 153205, 153676,
155875, 156353
B41N – 166910
B63B – 154672
B63H – 157804
B65D– 158551
C01B – 146440
A61L – 140972
C02F – 159911
A61M – 151465, 151579, 151864,
151930, 152321
A61N – 142409, 142808, 146217,
150552
C04B – 154335, 161555
C07C – 134851, 144619, 144636,
146187, 147958, 150528,
150621, 151083, 152537
A62B – 147685
vi
June 17, 2007 – ‫א' בתמוז התשס"ז‬
F42C – 138823
C07D – 131750, 132962, 133512,
134192, 136738, 138477,
138745, 139012, 139301,
141157, 141680, 145192,
149010, 149030, 149134,
149444, 149681, 150377,
151392, 158360
C07F – 149601, 151248, 158798
G01B – 143453
G01C – 156362
G01F –151612, 162821
G01K – 155352
G01L – 155562
C07H– 145946
G01M –147725
C07K – 112699, 118570, 130309,
137449, 137522, 138281,
146396
G01N – 128042, 137601,145135,
146729, 160418
C08F – 122115, 152087
G01S – 157521
C08K – 158505
G03F– 148566
C09K – 151803
G06F – 146680, 147879, 150106,
150583
C12N – 115792, 126843, 128727,
130245, 132768, 135458,
137178, 137564
G06K – 146606, 146652, 149303,
153925, 155882
C12P – 132671, 135103, 144679
G06Q – 147015, 147399
C23C – 156656
G06T – 149080
D04H –154630
G08G – 157864
E04B – 159329
G10L – 122023
E04C – 148274, 148400
G11B – 132796, 139083, 147543
E05D – 151447
H01F – 156426
F04C – 160096
H01H – 156757
F16F – 164561
H01M – 157252
F16K – 156797
H01Q – 152139
F23R – 145349
H03M – 137199
F24J – 158726
H04B – 147792, 148370, 148412
June 17, 2007 – ‫א' בתמוז התשס"ז‬
vii
H04L – 148069, 148367, 148700
H04N – 144017, 148431, 149877
H04Q – 135786
H05K – 157410
viii
June 17, 2007 – ‫א' בתמוז התשס"ז‬
‫ ירושלים‬,‫ משרד המשפטים‬,‫נערך ע"י רשות הפטנטים‬
‫ ירושלים‬,‫הופק והודפס במדפיס הממשלתי‬
EDITED BY THE PATENT OFFICE, MINISTRY OF JUSTICE, JERUSALEM
PRINTED AND PUBLISHED BY THE GOVERNMENT PRINTER
June 17, 2007 – ‫א' בתמוז התשס"ז‬
9